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Background: Self-harm in adolescents is common and repetition rates high. There is limited evidence of
the effectiveness of interventions to reduce self-harm.
Objectives: To assess the clinical effectiveness and cost-effectiveness of family therapy (FT) compared with
treatment as usual (TAU).
Design: A pragmatic, multicentre, individually randomised controlled trial of FT compared with TAU.
Participants and therapists were aware of treatment allocation; researchers were blind to allocation.
Setting: Child and Adolescent Mental Health Services (CAMHS) across three English regions.
Participants: Young people aged 11–17 years who had self-harmed at least twice presenting to CAMHS
following self-harm.
Interventions: Eight hundred and thirty-two participants were randomised to manualised FT delivered by
trained and supervised family therapists (n = 415) or to usual care offered by local CAMHS following
self-harm (n = 417).
Main outcome measures: Rates of repetition of self-harm leading to hospital attendance 18 months
after randomisation.
Results: Out of 832 young people, 212 (26.6%) experienced a primary outcome event: 118 out of 415
(28.4%) randomised to FT and 103 out of 417 (24.7%) randomised to TAU. There was no evidence of a
statistically significant difference in repetition rates between groups (the hazard ratio for FT compared with
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TAU was 1.14, 95% confidence interval 0.87 to 1.49; p = 0.3349). FT was not found to be cost-effective
when compared with TAU in the base case and most sensitivity analyses. FT was dominated (less effective
and more expensive) in the complete case. However, when young people’s and caregivers’ quality-adjusted
life-year gains were combined, FT incurred higher costs and resulted in better health outcomes than
TAU within the National Institute for Health and Care Excellence cost-effectiveness range. Significant
interactions with treatment, indicating moderation, were detected for the unemotional subscale on the
young person-reported Inventory of Callous–Unemotional Traits (p = 0.0104) and the affective involvement
subscale on the caregiver-reported McMaster Family Assessment Device (p = 0.0338). Caregivers and
young people in the FT arm reported a range of significantly better outcomes on the Strengths and
Difficulties Questionnaire. Self-reported suicidal ideation was significantly lower in the FT arm at 12 months
but the same in both groups at 18 months. No significant unexpected adverse events or side effects were
reported, with similar rates of expected adverse events across trial arms.
Conclusions: For adolescents referred to CAMHS after self-harm, who have self-harmed at least once
before, FT confers no benefits over TAU in reducing self-harm repetition rates. There is some evidence to
support the effectiveness of FT in reducing self-harm when caregivers reported poor family functioning.
When the young person themselves reported difficulty expressing emotion, FT did not seem as effective as
TAU. There was no evidence that FT is cost-effective when only the health benefits to participants were
considered but there was a suggestion that FT may be cost-effective if health benefits to caregivers are
taken into account. FT had a significant, positive impact on general emotional and behavioural problems at
12 and 18 months.
Limitations: There was significant loss to follow-up for secondary outcomes and health economic
analyses; the primary outcome misses those who do not attend hospital following self-harm; and the
numbers receiving formal FT in the TAU arm were higher than expected.
Future work: Evaluation of interventions targeted at subgroups of those who self-harm, longer-term
follow-up and methods for evaluating health benefits for family groups rather than for individuals.
Trial registration: Current Controlled Trials ISRCTN59793150.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 22, No. 12. See the NIHR Journals Library website
for further project information.
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Plain English summary
Young people (aged 11–17 years) who had self-harmed at least twice, and their families, were randomlyallocated to receive either family therapy (FT) or treatment as usual (TAU) in their local Child and
Adolescent Mental Health Services. Eight hundred and thirty-two young people from Yorkshire, Greater
Manchester and London agreed to take part. The participants were recruited from hospital and the
community.
Information was collected from the young people and their families at the beginning of the study and then
again 3, 6, 12 and 18 months later in order to compare the effects of the two treatments. Information was
also collected from health records.
The main focus was whether or not FT would reduce the number of times young people attended hospital
with further self-harm. No significant differences were found in further self-harm between the two groups,
nor was FT more cost-effective than the type of treatment young people usually get in the NHS (TAU).
Looking more closely at the characteristics of those taking part, there was a suggestion that young people
who said that they found it harder to talk about feelings did better (self-harmed less) with TAU. On the
other hand, when caregivers reported that the family did not talk about feelings easily, young people did
better with FT.
Fewer emotional and behavioural problems were found in the group that had FT. FT was not found to be
cost-effective.
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Scientific summary
Background
Self-harm in adolescents is a major public health issue and, globally, suicide is the second most common
cause of death in the 10–24 years age group after road traffic accidents. As many as 10% of adolescents
self-harm in the community each year, with the most common methods being cutting and overdose.
Only one in eight episodes of self-harm leads to a hospital presentation.
The estimates of the risk of 1-year repetition of self-harm vary between 5% and 25% per year.
Actual rates may be much higher when repetition that does not come to clinical or medical attention
is considered.
There is limited evidence for the effectiveness of clinical interventions for young people who engage in
self-harm. Two recent studies have suggested that dialectical behaviour therapy and mentalisation-based
treatment may be effective in reducing self-harm. Both had small numbers of participants and shorter
follow-up periods than this study and relied on self-report as the primary outcome measure. A systematic
review of interventions to reduce self-harm in adolescents calculated pooled risk differences comparing the
proportion of young people who self-harmed at least once in the follow-up period of each study versus
those who did not self-harm at all. Overall, the proportion of participants who self-harmed was slightly
(but statistically significantly) lower in those allocated to treatment interventions. However, the authors
acknowledged that the quality of studies examined was poor and that ‘more research and replication of
the positive findings by independent groups are urgently required’ (Ougrin D, Tranah T, Stahl D, Moran P,
Asarnow JR. Therapeutic interventions for suicide attempts and self-harm in adolescents: systematic review
and meta-analysis. J Am Acad Child Adolesc Psychiatry 2015;54:97–107).
Methods
Design
The Self-Harm Intervention: Family Therapy (SHIFT) trial was a pragmatic, Phase III, multicentre, individually
randomised controlled trial of family therapy (FT) compared with treatment as usual (TAU) in 832 adolescents
aged 11–17 years who had engaged in self-harm on at least two occasions and for whom a recent self-harm
episode was a key reason for contact with Child and Adolescent Mental Health Services (CAMHS).
Objectives
The primary objective assessed the effectiveness of FT compared with TAU as measured by young people’s
rates of repetition of self-harm leading to hospital attendance 18 months after randomisation.
The secondary objectives assessed were:
l repetition rates of self-harm leading to hospital attendance 12 months after randomisation
l the cost per self-harm event avoided as a result of FT, measured using a structured, trial-specific health
economics questionnaire
l the characteristics of all further episodes of self-harm (both those resulting in hospital attendance and
self-report of all episodes)
l changes in a range of measures of participant and family functioning (see Outcome measures)
l moderator and mediators influencing benefit from treatment
l therapeutic engagement and adherence.
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Setting and participants
The participants were young people aged 11–17 years who had self-harmed at least twice presenting to
CAMHS following an episode of self-harm, recruited from NHS CAMHS across three ‘hubs’ in England:
Greater Manchester, London and Yorkshire. Young people were screened for trial suitability and
approached, if eligible, at their first visit to CAMHS following self-harm.
Interventions
The FT intervention was based on a modified version of the Leeds Family Therapy & Research Centre
Systemic Family Therapy Manual. Qualified family therapists were appointed specifically to work on the
trial, received standardised training and worked in teams of three or four, providing trial FT as a team for a
cluster of CAMHS.
Treatment as usual was the care offered by local CAMHS teams to young people referred following
self-harm. It was expected that TAU would be diverse and involve individual and/or family-orientated work,
delivered by a range of practitioners with various theoretical orientations.
Outcome measures
The duration of treatment was designed to be approximately 6 months.
Measures were as follows: Inventory of Callous–Unemotional Traits [(ICU) young person and caregiver
self-report at baseline], Family Questionnaire (caregiver self-report at 3 and 6 months), System for Observing
Family Therapy Alliances (SOFTA; completed by family therapist and participants at FT session 3) and, at
12 and 18 months, the Suicide Attempt Self-Injury Interview (SASII) with the young person, Children’s
Depression Rating Scale – Revised (CDRS-R), health economics questionnaire, young person and caregiver
self-report for the McMaster Family Assessment Device (FAD), Strengths and Difficulties Questionnaire
(SDQ), young person self-report for the Beck Scale for Suicide Ideation (BSS), Hopelessness Scale for Children
(young person), Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q), EuroQol-5
Dimensions [(EQ-5D) also at 6 months] and caregiver self-report for the General Health Questionnaire,
12 questions (GHQ-12), Health Utilities Index 3 [(HUI-3) also at 6 months] and health economics questionnaire.
Results
Characteristics of the sample
A total of 3554 young people were screened within participating CAMHS, of whom the clinician deemed
1603 (45.1%) to be eligible for the trial. The most common reason for a young person to be ineligible was
that they had not engaged in self-harm prior to the current CAMHS referral. A total of 993 (61.9%)
eligible young people consented to researcher contact, and 832 (83.8%) consented to trial participation
and were randomised (51.9% of those eligible): 415 to FT and 417 to TAU.
The mean age at randomisation was 14.3 [standard deviation (SD) 1.38] years in the FT arm and 14.4
(SD 1.35) years in the TAU arm. In both arms there were more females than males: 368 (88.7%) in the FT
arm and 369 (88.5%) in the TAU arm. More young people had self-harmed on at least three previous
occasions than on two occasions: 369 (88.9%) in the FT arm and 370 (88.7%) the TAU arm. The type of
most recent episode was most commonly self-injury, for 297 (71.6%) in the FT arm and 297 (71.2%) in
the TAU arm, with self-poisoning attributed to a further 93 (22.4%) and 91 (21.8%), respectively. Those
remaining used combined methods. All but two participants were living with their parents/guardians as
opposed to in foster care. The majority were in full-time education: 398 (95.9%) in the FT arm and 386
(92.6%) in the TAU arm. Ethnicity was also well balanced between the arms.
Baseline characteristics suggest that participants had experienced significant difficulties and were not
dissimilar to UK CAMHS referrals as a whole: 26.2% reported a health or disability problem, 29.3% had
been involved with CAMHS in the past, 21.4% reported marked physical abuse and 16.6% reported sexual
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abuse. On the total difficulties score of the SDQ, 66.2% of participants scored in the high/very high range,
with 69.6% of caregivers reporting scoring participants in this range. On the general functioning subscale
of the FAD, 84.7% of participants scored their families as ‘unhealthy’, with the equivalent figure from
caregivers being 75.8%. On the CDRS-R, 65.7% of participants scored themselves as being in the
moderate, severely or very severely depressed category. Nearly two-thirds of the participants (63.5%) were
referred directly to CAMHS from the community: some had been discharged from hospital without a
CAMHS referral and had then been referred via community services; others had never presented to hospital
in the first place. The self-harm method used by the young people in the sample was much more slanted
towards self-injury than in samples of hospital cases.
Clinical effectiveness
Primary outcome data were available for 795 out of 832 (95.6%) participants. A total of 221 (26.6%)
young people experienced the primary outcome event, that is, a repeat self-harm event leading to hospital
attendance within 18 months post randomisation: 118 (28.4%) in the FT arm and 103 (24.7%) in the TAU
arm. There was no evidence to suggest a statistically significant difference in self-harm repetition rates
between the treatment groups. The hazard ratio for FT compared with TAU was 1.14 [95% confidence
interval (CI) 0.87 to 1.49] with a p-value of 0.3349.
Cost-effectiveness
Both trial arms showed an increase in the mean EQ-5D over 18 months’ follow-up. The largest differences
in EQ-5D scores between the two arms were at 6 and 12 months, with the FT group exhibiting higher
scores at the 5% significance level than the TAU group, but there were no significant differences in quality
of life between the two study arms at 18 months.
Family therapy participants incurred higher costs (mean £1266.23, 95% CI £736.04 to £1796.43) and
gained more quality-adjusted life-years (QALYs) (mean 0.034, 95% CI –0.004 to 0.065) than TAU patients,
equivalent to an extra 12.4 days of perfect health. The incremental cost-effectiveness ratio (ICER) equalled
£36,811.80 per QALY, which is above the recommended threshold range currently specified for National
Institute for Health and Care Excellence (NICE) decision-making in England and Wales (£20,000–30,000
per QALY gain). FT was unlikely to be cost-effective in most sensitivity analyses and was dominated by TAU
in the complete-case analysis (less effective and more costly).
However, when combining young people’s and caregivers’ QALY gains, the FT arm incurred higher costs
and exhibited better health outcomes than those in the TAU arm, resulting in an ICER of £20,808.21 per
QALY gain; this ICER is within the NICE cost-effectiveness range, with a probability of being cost-effective
of 41% at £20,000 (and 64% at £30,000) per QALY.
Secondary clinical outcomes
There were no significant treatment differences in young person questionnaire outcomes on the CDRS-R,
PQ-LES-Q, Hopelessness Scale or FAD. However, adolescents treated with FT reported significantly better
outcomes on the prosocial scale of the SDQ, with a mean improvement of 0.4 points (95% CI 0.1 to 0.7
points; p = 0.0064) at 12 months and of 0.3 points (95% CI 0.0 to 0.7 points; p = 0.0337) at 18 months,
and on the impact of their problems scale at 12 months (mean improvement of –0.7 points, 95% CI
–1.1 to –0.2 points; p = 0.0033), but not at 18 months (mean improvement –0.3 points, 95% CI –0.8 to
0.2 points; p = 0.2153). There was good evidence of reduced odds of suicide ideation in FT at 12 months,
with an odds ratio of 0.64 (95% CI 0.44 to 0.94; p = 0.0242), but not at 18 months.
No significant treatment differences were found for the caregiver questionnaire outcomes on the GHQ-12
or Family Questionnaire. However, caregivers reported a range of significantly better outcomes on the SDQ
for FT, with the following improvements in scores:
l total difficulties: mean –1.3 points (95% CI –2.4 to –0.2 points; p = 0.0260) at 12 months and mean
–1.6 points (95% CI –2.9 to –0.4 points; p = 0.0131) at 18 months
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l emotional problems: mean –0.5 points (95% CI –1.0 to –0.1 points; p = 0.0166) at 12 months and
mean –0.6 points (95% CI –1.1 to –0.1 points; p = 0.0218) at 18 months
l peer problems: mean –0.3 points (95% CI –0.7 to –0.0 points; p = 0.0366) at 12 months and mean
–0.5 points (95% CI –0.9 to –0.1 points; p = 0.0092) at 18 months
l internalising subscale: mean –0.9 points (95% CI –1.5 to –0.2 points; p = 0.0111) at 12 months and
mean –1.1 points (95% CI –1.9 to –0.3 points; p = 0.0074) at 18 months
l at 18 months only, conduct problems: mean –0.3 points (95% CI –0.6 to –0.0 points; p = 0.0499) and
externalising –0.7 points (95% CI –1.3 to –0.0 points; p = 0.0446)
l impact subscale: mean –0.7 points (95% CI –1.3 to –0.1 points; p = 0.0309) at 12 months only.
Caregivers in the FT arm also reported significantly better outcomes on the roles subscale of the FAD at
12 months, with a mean improvement of –0.1 points (95% CI –0.2 to –0.0 points; p = 0.0020), but not at
18 months.
The numbers of participants with other ‘administrative’ outcomes, such as referrals to other services,
including to inpatient units, and safety outcomes, including re-referrals to CAMHS, accident and
emergency (A&E) attendances and hospital admissions for any reason, were similar in both treatment arms.
Moderator analyses
Significant interactions with treatment, indicating moderation, were detected for the unemotional subscale
on the young person-reported ICU (p = 0.0104) and for the affective involvement subscale on the
caregiver-reported FAD, for both the score (p = 0.0338) and the categorisation of healthy versus unhealthy
families (p = 0.0444).
Young people in the FT arm whose scores on the unemotional subscale suggested that they had difficulty
talking about their feelings at baseline had higher risk of self-harm than those in the TAU arm, while those
in the FT arm whose scores indicated that they found talking about their feelings to be easier had a lower
risk of self-harm than those in the TAU arm.
Among young people whose caregivers reported higher affective involvement scores (the degree to which
family members are involved and interested in one another) on the FAD, risk of self-harm was higher in
the FT arm than in the TAU arm, while among those with lower affective involvement scores risk of
self-harm was lower in the FT arm than in the TAU arm.
Conclusions
This study did not demonstrate that SHIFT manualised FT following repeated self-harm reduced subsequent
hospital attendances for self-harm when compared with TAU.
The high proportion of young people whose index episode of self-harm involved self-injury and who were
referred into CAMHS through the community rather than recruited directly following admission to hospital
means that the sample is representative of self-harm referrals to CAMHS. However, the findings may not
be generalisable to the smaller subset of adolescents who present to hospital following a first episode of
self-harm.
There was some evidence to support the effectiveness of FT over TAU in reducing self-harm when
caregivers reported poor family functioning, particularly in relation to talking about feelings, or young
people reported ease in discussing emotions. Conversely, when the young people themselves reported
difficulty in expressing emotion, or families reported healthy functioning on the affective involvement scale,
FT was not as effective as TAU.
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Although there was no evidence of cost-effectiveness of FT in the base-case analysis and most sensitivity
analyses focused on health benefits to young people, there is a suggestion that FT may be cost-effective if
health benefits to the caregiver are additionally taken into account.
There was clear evidence that FT had a statistically significant, positive impact on young people’s prosocial
behaviour at 12 and 18 months and on suicidal ideation at 12 but not 18 months and on caregivers’ views
on young people’s total difficulties and emotional and peer problems at 12 and 18 months and conduct
problems at 18 months.
Recommendations for future research
There remains a need for research exploring effective interventions to reduce self-harm. Self-harm is likely
to be the final common pathway for a wide range of interpersonal and mental health predicaments.
Future research needs to evaluate interventions targeted at the characteristics of specific subgroups who
self-harm. Obvious candidate groups arising from this research would be families who self-report poorer
family functioning and young people who are more unemotional.
Further research into the characteristics of these two groups is also indicated. What is the exact nature of
the family dysfunction that some groups report and how might psychological interventions be targeted at
this group? Are unemotional traits shared by other family members and is it possible that these two
findings are aspects of the same underlying issue?
The accumulation of health benefits for the young person and the carer requires further exploration as to
how health economic benefits might be aggregated for family members.
Studies with longer follow-ups are needed to explore any longer-term impact of interventions. The National
Institute for Health Research Health Technology Assessment programme has already provided funding to
allow follow-up of the SHIFT participants for a further 18 months, looking at the primary outcome only.
The significant differences observed in self-reported episodes of self-harm and episodes requiring hospital
attendance and the very different patterns of self-harm recorded suggest that further work is needed
to clarify the most appropriate outcome measures in self-harm research and how these might best
be measured.
Trial registration
This trial is registered as ISRCTN59793150.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
What is self-harm?
In this study, in accordance with the commissioning brief and in line with current UK clinical practice,
self-harm is defined as any form of non-fatal self-poisoning or self-injury (such as cutting, taking an
overdose, hanging, self-strangulation, jumping from a height and running into traffic), regardless of the
motivation or the degree of intention to die. This definition includes what in the USA would be described
as non-suicidal self-injury (NSSI) and suicidal behaviour.1
How common is self-harm?
Self-harm in adolescents is a major public health issue and, globally, suicide is the most common cause of
death in the 10–24 years age group after road traffic accidents.2 A relatively recent systematic review
reported that 9.7% of adolescents had self-harmed in the previous year in the community,3 and a recent
pan-European study reported a lifetime prevalence of 27.6% for NSSI,4 with rates of self-harm higher
among females than males, although in later adolescence there is nearly parity between male and female
hospital attendances.2
At the community level, the most common methods of self-harm in young people are cutting and
overdose.5 Only one in eight episodes of self-harm leads to a hospital presentation,5 but, even so, it is likely
that > 30,000 adolescents present to hospital in England each year having harmed themselves.6 In studies
based on presentations to general hospitals in the UK, most adolescents have harmed themselves by
taking an overdose, with self-poisoning with analgesics being particularly common.7
Self-harm is associated with an elevated risk of overall mortality2,8–11 and suicide. In one follow-up study of
15- to 24-year-olds who had presented to hospital following an episode of self-harm between 2000 and
2005, the overall number of deaths from all causes was 3% of the cohort at follow-up in 2007, four times
higher than expected. This was mainly because of an excess of suicides (2% of the cohort), which were
10 times more frequent than expected. The main risk factors for suicide were male gender, previous
multiple episodes of self-harm, prior psychiatric history and high suicide intent.12,13 Because of the young
ages at which these deaths occur, the number of life-years lost to the community as a result of suicide and
the impact on family members is significant.
The estimates of the risk of 1-year repetition of self-harm vary between 5% and 25% per year:14,15 18% in
a recent UK multicentre monitoring study of > 5000 adolescents16 and as high as 27% over an average
of 5 years’ follow-up of around 4000 adolescents.13 In addition, actual rates may be much higher when
repetition that does not come to clinical or medical attention is considered.17 The risk of repetition persists
for many years after an episode9,18 and is associated with self-cutting (rather than overdose), depression,
reports of childhood sexual abuse and exposure to models of self-harm.2
What is the aetiology?
Self-harm behaviour results from the convergence of a range of biopsychosocial risk factors across a
number of domains, including genetic, biological, social, environmental and demographic factors,
personality and cognitive styles and psychiatric morbidity.19 Several reviews synthesise the full range of risk
factors in adolescents.2,14,20,21
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Family factors are also important.11,22–24 Difficulties in parent–child relationships, including those related to
early attachment problems, and perceived low levels of parental caring and communication are related to
increased risk of suicide and self-harm among children and adolescents.25 Exposure to sexual and physical
abuse is an important risk factor.25 Families are not always aware of, or do not have the capacity to
respond to, the suicidal behaviour of their offspring,26,27 particularly families in which there are low levels of
social support. Parent reactions to self-harm include a range of strong and often negative emotions.28
Depression is the most common psychiatric diagnosis associated with suicide in adolescents29–31 and with
non-fatal self-harm,20 and hopelessness is an important mediating variable between depression and
self-harm.32 Depression is also a key factor associated with repetition of self-harm in adolescents33 and may
also moderate responsiveness to treatment.34
Parental mental illness and substance abuse are significant risk factors,14 and a family history of self-harm is
associated with increased risk of suicide deaths30,35–37 and non-fatal self-harm by adolescents.5,30 However,
although suicidal behaviour runs in families, this risk is over and above the heritability of mental illness
between generations.38–40
Young people who self-harm experience higher rates of exposure to recent stressful life events such as
rejection, conflict or loss following the break-up of a relationship, conflicts and disciplinary or legal crises,5
and a strong association exists between adolescent self-harm and both childhood sexual abuse and
physical abuse.41
What might we do to prevent self-harm?
An overall model of suicide behaviour provides a framework to support research studies in addition to
formulations and treatment planning by clinicians. There is a long history of psychological and psychosocial
models of suicidal behaviour such as Durkheim, Shneidman and, more recently, Beck, although these focus
mainly on adults. Two relevant exceptions are Beautrais19 and Bridge et al.,14 who take a more developmental
approach and are pertinent to the Self-Harm Intervention: Family Therapy (SHIFT) trial. Beautrais19 posits
that suicidal behaviours are the end point of adverse life events in which multiple risk factors combine to
encourage their development. This approach represents a stress–diathesis model (for a review, see van
Heeringen42), which suggests that temperamental and genetic factors and early experiences may make some
young people particularly vulnerable to subsequent internal or external stressors. Bridge et al.14 also proposed
a developmental transactional model of behaviour, which recognises that most factors associated with
suicidal behaviour among children and adolescents are familial. Levers for prevention include positive
parent–child connections, active parental supervision and high behavioural expectations.
Building on this and the evidence described above, we suggest that the focus of family-orientated
treatment with young people who have self-harmed should be on maximising cohesion, attachment,
adaptability, family support and parental warmth, while reducing maltreatment and scapegoating and
moderating parental control.28
However, there is limited evidence for the effectiveness of any clinical interventions for young people who
engage in self-harm, with a failure to demonstrate any effect on reducing repetition of self-harm among
adolescents receiving a range of treatment approaches, including therapeutic assessments and compliance
enhancement in hospitals, involvement of youth-nominated support teams, tokens for hospital admission
and home- and family-focused interventions.21,43–45 Two recent studies have suggested that dialectical
behaviour therapy46 and mentalisation-based treatment47 may be effective in reducing self-harm. Both had
small numbers of participants, shorter follow-up periods than this study and relied on self-report as the
primary outcome measure.
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Brent et al.48 concluded that interventions that activated family support or addressed motivations for
change were quickly mobilised (to reflect the elevated risk of repetition immediately post episode) and
promoted positive affect are the most likely to be able to demonstrate effectiveness. The reviewers also
commented that the heterogeneity of treatment as usual (TAU) and the lack of its characterisation, in
addition to the many underpowered studies, have held back advances in this field.48
Ougrin et al.49 reviewed 19 studies describing interventions to reduce self-harm in adolescents. They
calculated pooled risk differences using the outcome of the proportion of young people who self-harmed
at least once in the follow-up period of each study versus those who did not self-harm at all. Overall, the
proportion of participants who self-harmed was slightly (but statistically significantly) lower in those allocated
to treatment interventions. However, the authors acknowledge that the quality of studies examined was poor
and that ‘more research and replication of the positive findings by independent groups are urgently required’.
The limited evidence that we have suggests that properly powered studies involving the family in
treatment, and focusing treatment on both child and parent skills, characterises successful treatment
approaches in this area.50,51
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Chapter 2 Trial design and methods
Trial design
The trial was a pragmatic, Phase III, multicentre, individually randomised controlled trial of family therapy
(FT) compared with TAU in 832 adolescents aged 11–17 years who had engaged in previous episodes of
self-harm on at least two occasions and where a recent self-harm episode was a key characteristic of the
reason for Child and Adolescent Mental Health Services (CAMHS) contact.
The primary outcome was attendance at hospital following self-harm at 18 months post randomisation.
The design and outcomes were influenced by the fact that this project was funded following a
commissioned call for research (see Appendix 1).
Objectives and outcome measures
The primary objective was to assess the effectiveness of FT compared with TAU as measured by young
people’s rates of repetition of self-harm leading to hospital attendance 18 months after randomisation.
This outcome was selected following discussion with clinical colleagues and our review of the literature.
The following issues were considered:
l high loss to follow-up in other self-harm intervention studies
l clinical reports that young people were not always regular attenders following self-harm
l wide fluctuations in rates of self-harm, with some young people engaging in self-harm many times per
day, complicating outcome measurement in other studies
l high rates of self-harm in young people who do not present to hospital but who are difficult to identify
and follow up.
We prioritised an outcome that could be operationally defined and measured even if participants were
difficult to follow up. This gave us the potential to assist in answering the clinical question ‘what is the most
effective course of action when a young person presents to CAMHS following self-harm’. The implications
of this decision are discussed further in the results (see Chapters 3 and 4) and discussion (see Chapter 5).
Secondary objectives were to assess:
l the effectiveness of FT compared with TAU as measured by repetition rates of self-harm leading to
hospital attendance at 12 months after randomisation
l the characteristics of all further episodes of self-harm leading to hospital attendance
l the cost per self-harm event avoided as a result of FT, measured using a structured, trial-specific health
economics questionnaire
l the characteristics of all further episodes of self-harm (not just those resulting in hospital attendance).
This included the number of subsequent self-harm events, time to next event, severity of event (fatal,
near fatal or not) and dangerousness of method used, as measured by the Suicide Attempt Self-Injury
Interview (SASII)52
l suicidal ideation, measured by the Beck Scale for Suicide Ideation (BSS)53
l quality of life, measured by the Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire
(PQ-LES-Q)54 and parental completion of the General Health Questionnaire, 12 questions (GHQ-12)55
l depression, measured by the Children’s Depression Rating Scale – Revised (CDRS-R)56
DOI: 10.3310/hta22120 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 12
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Cottrell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5
l overall mental health and emotional and behavioural difficulties via young person and parental
completion of the Strengths and Difficulties Questionnaire (SDQ)57
l hopelessness, via completion of the Hopelessness Scale for Children58
l family functioning, measured by the McMaster Family Assessment Device (FAD)59 and the
Family Questionnaire60
l mediator and moderator variables that influence engagement with and benefit from treatment
(e.g. number of sessions, medication use, referrals)
l therapeutic alliance to FT, via family therapist, young person and parental completion of the System for
Observing Family Therapy Alliances (SOFTA)61
l therapist adherence to the FT manual.
Participants and setting
Participants were young people who met the eligibility criteria detailed below. In addition, for each young
person a primary caregiver was identified who was willing to be involved in the research to provide
outcome measures.
Young people and their caregivers were identified from NHS CAMHS across three ‘hubs’ in England: Greater
Manchester, London and Yorkshire. Young people were screened for trial suitability and approached, if
eligible, at their first visit to CAMHS following self-harm. To be included in the trial, young people were
required to meet the following eligibility criteria and subsequently provide written informed consent,
together with their primary caregiver.
Inclusion criteria
1. Aged 11–17 years.
2. Self-harmed prior to assessment by the CAMHS team.
3. Engaged in at least one previous episode of self-harm prior to the index presentation.
4. Assessed in hospital following current episode, or referred directly to CAMHS from primary care with
recent self-harm as a key feature of presentation.
5. When the presenting episode was because of alcohol or recreational drugs, the young person had
explicitly stated that he or she was intending self-harm by use of these substances.
6. The clinical intention was to offer CAMHS follow-up for self-harm.
7. Lived with primary caregiver.
Exclusion criteria
1. At serious risk of suicide (clinical judgement) and so requiring more than TAU.
2. An ongoing child protection investigation within the family, which would have made treatment
difficult to deliver.
3. Would ordinarily have been treated not in generic CAMHS but rather by a specific service, and so
would not normally have received TAU.
4. Pregnant at time of trial entry and thus likely to have to interrupt treatment in either arm.
5. Actively being treated in CAMHS (as the possibility of randomisation might disrupt ongoing therapy).
6. In a children’s home or short-term foster placement and so no continuity of treatment possible in either arm.
7. Moderate to severe learning disability or lacked capacity to comply with trial requirements.
8. Involved in another research project – at the time of trial entry or within the last 6 months so as not to
overburden participants and to avoid possibility of conflicting requirements across two studies.
9. Sibling had been randomised to the SHIFT trial or was receiving FT within CAMHS. As the intervention
studied is a family intervention, if a sibling was already in the trial, randomisation would not have
been possible.
10. The young person and one main caregiver had insufficient proficiency in English to contribute to the
data collection.
TRIAL DESIGN AND METHODS
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Recruitment
All young people presenting via hospital or from primary care to participating CAMHS following a recent
episode of self-harm were screened by CAMHS clinicians. When a young person met the criteria, the
assessing CAMHS clinician discussed trial participation at the assessment appointment, passed on the
participant information sheets and requested consent (written ideally, but verbal was allowed) for
subsequent contact by a researcher. Those providing such consent were contacted by the researcher, who
arranged to visit the family at home, discussed the trial in detail, obtained consent for participation and
administered the baseline assessment.
Randomisation and blinding
Following consent and baseline assessment, researchers randomised participants sequentially via an
automated system at the Clinical Trials Research Unit (CTRU) at the University of Leeds. Participants were
randomly allocated on a 1 : 1 basis to receive FT or TAU through the use of a computer-generated
minimisation program incorporating a random element. The stratification factors were centre (CAMHS team),
gender, age (11–14 years/15–17 years), living arrangements (with parents or guardians/foster care), number
of previous self-harm episodes including index event (2/≥ 3) and type of index episode (self-poisoning,
self-injury, combined). When therapists were not aligned to a specific service but covered a number of
services, additional randomisation of the lead therapist took place within the FT team in order to minimise
case selection bias. This occurred across the whole Manchester hub, in two sites in Yorkshire and in two sites
in London.
The participants and therapists were, of necessity, aware of treatment allocation, but the researchers were
blind to allocation to allow the unbiased collection of follow-up data. The CTRU was responsible for
informing CAMHS clinicians and family therapists of randomisation outcome in order to maintain researcher
blinding. Clinicians and family therapists informed families of their allocation and arranged subsequent
appointments for treatment in CAMHS.
Interventions
Both therapeutic interventions were delivered within CAMHS, and all participants were treated within their
local service. Family therapists were formally linked with specific CAMHS teams to ensure clear lines of
clinical responsibility, and clinicians in both trial arms had access to local child and adolescent psychiatrists
if medication or hospitalisation needed to be considered.
Family therapy
The FT intervention was based on a modified version of the Leeds Family Therapy & Research Centre
Systemic FT Manual, the development and validation of which was funded by the Medical Research
Council to support trials of FT.62 This manual was updated by the FT expert members from the Trial
Management Group (TMG) to ensure that it was appropriate for work with families following self-harm.
The SHIFT FT Manual can be requested from the trial team via http://medhealth.leeds.ac.uk/SHIFTManual.
Our systemic orientation to self-harm assumes that there is an interplay between a number of factors that
can lead to the development of individual difficulties and problems such as self-harm. However, rather
than focus on the causal explanation of individual problems, systemic FT is concerned with the way in
which these problems will have become embedded in the matrix of family and wider social relationships,
the felt experiences and the meanings and narratives that have become attached to and that shape these
difficulties.63 Looking for a causal account in the individual case is seen as unhelpful, partly because it
inevitably oversimplifies the complexity of the individual aetiological pathway and partly because it tends to
reinforce disabling, blaming narratives.64
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Self-harm in an individual case will, in part, have been a response and have meaning in relation to particular
issues (e.g. problems in emotional regulation, sense of hopelessness, low self-esteem, developmental and
life-cycle issues, school and peer issues, attachment difficulties, relationship problems, parental situations
or problems in family communication), but it also highlights that, for some reason, alternative, more
constructive solutions were unavailable. The self-harming response will have been influenced by and in turn
will influence subsequent patterns of interaction and will give new meaning to them.65 It becomes a means
of communicating and constrains alternative responses. By considering these behavioural and linguistic
patterns in greater detail, facilitating understanding and noticing and supporting alternatives that encourage
more positive narratives to emerge, the therapist can help the client and family create a different response
pattern to the issues that showed themselves in self-harm.
Family therapists [those eligible for registration with the UK Council for Psychotherapy (UKCP)] were
appointed specifically to work on the trial, following the formal advertisement of a clear job description
and subsequent interview. All were qualified systemic family therapists who had trained in the UK to the
level of a master’s degree, which included 2 years of supervised practice. The therapists had a primary
professional mental health background and qualification (generally social work or nursing), and most of
them had experience in CAMHS and post-qualification experience in FT practice.
The therapists joining SHIFT at the outset attended a 2-day group training event prior to the start of the
trial and then 1-day training events annually thereafter. The authors of the manual provided the training,
which included review and discussion of the manual, reflections on their own experiences with/as young
people, their relationship to clinical risk and team building. Additional material on adolescent self-harm
was presented by a specialist on the trial. Role play and experiential exercises were included. Each family
therapist worked with a pilot case (CAMHS non-trial case) with supervision. After each therapist had
completed a number of sessions, they were deemed ready to commence with trial participants. The
orientation of replacement family therapists for departing original trial therapists involved one-to-one
training with one of the trial’s senior family therapists, a period of observation of the remaining team
members’ therapy and a one-to-one session with the supervisor to review the material.
Family therapists worked in teams of three or four and provided trial FT as a team for a cluster of CAMHS.
Within each team, each family therapist would be the lead for a subset of participants (the other family
therapists in the team would act as observers and make only a small face-to-face contribution for
those participants).
Monthly group supervision of 2 hours was provided for each team by senior family therapists (two of
whom were authors of the treatment manual). Supervision included discussion of cases, adherence to the
manual, broader trial issues and team dynamics. Generally, the focus of the supervision was determined by
the family therapists at each meeting.
Young people and their families were offered FT sessions of approximately 1.25 hours’ duration each,
delivered over 6 months at approximately monthly intervals, but with more frequent initial appointments.
This equated to approximately eight sessions, but there was the expectation that some participants would
receive fewer sessions because of dropout or mutually agreed termination of treatment. Equally, it was
anticipated that some participants might receive more sessions if this was deemed clinically appropriate.
Wherever possible, and when consent was provided, the sessions were video-recorded, as this is part of
good FT practice and facilitates supervision.
Originally, it had been intended that supervision would include a review of recordings of current cases.
This proved difficult for technical reasons and so most supervision was based on therapist presentation.
The adherence measure was developed at a later stage in the trial and applied retrospectively.
TRIAL DESIGN AND METHODS
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A selection of video-recorded sessions was centrally reviewed, whereby the first and a subsequent therapy
session were reviewed for each therapist to monitor their adherence to the manual and to allow the
reporting of this. Adherence was assessed through use of a tool developed specifically for the trial.66
In addition, administrative processes that were required in the manual were also monitored, for example
number of sessions offered and attended and whether or not formulation letters (summarising the
therapist’s understanding of the family situation) were sent to families following attendance at their
second therapy session, as expected in the manual.
Treatment as usual
Treatment as usual was the care offered by local CAMHS teams to young people referred following self-harm.
It was expected that this treatment would be diverse and involve individual and/or family-orientated work,
delivered by a range of practitioners with various theoretical orientations. As SHIFT was a pragmatic trial
involving a number of collaborating CAMHS teams, it was not deemed possible or appropriate to specify TAU,
although it was expected that CAMHS practitioners would be working in line with best practice as set out
in several National Institute for Health and Care Excellence (NICE) guidelines (e.g. guidance on self-harm
and depression in childhood).67,68 Generic TAU was not delivered to the FT group as part of their clinical
intervention, unless specific additional assessment or treatment was indicated during or after FT, for example
referral for formal mental state assessment or for medication.
Contamination
The possibility of cross-arm contamination was considered during the design stage of the trial, with the
following points mandated whenever possible and monitoring processes implemented:
l Different teams of therapists delivered the two interventions in each CAMHS site and SHIFT family
therapists were prohibited from treating participants in the TAU arm for the duration of the trial. There
were processes in place to record contamination if this occurred.
l Owing to the nature of appointment scheduling and the fact that this was family-specific therapy
(i.e. not a group intervention), there was little opportunity for participants to meet and discuss
treatment, so contamination at the participant level was very unlikely.
l Any family-orientated clinical interventions in the TAU group were likely to be different from the trial
FT intervention, which required adherence to the Leeds Family Therapy & Research Centre manual,
fully-trained family therapists eligible for UKCP registration, therapy delivered in a team context and
regular supervision. Thus, use of family interventions in the TAU arm was not prohibited, but details of
all treatment received by participants in both arms were recorded.
Assessments and data collection
All required data, assessment tools, collection time points and processes are summarised in Table 1.
Screening
Data were recorded anonymously for young people who did not meet the eligibility criteria, and for those
who were eligible but not willing to provide consent, in order to monitor trial uptake and representativeness
of the trial population. Screening data for randomised participants were linked to the main trial data, and
also provided details of the outline ‘index’ event that had prompted their referral to CAMHS and eligibility
for the trial. Screening data, eligibility and consent for researcher contact were assessed and recorded by the
screening clinician. During the baseline visit, the researcher confirmed the participant’s eligibility, obtained
and recorded consent for trial participation, and obtained further details, including current physical and
mental health comorbidities, psychotropic medications and history of abuse.
Participant assessments and follow-up
At the baseline assessment the researcher administered questionnaires to the young person, and self-reported
questionnaires were also completed by the young person and caregiver.
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TABLE 1 Data collection schedule
Assessment (including who is involved)
Timeline (months post randomisation)
Baseline 3 6 12 18
Eligibility and consent
Eligibility (assessed by clinician) ✗
Consent (young person, P, R) ✗
Background and demographics (young person, P, R – interview and case notes)
Personal details ✗
Outline ‘index’ event details ✗
Current comorbid physical/mental health ✗
Current psychotropic medications ✗
History of abuse ✗
Follow-up data (collected from case notes)
Therapy details (provided by therapist) ✗ ✗
Therapist supervision details (provided by
therapist/supervisor)
✗ ✗
Details of further self-harm episodes since consent (R) ✗ ✗
Psychotropic medication details (R) ✗ ✗
Referrals to other MH services (R) ✗ ✗
Re-referral to CAMHS (R) ✗ ✗
Admissions to hospital relating to mental health (R) ✗ ✗
All-cause mortality (NHS Digital) ✗
SAE reporting and hospital attendance (R and NHS
Digital)
Ongoing collection
Questionnaires (completed at researcher visit unless otherwise stated)
Family Questionnaire (P self-report, CTRU postal
administration at 3 and 6 months)
✗ ✗ ✗
SOFTA (completed by the family therapist and
participants at FT session 3)
✗
SASII (interview with young person) ✗ ✗ ✗
BSS (young person self-report) ✗ ✗ ✗
Hopelessness Scale for Children (young person
self-report)
✗ ✗ ✗
McMaster FAD (young person and P self-report) ✗ ✗ ✗
GHQ-12 (P self-report) ✗ ✗ ✗
SDQ (young person and P self-report) ✗ ✗ ✗
CDRS-R (Interview with young person) ✗ ✗ ✗
PQ-LES-Q (young person self-report) ✗ ✗ ✗
ICU (young person self-report) ✗
TRIAL DESIGN AND METHODS
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Postal questionnaires were administered by CTRU at 3 and 6 months post randomisation. These were
preceded by a telephone call from researchers, when it was possible to make contact. If questionnaires
were not returned, postal reminders were sent 2 weeks after the initial mailing and then again a further
2 weeks later.
Further follow-up to administer questionnaires took place at 12 and 18 months following randomisation
via face-to-face researcher interviews. When it was not possible to arrange face-to-face interviews and
when participants agreed, self-reported questionnaires were posted to participants for completion.
The offer of incentives to young people for participating in the 12- and 18-month follow-up interviews
was introduced in August 2013 (see amendments in Appendix 2) in an effort to improve compliance.
Clinical follow-up
The primary outcome measure was obtained from accident and emergency (A&E) and inpatient Hospital
Episode Statistics (HES) data downloads from NHS Digital. This method of primary outcome data collection
was augmented by directed hospital record searches, which were undertaken by researchers at frequent
intervals throughout the trial. Researchers searched acute trust records for further details of all attendances
that were unclear from the central HES data (i.e. where self-harm relatedness or method of self-harm
could not be determined from HES data alone) and for any hospital attendances for those participants who
had not consented to data sharing with NHS Digital or could not be linked to HES. Given that HES data
sets are England-wide, this maximised the collection of hospital attendance data, allowing for participants
moving out of the catchment area (within England). The collection of these routine data also minimised
bias by eliminating the possibility of preferential researcher data collection at certain acute trusts. Further
details of the comparison of HES records and researcher-collected hospital records and the success of using
HES data for the trial will be published separately.
Data relating to treatment received in CAMHS following trial entry were provided by the treating CAMHS
clinicians or family therapists, by clinical studies officers (CSOs) employed by the Research Networks in each
locality and by the researchers when blinding was no longer required (i.e. after participant-reported follow-up
data had been collected). Data included initial session attendance (FT and TAU), therapeutic approach (for
TAU), referrals within CAMHS for additional or alternative sessions, requirements for psychotropic medications,
liaison and referrals to other agencies outside CAMHS and re-referral to CAMHS following discharge. In
addition, treating clinicians and participants completed the SOFTA44 at the end of the third treatment session.
Supervision sessions for family therapists and routinely provided clinical supervision for CAMHS clinicians were
also recorded. Details of the scoring of questionnaires are in Appendix 3. These appendices provide further
detail concerning the collection of clinical follow-up data.
TABLE 1 Data collection schedule (continued )
Assessment (including who is involved)
Timeline (months post randomisation)
Baseline 3 6 12 18
EQ-5D (young person self-report, postal administration
at 6 months)
✗ ✗ ✗ ✗
HUI-3 (P self-report, postal administration at 6 months) ✗ ✗ ✗ ✗
Health Economics questionnaire (young person and P
self-report, postal administration at 3 and 6 months)
✗ ✗ ✗ ✗ ✗
EQ-5D, EuroQol-5 Dimensions; HUI-3, Health Utilities Index 3; ICU, Inventory of Callous-Unemotional Traits; P, parent/caregiver;
R, researcher; SAE, serious adverse event.
Adapted from Wright-Hughes et al.69 under the Creative Commons Attribution Licence 4.0 (CC BY 4.0; https://creativecommons.
org/licenses/by/4.0/); and Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license.
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Safety
Non-serious adverse events (AEs) were operationally defined in SHIFT as treatment on an emergency
outpatient basis and re-referral to CAMHS, as these events were expected to occur within the adolescent
study population. Deaths and hospital admissions were defined as serious adverse events (SAEs).
Adverse event data were obtained through researcher collection of data from CAMHS and acute trusts
and via data transfer from NHS Digital.
Assessment instruments
Assessment instruments were incorporated into participant assessment packs for both the young person
and their caregiver. The standardised questionnaires used were selected following our literature review
because they related to factors thought to be important secondary outcomes in their own right or possible
mediators or moderators of treatment effects. In selecting individual measures, we also tried to use those
measures that would enable comparisons with other studies in the field. In one case [the Inventory of
Callous–Unemotional Traits (ICU)] we were influenced by our knowledge of a large randomised controlled
trial about to commence at the same time as SHIFT with a similar age group that we wanted to be able to
compare with our sample. All measures were appropriate to the age range of young people and have
been widely used in a range of ethnic communities. Appendix 3 contains details of scoring.
Suicide Attempt Self-Injury Interview
The researcher completed the SASII52 during the interview with the young person. The SASII is designed
to assess the factors involved in non-fatal suicide attempts and intentional self-injury. It contains six
screening items, nine open-ended questions to provide information for interviewer coding, and 22 items
and associated subitems measuring timing and frequency of self-injurious acts, methods used and lethality
of the method, suicidal as well as non-suicidal intent associated with the episode, communication of
suicide intent before the episode, impulsivity and rescue likelihood, physical condition and level of medical
treatment. The SASII also collects a timeline of all self-reported self-harm with details of the timing,
methods and treatment received. At baseline the SASII focused on the index episode of self-harm and
provided a timeline over the preceding 12 months; at 12-month completion the focus was on the first
post-randomisation episode and the timeline since baseline; and, at 18 months, the focus was on the first
episode following the 12-month researcher visit and a timeline since the 12-month researcher visit.
Inventory of Callous–Unemotional Traits
The ICU71 was completed by the young person and by the caregiver in reference to the young person.
It is a 24-item questionnaire in which participants are asked to indicate how well each statement
describes them on a 4-point scale and is designed to provide a comprehensive assessment of callous and
unemotional traits, with three subscales: callousness, uncaring and unemotional. Higher scores represent
higher callous and unemotional traits. ICU measures are helpful in predicting different outcomes and
developmental pathways in children with conduct disorder.
Beck Scale for Suicide Ideation
The BSS53 was completed by the young person and is used to examine suicidal intent. The first 19 of
21 items measure the severity of actual suicidal wishes and plans, each on a 3-point scale, with a higher
score indicating a higher level of suicide ideation. The first five items also serve as a screen for suicide
ideation.
Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire
The PQ-LES-Q54 was completed by the young person and is used to examine quality of life. It consists of
15 items, each on a 5-point scale, providing a single overall score with higher total scores indicative of
greater enjoyment and satisfaction.
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Children’s Depression Rating Scale – Revised
The CDRS-R56 was completed by the researcher during the young person interview and is used to assess
the severity of depressive syndrome. It is a brief rating scale based on a semistructured interview rating
17 symptom areas on a 5- to 7-point scale, including impaired schoolwork, difficulty having fun, appetite
disturbance, excessive fatigue and low self-esteem. Higher scores are indicative of greater depression and
are categorised to indicate mild, moderate, severe and very severe depression.
Strengths and Difficulties Questionnaire
The SDQ57 was completed by the young person and the caregiver, giving their views of the young
person’s behaviours, and is a brief behavioural screening questionnaire assessing levels of emotional and
behavioural problems. Both young person and caregiver versions ask about 25 attributes, each with three
responses, across five scales: emotional symptoms, conduct problems, hyperactivity/inattention, peer
relationship problems and prosocial behaviour. A ‘Total difficulties’ score combines all scales except the
prosocial scale. ‘Externalising’ and ‘Internalising’ scores are also generated and an impact supplement is
included in the caregiver version, in which the respondent is asked whether or not they think the young
person has a problem, enquiring further about chronicity, distress, social impairment and burden to others.
Higher scores in all but the prosocial score represent greater issues in that category. For the prosocial
score, lower scores represent greater issues. Responses are also categorised according to a four-band
categorisation.
Hopelessness scale
The Hopelessness Scale58 was completed by the young person and is used to measure the degree to which
young people have negative expectancies about themselves and the future. It consists of 17 items with
true or false responses, providing a single overall score with higher scores reflecting greater hopelessness
or negative expectations towards the future.
McMaster Family Assessment Device
The McMaster FAD59 was completed by the young person and caregiver. It measures family functioning
across 60 items, each on a 4-point scale measuring agreement, based on the McMaster Model on six
different dimensions: problem-solving (ability to resolve problems), communication (exchange of clear and
direct verbal information), roles (division of responsibility for completing family tasks), affective responsiveness
(ability to respond with appropriate emotion), affective involvement (degree to which family members are
involved and interested in one another) and behaviour control (manner used to express and maintain
standards of behaviour); it also includes an independent dimension of general functioning (overall functioning
of family). Higher scores are indicative of poorer family functioning. Miller et al.72 documented clinical cut-off
scores differentiating ‘healthy’ versus ‘unhealthy’ family functioning for each dimension (see Appendix 3).
Family Questionnaire
The Family Questionnaire60 was completed by the consenting caregiver in reference to the young person
and is a brief 20-item self-report questionnaire relating to the different ways in which families try to cope
with everyday problems. It assesses expressed emotion directed at the young person by family members
with responses on a 4-point scale. In addition to the total score, it has two subscales: critical comments
(unfavourable statements about the personality or behaviour of the young person) and emotional
overinvolvement (overintrusiveness, protectiveness and identification). Higher scores indicate greater levels
of expressed emotion.
Parent General Health Questionnaire, 12 questions
The GHQ-1273 was completed by the caregiver and is a measure of current mental health focusing on
two major areas: the inability to carry out normal functions and the appearance of new and distressing
experiences. It includes 12 items, each on a 4-point scale to indicate whether or not symptoms of mental ill
health are present, with high total scores indicative of greater psychological distress.
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EuroQol-5 Dimensions
The EuroQoL-5 Dimensions (EQ-5D)74 was completed by the young person. The respondents are asked to
describe their levels of health problems using a descriptive system comprising five dimensions (mobility,
self-care, usual activities, pain/discomfort and anxiety/depression), each with three levels: no problems,
some problems, extreme problems. The combination of answers leads to a health profile of five digits
(243 unique health profiles) that can then be converted into a utility that represents the overall quality of
life of the young person. The EQ-5D utility score varies from 0 to 1, with 0.0 meaning death and 1.0
complete health. While the original protocol suggested the use of the Health Utilities Index 3 (HUI-3) to
measure the young person’s quality of life, we undertook a pilot study in a school setting and decided that
the EQ-5D was easier for young people to complete.75
Health Economics Questionnaire
The Health Economics Questionnaire was completed by the young person and the caregiver. The caregiver
reported health care use for the young person as well as for their own care. The questionnaire was designed
for use in the SHIFT trial to collect information on A&E attendances, inpatient/outpatient attendances,
primary/community care provided by the NHS/social services and medications. Data on personal costs were
also collected, such as out-of-pocket expenses and productivity costs to both young persons and caregivers
and any use of education and justice services. A reduced self-reported questionnaire was used within the
trial from the autumn of 2011; it excluded questions on A&E attendances, inpatient attendances as this was
obtained via data downloads from NHS Digital records and questions on private expenses and time off
work. The recall period was the past 3 months at every data collection point.
Health Utilities Index 3
The HUI-376 was completed by the caregiver and is widely used in population health surveys, clinical studies
and cost–utility analyses. The HUI3 is a health status classification system including eight attributes (vision,
hearing, speech, ambulation, dexterity, emotion, cognition and pain), each with five or six levels of ability/
disability. Answers are then scored using a multiattribute scoring function derived from community
preference measures for health states. The scoring systems provide a utility score on a generic scale where
dead = 0.00 and perfect health = 1.00.
System for Observing Family Therapy Alliances
The SOFTA61 was completed in clinic by the lead family therapist, young person and caregiver after the third
therapy session and is a self-reported questionnaire used to evaluate the strength of the therapeutic alliance
in FT. If the consenting primary caregiver was not present, it could be completed by another member of
the family, or during another therapy session. It includes 16 items, each on a 5-point scale, measuring
agreement for behaviours in four dimensions: engagement in the therapeutic process, emotional connection
with the therapist, safety within the therapeutic system and shared sense of purpose within the family.
Higher scores represent greater alliance.
Scoring and missing item data
When a questionnaire was received but questionnaire item data were missing (item non-response),
documented instructions for dealing with missing data were followed when these were available (EQ-5D,
SDQ, McMaster FAD77). Otherwise, in the absence of documented instructions, the half rule78 was used
(CDRS-R, BSS, PQ-LES-Q, Hopelessness Scale, Family Questionnaire, GHQ-12, ICU, SOFTA), allowing for
substitution of the mean of answered questions of specific subscales/totals provided that at least half the
questions on a given scale were answered. Further details of scoring and categorisation can be found in
Appendix 3.
Data quality and monitoring
Data were monitored for quality and completeness by the CTRU using established verification, validation
and checking processes. Missing data, except individual data items collected via the postal questionnaires,
were chased for until they were received or confirmed as not available or until the trial was at analysis.
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Protocol adherence, trial uptake, loss to follow-up, withdrawal, participant safety, data quality and data/
questionnaire return rates were monitored, as appropriate to each group, at each TMG, Trial Steering
Committee (TSC) [which included a patient and public involvement (PPI) member] and Data Monitoring
and Ethics Committee (DMEC) meeting.
The DMEC reviewed, on an annual basis and by trial arm, the number and frequency of hospitalisations
and deaths as a consequence of self-harm. Processes were in place to escalate any concerns raised by the
DMEC or to escalate concerns identified by the trial team to the DMEC in the interim periods between
meetings. The DMEC reviewed interim primary outcome data after half the events had occurred.
Quality assurance
The trial was conducted in accordance with current Medical Research Council good clinical practice guidelines,
the NHS Research Governance Framework and through adherence to CTRU standard operating procedures.
The trial was reviewed and approved by the National Research Ethics Service Committee (NRES) Yorkshire
and the Humber – Leeds West [Research Ethics Committee (REC) reference 09/H1307/20]. SHIFT also
received research and development approval from all participating CAMHS’ host organisations. For the
purposes of collecting routine data from acute trusts to inform the primary outcome, the REC agreed that
the study was exempt from site-specific assessment, but researchers required letters of access from each
trust to access records.
Protocol amendments
There were 11 substantial amendments to the protocol (see Appendix 2 for full details) throughout the
lifetime of the SHIFT trial. The methods detailed here cover all protocol amendments.
Three substantial amendments were made prior to the start of recruitment. These included clarification of
the eligibility criteria and of the secondary outcome measures to be used.
After recruitment commenced, eight further substantial amendments were made, some of which covered
more than one issue.
In brief, these included an amended process for obtaining consent for FT sessions to be video-recorded
(and confirmation of data transfer processes), clarification of eligibility criteria, randomisation of family
therapists (prior to the relevant teams commencing recruitment), augmenting follow-up processes
(additional researcher contact prior to postal follow-up, thank-you letters at 12 or 18 months where
questionnaires were returned by post), inclusion of verbal consent to researcher contact where written
consent was not possible, clarification of who is appropriate to take on the consenting caregiver role,
production of a FT leaflet for those allocated FT, sending Christmas cards to participants, collection of
multiple contacts at baseline to aid follow-up, introduction of participant incentives and participant
information amendments to confirm duration of follow-up.
Patient and public involvement contribution
A local young persons’ group in Leeds was consulted regarding the content of the participant information
sheets.
A PPI expert was a member of the TSC from the first meeting in 2010 to October 2012.
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Unsuccessful attempts were made to invite a young person and her primary caregiver to join the TSC.
Over the course of the trial there was further consultation with young people who work with the charity
Young Minds and with the National Institute for Health Research (NIHR)’s Young People’s Mental Health
Advisory Group.
Statistical methods
Sample size
The power calculation was based on a minimally important reduction in 18-month repetition rates of
self-harm (leading to hospital attendance) from 29% in participants receiving TAU6 to 18.8% in
participants receiving FT, that is, a reduction of 35%, providing a constant hazard ratio (HR) of 1.64.
Using a 5% significance level log-rank test for equality of survival curves, 374 participants per arm were
required, with 172 total events, to give 90%. Assuming, at most, 10% loss to follow-up by 18 months,
the total sample size required was 416 per arm, 832 in total.
Although SHIFT was individually randomised, the inherent clustering of participants nested within
therapists is known to have an impact on power and is related to the level of the intracluster correlation
coefficient (ICC) and the cluster size. It was expected that the level of clustering would be low, possibly
around 0.01 but no higher than 0.05 (owing to the use of therapy manuals, therapist selection, training,
supervision and monitoring). It was also expected that the number of participants per therapist would be
small. It was estimated that between 8 and 15 therapists would be available in the TAU team at any one
centre, so across the anticipated 15 participating trusts there would be 120–225 therapists available to
treat 416 participants; thus, each therapist would treat between two and four participants (maximum
cluster size of four). In FT, we estimated that there would be approximately 35 therapists available across
all sites to treat 416 participants; thus, each lead therapist would have direct contact with approximately
12 participants (maximum cluster size).
The design effect, describing the extent to which the sample size must be increased to obtain the same
power as an individually randomised study without clustering, was therefore assumed likely to be no
greater than 1.55 (ICC of 0.05), effectively reducing the sample size from 416 per group to 270 per group
and the power from 90% to around 75%. If the ICC were as low as 0.01, then the design effect would
be 1.11, reducing the sample size to 374 per group and the power to around 85%. We anticipated that
the ICC would be towards the lower end of the possible range and therefore the trial would still be
adequately powered with the sample size planned.
Participant populations
The intention-to-treat (ITT) population consisted of all randomised young people who had consented,
regardless of non-compliance with the intervention, whether they were found to be ineligible post
randomisation and/or remained in the trial and were analysed according to the treatment they were
randomised to receive.
The per-protocol population consisted of all randomised, consented young people, excluding those who
were found not to satisfy the eligibility criteria.
Statistical analysis
A single formal interim analysis was planned for the primary end point, repetition of self-harm leading to
hospital attendance within 18 months of randomisation, when at least half the required number of events
were reached (86 events). It was planned that the DMEC, in light of interim data, would if necessary report
to the TSC with a recommendation of trial adaptation or early closure if, compared with TAU, the effect
of FT was significantly inferior (p < 0.005). Final analyses were planned after all participants had reached the
end of the 18-month follow-up period, when it was expected that at least 172 events would have occurred.
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Analysis methods
All data analyses and summaries were performed using SAS version 9.4 (SAS institute, Cary, NC, USA),
and, unless otherwise specified, were conducted on the ITT population. An overall two-sided 5%
significance level was used for all end-point comparisons; however, for the primary end point, the O’Brien
and Fleming79 alpha spending function was used to account for the interim analysis, allowing an alpha
level of 0.047 for the final analysis and 0.005 for the interim analysis.
General calculations
Time from randomisation was calculated in days with estimates presented in months, where 1 month was
defined as time in days/30.44, and 18 months calculated as 528 days.
All clinical data included data up to 18 months post randomisation. Attendances and other clinical data,
that is, referrals, occurring post 18 months were excluded from the analysis as these data were not
collected reliably for all participants.
Covariates
All multivariable analyses were adjusted by the randomisation stratification factors age, gender, number
of previous self-harm episodes, type of self-harm (if there were errors during randomisation the true
value was used) and by participants’ recruiting trust and source of referral (through hospital or not).
The stratification factor ‘living arrangements’ was not included as a covariate as all but two young people
were living with parents/guardians. Adjustment was made for centre grouped at the trust level as, with
40 centres recruiting to SHIFT and between two and 58 participants recruited from each centre, an
adjusted analysis by centre could prove problematic because of instability and lack of convergence
(i.e. there could be some small centres where no events were observed).
Study summary, baseline characteristics, treatment and safety
Summaries of screening, accrual, protocol violators, withdrawals, participants’ follow-up rates and
unblinding were produced and an overall CONSORT diagram presented. All baseline characteristics of
participants, treatment received and safety data were summarised by treatment group and described
descriptively without statistical comparison.
Primary end-point analysis
Derivation
The timing of repeat self-harm was calculated from the date of randomisation to the date of hospital
attendance corresponding to the first instance of repeat self-harm within 18 months of randomisation.
Young people without any reported instances of repeat self-harm leading to hospital attendance were
censored at their final date of hospital follow-up or 18 months post randomisation, whichever was earlier.
Young people without follow-up (i.e. withdrawn prior to a hospital follow-up search) were censored
at baseline.
Timing of young people’s final hospital follow-up was based on the most recent data cut-off point for HES
data collected via NHS Digital and researchers’ Acute Trust searches. Follow-up dates based on researchers’
Acute Trust searches were calculated for each young person based on the hospital(s) most frequented for
participants recruited from the same CAMHS service. For the majority of young people, full 18-month
follow-up was achieved via successful linkage to HES, with HES data covering participants’ full follow-up
period; or, where HES linkage was not possible, via full researcher follow-up at the Acute Trusts to which
participants would most likely present. However, full 18-month hospital follow-up was not achieved for
participants for whom the final HES data download did not cover their full follow-up period (owing to HES
data being provided 3 months in arrears); HES linkage was not possible and researcher follow-up did
not cover participants’ full follow-up period; or where consent was withdrawn for further clinical data
collection and hospital follow-up was based on the HES data cut-off or researcher follow-up preceding
the withdrawal.
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Attendances at minor injury units (MIUs) and walk-in centres (WIC) identified via HES, without subsequent
A&E or inpatient attendance, did not fit the definition of the primary outcome and were excluded.
Attendances reported via both HES and the researcher were combined, in order to avoid double counting.
Where there was conflicting information, the more serious case was used, that is, admissions to hospital
were deemed more serious than attendance at A&E only, self-harm more serious than non-self-harm and,
if uncertain, HES data were used to ensure consistency.
Full details of data cleaning, derivation and use of HES data to identify attendances resulting from
self-harm will be published separately.
Missing data
Missing presenting (resulting from self-harm or not) details for hospital attendances reported in HES were
queried by trial researchers at relevant acute trusts. At the time of analysis, attendances with missing
details were reviewed by the chief investigator (blind to treatment allocation). Information was provided
on the length of hospital stay, diagnoses where available and treatment received and as a result it was
possible to further categorise 73 of all 915 hospital attendances (8%; A&E, MIU or WIC) as not being
self-harm related. Remaining unclassified attendances were assumed not to be related to self-harm in the
primary analysis.
Analysis
A multivariable Cox proportional hazards model, accounting for covariates, was used to test for differences
in 18-month repetition rates between treatment arms. The assumption of proportional hazards was assessed
by plotting the hazards over time (i.e. the log-cumulative hazard plot) and the methods of Lin et al.80 were
further used to check the adequacy of the model.
Kaplan–Meier curves were constructed for each group. Repetition estimates at each month post
randomisation with corresponding 95% confidence intervals (CIs) are also presented for each treatment
arm and for the difference between arms.
Although the significance level was reduced to account for an interim analysis, CIs are still presented at the
95% level.
Sensitivity analysis
The extent of clustering caused by therapists and the impact on the precision of the treatment effect
estimate was investigated using a multivariable multilevel survival frailty model,81,82 in which a common
frailty for individuals treated by the same therapist allows for heterogeneity between groups of participants
treated by different therapists and accounts for within-group correlations (using the RANDOM statement in
PROC PHREG).
Clustering by therapist was derived according to the ‘main’ therapist delivering the greatest number of
sessions for FT or TAU. Where an equal number of sessions were delivered by different therapists, the
main therapist was defined as the earliest of the therapists involved. Participants who received no
treatment, were missing treatment data or missing the name of their main therapist were classed as
belonging to their own individual cluster of size 1.
Missing presenting details A sensitivity analysis was also conducted to assess the impact of missing
details of hospital attendance (i.e. where it is unclear whether or not an attendance had resulted from
self-harm), in which unclassified attendances were classed as self-harm related, thus contributing to the
primary outcome.
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Associations with trust Given that the proportional hazard assumption was questionable for a number
of trusts, further multivariable Cox proportional hazards regression models were fitted to investigate the
effect on the treatment estimate without trust in the model and with hub, and associations between trust
and other covariates were explored. The primary analysis model was also fitted accounting for the shared
frailty by trust, therefore treating trust as a random effect rather than a fixed effect.
Secondary end-point analysis
Repetition rates of self-harm leading to hospital attendance 12 months after randomisation
The analysis of 12-month repetition rates followed that of the 18-month data detailed in the primary
end-point analysis, with events and follow-up curtailed at 12 months rather than 18 months.
Characteristics of further episodes of self-harm leading to hospital attendance
Further episodes of self-harm were analysed using a multivariable recurrent event analysis, incorporating the
timing and cumulative number of self-harm events. We used a counting process model83 with robust sandwich
variance estimator for standard errors (SEs) of coefficients84 to take account of the within-subject correlation
(also known as the proportional means model or the independent increment model). The counting process
model is an extension of the Cox regression model and, when unrestricted (as per the Andersen and Gill83
model), regards all subjects to be at risk of an event regardless of the number of events experienced thus far.
Sensitivity analysis further analysed recurrent events using the conditional, restricted gap time model of
Prentice et al.,85 which assumes that the occurrence of the first event increases the likelihood of further
recurrence and participants are considered to be at risk of an event only if the previous event occurred.
Characteristics of all self-harm events (SASII)
No formal statistical analysis was undertaken; characteristics are summarised descriptively only.
Derivation Characteristics of the first self-reported self-harm episode (regardless of hospital attendance)
were summarised for participants with sufficient SASII completion from baseline to 12 or 18 months, that is,
completion at the 12-month researcher visit at least or at both the 12- and 18-month visits. Furthermore,
participants with an 18-month researcher visit only (not a 12-month visit) with self-harm reported between
12 and 18 months post randomisation were included in the overall number of participants with self-harm
reported, as these instances of self-harm during follow-up were known.
The timing of first self-reported self-harm post baseline was calculated from the date of randomisation
to the first reported date of self-harm within 18 months of randomisation. Participants without any
self-reported self-harm and with sufficient SASII completion were censored at their date of follow-up, that
is, the date of either the 12-month researcher visit or the 18-month visit if both 12- and 18-month visits
were conducted. Participants missing the 12-month SASII were censored at baseline, including those
where self-harm was known to have occurred between 12 and 18 months as the timing of the first
self-harm post randomisation could not be determined.
Owing to the large variability in the level of self-reported self-harm over the SASII timeline, responses were
summarised according to the occurrence and frequency of self-harm for each 3-month period post
randomisation (0–3 months, 3–6 months, etc.) with frequency categorised as none (0 episodes), less than
once per month (fewer than three episodes), less than once per fortnight (3–6 episodes), less than once per
week (7–12 episodes), once or more per week (13–25 episodes), twice or more per week (26–45 episodes),
most days (46–91 episodes).
Patient-reported outcomes
For the secondary end points (Beck Scale, CDRS-R, PQ-LES-Q, SDQ, GHQ-12, Hopelessness Scale,
McMaster FAD and Family Questionnaire) repeated-measures models were used to estimate differences
between the treatment groups over time. Linear repeated-measures models for continuous scores were
used for all end points with the exception of the Beck Scale, for which the proportion of participants
identified as having suicide ideation was modelled using a logistic repeated-measures model owing to a
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zero-inflated total score. A covariance pattern model was used, which accounts for repeated measures on
the same participant, which may be correlated, with a first-order heterogeneous autoregressive covariance
matrix and allowing for randomised treatment, time effects, baseline score, covariates and treatment–time
interactions as fixed effects. This model was chosen over a random-effects model, as there were just two
follow-up time points at 12 and 18 months (3 and 6 months for the Family Questionnaire), with only a
small proportion (< 3%) of questionnaires completed outside the 2-month acceptable time window.
Model assumptions were checked using Pearson and Studentised residuals.
Responder characteristics were summarised by trial arm to explore whether or not differential patterns
existed that could impact on the conclusions for the secondary outcomes; characteristics explored included
self-harm during follow-up, covariates, age, questionnaire total scores and questionnaire subscales, for
subscales for which significant (p < 0.05) treatment effects were detected at 12 or 18 months. Logistic
regression modelling was used to assess participants’ response status against participant characteristics
and treatment.
Missing data To allow the ITT population to be used, missing questionnaire data were assumed to be
missing at random and missing scores were estimated using multiple imputations for all participants.
Multiple imputation uses the distribution of the observed data to estimate a set of plausible values for the
missing data. The multivariate normal model via the MCMC (Markov Chain Monte Carlo) method was used
to impute missing values for each of the questionnaire scores, allowing for the imputation of normally
distributed data with a non-monotone missing pattern.86 Missing values for each score were imputed
separately and the following predictor variables were incorporated in the model: covariates, randomised
treatment and participants’ scores at all available assessments (i.e. baseline, 6 and 12 months). The
imputation process was repeated according to the percentage of missing data. If 20% were missing, then
20 imputations were made, with a minimum of 10 imputations. Results reported were calculated using
Rubin’s rules87 for combining the results of identical analyses performed on each of the imputed data sets.
A sensitivity analysis based on an alternative modelling strategy, also assuming that data are missing at
random, using data observed for at least one follow-up time point, was also conducted. In this case, as
baseline score was a covariate in the model, participants’ missing baseline scores were imputed by the mean
across observed baseline values.88
Predictive and process measures
Moderator analysis
Moderator analysis explored whether or not the treatment effect in the primary analysis Cox proportional
hazards model depended upon participants’ baseline characteristics via inclusion of the proposed moderator
alongside the interaction effect of treatment × moderator in the primary analysis model (including covariates).
Covariates and responses to all baseline questionnaires were explored for moderation. Questionnaire
responses were also categorised for the young person Beck Scale to indicate whether or not suicidal ideation
was present; the young person CDRS-R for whether or not depression was present; and the young person
and caregiver McMaster FAD subscales to indicate whether family functioning was healthy or unhealthy.
A 5% significance level was used to identify moderation through the interaction of the potential moderator
with treatment, irrespective of the main effect of the potential moderator, although it is acknowledged that
interaction testing is not a powerful test for moderation. Analysis was of the ITT population to availability of
data (complete case) for each proposed moderator.
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Mediator analysis
Complier average causal effect analysis A complier average causal effect (CACE) analysis was conducted
to model the causal effect of FT receipt (as opposed to randomisation) on the primary outcome (Figure 1).
An instrumental variable model was used to adjust for potential selection bias occurring because of participants
who did not receive their allocated treatment, while addressing potential confounds. Randomisation allocation
was used as the instrumental variable, creating additional variance unaccounted for by FT receipt alone to
obtain an unbiased estimate of the effect of FT receipt, in a two-stage instrumental variable analysis using
the qualitative and limited dependent model (QLIM) procedure in SAS,89 to simultaneously estimate the first
equation of treatment selection (stage 1) and the second equation of the unbiased effect of treatment on
outcome (stage 2). Covariates were included in each stage of the model. The primary outcome was considered
as a binary variable and a probit transformation was used. The primary ITT analysis was repeated on this
transformed scale for comparison with the CACE estimates, alongside a further ‘as treated’ analysis (using the
QLIM procedure). TAU participants with missing treatment data were assumed to have not received FT in the
analysis. Kaplan–Meier curves were also constructed for each group by receipt of FT and receipt of FT overall.
Mediation Process variables identified as potential mediators included the overall number of sessions
attended, the use of psychotropic medications and therapist characteristics.
Responses to the 3- and 6-month Family Questionnaire (subscores) and 12-month questionnaires
(total scores and subscales found to have a significant treatment effect at 12 months in the secondary
end-point analysis or moderator analysis) were also explored for mediation. For questionnaire responses,
mediation was explored in relation to the time to event, self-harm resulting in hospital attendance, after
measurement of the potential mediator. Therefore, events after 3, 6 and 12 months post randomisation
were included for 3-, 6- and 12-month questionnaires, respectively. Responses at 18 months were not
considered in the analysis, as outcomes were collected up to 18 months only and responses could not
mediate an outcome observed before this date.
The Baron and Kenny90 steps were employed to explore mediation (Figure 2):
l Step 1 – establish an effect of randomisation on outcome that may be mediated, that is, Cox
regression with Y as the dependent variable and X as predictor, estimate and test path c the
total effect:
Y = h0(t)exp (β10X ). (1)
l Step 2 – establish that there is an effect of randomisation on the mediator, that is, linear or logistic
regression with M as the dependent variable and X as predictor, estimate and test path a:
Me = β20 + β21X . (2)
Observable risk factors
(covariates)
Instrumental
variable
(randomisation)
FT
receipt
Outcome
(self-harm)
Stage 1 Stage 2
FIGURE 1 Schematic representation of CACE analysis.
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l Step 3 – establish that there is an effect of mediator on outcome while controlling for randomisation,
that is, Cox regression with Y as the dependent variable and X and M as predictors, estimate and test
paths b and c’:
Y = h0(t)exp (β31X + β32Me). (3)
Following these steps, complete mediation is the case in which variable X (randomisation) no longer affects
Y (time to self-harm) after M (mediator) has been controlled and so path c’ is zero. Partial mediation is the
case in which the path from X (randomisation) to Y (time to self-harm) is reduced in absolute size but is
still different from zero when the mediator is introduced.
Steps 1 and 3 were fitted using a Cox proportional hazards model adjusted for all covariates. For
continuous mediators, Step 2 was fitted using a linear regression model containing randomised treatment
and all covariates; and for binary outcomes (Beck suicide ideation, psychotropic medications, therapist
characteristics) logistic regression was used containing randomised treatment and all covariates apart from
NHS trust (owing to lack of convergence). For mediators based on questionnaire responses, the baseline
score was also included as a covariate in each step.
Adherence and alliance to family therapy
Summaries of therapist baseline characteristics, training, therapy session recordings, initial and specialist
adherence review, formulation letters to families and therapist supervision were produced. In addition,
mean scores and 95% CIs are presented for the total score and for each subscale of the SOFTA.
Economic methods
The economic evaluation aimed to assess the cost-effectiveness of FT compared with TAU in the
management of self-harm in adolescents from a health and social care costs perspective. It consisted
of a within-trial analysis, in which cost-effectiveness was assessed within the 18-month trial period and
a decision-analytic model in which cost-effectiveness was assessed by extrapolating the trial results to a
longer time horizon.
Outcomes
Young people’s health-related quality of life was assessed using the EQ-5D,91,92 which was included at
baseline and along with the young person’s resource use questionnaire at 6, 12 and 18 months. Changes
in EQ-5D scores across time points were evaluated using two-sample t-tests to explore any important
differences in these end points within the time frame of the trial. These tests are useful in understanding
the impact of the length to follow-up on the health outcome measures, as insufficiently long follow-up
periods may introduce biases in the subsequent cost-effectiveness analysis. In line with the NICE reference
case93 the primary outcome for the economic evaluation was quality-adjusted life-years (QALYs). Young
Mediator (M)
Step 1 – c’
Step 3 – c’
Step 3 – bStep 2 – a
Time to self-harm (Y)Randomisation (X)
Randomisation (X) Time to self-harm (Y)
FIGURE 2 Baron and Kenny mediation model.
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people’s responses to the EQ-5D were converted into health state utility values and multiplied by the
proportion of 1 year the time period represented (baseline to 6 months = 0.5; 6 to 12 months = 0.5; 12 to
18 months = 0.5) to calculate QALYs.94 Average QALYs between adjacent time points were calculated to
generate smoothed estimates between time points. Therefore, QALYs were calculated using the area
under the curve approach as shown below:
QALYyoung person = f½(EQ5D Baseline + EQ5D 6month)/2 × 0:5g + f½(EQ5D 6month
+ EQ5D 12month/2 × 0:5g + f½(EQ5D 12month + EQ5D 18month/2 × 0:5g.
(4)
Quality-adjusted life-years represent a quality-of-life-weighted survival value in which 1 QALY is equivalent
to 1 year of full health.
The number of self-harm events avoided at 18 months was considered as a secondary outcome.
Additionally, the sensitivity analysis used the aggregated QALY gain for both the young person and his/her
main carer as the health outcome. The caregiver’s health-related quality of life was assessed using the
HUI,95,96 which was included along with the carer resource use questionnaire. The carer’s responses to the
HUI were converted into health state utility values76 and the carer’s QALYs were calculated in a similar way
to the young person’s QALYs.
QALYcaregiver = f½(HUI Baseline + HUI 6month)/2 × 0:5g + f½(HUI 6month + HUI 12month)/2 × 0:5g
+ f½(HUI 12month + HUI 18month)/2 × 0:5g.
(5)
Resource use
Resource use data were collected at baseline and at 3, 6, 12 and 18 months from the young person and
from his/her main carer. Resource usage was converted into costs using unit cost figures from the British
National Formulary (BNF), Personal Social Services Research Unit (PSSRU) and the Department of Health’s
National Schedule of Reference Costs.97–99 The base-case economic evaluation focused on health and social
care costs. The currency used was the pound sterling (£) and 2014 was used as the reference financial year.
Costs and benefits were discounted at 3.5% per annum.
Missing data
Missing data were imputed using multiple imputations via chained equations86,100,101 as recommended for
economic analyses alongside clinical trials.102 For consistency with the statistical analysis and to ensure best
fit, imputations were based on predictor variables including treatment allocation, gender, age, centre, total
number of self-harm episodes, type of index episode, source of referral from hospital and derived scores
for a number of assessment instruments (BSS, CDRS-R, Hopelessness Scale for Children and PQ-LES-Q).
Within-trial cost-effectiveness
The within-trial analysis aimed to determine the intervention that maximised health outcomes at 18 months.
It used an ITT perspective.
Base-case analysis 1 was a cost–utility analysis over 18 months examining the cost per QALY gained for all
participants. Descriptive statistics of costs and EQ-5D scores and parametric tests to evaluate any important
differences between the two trial arms at each time point in the trial were produced. Thereafter, incremental
cost-effectiveness ratios (ICERs) were calculated by dividing the average difference in costs between the two
arms by the average difference in QALYs between the two trial arms:
ICER =
(MeanCostTR – MeanCostHR)
(MeanQALYTR – MeanQALYHR)
(6)
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The ICER represents the additional cost per unit of outcome gained. This indicates the trade-off
between total cost and effectiveness when choosing between FT and TAU. When compared against the
cost-effectiveness threshold, this gives an indication of whether or not spending additional money on FT
appears efficient. As a rule, the NICE implicit cost per QALY threshold of £20,000–30,000 per QALY was
used. An intervention is cost-effective so long as its ICER is within or below the £20,000–30,000 per
QALY range.
Base-case analysis 2 calculated the incremental cost per self-harm event avoided because of FT at 18 months
compared with TAU and was carried out in a similar way; however, there is not a clear decision rule on
the cost-effectiveness threshold per self-harm event avoided and so the results were presented for a range
of cost-effectiveness thresholds.
Cost-effectiveness over a longer time horizon
The NICE reference case recommends exploring cost-effectiveness over a time horizon that is long enough
to reflect any important differences in costs or consequences between treatments being compared.
The NHS might be interested to understand the cost and the consequences of FT and TAU beyond the trial
follow-up, and decision-analysis modelling is key in this context. As far as we know, there are no prior
studies in which a decision-analysis model was built to study the long-term cost-effectiveness of FT for
adolescents. Considering that a cohort of young people will face such a large number of events over their
adult life, we considered that building a decision-analysis model that reflects a lifetime horizon would
require a larger amount of assumptions and probabilities to estimate. Therefore the decision-analysis
model evaluated the cost-effectiveness of FT compared with TAU up to 5 years after randomisation.
It considered health and social care costs and used young people’s QALY gain as the outcome. The results
from the within-trial analysis were mainly used to make reliable assumptions for the model as appropriate
literature references were not identified from which health states or probabilities beyond an 18-month
follow-up could be extracted.
A Markov model with three health states was used (Figure 3). The model included three possible health
states: self-harm, defined as self-harming at least once in a period of 6 months; no self-harming; and
death. Markov models describe participant progression over time through a pathway of health states, with
movement between the health states being triggered by events; in this case, self-harm events or death.
Resource use and costs were associated with each health state and participants accumulated costs and
health benefits in each state over 6-month cycles. Participant cost and utility data were available at 6, 12
and 18 months from the trial data and were directly included into the model to estimate longer-term costs
and health benefits.
The model inputs were derived from the trial data. Specifically, the proportion of the participants beginning
in each health state in the model was derived directly from the proportion of participants in the trial who
remained in the self-harm state or moved to no self-harming. In the first cycle of the model, all participants
Death
SH
noSH
FIGURE 3 Three-state Markov model. SH, self-harm; noSH, no self-harm. Reproduced from Cottrell et al.70
© The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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started from self-harm in both arms and this was informed by the inclusion criteria for the trial. No
participants died over the 18-month trial follow-up, but to account for possible death it was assumed that
the probability of a participant moving from self-harm to death or from no self-harm to death was minimal
and equal to 0.0001, regardless of the trial arm. Derivation of the post-18-month transition rates between
the different states required extrapolation beyond the follow-up period of the trial.
Regarding costs and utility related to each model state, death was assumed to be associated with zero
utility and zero cost. For self-harm and no self-harming states, the associated costs and utility values at
each follow-up time point (6 months, 12 months and 18 months) were derived directly from the trial data.
Any intervention costs were assumed to occur equally over the first 12 months for each arm based on the
trial data. Given that it was not possible to distinguish if these costs were incurred only by those in the
self-harm state, in the no self-harming state or both, it was assumed to be the same for any of the states.
Presentation of results
The outputs of both the within-trial analysis and the decision-analysis model were presented as expected
ICERs of FT compared with TAU, scatterplots on the cost-effectiveness plane and cost-effectiveness
acceptability curves using non-parametric bootstrapping to determine the level of sampling uncertainty.
In order to test the robustness of the results of the within-trial analysis, a number of sensitivity analyses
were conducted to explore the impact of costs and missing data on the results of the study as
described below:
1. a non-parametric bootstrapping with 10,000 replications
2. an analysis in which it was assumed that only one therapist was involved in each treatment session in
the FT arm (intervention costs from scenario 1)
3. an analysis in which it was assumed that the average number of therapists were involved in each
treatment session in the FT arm (intervention costs from scenario 2)
4. an adjusted analysis to account for EQ-5D differences between arms at baseline, using a set of baseline
characteristics such as treatment allocation, gender and age group (baseline EQ-5D was also included
as a control to account for any impossible imbalance and to improve the precision of the estimates)
5. a complete-case analysis including only those participants with no missing quality-of-life and cost data
at any time point before imputation
6. an analysis using an aggregate QALY, taking into consideration both the young people’s and
caregivers’ QALY gains.
In order to test the robustness of the results of the decision model, deterministic one-way sensitivity analyses
were conducted to assess the impact of individual parameter uncertainty and key model assumptions on the
results. Probabilistic sensitivity analyses were conducted to assess the impact of parameter uncertainty on
the results. Probabilistic analysis accounts for joint parameters uncertainty in non-linear models by assigning
probability distributions to each of the input parameters and randomly drawing from these probabilities
over a number of Monte Carlo model simulations to produce different cost and QALY estimates in each
simulation of the model. In our model, we chose to do 30,000 simulations owing to the results being highly
sensitive to a smaller number of simulations.
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Chapter 3 Main trial results
Recruitment, retention and participant characteristics
Participant flow
The numbers of young people screened for entry into SHIFT, eligible, randomised, followed up via post at
3 and 6 months, visited by a researcher at 12 and 18 months, withdrawn and analysed are presented in
the CONSORT diagram in Figure 4.
Screening and recruitment
A total of 3554 young people were screened within CAMHS, of whom the clinician deemed 1603 (45.1%)
to be eligible for the trial (see Figure 4). Of the remaining young people, 1831 (51.5%) were deemed to be
ineligible and no eligibility information was provided for a further 120 (3.4%). The most common reasons
for ineligibility were not having engaged in self-harm prior to the current CAMHS referral (44.8% of those
ineligible), already being treated within CAMHS (25.2%), not intending to offer CAMHS follow-up for
self-harm (21.7%), not living with their primary caregiver (17.6%), recent self-harm was not a key feature
of presentation and referral into CAMHS (16.4%), presenting episode resulted from consumption of alcohol
or drugs where specific intent to self-harm was not established (13.7%), in a children’s home or short-term
foster placement (10%), would not ordinarily be treated in CAMHS (9.2%), currently undergoing a child
protection investigation (7.8%) and at serious risk of suicide (7%).
A total of 993 (61.9%) eligible young people consented to researcher contact, of whom 481 (48.4%)
provided verbal consent and 512 (51.6%) provided written consent; 273 (17%) young people did not
consent, and details of researcher consent were missing for 337 (21%) eligible young people. Of the 273
young people not providing consent, 160 (58.6%) refused consent, 85 (31.1%) did not attend their first
CAMHS follow-up appointment and 18 (6.6%) were not approached by the CAMHS clinician.
Researcher contact and baseline visits were sought for the 993 young people consenting to researcher
contact. A total of 832 (83.8%) consented to trial participation and were randomised into the trial, 51.9%
of those eligible. A further 127 (12.8%) young people did not provide consent for trial participation
(100 refused; 11 could not be contacted in sufficient time).
Screening and recruitment took place over 4 years: the first participant was randomised on 14 April 2010 and
the last on 30 December 2013 once the target of 832 participants had been reached, with 415 participants
randomised to receive FT and 417 participants randomised to receive TAU. Figure 5 shows overall, monthly
and cumulative recruitment of participants into the trial, and Figure 6 presents overall recruitment by CAMHS
and hub and treatment arm while Table 102 in Appendix 4 provides a summary of overall recruitment activity
by CAMHS centre, trust, hub and treatment arm and by CAMHS.
Characteristics of the screened, eligible and randomised participants – generalisability
Tables 2 and 3 compare the characteristics of the screened, eligible and randomised young people and
show similar characteristics according to gender, ethnicity and treatment received. Between 82% and 89%
were female within each population; and between 79% and 84% were of white ethnicity. The mean age
was 14.8 [standard deviation (SD) 1.55], 14.6 (SD 1.38) and 14.3 (1.37) in each respective population with
an increasing proportion of younger adolescents (aged 11–14 years) in later stages of the screening process.
There were more marked differences according to referral source; almost 60% of those screened were
referred via hospital while 25% had been referred via their general practitioner (GP). However, of those
randomised, only 37% had been referred via hospital while 46% had been referred via their GP; this is
discussed in relation to the primary outcome in Primary analysis: Cox proportional hazards regression.
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Similarly, the proportion of participants whose most recent index self-harm episode was poisoning
decreased from 41% of screened to 23% of randomised while the proportion cutting increased from 40%
to 63%.
Young people referred to CAMHS through hospital therefore had a far lower eligibility rate than those
from the community (31.8% vs. 70.2%) and a lower rate of consent for researcher contact (54.6% vs.
67.8%), suggesting that hospital referrals were a more highly selected group.
Ineligible, n = 1831 (51.5%)
Reason ineligible (not mutually exclusive):
• Engaged in < 1 prior self-harm episode, 
   n = 821 (44.8%)
• Already being treated in CAMHS, n = 461 (25.2%)
• Not intended to offer CAMHS follow-up for 
   self-harm, n = 397 (21.7%)
• Does not live with primary caregiver, 
   n = 323 (17.6%)
• Recent self-harm not a key feature of 
   presentation, n = 300 (16.4%)
• Due to alcohol/drugs, specific intent to self-harm 
   not established, n = 250 (13.7%)
• In a children’s home or short-term foster
   placement, n = 183 (10.0%)
• Would not ordinarily be treated in CAMHS,
   n = 169 (9.2%)
• Currently undergoing child protection
   investigation, n = 143 (7.8%)
• At serious risk of suicide, n = 129 (7.0%)
• Insufficient proficiency in English, n = 58 (3.2%)
• Learning disability/lacks capacity, n = 49 (2.7%)
• Not aged 11–17 years, n = 42 (2.3%)
• Involved in other research project, n = 19 (1.0%)
• Pregnant, n = 9 (0.5%)
• Sibling in SHIFT/CAMHS FT, n = 7 (0.4%)
• Unknown, n = 36 (2.0%)
Did not provide consent to trial
participation, n = 127 (12.8%)
Reason for non-consent:
• Could not contact, n = 11 (8.7%)
• Refused, n = 100 (78.7%)
• Unknown, n = 16 (12.6%)
Of those who refused:
• Parent/caregiver, n = 19 (19.0%)
• Young person, n = 55 (55.0%)
• Both, n = 25 (25.0%)
• Missing, n = 1 (1.0%)
Missing, n = 34 (3.4%)
No consent to researcher
contact, n = 273 (17.0%)
Reason for non-consent:
• Refused consent, n = 160 (58.6%)
• Did not attend first follow-up
   appointment, n = 85 (31.1%)
• Not approached by CAMHS
   clinician, n = 18 (6.6%)
• Unknown, n = 10 (3.7%)
Of those who refused:
• Parent/caregiver, n = 22 (13.8%)
• Young person, n = 67 (41.9%)
• Both, n = 64 (40.0%)
• Missing, n = 7 (4.4%)
Missing, n = 337 (21.0%)
Eligible,
n = 1603 (45.1%)
Screened,
n = 3554
Consented to
researcher
contact,
n = 993 (61.9%)
Consented to trial
participation and
randomised,
n = 832 (83.8%)
Lost to follow-up Lost to follow-up
Young person postal questionnaires
• 3 months, n = 187 (45.1%)
• 6 months, n = 211 (50.8%)
Researcher visits for questionnaires
• 12 months, n = 167 (40.2%)
• 18 months, n = 211 (50.8%)
Young person withdrawals
• Clinical data collection, n = 8 (1.9%)
• Researcher follow-up, n = 56 (13.5%)
• Postal questionnaires, n = 44 (10.6%)
Young person postal questionnaires
• 3 months, n = 219 (52.5%)
• 6 months, n = 268 (64.3%)
Researcher visits for questionnaires
• 12 months, n = 228 (54.7%)
• 18 months, n = 252 (60.4%)
Young person withdrawals
• Clinical data collection, n = 13 (3.1%)
• Researcher follow-up, n = 97 (23.3%)
• Postal questionnaires, n = 84 (20.1%)
TAU (n = 417)
Received ≥1 initial TAU session, n = 311
(74.6%) [missing n = 45 (5.4%)]
Family therapy (n = 415)
Received >1 SHIFT FT session, n = 394
(94.9%)
Allocation
Follow-up
Analysed intention to treat (n = 415) Analysed intention to treat (n = 417)
Analysis
FIGURE 4 Consolidated Standards of Reporting Trials flow diagram. Adapted from Cottrell et al.70 © The Author(s).
Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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Compared with community referrals, young people referred through hospital were more likely to be
ineligible because their index episode was their first reported episode of self-harm (48.8% vs. 29.9%) or
because they were already being actively treated in CAMH (28.3% vs. 14.5%). The proportion of young
people who did not consent to researcher contact because they did not attend their CAMHS follow-up
appointment was higher among those referred from hospital than among those referred through the
community (37.9% vs. 23.8%), while the proportion of non-consent caused by refusal was far lower
(47.9% in hospital referrals vs. 70% in community withdrawals).
The characteristics of young people referred from hospital differed from those of community referrals in
that they were slightly older [mean age of 14.9 (SD 1.49) years vs. 14.5 (SD 1.57) years], their index
episode of self-harm was more likely to be caused by self-poisoning (63.5% vs. 6.2%), and they were
more likely to have received at least some treatment following the episode (31.3% required no treatment,
compared with 66.7% of community referrals).
Baseline characteristics
Clinical characteristics
Baseline characteristics and clinical details of the 832 randomised participants are presented by arm in
Tables 4–10. The two groups are largely well balanced with respect to these characteristics.
The mean age at randomisation was 14.3 (SD 1.38) years in the FT group and 14.4 (SD 1.35) years in the
TAU group. There were more females than males in both arms: 368 (88.7%) in the FT arm and 369 (88.5%)
in the TAU arm (Table 4). Most young people had self-harmed on at least three previous occasions [369
(88.9%) in the FT arm and 370 (88.7%) in the TAU arm] as opposed to on only two occasions, and the type
of most recent episode was largely self-injury [297 (71.6%) in the FT arm and 297 (71.2%) in the TAU arm],
with a further 93 (22.4%) in the FT arm and 91 (21.8%) in the TAU arm due to self-poisoning; the
remainder used combined methods. Almost two-thirds (63.5%) of participants were referred to CAMHS
through the community rather than from hospital. Almost all participants were living with their parents/
guardians, with only two in foster care, and the majority were in full-time education [398 (95.9%) in the FT
arm and 386 in the TAU arm (92.6%)]. Ethnicity was also well balanced across the arms. The overall
proportions are presented in Table 2.
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FIGURE 5 Recruitment graph.
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Over one-quarter of participants were reported to have a health or disability problem (218, 26.2%) and a
similar proportion had past involvement with CAMHS (244, 29.3%). The most common health or disability
problem (Table 5) was asthma (reported by 91 participants), followed by musculoskeletal problems
(reported by 35 participants). Slightly more participants in the FT arm than in the TAU arm reported past
involvement with CAMHS [136 (32.8%) compared with 108 (25.9%), respectively] (Table 6). Reasons for
prior involvement were mainly self-harm related (128 participants), followed by emotional and behavioural
problems, reported by 31 and 24 participants, respectively.
Just under 5% of participants were taking a prescribed psychotropic medication at the time of randomisation,
with antidepressants being the most common (taken by 28 participants) (Table 7).
Parental abuse was reported by almost one-quarter of participants (n = 198, 23.8%). Marked physical
abuse was reported by > 20% of participants (n = 178, 21.4%) and 138 (16.6%) participants reported
sexual abuse (parental or otherwise) (Table 8). Furthermore, when asked about any other bad or scary
things that had happened to them, 293 (35.2%) participants reported such events, including witnessing or
experiencing a traumatic incident, relationship difficulties with family and friends, harassment or bullying,
domestic violence, and other sexual, emotional or physical abuse.
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TABLE 2 Characteristics of the screened, eligible and randomised populations
Participant characteristics, n (%)
Screened
(N= 3554)
Eligible
(N= 1603)
Randomised
(N= 832)
Gender (female) 2904 (81.7) 1404 (87.6) 737 (88.6)
Age category (years)
< 11 29 (0.8) 1 (0.1)
11–14 1389 (39.1) 722 (45.0) 441 (53.0)
15–17 2016 (56.7) 861 (53.7) 390 (46.9)
> 17 3 (0.1) 1 (0.1) 1 (0.1)
Missing 117 (3.3) 18 (1.1)
Ethnicity
White 2799 (78.8) 1299 (81.0) 701 (84.3)
Black (Caribbean, African, mixed, other) 273 (7.7) 131 (8.2) 60 (7.2)
Asian (Pakistani, Indian, Bangladeshi, mixed, other) 150 (4.2) 56 (3.5) 29 (3.5)
Other ethnic group 121 (3.4) 73 (4.6) 40 (4.8)
Not stated/missing 211 (5.9) 44 (2.7) 2 (0.2)
Young person referred from
Hospital 2129 (59.9) 678 (42.3) 304 (36.5)
GP 889 (25.0) 651 (40.6) 382 (45.9)
School 186 (5.2) 139 (8.7) 77 (9.3)
Other 213 (6.0) 111 (6.9) 58 (7.0)
Missing 137 (3.9) 24 (1.5) 11 (1.3)
Treatment required
None 1571 (44.2) 780 (48.7) 428 (51.4)
Minimal 1204 (33.9) 578 (36.1) 301 (36.2)
Significant intervention 444 (12.5) 139 (8.7) 56 (6.7)
Intervention potentially life-saving 27 (0.8) 10 (0.6) 5 (0.6)
Missing 308 (8.7) 96 (6.0) 42 (5.0)
Hospital care
Discharged from A&E 587 (16.5) 252 (15.7) 124 (14.9)
General admission 1122 (31.6) 368 (23.0) 168 (20.2)
ICU/HDU/other specialist unit 19 (0.5) 5 (0.3)
N/A, community referral 1246 (35.1) 873 (54.5) 511 (61.4)
Missing 580 (16.3) 105 (6.6) 29 (3.5)
GP, general practitioner; HDU, high-dependency unit; N/A, not applicable.
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TABLE 3 Type of most recent self-harm episode (not mutually exclusive)
Type of self-harm
Screened,
n (%)
Eligible,
n (%)
Randomised,
n (%)
Poisoning 1452 (40.9) 444 (27.7) 189 (22.7)
Cutting 1421 (40.0) 919 (57.3) 527 (63.3)
Poisoning and cutting 218 (6.1) 123 (7.7) 54 (6.5)
Other self-injury (biting, burning, electrocution) 176 (5.0) 101 (6.3) 68 (8.2)
Other violent method (drowning, hanging/strangulation) 129 (3.6) 44 (2.7) 24 (2.9)
Threat/thoughts of self-harm or suicide only, or non-self-harm only 112 (3.2) 18 (1.1) 9 (1.1)a
Missing 127 (3.6) 12 (0.7)
Total 3554 (100) 1603 (100) 832 (100)
a Note that the nine randomised participants with threats/thoughts of self-harm or suicide only were confirmed at
randomisation to have self-harmed as a result of self-injury (and for one combined self-injury and poisoning) and the
SASII confirmed the occurrence of prior self-harm for these nine participants.
TABLE 4 Summary of treatment allocations at randomisation for true values of stratification factors
(excluding centre) and educationa
Stratification factors, n (%)
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
Gender (female) 368 (88.7) 369 (88.5) 737 (88.6)
Age (years)
11–14 220 (53.0) 221 (53.0) 441 (53.0)
15–17 195 (47.0) 195 (46.8) 390 (46.9)
18 0 (0.0) 1 (0.2) 1 (0.1)
Living arrangements
With parents/guardians 414 (99.8) 416 (99.8) 830 (99.8)
Foster care 1 (0.2) 1 (0.2) 2 (0.2)
Number of known self-harm episodes (≥ 3 vs. 2) 369 (88.9) 370 (88.7) 739 (88.8)
Type of most recent episode
Self-poisoning 93 (22.4) 91 (21.8) 184 (22.1)
Self-injury 297 (71.6) 297 (71.2) 594 (71.4)
Combined 25 (6.0) 29 (7.0) 54 (6.5)
Non-stratification factors
Referred into CAMHS via hospital
Yes 156 (37.6) 148 (35.5) 304 (36.5)
No 259 (62.4) 269 (64.5) 528 (63.5)
Young person in full-time education 398 (95.9) 386 (92.6) 784 (94.2)
a Discrepancies at randomisation: two females incorrectly randomised as male; two errors in age group (one aged
11–14 years incorrectly randomised as aged 15–17 years and the 18-year-old incorrectly randomised as aged 15–17 years);
12 errors in the number of previous self-harm episodes (six ≥ 3 incorrectly randomised under= 2 and six = 2 randomised
incorrectly under ≥ 3); seven errors in the type of most recent episode (two with self-poisoning incorrectly randomised
under self-injury, two self-injury incorrectly randomised under combined and three self-injury incorrectly randomised under
self-poisoning).
Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license.
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TABLE 5 Young people’s physical health
Physical health problems, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Young person has a health or disability problem 110 (26.5) 108 (25.9) 218 (26.2)
Type of problem (not mutually exclusive)
Asthma 47 (42.7) 44 (40.7) 91 (41.7)
Blood problem 9 (8.2) 9 (8.3) 18 (8.3)
Diabetes 2 (1.8) 4 (3.7) 6 (2.8)
Eczema 11 (10.0) 9 (8.3) 20 (9.2)
Gastrointestinal disease 1 (0.9) 5 (4.6) 6 (2.8)
Hay fever/allergies 8 (7.3) 6 (5.6) 14 (6.4)
Headaches/migraine 4 (3.6) 7 (6.5) 11 (5.0)
Musculoskeletal problem 16 (14.5) 19 (17.6) 35 (16.1)
Neurological problem 10 (9.1) 2 (1.9) 12 (5.5)
Other 20 (18.2) 18 (16.7) 38 (17.4)
Missing 4 (3.6) 3 (2.8) 7 (3.2)
TABLE 6 Past involvement with CAMHS
Past involvement with CAMHS, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Past involvement with CAMHS 136 (32.8) 108 (25.9) 244 (29.3)
Reason for past referral
Self-harm related 73 (53.7) 55 (50.9) 128 (52.5)
Emotional problems 18 (13.2) 13 (12.0) 31 (12.7)
Behavioural problems 14 (10.3) 10 (9.3) 24 (9.8)
Emotional and behavioural problems 2 (1.5) 3 (2.8) 5 (2.0)
ADHD/ADD 2 (1.5) 2 (1.9) 4 (1.6)
Eating disorder 3 (2.2) 1 (0.9) 4 (1.6)
Autism assessment 1 (0.7) 0 (0.0) 1 (0.4)
Behavioural problems and autism assessment 1 (0.7) 0 (0.0) 1 (0.4)
Emotional problems and ADHD/ADD 0 (0.0) 1 (0.9) 1 (0.4)
Self-harm related and autism assessment 1 (0.7) 0 (0.0) 1 (0.4)
Unknown 4 (2.9) 8 (7.4) 12 (4.9)
Other 6 (4.4) 4 (3.7) 10 (4.1)
Missing 11 (8.1) 11 (10.2) 22 (9.0)
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TABLE 7 Prescribed psychotropic medications
Prescribed psychotropic medication FT (N= 415) TAU (N= 417) Total (N= 832)
Young person taking prescribed psychotropic medication (Yes),
n (%)
17 (4.1) 24 (5.8) 41 (4.9)
Type of psychotropic (not mutually exclusive), n (%)
Antidepressant drug 14 (82.4) 14 (58.3) 28 (68.3)
ADHD drug 3 (17.6) 3 (12.5) 6 (14.6)
Sedative/sleep medication 0 (0.0) 5 (20.8) 5 (12.2)
Antipsychotic drug 2 (11.8) 0 (0.0) 2 (4.9)
Anti anxiety drug 0 (0.0) 1 (4.2) 1 (2.4)
Missing 0 (0.0) 3 (12.5) 3 (7.3)
Longest length of time (months) on each medication, mean (SD), n 4.7 (8.09), 17 3.2 (5.46), 22 3.9 (6.68), 39
TABLE 8 Participant report of bad things that can happen
Types of bad event, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Parental abuse: when your parents get cross with you, have they
ever hit you? (Yes)
89 (21.4) 109 (26.1) 198 (23.8)
Marked physical abuse: have you ever been hit so hard you had
bruises or marks on your body or were hurt? (Yes)
80 (19.3) 98 (23.5) 178 (21.4)
Sexual abuse: has someone ever touched you in a way that made
you feel uncomfortable (Yes)
75 (18.1) 63 (15.1) 138 (16.6)
Other information: anything else bad or scary (Yes) 147 (35.4) 146 (35.0) 293 (35.2)
Details of other bad things
Witnessed/had traumatic incident 46 (31.3) 46 (31.5) 92 (31.4)
Relationship difficulties: family 39 (26.5) 31 (21.2) 70 (23.9)
Harassment/bullying 22 (15.0) 25 (17.1) 47 (16.0)
Domestic violence 19 (12.9) 19 (13.0) 38 (13.0)
Relationship difficulties: friends 7 (4.8) 9 (6.2) 16 (5.5)
Childhood sexual abuse 5 (3.4) 3 (2.1) 8 (2.7)
Emotional abuse 3 (2.0) 1 (0.7) 4 (1.4)
Physical abuse 0 (0.0) 3 (2.1) 3 (1.0)
Unknown 1 (0.7) 3 (2.1) 4 (1.4)
Missing 5 (3.4) 6 (4.1) 11 (3.8)
Note
Marked physical abuse is missing for a large number because of case report form and question wording. If the previous
question, parental abuse, had been answered no (as for 37 of the missing here) it could have been assumed that this
question was not required.
Furthermore, it is important to note that of the eight reporting other bad things as childhood sexual abuse, one had
detailed a different incident for the prior sexual abuse question, one had not provided prior information and six had said no
to the prior sexual abuse question, as these incidents may have been deemed to be of a different nature to those reported
as sexual abuse (i.e. may not have been touched in a way that made you feel bad).
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Self-reported details of the young person’s most recent index episode of self-harm are presented in Table 9,
and further details from the timeline showing all self-harm methods, treatment and suicide attempts
reported over the past year are presented in Table 103, Appendix 4. The participant’s behaviour was rated
by the interviewing researcher as a suicide attempt in 313 (37.6%) cases. The remaining episodes were
largely classed as NSSI (516, 62%), and three participants reported non-intentional self-injury, which was
victim precipitated or planned but not acted on. There was some intent to die for just under half of the
participants; for over three-quarters of participants there was a low medical risk of death, and medical
treatment was sought or received for 659 (79.2%) participants.
Details of the primary caregiver are provided in Table 10. The majority of caregivers consenting to the trial
were the mother of the young person (719, 86.4%) and their mean age was 42.5 years (SD 6.39 years).
Three hundred and two (36.3%) were in full-time employment and 216 (26%) were in part-time employment.
TABLE 9 Characteristics of the index self-harm episode from the SASII
Characteristics of index self-harm episode, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Interviewer-rated behaviour
Suicide attempt (SA) 148 (35.7) 165 (39.6) 313 (37.6)
NSSI 265 (63.9) 251 (60.2) 516 (62.0)
Non-intentional self-injury (victim precipitated, did not act)a 2 (0.5) 1 (0.2) 3 (0.4)
Interviewer-rated intent to die (some intent to die) 197 (47.5) 215 (51.6) 412 (49.5)
Interviewer-rated medical risk of death
Low 326 (78.6) 302 (72.4) 628 (75.5)
Moderate 76 (18.3) 105 (25.2) 181 (21.8)
High 12 (2.9) 10 (2.4) 22 (2.6)
Missing 1 (0.2) 0 (0.0) 1 (0.1)
Interviewer-rated impulsivity (planned) 88 (21.2) 78 (18.7) 166 (20.0)
Communication of suicide intent (Yes: indirect/direct) 107 (25.8) 118 (28.3) 225 (27.0)
Interpersonal influence mentionedb 156 (37.6) 179 (42.9) 335 (40.3)
Emotion relief mentionedc 386 (93.0) 391 (93.8) 777 (93.4)
Medical treatment sought/received (Yes) 326 (78.6) 333 (79.9) 659 (79.2)
Interviewer-rated physical condition following episode
No effect 64 (15.4) 56 (13.4) 120 (14.4)
Mild effect 299 (72.0) 310 (74.3) 609 (73.2)
Moderate effect 45 (10.8) 46 (11.0) 91 (10.9)
Severe effect 6 (1.4) 5 (1.2) 11 (1.3)
Missing 1 (0.2) 0 (0.0) 1 (0.1)
a These three events were included as, in the judgement of the research team, the young people were in the process of
self-harming as described in the eligibility criteria but the act was interrupted either by the young person or another
person. Thus, had medication but called for help and did not take it (participant 100); took a knife with the intention of
self-harming but was interrupted (participant 243); hitting fists against head with undue risk-taking/unreasonable
expectation of safety (participant 621). All three young people had other prior self-harm confirmed in the SASII timeline.
b With reason(s) for self-harm according to any of the following indicators of interpersonal influence: to communicate to
or let others know how desperate I was; to get help; to gain admission into a hospital or treatment program; to shock or
impress others; to get other people to act differently or change; to get back at or hurt someone; to demonstrate to
others how wrong they are/were; to make others understand how desperate I am.
c With reason(s) for self-harm according to any of the following indicators of emotion relief: to stop bad feelings; to stop
feeling angry or frustrated or enraged; to relieve anxiety or terror; to relieve feelings of aloneness, emptiness or isolation;
to stop feeling self-hatred, shame; to obtain relief from a terrible state of mind.
Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license.
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Baseline questionnaires
Baseline questionnaire scores are displayed in Table 11 for questionnaires completed by both the young
person and caregiver (ICU, SDQ, McMaster FAD), in Table 12 for questionnaires completed by the young
person only (CDRS, PQ-LES-Q, Beck, Hopelessness Scale) and in Table 13 for questionnaires completed by
the caregiver only (GHQ-12, Family Questionnaire). Appendix 3 summarises the description of questionnaire
scores and cut-off points applied.
Scores were largely similar across both groups. Over half the young people and caregivers demonstrated a
very high total difficulties score on the SDQ, and over three-quarters of young people demonstrated
unhealthy family functioning on all scales of the McMaster FAD (while caregivers reported less unhealthy
traits). At least mild depression was reported for the majority of participants (762, 91.7%) and suicidal
ideation was demonstrated for 543 (66.5%).
Study conduct
Protocol violators
A total of 16 (1.9%) young people were identified as not fulfilling the eligibility criteria (Table 14), five in
the FT arm and 11 in the TAU arm. The main criterion violated was participants already being treated
within CAMHS (defined as three or more sessions of active treatment in the months preceding
randomisation) for seven participants: three in the FT arm and four in the TAU arm.
TABLE 10 Primary caregiver details
Primary caregiver details FT (N= 415) TAU (N= 417) Total (N= 832)
Relationship to young person, n (%)
Mother 356 (85.8) 363 (87.1) 719 (86.4)
Father 45 (10.8) 48 (11.5) 93 (11.2)
Guardian 8 (1.9) 3 (0.7) 11 (1.3)
Stepmother 3 (0.7) 2 (0.5) 5 (0.6)
Foster parent 1 (0.2) 1 (0.2) 2 (0.2)
Stepfather 2 (0.5) 0 (0.0) 2 (0.2)
Gender (female), n (%) 366 (88.2) 369 (88.5) 735 (88.3)
Age mean (SD) 42.5 (6.68), n = 377 42.4 (6.08), n= 363 42.5 (6.39), n = 740
Employment status, n (%)
Employee/self-employed, full time 152 (36.6) 150 (36.0) 302 (36.3)
Employee/self-employed, part-time 112 (27.0) 104 (24.9) 216 (26.0)
Homemaker 71 (17.1) 87 (20.9) 158 (19.0)
Employee on sick leave 13 (3.1) 12 (2.9) 25 (3.0)
Unemployed 42 (10.1) 51 (12.2) 93 (11.2)
Not in paid employment (e.g. working for charity) 4 (1.0) 4 (1.0) 8 (1.0)
Retired 6 (1.4) 3 (0.7) 9 (1.1)
Learning a trade, government-supported training 1 (0.2) 1 (0.2) 2 (0.2)
Full-time education 6 (1.4) 1 (0.2) 7 (0.8)
Missing 8 (1.9) 4 (1.0) 12 (1.4)
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TABLE 11 Young person and caregiver baseline questionnaire outcomes
Outcome, mean (SD), n
Young person Caregiver
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
ICUa
ICU total score (0–72) 28.2 (9.10),
410
28.5 (9.09),
403
28.4 (9.09),
813
32.6 (11.59),
413
32.9 (11.43),
415
32.8 (11.50),
828
ICU callousness (0–33) 8.3 (4.61),
410
8.6 (4.99),
403
8.5 (4.80),
813
10.4 (6.62),
413
10.7 (6.68),
415
10.5 (6.65),
828
ICU uncaring score (0–24) 11.0 (4.65),
410
10.8 (4.57),
403
10.9 (4.61),
813
14.5 (4.85),
413
14.5 (4.82),
415
14.5 (4.83),
828
ICU unemotional score
(0–15)
8.9 (2.82),
410
9.1 (3.09),
403
9.0 (2.96),
813
7.6 (3.08),
413
7.7 (3.08),
415
7.7 (3.07),
828
SDQb
Total difficulties score
(0–40)
19.6 (5.70),
413
20.1 (5.60),
415
19.8 (5.65),
828
19.4 (6.56),
412
19.8 (6.83),
415
19.6 (6.69),
827
Close to average,
n (%)
84 (20.3) 70 (16.9) 154 (18.6) 78 (18.9) 86 (20.7) 164 (19.8)
Slightly raised, n (%) 58 (14.0) 68 (16.4) 126 (15.2) 51 (12.4) 36 (8.7) 87 (10.5)
High, n (%) 60 (14.5) 44 (10.6) 104 (12.6) 67 (16.3) 66 (15.9) 133 (16.1)
Very high, n (%) 211 (51.1) 233 (56.1) 444 (53.6) 216 (52.4) 227 (54.7) 443 (53.6)
Prosocial score (0–10) 7.1 (1.84),
414
7.2 (1.87),
415
7.2 (1.85),
829
6.3 (2.33),
414
6.3 (2.30),
416
6.3 (2.31),
830
Emotional problems score
(0–10)
6.2 (2.34),
414
6.5 (2.31),
415
6.4 (2.33),
829
6.2 (2.39),
414
6.2 (2.60),
415
6.2 (2.49),
829
Conduct problems score
(0–10)
3.9 (2.11),
414
4.0 (1.94),
415
3.9 (2.02),
829
4.2 (2.42),
413
4.3 (2.47),
416
4.2 (2.44),
829
Hyperactivity score (0–10) 6.3 (2.22),
413
6.2 (2.17),
415
6.2 (2.20),
828
5.5 (2.48),
414
5.7 (2.56),
415
5.6 (2.52),
829
Peer problems score
(0–10)
3.1 (1.87),
413
3.5 (2.08),
415
3.3 (1.98),
828
3.5 (2.09),
413
3.6 (2.14),
415
3.6 (2.11),
828
Impact score (0–10) 3.3 (2.41),
413
3.5 (2.52),
414
3.4 (2.47),
827
4.4 (2.73),
410
4.3 (2.73),
413
4.4 (2.73),
823
Externalising score (0–20) 10.2 (3.80),
413
10.1 (3.48),
415
10.2 (3.65),
828
9.7 (4.30),
413
10.0 (4.50),
415
9.9 (4.40),
828
Internalising score (0–20) 9.4 (3.41),
413
10.0 (3.63),
415
9.7 (3.53),
828
9.8 (3.69),
413
9.8 (4.02),
415
9.8 (3.86),
828
McMaster FAD (1–4)c
Overall FAD score 2.5 (0.33),
404
2.4 (0.36),
405
2.5 (0.35),
809
2.2 (0.36),
408
2.2 (0.36),
415
2.2 (0.36),
823
General functioning 2.5 (0.53),
410
2.5 (0.56),
408
2.5 (0.54),
818
2.3 (0.48),
415
2.3 (0.47),
416
2.3 (0.47),
831
Unhealthy (≥ 2.0),
n (%)
354 (86.3) 339 (83.1) 693 (84.7) 314 (75.7) 316 (76.0) 630 (75.8)
continued
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Research withdrawals
Participants could withdraw from further clinical data collection, further researcher follow-up visits or
postal questionnaire follow-up. In 160 (19.2%) cases, the young person, the caregiver or both withdrew
from some or all of the study process: 60 (14.5%) in the FT arm and 100 (24.0%) in the TAU arm.
Table 15 presents the type of withdrawals and who withdrew (young person or caregiver). All 160
participants withdrew from researcher follow-up visits, 136 (16.3%) withdrew from postal questionnaire
follow-up (FT arm, 11.6%; TAU arm, 21.1%) and 22 (2.6%) withdrew from further clinical data collection
(i.e. the primary end point), nine in the FT arm and 13 in the TAU arm.
Figure 7 presents the timing of withdrawals and shows that these were largely clustered around postal and
researcher follow-up time points at 3, 6, 12 and 18 months post randomisation. The main reasons for
withdrawal (Table 16) included the participant not wanting to be involved any more (38 participants);
other issues or events going on in the participants’ or their family life, which meant that they were too
busy to continue (30 participants); the participant having improved or moved on and not wanting to revisit
the past (26 participants); and dissatisfaction with the therapy offered or received (18 participants).
TABLE 11 Young person and caregiver baseline questionnaire outcomes (continued )
Outcome, mean (SD), n
Young person Caregiver
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
Behaviour control
subscale
2.1 (0.38),
413
2.1 (0.37),
409
2.1 (0.38),
822
1.8 (0.41),
411
1.8 (0.41),
416
1.8 (0.41),
827
Unhealthy (≥ 1.9),
n (%)
319 (77.2) 311 (76.0) 630 (76.6) 197 (47.9) 226 (54.3) 423 (51.1)
Affective involvement
subscale
2.5 (0.48),
412
2.5 (0.49),
409
2.5 (0.48),
821
2.2 (0.45),
412
2.3 (0.51),
415
2.2 (0.48),
827
Unhealthy (≥ 2.1),
n (%)
345 (83.7) 341 (83.4) 686 (83.6) 270 (65.5) 272 (65.5) 542 (65.5)
Affective responsiveness
subscale
2.6 (0.48),
410
2.6 (0.51),
408
2.6 (0.50),
818
2.1 (0.55),
411
2.1 (0.57),
415
2.1 (0.56),
826
Unhealthy (≥ 2.2),
n (%)
343 (83.7) 335 (82.1) 678 (82.9) 195 (47.4) 197 (47.5) 392 (47.5)
Roles subscale 2.5 (0.35),
412
2.5 (0.37),
409
2.5 (0.36),
821
2.5 (0.42),
415
2.5 (0.42),
415
2.5 (0.42),
830
Unhealthy (≥ 2.3),
n (%)
310 (75.2) 309 (75.6) 619 (75.4) 304 (73.3) 309 (74.5) 613 (73.9)
Communication subscale 2.6 (0.37),
413
2.6 (0.38),
409
2.6 (0.37),
822
2.3 (0.44),
413
2.3 (0.41),
415
2.3 (0.43),
828
Unhealthy (≥ 2.2),
n (%)
360 (87.2) 343 (83.9) 703 (85.5) 248 (60.0) 255 (61.4) 503 (60.7)
Problem-solving subscale 2.5 (0.47),
410
2.5 (0.53),
409
2.5 (0.50),
819
2.2 (0.48),
411
2.2 (0.48),
416
2.2 (0.48),
827
Unhealthy (≥ 2.2),
n (%)
331 (80.7) 306 (74.8) 637 (77.8) 234 (56.9) 249 (59.9) 483 (58.4)
a Higher scores represent higher callous and unemotional traits.
b Higher scores in all but the prosocial score represent greater issues in that category. For the prosocial score lower scores
represent greater issues. See Appendix 3 for categorisation of the total difficulties score (differs for young person
and caregiver).
c Higher scores are indicative of poorer family functioning.
Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license.
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Questionnaire follow-up
Postal questionnaires were completed and returned by 426 (51.2%) young people and 440 (52.9%)
caregivers at 3 months, and by 353 (42.4%) young people and 363 (43.6%) caregivers at 6 months
(Table 17). Response rates were higher in the FT group than in the TAU group.
TABLE 12 Young person baseline questionnaire outcomes
Outcome FT (N= 415) TAU (N= 417) Total (N= 832)
CRDSa
Total CDRS-R score (17–113), mean (SD), n 48.0 (14.19), 415 49.4 (13.29), 416 48.7 (13.76), 831
Not depressed (< 30), n (%) 45 (10.8) 24 (5.8) 69 (8.3)
Mild depression (30–42), n (%) 108 (26.0) 108 (26.0) 216 (26.0)
Moderate depression (43–57), n (%) 154 (37.1) 168 (40.4) 322 (38.7)
Severe depression (58–72), n (%) 91 (21.9) 102 (24.5) 193 (23.2)
Very severe depression (> 72), n (%) 17 (4.1) 14 (3.4) 31 (3.7)
PQ-LESb
Total PQ-LES-Q score (14–70), mean (SD), n 41.2 (9.37), 411 41.2 (9.45), 408 41.2 (9.41), 819
Overall self-assessment score (1–5), mean (SD), n 2.7 (1.04), 405 2.7 (1.00), 405 2.7 (1.02), 810
Overall, how has your life been?, n (%)
Very poor 57 (14.1) 53 (13.1) 110 (13.6)
Poor 107 (26.4) 102 (25.2) 209 (25.8)
Fair 162 (40.0) 167 (41.2) 329 (40.6)
Good 59 (14.6) 70 (17.3) 129 (15.9)
Very good 20 (4.9) 13 (3.2) 33 (4.1)
Beckc
Beck score (0–38),d mean (SD), n 10.8 (8.94), 408 10.4 (9.42), 408 10.6 (9.18), 816
Suicide ideation (BSS screening: Q4 and Q5) (Yes), n (%) 276 (67.6) 267 (65.4) 543 (66.5)
Number of previous suicide attempts (N) 395 403 798
Never attempted suicide, n (%) 176 (44.6) 170 (42.2) 346 (43.4)
Attempted suicide once, n (%) 114 (28.9) 124 (30.8) 238 (29.8)
Attempted suicide two or more times, n (%) 105 (26.6) 109 (27.0) 214 (26.8)
Severity of last suicide attempt (N) 213 226 439
Wish to die was low, n (%) 37 (17.4) 41 (18.1) 78 (17.8)
Wish to die was moderate, n (%) 78 (36.6) 79 (35.0) 157 (35.8)
Wish to die was high, n (%) 98 (46.0) 106 (46.9) 204 (46.5)
Hopelessnesse
Total hopelessness score (0–17),e mean (SD), n 7.7 (4.30), 409 7.3 (4.19), 406 7.5 (4.25), 815
a Higher scores represent greater levels of depression.
b Higher scores indicative of greater enjoyment and satisfaction.
c Median presented as Beck scores considerably skewed and zero inflated at follow-up.
d Higher scores indicate a higher level of suicide ideation.
e Higher scores reflect greater hopelessness or negative expectations towards the future.
Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
4.0 license
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Questionnaire completion at the 12- and 18-month researcher follow-up visits (Table 18) was similar to
postal follow-up, with 465 (55.9%) young person questionnaires completed at 12 months and 395
(47.5%) at 18 months, again with higher follow-up rates in the FT group than in the TAU group.
At the 12-month researcher visit, full follow-up, defined as completion of questionnaires by the young
person, caregiver and researcher, was achieved for 411 (49.4%) participants: 237 (57.1%) in the FT arm
and 174 (41.7%) in the TAU. In the case of 350 (42.1%) participants, 147 (35.4%) in the FT arm and 203
(48.7%) in the TAU arm, no questionnaires at all were completed. Of the 421 participants for whom at least
one questionnaire was missing, the most frequent reasons for loss to follow-up were that the researcher
was unable to contact the participant (29%), the researcher made contact but was unable to arrange the
visit (24.5%), both the young person and the caregiver withdrew consent (21.1%) and that a visit was
arranged but was subsequently cancelled or no one was at home when the researcher visited (8.3%).
TABLE 14 Number and reasons for eligibility violation
Reasons for eligibility violation, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Has the participant fulfilled the eligibility criteria?
Yes 410 (98.8) 406 (97.4) 816 (98.1)
No 5 (1.2) 11 (2.6) 16 (1.9)
Reason for protocol violation
Already being treated in CAMHS 3 (60.0) 4 (36.4) 7 (43.8)
Not intended to offer CAMHS follow-up for self-harma 1 (20.0) 2 (18.2) 3 (18.8)
Currently undergoing child Protection investigation 0 (0.0) 2 (18.2) 2 (12.5)
Not aged 11–17 years 0 (0.0) 1 (9.1) 1 (6.3)
Insufficient proficiency in English 0 (0.0) 1 (9.1) 1 (6.3)
Young person is pregnant 1 (20.0) 0 (0.0) 1 (6.3)
Sibling in SHIFT or already receiving FT in CAMHS 0 (0.0) 1 (9.1) 1 (6.3)
Total 5 (100.0) 11 (100.0) 16 (100.0)
a For young person to whom it was not intended to offer CAMHS follow-up for self-harm, one young person in TAU
turned 18 years old 4 days post randomisation and follow-up was offered by adult mental health services; the other
young person did go on to receive at least one allocated treatment session (one TAU session and six SHIFT FT
sessions each).
TABLE 13 Caregiver baseline questionnaire outcomes
Outcome, mean (SD), n FT (N= 415) TAU (N= 417) Total (N= 832)
GHQ-12a
GHQ-12 score. Likert scale (0–36) 17.7 (7.06), 414 18.6 (7.24), 415 18.2 (7.16), 829
Family Questionnaireb
Total score (20–80) 52.9 (10.67), 415 52.9 (10.85), 416 52.9 (10.75), 831
Emotional overinvolvement (10–40) 27.2 (4.93), 415 27.2 (5.03), 416 27.2 (4.98), 831
Criticism (10–40) 25.7 (6.97), 415 25.7 (7.06), 416 25.7 (7.01), 831
a Higher scores are indicative of greater psychological distress.
b Higher scores indicate greater levels of expressed emotion.
Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license.
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At the 18-month researcher visit, full follow-up was achieved for 352 (42.3%) participants: 197 (47.5%)
in the FT group and 155 (37.2%) in the TAU group. No questionnaires at all were completed for 412 (49.5%)
participants: 186 (44.8%) in the FT group and 226 (54.2%) in the TAU group. Of the 480 participants for
whom at least one questionnaire was missing, the most frequent reasons for loss to follow-up largely mirrored
the reasons at 12 months; however, inability to contact the participant and withdrawal were more frequently
cited as reasons for all questionnaires being missing (37.1% and 29.6% of participants, respectively).
The timing of questionnaire completion for the young person is presented in Figure 8 with completion
largely well defined around required time points and a similar distribution for the caregiver and the
researcher questionnaires (at 12 and 18 months).
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FIGURE 7 Time between randomisation and withdrawal.
TABLE 15 Withdrawals
Withdrawals, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Number of participants with at least one type of withdrawala 60 (14.5) 100 (24.0) 160 (19.2)
Young person with at least one type of withdrawal 56 (13.5) 97 (23.3) 153 (18.4)
Caregiver with at least one type of withdrawal 49 (11.8) 87 (20.9) 136 (16.3)
Withdrawn from
Clinical data collection 9 (2.2) 13 (3.1) 22 (2.6)
Parent/caregiver only 1 (0.2) 0 (0.0) 1 (0.1)
Both 8 (1.9) 13 (3.1) 21 (2.5)
Researcher follow-up visits 60 (14.5) 100 (24.0) 160 (19.2)
Young person only 11 (2.7) 13 (3.1) 24 (2.9)
Parent/caregiver only 4 (1.0) 3 (0.7) 7 (0.8)
Both 45 (10.8) 84 (20.1) 129 (15.5)
Postal questionnaire follow-up 48 (11.6) 88 (21.1) 136 (16.3)
Young person only 6 (1.4) 10 (2.4) 16 (1.9)
Parent/caregiver only 4 (1.0) 4 (1.0) 8 (1.0)
Both 38 (9.2) 74 (17.7) 112 (13.5)
a Note that withdrawals were made on a total of 167 occasions for 160 participants (five participants withdrew at two
different time points and one withdrew at three different time points).
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TABLE 17 Postal questionnaire follow-up
Follow-up completion,
n (%)
3 monthsa 6 monthsb
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
Young person completed 228 (54.9) 198 (47.5) 426 (51.2) 204 (49.2) 149 (35.7) 353 (42.4)
Caregiver completed 241 (58.1) 199 (47.7) 440 (52.9) 213 (51.3) 150 (36.0) 363 (43.6)
Overall questionnaire completion
Both young person
and caregiver
completed
213 (51.3) 180 (43.2) 393 (47.2) 187 (45.1) 125 (30.0) 312 (37.5)
Young person
completed only
15 (3.6) 18 (4.3) 33 (4.0) 17 (4.1) 24 (5.8) 41 (4.9)
Caregiver completed
only
28 (6.7) 19 (4.6) 47 (5.6) 26 (6.3) 25 (6.0) 51 (6.1)
Not completed 159 (38.3) 200 (48.0) 359 (43.1) 185 (44.6) 243 (58.3) 428 (51.4)
a At 3 months, a further three young person questionnaires and one caregiver questionnaire was completed
retrospectively at the 12-month researcher visit; and six young person and seven caregiver questionnaires were
completed retrospectively at the 18-month visit (health economic data only). Furthermore, six young person and four
caregiver questionnaires were completed over the telephone at 3 months.
b At 6 months: a further five young person and eight caregiver questionnaires were completed retrospectively at the
12-month researcher visit and 11 young person and 10 caregiver questionnaires were completed retrospectively at the
18-month visit (health economic data only). Furthermore, seven young person and eight caregiver questionnaires were
completed over the telephone at 6 months.
TABLE 16 Reasons for withdrawal
Reason for withdrawal, n (%)
Young persona Caregiver
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
Did not want to be involved any longer 10 (17.9) 28 (28.9) 38 (24.8) 10 (20.4) 20 (23.0) 30 (22.1)
Other things going on in the young
person’s or their family life
13 (23.2) 17 (17.5) 30 (19.6) 10 (20.4) 17 (19.5) 27 (19.9)
Improvement/moved on – did not want to
revisit past
7 (12.5) 19 (19.6) 26 (17.0) 4 (8.2) 15 (17.2) 19 (14.0)
Dissatisfaction with the therapy offered/
received
10 (17.9) 8 (8.2) 18 (11.8) 9 (18.4) 11 (12.6) 20 (14.7)
Dissatisfaction with research process/
burden of questionnaires
2 (3.6) 4 (4.1) 6 (3.9) 2 (4.1) 4 (4.6) 6 (4.4)
Did not want to think or talk about it 2 (3.6) 4 (4.1) 6 (3.9) 1 (2.0) 3 (3.4) 4 (2.9)
Young person moved away/no longer in
contact with caregiver
1 (1.8) 2 (2.1) 3 (2.0) 6 (12.2) 6 (6.9) 12 (8.8)
Missing 11 (19.6) 16 (16.5) 27 (17.6) 7 (14.3) 11 (12.6) 18 (13.2)
Total 56 (100) 97 (100) 153 (100) 49 (100) 87 (100) 136 (100)
a Note that the young person’s reasons for withdrawal are not mutually exclusive as one young person withdrew on two
occasions and provided different reasons each time.
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TABLE 18 Researcher-administered questionnaire completion and loss to follow-up
Questionnaire completion,
n (%)
12 month-follow-upa 18-month follow-upb
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
Young person questionnaire
completed
261 (62.9) 204 (48.9) 465 (55.9) 213 (51.3) 182 (43.6) 395 (47.5)
Caregiver questionnaire
completed
254 (61.2) 195 (46.8) 449 (54.0) 220 (53.0) 176 (42.2) 396 (47.6)
Researcher questionnaire
completed
248 (59.8) 189 (45.3) 437 (52.5) 204 (49.2) 165 (39.6) 369 (44.4)
Overall questionnaire completion
Young person, caregiver and
researcher completed
237 (57.1) 174 (41.7) 411 (49.4) 197 (47.5) 155 (37.2) 352 (42.3)
Young person and researcher
completed only
8 (1.9) 12 (2.9) 20 (2.4) 4 (1.0) 10 (2.4) 14 (1.7)
Young person and caregiver
completed only
13 (3.1) 14 (3.4) 27 (3.2) 10 (2.4) 12 (2.9) 22 (2.6)
Young person completed only 3 (0.7) 4 (1.0) 7 (0.8) 2 (0.5) 5 (1.2) 7 (0.8)
Caregiver completed only 4 (1.0) 7 (1.7) 11 (1.3) 13 (3.1) 9 (2.2) 22 (2.6)
Researcher completed only 3 (0.7) 3 (0.7) 6 (0.7) 3 (0.7) 0 (0.0) 3 (0.4)
Not completed at all 147 (35.4) 203 (48.7) 350 (42.1) 186 (44.8) 226 (54.2) 412 (49.5)
Reason (least one) not completed
Unable to contact 61 (34.3) 61 (25.1) 122 (29.0) 84 (38.5) 94 (35.9) 178 (37.1)
Contacted but unable to
arrange visit
40 (22.5) 63 (25.9) 103 (24.5) 41 (18.8) 41 (15.6) 82 (17.1)
Withdrawal (young person
and/or caregiver)
33 (18.5) 56 (23.0) 89 (21.1) 51 (23.4) 91 (34.7) 142 (29.6)
Visit cancelled/no one in 15 (8.4) 20 (8.2) 35 (8.3) 16 (7.3) 9 (3.4) 25 (5.2)
Young person moved 10 (5.6) 6 (2.5) 16 (3.8) 9 (4.1) 7 (2.7) 16 (3.3)
Visit not arranged in error 1 (0.6) 7 (2.9) 8 (1.9) 5 (2.3) 1 (0.4) 6 (1.3)
Young person in foster/
support care
1 (0.6) 5 (2.1) 6 (1.4) 0 (0.0) 2 (0.8) 2 (0.4)
Young person in hospital/
psychiatric unit
2 (1.1) 1 (0.4) 3 (0.7) 1 (0.5) 1 (0.4) 2 (0.4)
Risk issues 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.2)
Other 0 (0.0) 1 (0.4) 1 (0.2) 1 (0.5) 1 (0.4) 2 (0.4)
Not known 15 (8.4) 23 (9.5) 38 (9.0) 9 (4.1) 15 (5.7) 24 (5.0)
Total 178 (100.0) 243 (100.0) 421 (100.0) 218 (100.0) 262 (100.0) 480 (100.0)
a At 12 months, a further 24 researcher questionnaires (SASII only) were completed retrospectively at the 18-month visit.
The majority of 12-month questionnaires were completed face to face during the researcher visit, however, 30 young
person and 34 caregiver questionnaires were completed via post; one young person and five researcher questionnaires
were completed over the telephone; and the completion method was unclear for four young person questionnaires,
14 caregiver questionnaires and five researcher questionnaires. The caregiver booklet was known to have been
completed by a non-consenting caregiver for three participants.
b At 18 months, the majority of 18-month questionnaires were completed face to face during the researcher visit, however,
23 young person and 33 caregiver questionnaires were completed via post; five young person and 10 researcher
questionnaires were completed over the telephone; and the completion method was unclear for four young person
questionnaires, 13 caregiver questionnaires and two researcher questionnaires. The caregiver questionnaire was known to
have been completed by a non-consenting caregiver for one participant.
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Researcher unblinding
Unblinding of one or more researchers occurred on a total of 190 occasions for 161 (19.4%) participants:
109 times in 93 participants (22.4%) in the FT group and 81 times in 68 participants (16.3%) in the TAU
group (Table 19 and Figure 9). Unblinding most frequently occurred around the 12- and 18-month
researcher follow-up time points (45.3% and 17.4%, respectively); however, 25.8% of unblinding
occurred irrespective of a specific follow-up visit, largely within the first few months post randomisation
and because a clinician notified the researcher. The rates and reasons for unblinding were similar across
trial arms, with the most frequent cause of unblinding arising from the researcher being informed by the
caregiver (74 cases, 38.9%), a clinician (44 cases, 23.2%), the young person (34 cases, 17.9%) or both
the young person and the caregiver (18 cases, 9.5%), with a smaller number resulting from the young
person’s response implying a particular intervention (eight cases, 4.2%). Some unblinding occurred during
researcher follow-up: 22 prior to the assessment, 56 during the assessment and 30 after the assessment.
To investigate the potential impact of unblinding on the primary outcome, we identified attendances
where the only source of reason for presentation (self-harm related or not) was the unblinded researcher
record [due to unclassified HES data, or researcher collected only attendances (two cases)]. There were 23
such attendances, involving 16 participants. Ten participants in the FT arm accounted for 16 attendances
and six participants in the TAU arm accounted for seven attendances. The researchers reported three of
these attendances to be related to self-harm (two in the FT arm and one in the TAU arm) and hospital
follow-up took place a mean of 7 (SD 5.3) months after the researchers were unblinded (range
0–16 months).
Analysis populations
Intention-to-treat population
All summaries and analyses have been carried out using the ITT population, which consists of all
randomised participants, excluding those who withdrew their full consent to trial participation or for whom
written informed consent was not obtained.
Written informed consent was received for all randomised participants and, although some participants
withdrew their consent to researcher and postal contact and further clinical data collection, no participants
withdrew their full consent and asked for data already collected to be removed. Therefore, the ITT
population consists of all 832 participants.
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FIGURE 8 Time between randomisation and young person questionnaire follow-up.
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TABLE 19 Researcher unblinding
Research unblinding, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Number of participants for whom unblinding occurred 93 (22.4) 68 (16.3) 161 (19.4)
Number of times researchers were unblinded 109 81 190
Timing of unblinding
3 months 6 (5.5) 7 (8.6) 13 (6.8)
6 months 4 (3.7) 5 (6.2) 9 (4.7)
12 months 58 (53.2) 28 (34.6) 86 (45.3)
18 months 16 (14.7) 17 (21.0) 33 (17.4)
Other 25 (22.9) 24 (29.6) 49 (25.8)
Total 109 (100.0) 81 (100.0) 190 (100.0)
How did unblinding occur
Informed by caregiver 44 (40.4) 30 (37.0) 74 (38.9)
Informed by clinician 24 (22.0) 20 (24.7) 44 (23.2)
Informed by young person 19 (17.4) 15 (18.5) 34 (17.9)
Informed by young person and caregiver 14 (12.8) 4 (4.9) 18 (9.5)
Young person’s responses implied a particular intervention 2 (1.8) 6 (7.4) 8 (4.2)
Other 4 (3.7) 6 (7.4) 10 (5.3)
Missing 2 (1.8) 0 (0.0) 2 (1.1)
Total 109 (100.0) 81 (100.0) 190 (100.0)
When did unblinding occur during the 12- or 18-month visit
Before the assessment 14 (18.9) 8 (17.8) 22 (18.5)
During the assessment 38 (51.4) 18 (40.0) 56 (47.1)
After the assessment 17 (23.0) 13 (28.9) 30 (25.2)
Missing 5 (6.8) 6 (13.3) 11 (9.2)
Total 74 (100.0) 45 (100.0) 119 (100.0)
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FIGURE 9 Time between randomisation and unblinding.
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Two participants consented to all trial procedures excluding the registration of their details with NHS
Digital. Primary outcome data for these participants were not obtained from NHS Digital and were
collected only during visits by the researcher to acute trusts.
Complete written informed consent was obtained from the primary caregiver for all but two participants:
in one case, the caregiver’s consent form was not received and in another the form had not been dated.
Implied consent was, however, obtained for both caregivers following the completion of the caregiver set
of baseline questionnaires.
Per-protocol population
The per-protocol population consisted of the 816 (98.1%) participants without an eligibility violation.
The number of patients excluded from the per-protocol population and the reasons are summarised in
Table 14. No analyses were repeated for the per-protocol population.
Treatment summaries
Process and treatment summaries
Child and Adolescent Mental Health Services treatment pathways
Following randomisation, participants attended sessions within CAMHS following one of three main
pathways (Figure 10 and Tables 20 and 21).
l Initial SHIFT FT or TAU sessions as per randomisation: at least one session was attended by the
young person and/or a family member for 394 (94.9%) participants allocated to FT and 338 (81.1%)
participants allocated to TAU.
Slightly more participants in the TAU arm did not attend initial therapy: 34 (8.2%) participants,
compared with 21 (5.1%) participants in the FT arm. At the end of initial treatment, 233 (56.1%) FT
participants and 158 (37.9%) TAU participants had completed all of the required sessions.
In the FT arm, 173 (41.7%) participants attended SHIFT FT for more than the anticipated 6 months
or had more than the intended eight sessions. This was primarily as a result of unresolved issues,
difficulties with timetabling or cancellations.
l Referrals within CAMHS for additional or alternative sessions: referrals were reported for
98 (23.6%) participants allocated to FT during or following their SHIFT FT and for 96 (23.0%) TAU
participants referred as part of usual care. In the FT arm, 77 (18.6%) young people and/or a family
member attended at least one referred session while 68 (16.3%) participants did so in the TAU arm.
Reasons for referral show that the proportion of participants referred for psychiatric mental state/risk
assessment including medication was higher in the FT arm than in the TAU arm (43.9% vs. 28.1%), as
was the proportion referred for ongoing treatment after trial treatment finished (19.4% vs. 2.1%). In
contrast, the proportion of participants referred for alternative/additional therapeutic input was higher
in the TAU arm than in the FT arm (47.9% vs. 17.3%).
l Sessions that took place prior to initial SHIFT FT: in the FT arm, 84 (20.2%) participants and/or a
family member attended at least one session. These sessions occurred because they had been booked
prior to randomisation, or were booked as holding appointments because of waiting times, with the
majority of sessions (88.1%) consisting of assessment only. Only 13 (11.9%) sessions in 10 (2.4%)
participants were for treatment.
Overall, 399 (96.1%) FT participants and 339 (81.3%) TAU participants had at least one session attended
within CAMHS by either the participant (young person) or family member.
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TABLE 20 Attendance of sessions within initial randomised treatment in CAMHS
Attendance at sessions, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Any attendance (young person or family) during initial FT/TAU
Yes 394 (94.9) 338 (81.1) 732 (88.0)
No 21 (5.1) 34 (8.2) 55 (6.6)
Missing 0 (0.0) 45 (10.8) 45 (5.4)
Young person’s attendance summary
Did not attend at all 23 (5.5) 39 (9.4) 62 (7.5)
Dropped out with no negotiation 66 (15.9) 83 (19.9) 149 (17.9)
Negotiated ending in response to threat of dropout 92 (22.2) 57 (13.7) 149 (17.9)
Completed all required sessions 233 (56.1) 158 (37.9) 391 (47.0)
Treatment ongoing 0 (0.0) 10 (2.4) 10 (1.2)
Missing 1 (0.2) 70 (16.8) 71 (8.5)
Did the family attend SHIFT FT for more than 6 months and/or more than eight sessions?
Yes 173 (41.7)
No 242 (58.3)
Rationale for additional time/sessions
Issues not resolved, more sessions required 104 (60.1)
Difficulty timetabling/cancellations 42 (24.3)
Othera 5 (2.9)
Missing 22 (12.7)
Total – attending for > 6 months or > 8 sessions 173 (100.0)
a Other reasons for additional time/sessions were that the family was keen to have expected final session; because of
concerns arising and to minimise risks between SHIFT ending and referral for assessment and treatment commencing in
CAMHS; developmental history had to be taken for autistic spectrum disorder assessment referral; father joined therapy,
which extended the work; family felt issues were resolved.
Initial FT
n = 394 (94.9%)
267
Missing, n = 45 (10.8%)
54
FT, n = 415 TAU, n = 417
Initial TAU
n = 338 (81.1%)
271
Referrals
n = 77
(18.6%)
3
n = 68
(16.3%)
1
Sessions
prior to FT
n = 84 (20.2%)
1
1
28
45 67
Did not attend at all, n = 33 (7.9%)Did not attend at all, n = 16 (3.9%)
FIGURE 10 Diagram of attendance of at least one session, by anyone, within CAMHS pathways.
DOI: 10.3310/hta22120 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 12
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Cottrell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
TABLE 21 Referrals within CAMHS and additional sessions attended within CAMHS
Referrals within CAMHS and additional CAMHS sessions, n (%)
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
Young person referred within CAMHS
Yesa 98 (23.6) 96 (23.0) 194 (23.3)
Attended referred session(s) 77 (18.6) 68 (16.3) 145 (17.4)
No 314 (75.7) 267 (64.0) 581 (69.8)
Missing 3 (0.7) 54 (12.9) 57 (6.9)
Reason for referral (non-mutually exclusive)
Assessment
Psychiatric mental state/risk assessment including medication 43 (43.9) 27 (28.1) 70 (36.1)
Treatment
For alternative/additional therapeutic input 17 (17.3) 46 (47.9) 63 (32.5)
Ongoing treatment after trial treatment finished 19 (19.4) 2 (2.1) 21 (10.8)
For more intensive treatment (e.g. day/inpatient unit) 3 (3.1) 2 (2.1) 5 (2.6)
Assessment/treatment
For input to specific comorbid diagnoses (e.g. ASD, eating disorder) 12 (12.2) 7 (7.3) 19 (9.8)
Other
Administrative reasons (e.g. change of address, local protocol, travel
problems)
3 (3.1) 4 (4.2) 7 (3.6)
Missing 11 (11.2) 16 (16.7) 27 (13.9)
Total number referred 98 (100) 96 (100) 194 (100)
Young person attended sessions prior to SHIFT FT
Yes 84 (20.2) N/A N/A
Treatment sessions 8 (1.9)
Assessment sessions 74 (17.8)
Assessment and treatment sessions 2 (0.5)
No 302 (72.8)
Missing 29 (7.0)
Purpose of attended sessions
Treatment 13 (11.9)
Assessment 96 (88.1)
Total number of sessions prior to SHIFT 109 (100.0)
N/A, not applicable.
a Twenty-six young persons (11 FT, 15 TAU) were reported to have been referred but were missing details of
appointments for the referral and a further 23 young persons (10 FT, 13 TAU) were referred but attended no sessions.
There were a total of 202 referrals in 194 young persons with 141 (72 FT, 69 TAU) referred once, 24 (14 FT, 10 TAU)
referred twice, one young person (TAU) referred three times and two young persons (one FT, one TAU) referred five
times each, and the remaining 26 were missing details of all referrals.
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Number and duration of sessions within Child and Adolescent Mental Health Services
During participants’ initial randomised treatment, the number of SHIFT FT sessions attended by the family
or the young person ranged from 0 to 21, with a mean of 6.1 (SD 4.02) sessions over a mean period of
4.7 (SD 3.03) months. The number of initial sessions attended in the TAU arm was more variable, ranging
from 0 to 163, with a mean of 8.2 (SD 12.61) sessions over a mean period of 5.7 (SD 5.41) months
(Tables 22 and 23 and Figures 11–14). As a result of highly skewed data, although some TAU participants
a large number of sessions, the overall median number of sessions and duration of attendance was lower
in the TAU arm, a median of 4 sessions over 4.1 months, compared with 6 sessions over 5.1 months in the
FT arm.
TABLE 22 Number of CAMHS sessions attended during initial randomised treatment, additional referrals and
sessions prior to SHIFT FT
Number of
sessions
attended
FT, n (%) (N= 415) TAU, n (%) (N= 417)
Total, n (%)
(N= 832)
Initial FT
Additional
TAU
referral
Sessions
prior to
initial FT
All
sessions
Initial
TAU
Additional
TAU
referral
All
sessions
All
sessions
0 21 (5.1) 324 (78.1) 302 (72.8) 16 (3.9) 34 (8.2) 280 (67.1) 33 (7.9) 49 (5.9)
1 40 (9.6) 16 (3.9) 68 (16.4) 28 (6.7) 52 (12.5) 23 (5.5) 45 (10.8) 73 (8.8)
2 29 (7.0) 19 (4.6) 11 (2.7) 32 (7.7) 37 (8.9) 10 (2.4) 36 (8.6) 68 (8.2)
3 37 (8.9) 2 (0.5) 2 (0.5) 36 (8.7) 45 (10.8) 8 (1.9) 43 (10.3) 79 (9.5)
4 32 (7.7) 5 (1.2) 2 (0.5) 29 (7.0) 23 (5.5) 4 (1.0) 23 (5.5) 52 (6.3)
5 29 (7.0) 6 (1.4) 1 (0.2) 31 (7.5) 28 (6.7) 4 (1.0) 30 (7.2) 61 (7.3)
6 43 (10.4) 3 (0.7) 41 (9.9) 13 (3.1) 1 (0.2) 15 (3.6) 56 (6.7)
7 29 (7.0) 2 (0.5) 32 (7.7) 15 (3.6) 2 (0.5) 10 (2.4) 42 (5.0)
8 50 (12.0) 4 (1.0) 38 (9.2) 11 (2.6) 1 (0.2) 12 (2.9) 50 (6.0)
9 30 (7.2) 3 (0.7) 21 (5.1) 12 (2.9) 2 (0.5) 11 (2.6) 32 (3.8)
10 24 (5.8) 2 (0.5) 23 (5.5) 10 (2.4) 4 (1.0) 9 (2.2) 32 (3.8)
11–15 38 (9.2) 7 (1.7) 48 (11.6) 29 (7.0) 2 (0.5) 32 (7.7) 80 (9.6)
16–20 12 (2.9) 3 (0.7) 25 (6.0) 27 (6.5) 3 (0.7) 26 (6.2) 51 (6.1)
21–25 1 (0.2) 0 (0.0) 6 (1.4) 17 (4.1) 2 (0.5) 19 (4.6) 25 (3.0)
> 26 0 (0.0) 5 (1.2) 9 (2.2) 19 (4.6) 2 (0.5) 28 (6.7) 37 (4.4)
Missing 0 (0.0) 14 (3.4) 29 (7.0) 0 (0.0) 45 (10.8) 69 (16.5) 45 (10.8) 45 (5.4)
Number of sessions attended
N 415 401 386 415 372 348 372 787
Missing 0 14 29 0 45 69 45 45
Mean (SD) 6.1 (4.02) 1.4 (5.39) 0.3 (0.64) 7.7 (7.23) 8.2 (12.61) 1.1 (4.44) 9.3 (13.85) 8.5 (10.90)
Median (range) 6 (0–21) 0 (0–57) 0 (0–5) 6 (0–70) 4 (0–163) 0 (0–51) 5 (0–163) 6 (0–163)
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The inclusion of additional referred sessions attended by 96 (23.0%) participants in the TAU arm referred
within CAMHS to additional sessions or sessions alternative to their initial treatment provides the overall
summary of all TAU received. Combined with initial TAU sessions, the overall number of all sessions
attended ranged from 0 to 163, with a mean of 9.3 (SD 13.85) sessions over a mean period of 6.2
(SD 5.63) months and a median of 5 sessions over a period of 4.4 months.
In the FT arm, 98 (23.6%) participants received additional TAU sessions as part of a referral within
CAMHS. The number of referred sessions attended ranged from 0 to 57, with a mean of 1.4 (SD 5.39)
sessions over a mean period of 4.7 (4.99) months and a median of 0 sessions over 3 months. Combined
with initial SHIFT FT sessions and sessions prior to starting FT, the overall number of all sessions attended in
the FT arm ranged from 0 to 70, with a mean of 7.7 (SD 7.23) sessions over a mean period of 5.5 months
(SD 4.06 months) and a median of 6 sessions over a median period of 5.3 months.
TABLE 23 Timing and duration of treatment
Timing and
duration of
treatment
FT TAU Total
Initial FT
(N= 415)
Additional
TAU
referral
(N= 98)
All
sessions
(N= 415)
Initial
TAU
(N= 417)
Additional
TAU
referral
(N= 96)
All
sessions
(N= 417)
All
sessions
(N= 832)
Time to first
attendance
(days/months) Days Months Days Days Months Days Days
n 394 77 399 338 67 339 738
Missing 0 11 0 45 16 45 45
Did not attend
sessions
21 10 16 34 13 33 49
Mean (SD) 24.5
(21.49)
4.8 (3.75) 19.9
(18.81)
37.0
(44.87)
6.2 (4.27) 36.8
(44.77)
27.6
(34.36)
Median (range) 18.0
(1–137)
4.1
(0.1–12.9)
15.0
(0–137)
22.0
(0–380)
5.3
(0.2–17.7)
22.0
(0–380)
17.0
(0–380)
Time to last attendance (months)
n 394 77 399 338 67 339 738
Missing 0 11 0 45 16 45 45
Did not attend
sessions
21 10 16 34 13 33 49
Mean (SD) 5.5 (3.06) 9.5 (5.83) 6.2 (4.03) 6.9 (5.40) 9.3 (5.31) 7.4 (5.59) 6.7 (4.84)
Median (range) 5.8
(0.3–17.4)
8.7
(0.7–18.0)
5.8
(0.3–18.0)
5.0
(0.2–18.0)
9.0
(1.1–18.0)
5.3
(0.2–18.0)
5.7
(0.2–18.0)
Duration first to last attendance (months)
n 394 77 399 338 67 339 738
Missing 21 21 16 79 29 78 94
Did not attend
sessions
21 10 16 34 13 33 49
Mean (SD) 4.7 (3.03) 4.7 (4.99) 5.5 (4.06) 5.7 (5.41) 3.1 (3.83) 6.2 (5.63) 5.8 (4.86)
Median (range) 5.1
(0.0–15.7)
3.0
(0.0–17.7)
5.3
(0.0–17.9)
4.1
(0.0–17.7)
1.4
(0.0–15.4)
4.4
(0.0–17.9)
5.1
(0.0–17.9)
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FIGURE 11 Number of initial sessions attended by anyone. Not displayed are three further participants in the TAU
arm who had 75, 90 and 163 initial and overall sessions attended by anyone and one participant in the FT arm who
had 70 overall sessions attended by anyone. (a) FT and (b) TAU.
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FIGURE 12 Number of overall sessions attended by anyone. Not displayed are three further participants in the
TAU arm with attendance of 75, 90 and 163 initial and overall sessions and one participant in the FT arm with
attendance of 70 overall sessions. (a) FT and (b) TAU.
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Composition of sessions
The vast majority of SHIFT FT sessions were family sessions (2412, 95.3%) as opposed to individual
sessions, with a mean of 1.5 (SD 0.75) family members attending in addition to, or without, the young
person. TAU consisted of 1464 (47.7%) individual sessions, 1353 (44.1%) family sessions, 109 (3.6%)
individual and family sessions (when a single session was mixed) and 98 (3.2%) group sessions (involving a
group of young people led by a therapist). The mean number of therapists per session was lower for TAU
sessions (1.2, SD 0.56) than for FT sessions (2.3, SD 0.72) (Table 24).
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FIGURE 13 Duration of initial randomised treatment (excluding referrals and sessions prior to SHIFT FT). (a) FT and
(b) TAU.
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FIGURE 14 Duration of overall treatment (including referrals and sessions prior to SHIFT FT). (a) FT and (b) TAU.
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TABLE 24 Length of sessions, number of therapists and family members involved
Length of
sessions,
number of
therapists
and family
members
involved
FT (N= 415) TAU (N= 417)
Total
(N= 832)
Initial FT
Additional
TAU
referral
Sessions
prior to
initial FT
All
sessions Initial TAU
Additional
TAU
referral
All
sessions
All
sessions
Number of
participants
represented
at or
attending at
least one
session
394 77 84 399 338 68 339 738
Number of
sessions
attended
2532 566 109 3207 3066 400 3466 6673
Length of sessions (minutes)
N 2422 363 Missing 2785 1825 218 2043 4828
Missing 110 203 422 1241 182 1423 1845
Mean (SD) 74.1
(14.36)
60.3
(13.75)
72.3
(15.01)
60.4
(9.88)
60.2
(9.96)
60.3
(9.89)
67.2
(14.36)
Median
(range)
75
(15–150)
60.0
(30–120)
70
(15–150)
60
(10–180)
60
(15–120)
60.0
(10–180)
60
(10–180)
Number of therapists involved
N 2525 549 Missing 3074 2944 394 3338 6412
Missing 7 17 133 122 6 128 261
Mean (SD) 2.3 (0.72) 1.3 (0.71) 2.2 (0.82) 1.2 (0.56) 1.4 (0.74) 1.2 (0.59) 1.7 (0.85)
Median
(range)
2.0
(1.0–4.0)
1.0
(1.0–5.0)
2.0
(1.0–5.0)
1.0
(1.0–8.0)
1.0
(1.0–5.0)
1.0
(1.0–8.0)
1.0
(1.0–8.0)
Type of session, n (%)
Individual 115 (4.5) 274 (48.4) 56 (51.4) 445 (13.9) 1464 (47.7) 203 (50.8) 1667 (48.1) 2112 (31.6)
Family 2412 (95.3) 247 (43.6) 47 (43.1) 2716 (84.7) 1353 (44.1) 174 (43.5) 1527 (44.1) 4243 (63.6)
Group N/A 26 (4.6) 1 (0.9) 27 (0.8) 98 (3.2) 21 (5.3) 119 (3.4) 146 (2.2)
Individual
and family
N/A 10 (1.8) 5 (4.6) 5 (0.2) 109 (3.6) 0 (0.0) 109 (3.1) 114 (1.7)
Missing 5 (0.2) 9 (1.6) 0 (0.0) 14 (0.4) 42 (1.4) 2 (0.5) 44 (1.3) 58 (0.9)
Number of family members in family sessions
N 2412 251 Missing 2663 1392 153 1545 4208
Missing 0 6 58 70 21 91 149
Mean (SD) 1.5 (0.75) 1.3 (0.62) 1.5 (0.75) 1.4 (0.67) 1.4 (0.78) 1.4 (0.68) 1.5 (0.73)
Median
(range)
1.0
(1.0–5.0)
1.0
(1.0–4.0)
1.0
(1.0–5.0)
1.0
(1.0–6.0)
1.0
(1.0–7.0)
1.0
(1.0–7.0)
1.0
(1.0–7.0)
N/A, not applicable.
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Overall therapeutic orientation and therapy pathways
Overall, 398 (95.9%) FT participants and 301 (72.2%) TAU participants attended at least one
therapeutically orientated session (excluding assessment sessions), and one FT participant and 32 TAU
participants attended assessment sessions only (Table 25). A further six TAU participants attended only
sessions for which the content was unknown, while 16 (3.9%) FT participants and 33 (7.9%) TAU
participants attended no sessions at all.
Therapeutic orientation of sessions in TAU varied considerably (Table 26). One-quarter of all sessions were for
supportive therapy/counselling, 17.4% were for cognitive–behavioural therapy (CBT), 11.5% were for family
work, 10.7% were for formal systemic FT and < 5% were for each of psychodynamic therapy, communication
skills/problem-solving, interpersonal therapy, dialectical behaviour therapy (DBT), psychoeducational therapies
and other therapy. The most frequently attended sessions on a per-participant basis were supportive therapy/
counselling, family work, CBT and formal systemic FT. A substantial proportion of sessions were for assessment
rather than therapy, with 12.5% of all sessions in 161 (38.6%) participants for other assessment/review.
Seventy-nine per cent of all sessions attended in the FT arm were SHIFT sessions, with other types of
sessions accounting for < 5% each. Eighty-nine participants (21.4%) attended an assessment/review and
47 participants (11.3%) attended a mental state/risk assessment.
The main therapeutic orientation(s), making up one-third or more of all therapy sessions per participant
(excluding assessment and unknown sessions), varied from one to a maximum of three main therapies per
participant (Table 27).
In the TAU arm, supportive therapy/counselling was again one of the main therapies for 115 (27.6%)
participants, CBT was the main therapy for 73 (17.5%), family work was the main therapy for 66 (15.8%)
and formal systemic FT was the main therapy for 57 (13.7%). As the main therapy comprised up to three
TABLE 25 Treatment mix of sessions: therapy and assessment
Treatment mix of sessions, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Any therapy sessions attended?
Yes 398 (95.9) 301 (72.2) 699 (84.0)
No 17 (4.1) 71 (17.0) 88 (10.6)
Missing 0 (0.0) 45 (10.8) 45 (5.4)
Any assessment sessions attended?
Yes 117 (28.2) 197 (47.2) 314 (37.7)
No 298 (71.8) 175 (42.0) 473 (56.9)
Missing 0 (0.0) 45 (10.8) 45 (5.4)
Overall session mix
No sessions attended 16 (3.9) 33 (7.9) 49 (5.9)
Assessment only 1 (0.2) 32 (7.7) 33 (4.0)
Therapy only 282 (68.0) 136 (32.6) 418 (50.2)
Assessment and therapy 116 (28.0) 165 (39.6) 281 (33.8)
Unknown only 0 (0.0) 6 (1.4) 6 (0.7)
Missing 0 (0.0) 45 (10.8) 45 (5.4)
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different therapies, these summaries are not mutually exclusive and full details of combinations of therapies
can be found in Table 28. In the TAU arm, 256 (61.4%) participants attended only one type of therapy in
over one-third of all attended sessions, 46 (11.0%) participants attended two main therapies and five
(1.2%) participants attended three main therapies.
In the FT arm, the allocated therapy, SHIFT, was the main therapy attended by the vast majority (94%) of
participants; however, the main therapies attended in addition to, or instead of, SHIFT are detailed in
Table 29.
Eighty-seven (20.9%) participants in the TAU arm were reported to have attended at least one formal
systemic FT session, albeit of a type different from SHIFT, which is a specific manualised form of formal
systemic FT (Table 30 and Figure 15). Furthermore, five (1.2%) participants in the FT arm, in addition to
attending 7–16 SHIFT sessions, also attended 1–5 sessions of formal systemic FT as part of a referral within
CAMHS for ongoing treatment after trial treatment finished.
TABLE 26 Therapeutic orientation of all sessions and per participant
Therapeutic orientation of sessions, n (%)
Therapeutic orientation per
session
Therapeutic orientation per
participant (non-mutually
exclusive)
FT (N= 3207) TAU (N= 3466) FT (N= 415) TAU (N= 417)
Therapy
SHIFT FT 2532 (79.0) 0 (0.0) 394 (94.9) 0 (0.0)
Supportive therapy/counselling 142 (4.4) 871 (25.1) 21 (5.1) 158 (37.9)
CBT 79 (2.5) 602 (17.4) 10 (2.4) 88 (21.1)
Family work 35 (1.1) 397 (11.5) 9 (2.2) 116 (27.8)
Formal systemic FT 14 (0.4) 371 (10.7) 5 (1.2) 87 (20.9)
Communication skills/problem-solving 0 (0.0) 62 (1.8) 0 (0.0) 29 (7.0)
Psychoeducational 22 (0.7) 29 (0.8) 6 (1.4) 18 (4.3)
Interpersonal therapy 5 (0.2) 38 (1.1) 1 (0.2) 10 (2.4)
DBT 0 (0.0) 30 (0.9) 0 (0.0) 8 (1.9)
Psychodynamic 1 (0.0) 131 (3.8) 1 (0.2) 5 (1.2)
Other therapy 78 (2.4) 168 (4.8) 17 (4.1) 28 (6.7)
Assessment
Mental state/risk assessment 110 (3.4) 137 (4.0) 47 (11.3) 58 (13.9)
Other assessment/review 153 (4.8) 434 (12.5) 89 (21.4) 161 (38.6)
Medication review 26 (0.8) 80 (2.3) 13 (3.1) 28 (6.7)
Non-therapya 2 (0.1) 27 (0.8) 1 (0.2) 23 (5.5)
Unknown: per session/all sessions 8 (0.2) 89 (2.6) 5 (1.2) 27 (6.5)
No sessions attended – – 16 (3.9) 33 (7.9)
Missing all treatment data – – 0 (0.0) 45 (10.8)
DBT, dialectical behaviour therapy.
a For example, introductory meetings/administration.
Reproduced from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
4.0 license.
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TABLE 27 Main therapeutic orientation(s) of sessions (> 33% of therapy sessions)
FT (N= 415) TAU (N= 417)
Main therapy (not mutually exclusive) n (%) Main therapy (not mutually exclusive) n (%)
No sessions attended 16 (3.9) No sessions attended 33 (7.9)
Assessment only 1 (0.2) Assessment only 32 (7.7)
SHIFT FT 389 (93.7) Supportive therapy/counselling 115 (27.6)
Supportive therapy/counselling 14 (3.4) CBT 73 (17.5)
CBT 6 (1.4) Family work 66 (15.8)
Other therapy 6 (1.4) Formal systemic FT 57 (13.7)
Psychoeducational 3 (0.7) Communication skills/problem-solving 15 (3.6)
Family work 2 (0.5) Other therapy 15 (3.6)
Interpersonal therapy 1 (0.2) Psychoeducational 5 (1.2)
Interpersonal therapy 4 (1.0)
Psychodynamic 4 (1.0)
DBT 3 (0.7)
Unknown session orientation 6 (1.4)
Missing all treatment data 45 (10.8)
Note
Up to three main therapeutic orientations were derived per young person. Note that four TAU young persons had evenly
spread sessions across three orientations, with each slightly below the 33% threshold, and these have been included.
TABLE 28 Main therapeutic orientation of sessions (> 33% of therapy sessions) for participants randomised to
receive TAU (mutually exclusive)
Main therapy, n (%) TAU (N= 417)
Single main therapy 256 (61.4)
Supportive therapy/counselling 85 (20.4)
CBT 51 (12.2)
Family work 44 (10.6)
Formal systemic FT 43 (10.3)
Other therapy 9 (2.2)
Communication skills/problem-solving 8 (1.9)
Unknown only 6 (1.4)
Interpersonal therapy 4 (1.0)
Psychodynamic 4 (1.0)
Psychoeducational 2 (0.5)
Two main therapies 46 (11.0)
Supportive therapy/counselling, family work 14 (3.4)
CBT, formal systemic FT 7 (1.7)
CBT, supportive therapy/counselling 6 (1.4)
CBT, family work 2 (0.5)
Communication skills/problem-solving, family work 2 (0.5)
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TABLE 28 Main therapeutic orientation of sessions (> 33% of therapy sessions) for participants randomised to
receive TAU (mutually exclusive) (continued )
Main therapy, n (%) TAU (N= 417)
DBT, supportive therapy/counselling 2 (0.5)
Formal systemic FT, other therapy 2 (0.5)
Supportive therapy/counselling, communication skills/problem-solving 2 (0.5)
Supportive therapy/counselling, other therapy 2 (0.5)
CBT, DBT 1 (0.2)
CBT, other therapy 1 (0.2)
CBT, psychoeducational 1 (0.2)
Communication skills/problem solving, formal systemic FT 1 (0.2)
Family work, formal systemic FT 1 (0.2)
Psycho-educational, supportive therapy/counselling 1 (0.2)
Supportive therapy/counselling, formal systemic FT 1 (0.2)
Three main therapies 5 (1.2)
CBT, family work, formal systemic FT 1 (0.2)
CBT, formal systemic FT, other therapy 1 (0.2)
CBT, supportive therapy/counselling, communication skills/problem-solving 1 (0.2)
CBT, supportive therapy/counselling, family work 1 (0.2)
Psychoeducational, communication skills/problem-solving, family work 1 (0.2)
Assessment only 32 (7.7)
No sessions attended 33 (7.9)
Missing 45 (10.8)
TABLE 29 Main therapeutic orientation of sessions (> 33% of therapy sessions) attended by participants
randomised to receive FT (mutually exclusive)
Main therapy, n (%) FT (N= 415)
Single main therapy 375 (90.4)
SHIFT FT 367 (88.4)
Supportive therapy/counselling 4 (1.0)
Other therapy 2 (0.5)
Family work 1 (0.2)
Psychoeducational 1 (0.2)
Two main therapies 23 (5.5)
SHIFT FT, supportive therapy/counselling 10 (2.4)
SHIFT FT, CBT 5 (1.2)
SHIFT FT, other therapy 4 (1.0)
SHIFT FT, psychoeducational 2 (0.5)
SHIFT FT, interpersonal therapy 1 (0.2)
CBT, family work 1 (0.2)
Assessment only 1 (0.2)
No sessions attended 16 (3.9)
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TABLE 30 Summary of FT sessions received
FT sessions received, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Any SHIFT FT?
Yes 394 (94.9) 0 (0.0) 394 (47.4)
No 21 (5.1) 372 (89.2) 393 (47.2)
Missing 0 (0.0) 45 (10.8) 45 (5.4)
Any TAU formal systemic FT?
Yes 5 (1.2)a 87 (20.9) 92 (11.1)
No 410 (98.8) 285 (68.3) 695 (83.5)
Missing 0 (0.0) 45 (10.8) 45 (5.4)
Any FT?
Yes 394 (94.9) 87 (20.9) 481 (57.8)
SHIFT FT 389 (93.7) 0 (0.0) 389 (46.8)
SHIFT FT and TAU FT 5 (1.2) N/A 5 (0.6)
TAU FT 0 (0.0) 87 (20.9) 87 (10.5)
No 21 (5.1) 285 (68.3) 306 (36.8)
Missing 0 (0.0) 45 (10.8) 45 (5.4)
N/A, not applicable.
a For three young persons, the TAU Formal systemic FT was delivered by non-SHIFT clinicians. For one young person, a
trained SHIFT clinician was involved; however, this clinician had not been part of the assigned team initially treating the
young person for SHIFT, whereas for the remaining young person, two additional non-SHIFT formal systemic FT sessions
were received immediately following the end of SHIFT FT involving the same clinicians, albeit with the addition of a
non-SHIFT clinician who continued to then see the young person for family work and other therapy.
SHIFT FT
FT = 394 (94.9%)
No FT, TAU = 285 (68.3%)
Missing: TAU = 45 
TAU formal
systemic FT
TAU = 87 (20.9%)
FT = 5 (1.2%)
No FT, FT = 21 (5.1%)
389
87
5
FT, n = 415 TAU, n = 417
FIGURE 15 Diagram of FT attendance across trial arms.
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Telephone contact, liaison and case manager meetings during initial treatment
During initial randomised treatment (i.e. not including further referrals within CAMHS), rates of telephone
contact with participants’ families were similar in both trial arms with 190 (45.8%) FT participants and
170 (40.8%) TAU participants receiving telephone contact, lasting in total a mean of 54.1 minutes and
49.1 minutes, respectively (Table 31).
Rates of liaison with other agencies by CAMHS were also similar in both groups (Table 32), this being the
case for 151 (36.4%) FT participants and 136 (32.6%) TAU participants. The most frequently contacted
host agencies were school/education services, which were contacted about 194 young people (67.6% of
TABLE 31 Details of telephone contact with participants between sessions
Telephone contact FT (N= 415) TAU (N= 417) Total (N= 832)
Any telephone contact with family between sessions, n (%)
Yes 190 (45.8) 170 (40.8) 360 (43.3)
No 212 (51.1) 194 (46.5) 406 (48.8)
Missing 13 (3.1) 53 (12.7) 66 (7.9)
Total length of telephone contact (minutes)
N 180 125 305
Missing 10 45 55
Mean (SD) 54.1 (47.47) 49.1 (50.56) 52.1 (48.74)
Median (range) 40.0 (7–295) 30.0 (5–442) 40.0 (5–442)
TABLE 32 Liaison with other agencies during initial therapy
Liaison with other agencies, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Liaison with other agencies during treatment
Yes 151 (36.4) 136 (32.6) 287 (34.5)
No 258 (62.2) 227 (54.4) 485 (58.3)
Missing 6 (1.4) 54 (12.9) 60 (7.2)
Host agency – per participant (non-mutually exclusive)
School/education 104 (68.9) 90 (66.2) 194 (67.6)
Social services 43 (28.5) 44 (32.4) 87 (30.3)
Child protection agency 5 (3.3) 4 (2.9) 9 (3.1)
Youth offending teams 2 (1.3) 7 (5.1) 9 (3.1)
Counselling services 7 (4.6) 15 (11.0) 22 (7.7)
Othera 47 (31.1) 53 (39.0) 100 (34.8)
Missing 2 (1.3) 7 (5.1) 9 (3.1)
Total 151 (100.0) 136 (100.0) 287 (100.0)
a Other agencies included A&E/hospital, adult mental health, adoption services, other CAMHS, dietitian, domestic violence
group, psychiatrist, family support service, GP, housing support, insight team, voluntary/charity (Connexions, Befriending
Society, Signpost), pharmacy, police, safeguarding, youth worker.
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those for whom liaison took place), followed by social services, which were contacted about 87 young
people (30.3%).
During the delivery of initial SHIFT FT, meetings were held with the case manager of 149 (35.9%)
participants. A total of 299 such meetings were held, with a mean of two meetings per participant, and
involved one professional; in the majority of meetings (71.2%) the family were not in attendance and the
meeting took place face to face (62.2%).
Contamination
Nine SHIFT-trained family therapists were involved in the direct contamination of 11 (2.6%) young people
in the TAU arm, with these participants attending at least one session in CAMHS with a SHIFT-trained
family therapist. Six (1.4%) attended at least one formal systemic FT session (between one and nine
sessions) with the SHIFT family therapist acting as the lead therapist for three (0.7%) participants and as
part of the reflecting team for three (0.7%) participants. Two (0.5%) further participants received family
work-based sessions with the SHIFT family therapist and sessions with the SHIFT family therapist for the
remaining three (0.7%) participants were for supportive therapy/counselling and review only.
Formal systemic FT or family work sessions involving SHIFT-trained family therapists and TAU participants
led to the possible contamination of a further nine TAU clinicians who were also present during these
sessions. Four of these TAU clinicians subsequently saw at least one further participant, a further six (1.4%)
TAU participants in total, of whom four (1%) received family work (but no systemic FT).
A further source of contamination occurred during 11 SHIFT FT sessions for seven (1.7%) FT participants,
during which a TAU clinician was present in addition to the SHIFT family therapists (all different SHIFT FT
teams). A total of seven TAU clinicians were contaminated in this way, three of whom subsequently saw at
least one further participant, a further seven (1.7%) TAU participants in total, of whom one received two
sessions of systemic FT and a further two received family work sessions.
Therapist characteristics and training
Thirty-one family therapists received training in SHIFT FT. Training was conducted in formal group sessions
for the majority of family therapists and via individual training and observation for those few therapists
who joined the trial late following staff changes. Family therapists recruited early to the trial had the
opportunity to deliver therapy to at least one pilot case prior to delivering trial FT; therapists recruited
following staff changes always observed existing team members prior to commencing trial FT.
Baseline characteristics were received for 189 (65.6%) of the 288 treating therapists: 29 (93.5%) SHIFT
family therapists and 160 (62.3%) TAU clinicians. The mean age of family therapists was 48.9 (SD 6.95)
years and of TAU clinicians was 43.6 (SD 10.58) years. There were more female therapists than males: 21
family therapists (72.4%) and 117 (73.1%) TAU clinicians were women. Job titles varied for TAU clinicians,
with over half listed as practitioners (31, 19.4%), clinical psychologists (28, 17.5%) or nurses (27, 16.9%).
Eighteen (11.3%) TAU clinicians had family therapist as their job title. As the use of job titles changes
from service to service, TAU clinicians were classified into ‘senior’ (doctors at consultant level and all other
non-medical staff on pay grade 8C or above) and ‘non-senior’ (all other clinicians). All SHIFT family
therapists were classified as ‘senior’ whereas only five (3.1%) TAU clinicians were. The majority of family
therapists (20, 60.6%) reported that their basic qualification was in social work, while TAU clinicians were
trained in nursing (51, 25.2%), social work (30, 16.9%) and clinical psychology (29, 16.4%). Of the
additional training received, 45.9% of training received by the SHIFT family therapists was in formal
systemic therapy, compared with 21.4% for the TAU clinicians. TAU clinicians received more additional
training in CBT and behaviour therapy and communication skills/problem-solving techniques.
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Adherence and supervision
One thousand six hundred and fifty-four (65.3%) initial FT sessions were recorded and, of those, the
digital versatile disc (DVD) was returned for 1433 (86.6%). Fifty-two (3.6%) DVDs underwent initial review
and, of these, the young person was present in all but one session. Twenty-three (44.2%) reviewed
recordings related to the first therapy session and 29 (55.8%) related to later sessions. Twenty-six (83.8%)
family therapists had therapy sessions reviewed; two sessions were reviewed for each therapist.
Overall adherence for the 52 reviewed sessions was scored between 0 and 5, with 5 indicating greater
adherence. Overall competence was scored between 0 and 6, with 6 indicating greater competence. Initial
reviews scored overall mean adherence as 4.6 (SD 0.72) and overall competence as 4.4 (1.03).
Specialist reviews were conducted when the overall competence score was 0, 1 or 2 or when requested by
the initial reviewer. Specialist reviews were conducted for 7 (13.5%) of the initially reviewed sessions and
the young person was present for all of the sessions. Three (42.9%) related to the first session and four
(57.1%) related to later therapy sessions. Five family therapists had specialist reviews; two sessions were
reviewed for two therapists and one session was reviewed for three therapists.
Tables 33 and 34 present a comparison of overall adherence scores and competence ratings between the
initial and specialist reviews.
Two hundred and thirty-eight (67.2%) families who attended at least two sessions of SHIFT FT received a
formulation letter from their family therapist. Formulation letters were sent by 25 (80.6%) of the 31 SHIFT
family therapists. Compliance by therapist, for those who sent letters, ranged between 22.0% and
100.0%, with a median of 80.0%.
All but one of the family therapists had at least one session of supervision; the family therapist who did
not receive supervision was not a main therapist and attended only one session of FT, as part of the
reflecting team. Two hundred and twenty-five supervision sessions were conducted in total: 98 in
Yorkshire, 38 in Manchester and 89 in London. The number of sessions received by individual therapist is
presented by hub in Table 35. Family therapists in Yorkshire received the most supervision followed by
London and Manchester. Two hundred and sixty-six young people (119 in Yorkshire, 56 in Manchester and
97 in London) were discussed 584 times in supervision; overall, each young person was discussed a mean
of 2.2 (SD 1.45) times, and this was similar for both Yorkshire and London; however, young people in
Manchester were discussed less often (1.5 times, SD 0.76 times). The mean length of supervision sessions
overall was 96.3 (SD 38.97) minutes and this was similar between hubs.
TABLE 33 Comparison of overall adherence scores
Initial review
Specialist review
0 1 2 3 4 5
0
1
2 1
3 1 1 1
4 1 1 1
5
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TABLE 34 Comparison of overall competence scores
Initial review
Specialist review
Highly
inappropriate
performance
Inappropriate
performance with
major problems
evident
Evidence of
competence but
numerous
problems/lack of
consistency
Competent but
some problems
and/or
inconsistencies
Good but minor
problems
and/or
inconsistencies
Very good,
minimal
problems and/or
inconsistencies
Excellent
performance even
in the face of
patient difficulties
Highly inappropriate
performance
Inappropriate
performance with
major problems
evident
Evidence of
competence but
numerous problems/
lack of consistency
1 3
Competent but some
problems and/or
inconsistencies
1 1
Good but minor
problems and/or
inconsistencies
1
Very good, minimal
problems and/or
inconsistencies
Excellent performance
even in the face of
client difficulties
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Family therapy alliance
The strength of therapeutic alliance as reported by the young person, caregiver and SHIFT family therapist as
captured in the SOFTA questionnaire at the participant’s third treatment session is summarised in Table 36
and Figure 16, with higher scores representing greater alliance. Caregivers consistently reported the highest
levels of alliance across all four dimensions, while the therapist generally reported the lowest, with the
exception of ‘engagement in the therapeutic process’, for which the young person reported lower alliance.
Young person and therapist alliance were most closely aligned, with overlapping CIs, for the two dimensions
reflecting the uniqueness of conjoint treatment ‘shared sense of purpose’ and ‘safety within the therapeutic
system’, while there was no overlap for engagement or ‘emotional connection’, nor for any of the caregiver
scores. Alliance is further explored by the participant’s primary outcome in the mediation results section.
Psychotropic medications
During treatment, clinicians and CAMHS notes reported that 104 (12.5%) young people had been prescribed
a psychotropic medication (Table 37): 44 (10.6%) young people in the FT arm and 60 (14.4%) young
people in the TAU arm. The most frequently prescribed psychotropic medications were antidepressants,
prescribed for 80 (76.9%) of these young people (reported by clinician, CSO or family), which in the
majority of cases (all but five prescriptions) were selective serotonin reuptake inhibitors as opposed to
tricyclic antidepressants.
TABLE 35 Number of sessions of supervision per therapist received by hub
Hub Number of supervision sessions received per therapist
Yorkshire
N 10
Missing 0
Mean (SD) 21.0 (6.68)
Median (range) 23 (9–29)
Manchester
N 6
Missing 0
Mean (SD) 10.8 (7.41)
Median (range) 11.5 (1–18)
London
N 15
Missing 1
Mean (SD) 15.5 (9.01)
Median (range) 18 (0–27)
Overall
N 31
Missing 1
Mean (SD) 16.4 (8.61)
Median (range) 18 (0–29)
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TABLE 36 Summary statistics for the SOFTA
SOFTA dimensions Young person (N= 415) Caregiver (N= 415) Family therapist (N= 415)
Shared sense of purpose (4–20), n 273 279 294
Mean (SD) 15.2 (3.31) 16.6 (2.75) 15.1 (2.87)
95% CI (14.9 to 15.6) (16.2 to 16.9) (14.8 to 15.4)
Median (range) 16.0 (5.0–20) 17.0 (4.0–20) 15.0 (4.0–20)
Engagement in the process (4–20), n 274 279 293
Mean (SD) 13.8 (3.01) 15.8 (2.62) 14.8 (2.65)
95% CI (13.4 to 14.1) (15.5 to 16.1) (14.5 to 15.1)
Median (range) 14.0 (4.0–20) 16.0 (4.0–20) 15.0 (4.0–20)
Emotional connection (4–20), n 274 278 293
Mean (SD) 15.2 (2.83) 16.5 (2.33) 14.3 (1.82)
95% CI (14.9 to 15.5) (16.2 to 16.7) (14.1 to 14.5)
Median (range) 16.0 (7.0–20) 17.0 (7.0–20) 14.0 (8.0–20)
Safety (4–20), n 274 279 294
Mean (SD) 13.8 (3.45) 16.7 (2.64) 13.3 (2.73)
95% CI (13.3 to 14.2) (16.3 to 17.0) (13.0 to 13.6)
Median (range) 14.0 (4.0–20) 17.0 (4.0–20) 14.0 (4.0–19)
Total score (16–80), n 274 279 293
Mean (SD) 57.9 (10.51) 65.4 (8.65) 57.5 (8.30)
95% CI (56.7 to 59.2) (64.4 to 66.4) (56.5 to 58.4)
Median (range) 58.3 (30–80) 66.0 (19–80) 59.0 (28–77)
Purpose
13
14
15
16
17
Engagement Emotional Safety
Subscale
SO
FT
A
 s
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re Completer
     Young person
     Caregiver
     Therapist
FIGURE 16 The SOFTA subscale scores with 95% CIs.
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A total of 118 (14.2%) young people were taking or had been prescribed a psychotropic medication at
baseline or during the 18-month trial period: 48 (11.6%) in the FT arm and 70 (16.8%) in the TAU arm.
Re-referrals to Child and Adolescent Mental Health Services
Re-referrals to CAMHS following discharge (or inactivity for 3 months) were reported from clinical notes
within CAMHS by the participant’s CAMHS clinician or a CSO, and also by the family during the 18-month
researcher visit (Table 38).
Based on clinical data, 108 (13%) participants were re-referred to CAMHS within 18 months of
randomisation, with similar rates between the trial arms; however, this information was missing for 19%
of participants. Of all re-referred participants, 12 (11.1%) were re-referred on more than one occasion and
the referrals of 83 (76.9%) were related to self-harm: 44 (84.5%) in the FT arm and 39 (69.6%) in the
TAU arm.
Details of family-reported re-referrals were missing for over three-quarters of participants (because no
researcher had visited or family had not been asked); however, re-referrals were reported for 39 (4.7%)
participants.
TABLE 37 Prescribed psychotropic medication use during treatment and overall at baseline and during 18-month
follow-up
Psychotropic
medication,
n (%)
During treatment At baseline and during 18-month follow-up
FT (N= 415) TAU (N= 417) Total (N= 832) FT (N= 415) TAU (N= 417) Total (N= 832)
Young person taking prescribed psychotropic
Yes 44 (10.6) 60 (14.4) 104 (12.5) 48 (11.6) 70 (16.8) 118 (14.2)
Noa 367 (88.4) 303 (72.7) 670 (80.5) 366 (88.2) 347 (83.2) 713 (85.7)
Missing 4 (1.0) 54 (12.9) 58 (7.0) 1 (0.2) 0 (0.0) 1 (0.1)
Total 415 (100.0) 417 (100.0) 832 (100.0) 415 (100.0) 417 (100.0) 832 (100.0)
Type of psychotropicb
ADHD drug 4 (9.1) 5 (8.3) 9 (8.7) 5 (8.2) 7 (9.1) 12 (8.7)
Anti anxiety
drug
1 (2.3) 1 (1.7) 2 (1.9) 1 (1.6) 1 (1.3) 2 (1.4)
Antipsychotic
drug
2 (4.5) 8 (13.3) 10 (9.6) 3 (4.9) 9 (11.7) 12 (8.7)
Antidepressant
drugc
33 (75.0) 47 (78.3) 80 (76.9) 48 (78.7) 59 (76.6) 107 (77.5)
Sedative/sleep
medication
5 (11.4) 13 (21.7) 18 (17.3) 8 (13.1) 18 (23.4) 26 (18.8)
Missing 5 (11.4) 5 (8.3) 10 (9.6) 3 (4.9) 4 (5.2) 7 (5.1)
Total 44 (100.0) 60 (100.0) 104 (100.0) 61 (100.0) 77 (100.0) 138 (100.0)
a Of those not on medications overall at baseline or during follow-up, six were missing data at baseline but not on
medications during initial treatment (five FT, one TAU) and 53 had no baseline medications but were missing data during
initial treatment (three FT, 50 TAU).
b Reported by clinician, CSO or additionally the researcher during follow-up (and baseline for overall use).
c Of the young people on antidepressants, only five were taking tricyclics (three FT, two FT), while the rest were taking
selective serotonin reuptake inhibitors..
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Referrals to psychiatric day or inpatient units
Referrals to psychiatric inpatient units within 18 months of randomisation were reported from clinical notes
within CAMHS by participants’ CAMHS clinician or CSO or via HES data, and also by the family during the
18-month researcher visit (Table 39).
Based on clinical data, a total of 25 (3%) participants were referred to a psychiatric inpatient unit during
the 18-month follow-up period, of whom 21 (84.0%) had a referral related to self-harm, with similar rates
between the trial arms. However, information was missing for 149 (17.9%) participants. The total length
of inpatient stays over all referrals ranged from 1 to 185 days, with a mean of 72.2 days in the FT arm and
43.3 days in the TAU arm.
A total of seven referrals to psychiatric inpatient units were reported for five (0.6%) participants by the
family, of which five had also been reported via the clinical data, with one referral in each arm reported by
the family but not from the clinical data.
TABLE 38 Re-referrals to CAMHS within 18 months of randomisation
Re-referrals
Method of reporting
Clinical data Family reported
FT (N= 415) TAU (N= 417) Total (N= 832) FT (N= 415) TAU (N= 417) Total (N= 832)
Young person re-referred to CAMHS?, n (%)
Yes 52 (12.5) 56 (13.4) 108 (13.0) 19 (4.6) 20 (4.8) 39 (4.7)
No 287 (69.2) 281 (67.4) 568 (68.3) 85 (20.5) 70 (16.8) 155 (18.6)
Missing 76 (18.3) 80 (19.2) 156 (18.8) 311 (74.9) 327 (78.4) 638 (76.7)
Number of re-referrals, n (%)
1 46 (88.5) 50 (89.3) 96 (88.9) 18 (94.7) 16 (80.0) 34 (87.2)
2 6 (11.5) 5 (8.9) 11 (10.2) 1 (5.3) 3 (15.0) 4 (10.3)
3 0 (0.0) 1 (1.8) 1 (0.9) 0 (0.0) 1 (5.0) 1 (2.6)
Total 52 (100.0) 56 (100.0) 108 (100.0) 19 (100.0) 20 (100.0) 39 (100.0)
Any referral related to self-harm?, n (%)
Yes 44 (84.6) 39 (69.6) 83 (76.9) 13 (68.4) 16 (80.0) 29 (74.4)
No 8 (15.4) 16 (28.6) 24 (22.2) 5 (26.3) 4 (20.0) 9 (23.1)
Missing 0 (0.0) 1 (1.8) 1 (0.9) 1 (5.3) 0 (0.0) 1 (2.6)
Total –
participants
52 (100.0) 56 (100.0) 108 (100.0) 19 (100.0) 20 (100.0) 39 (100.0)
Timing of first re-referral (months)
N 51 56 107 18 20 38
Missing 1 0 1 1 0 1
Mean (SD) 11.8 (3.79) 11.5 (3.91) 11.6 (3.84) 12.6 (4.13) 13.2 (3.64) 12.9 (3.84)
Median
(range)
12.2 (4.2–17.7) 12.2 (0.8–17.9) 12.2 (0.8–17.9) 12.9 (4.2–17.4) 13.5 (4.4–17.6) 13.5 (4.2–17.6)
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Referrals to other agencies
Referrals to adult mental health services or other agencies for the participating young person, their
caregiver(s) or sibling(s) within 18 months of randomisation were reported from clinical notes within
CAMHS by the participant’s CAMHS clinician or a CSO, and also by the family during the 18-month
researcher visit (Table 40).
Based on clinical data, a total of 18 (2.2%) young people or family members were referred to adult mental
health services: eight young people only referred, nine family members only referred, and one young person
and their family member referred. Information was missing for 155 (18.6%) young people. Referrals were
reported within CAMHS notes only if the referral had come from CAMHS or if the young person had been
in contact with CAMHS at the time. A higher proportion of adult mental health referrals were reported by
the family: 25 (3%) participants (nine young people, 11 caregivers and five siblings).
TABLE 39 Referrals to a psychiatric inpatient unit within 18 months of randomisation
Referrals to a
psychiatric inpatient
unit
Clinical data Family reporteda
FT (N= 415)
TAU
(N= 417)
Total
(N= 832) FT (N= 415)
TAU
(N= 417)
Total
(N= 832)
Young person referred to an inpatient unit?, n (%)
Yes 13 (3.1) 12 (2.9) 25 (3.0) 3 (0.7) 2 (0.5) 5 (0.6)
No 331 (79.8) 327 (78.4) 658 (79.1) 104 (25.1) 84 (20.1) 188 (22.6)
Missing 71 (17.1) 78 (18.7) 149 (17.9) 308 (74.2) 331 (79.4) 639 (76.8)
Number of referrals, n (%)
1 10 (76.9) 9 (75.0) 19 (76.0) 2 (66.7) 1 (50.0) 3 (60.0)
2 2 (15.4) 3 (25.0) 5 (20.0) 1 (33.3) 1 (50.0) 2 (40.0)
3 1 (7.7) 0 (0.0) 1 (4.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total number
referred
13 (100.0) 12 (100.0) 25 (100.0) 3 (100.0) 2 (100.0) 5 (100.0)
Any referral related to self-harm?, n (%)
Yes 11 (84.6) 10 (83.3) 21 (84.0) 3 (100.0) 1 (50.0) 4 (80.0)
No 2 (15.4) 2 (16.7) 4 (16.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0) 1 (20.0)
Total number
referred
13 (100.0) 12 (100.0) 25 (100.0) 3 (100.0) 2 (100.0) 5 (100.0)
Length of stay (over all referrals, days)
N 13 12 25 3 2 5
Missing 0 0 0 0 0 0
Mean (SD) 72.2 (49.74) 43.3 (46.89) 58.4 (49.62) 68.0 (89.44) 36.0 (28.28) 55.2 (67.13)
Median (range) 77.0 (11–185) 21.0 (1–139) 43.0 (1–185) 31.0 (3–170) 36.0 (16–56) 31.0 (3–170)
Timing of first referral (months)
N 13 12 25 3 2 5
Missing 0 0 0 0 0 0
Mean (SD) 7.8 (5.76) 5.8 (4.56) 6.9 (5.21) 3.2 (4.37) 6.7 (8.99) 4.6 (5.78)
Median (range) 8.0 (0.8–17.8) 6.0 (0.3–12.8) 6.5 (0.3–17.8) 1.3 (0.1–8.2) 6.7 (0.3–13.0) 1.3 (0.1–13.0)
a Five of the seven referrals reported by the family were also reported in the clinical data and, conversely, one of the TAU
referrals and one of the FT referrals were reported by the family at the researcher visit but not from the clinical data.
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Conversely, referrals to other agencies were reported for 143 (17.2%) young people, caregivers or siblings
via clinical data and for 38 (4.6%) young people, caregivers or siblings by the family. Based on clinical
report, 68 referrals were to social services, 24 referrals were to special education services, 10 referrals were
to the voluntary sector, six referrals were to youth offending team(s) and 118 referrals were to a wide
range of other agencies or services.
Overall safety
A total of 1036 AEs were reported, defined as treatment on an emergency outpatient basis through an
A&E attendance, attendance at a MIU or WIC and re-referral to CAMHS. A&E attendances constituted
the largest portion of AEs (Table 41). AEs were reported in 443 (53.2%) participants, with a similar
number of events and participants between the trial arms, and a mean of 1.2 AEs, ranging from 0 to
26 per participant.
TABLE 40 Referrals to adult mental health services and other agencies within 18 months of randomisation
Referrals to adult mental
health services and other
agencies, n (%)
Clinical data Family reported
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
FT
(N= 415)
TAU
(N= 417)
Total
(N= 832)
Young person, caregiver or sibling referred to adult mental health services
Yes 6 (1.4) 12 (2.9) 18 (2.2) 12 (2.9) 13 (3.1) 25 (3.0)
Young person 1 (0.2) 8 (1.9) 9 (1.1)a 4 (1.0) 5 (1.2) 9 (1.1)b
Parent/caregiver 5 (1.2) 5 (1.2) 10 (1.2) 5 (1.2) 6 (1.4) 11 (1.3)
Sibling 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.7) 2 (0.5) 5 (0.6)
No 333 (80.2) 326 (78.2) 659 (79.2) 97 (23.4) 76 (18.2) 173 (20.8)
Missing 76 (18.3) 79 (18.9) 155 (18.6) 306 (73.7) 328 (78.7) 634 (76.2)
Young person, caregiver or sibling referred to other agency
Yes 69 (16.6) 74 (17.7) 143 (17.2) 23 (5.5) 15 (3.6) 38 (4.6)
Young person 63 (15.2) 67 (16.1) 130 (15.6) 21 (5.1) 12 (2.9) 33 (4.0)
Parent/caregiver 20 (4.8) 18 (4.3) 38 (4.6) 6 (1.4) 4 (1.0) 10 (1.2)
Sibling 3 (0.7) 4 (1.0) 7 (0.8) 1 (0.2) 1 (0.2) 2 (0.2)
No 272 (65.5) 262 (62.8) 534 (64.2) 86 (20.7) 70 (16.8) 156 (18.8)
Missing 74 (17.8) 81 (19.4) 155 (18.6) 306 (73.7) 332 (79.6) 638 (76.7)
Agency referred to (non-mutually exclusive)
Social services 32 (46.4) 36 (48.6) 68 (47.6) 13 (56.5) 5 (33.3) 18 (47.4)
Special Education Services 7 (10.1) 17 (23.0) 24 (16.8) 4 (17.4) 4 (26.7) 8 (21.1)
Voluntary sector 2 (2.9) 8 (10.8) 10 (7.0) 6 (26.1) 1 (6.7) 7 (18.4)
Youth offending team 4 (5.8) 2 (2.7) 6 (4.2) 0 (0.0) 0 (0.0) 0 (0.0)
Otherc 58 (84.1) 60 (81.1) 118 (82.5) 13 (56.5) 9 (60.0) 22 (57.9)
Total 69 (100) 74 (100) 143 (100) 23 (100) 15 (100) 38 (100)
a All but one young person referral was related to self-harm.
b Referrals for five young persons were related to self-harm.
c Other agencies include, for example: support groups, counselling services, housing support, dermatologist, dietitian,
eating disorder team, drugs and alcohol team, family support/relate/welfare, homeless shelter, Improving Access to
Psychological Therapies, midwife paediatrician, pain clinic, parenting groups, physiotherapy, psychiatry, refuge, solicitor,
youth theatre.
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No deaths were reported. All 598 SAEs reported for 297 (35.7%) participants were hospital admissions
and readmissions. Again, similar rates were observed in both trial arms, although slightly more SAEs were
reported in fewer participants in the TAU arm than in the FT arm: 323 SAEs in 141 (33.8%) in the TAU
arm compared with 275 SAEs in 156 (37.6%) participants in the TAU arm.
Further details of the total number of hospital-related events – MIU/WIC attendances, A&E attendances
and hospital admissions – are presented in Table 42. Overall, 1513 attendances were reported in 511
(61.4%) participants, with similar rates in both trial arms and a mean of 1.8 attendances per participant.
Over half of all attendances were for non-mental health reasons (59.7%), while 26.7% were for self-harm,
4.2% were for other mental health reasons and 3.4% resulted from a combination of mental health and
non-mental health reasons (Table 43). A total of 387 (46.5%) participants attended hospital or a MIU or
WIC at least once for non-mental health reasons; 223 (26.8%) participants attended for self-harm, 85
(10.2%) participants for other mental health reasons and in eight (1.0%) participants the reasons for all
attendances were unknown.
TABLE 41 Adverse events and serious adverse events
AEs and SAEs FT (N= 415) TAU (N= 417) Total (N= 832)
Number of participants with one or more AE, n (%) 226 (54.5) 217 (52.0) 443 (53.2)
Number of participants with each type of AE (not mutually exclusive), n (%)
A&E attendance 189 (45.5) 176 (42.2) 365 (43.9)
MIU/WIC attendance 33 (8.0) 40 (9.6) 73 (8.8)
Re-referral to CAMHSa 52 (12.5) 56 (13.4) 108 (13.0)
Total number of AEs reported 512 524 1036
A&E attendance 409 372 781
MIU/WIC attendance 45 89 134
Re-referral to CAMHS 58 63 121
Number of AEs per participant
n 415 417 832
Mean (SD) 1.2 (2.00) 1.3 (2.25) 1.2 (2.13)
Median (range) 1.0 (0–17) 1.0 (0–26) 1.0 (0–26)
Number of participants with one or more SAE, n (%) 156 (37.6) 141 (33.8) 297 (35.7)
Total number of SAEs reported 275 323 598
Number of SAEs per participant
n 415 417 832
Mean (SD) 0.7 (1.26) 0.8 (1.94) 0.7 (1.64)
Median (range) 0.0 (0–11) 0.0 (0–27) 0.0 (0–27)
a Re-referrals to CAMHS from clinical data only (i.e. excluding family reports).
Reproduced from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license.
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TABLE 42 Number and details of all hospital, MIU and WIC attendances
Hospital, MIU and WIC attendances FT (N= 415) TAU (N= 417) Total (N= 832)
Number of participants with one or more hospital or
MIU/WIC attendance, n (%)
258 (62.2) 253 (60.7) 511 (61.4)
Total number of attendances 729 784 1513
Number of attendances per participant
n 415 417 832
Mean (SD) 1.8 (2.63) 1.9 (3.22) 1.8 (2.94)
Median (range) 1.0 (0–23) 1.0 (0–30) 1.0 (0–30)
Outcome of presentation, n (%)
Discharged 454 (62.3) 461 (58.8) 915 (60.5)
Admitted to hospital ward 275 (37.7) 323 (41.2) 598 (39.5)
Total attendances 729 (100.0) 784 (100.0) 1513 (100.0)
Discharge type, n (%)
Self-discharge 19 (4.2) 24 (5.2) 43 (4.7)
Did not require any follow-up treatment 172 (37.9) 195 (42.3) 367 (40.1)
With referral to GP or outpatient follow-up 250 (55.1) 232 (50.3) 482 (52.7)
Transferred to other health-care professional/provider 9 (2.0) 4 (0.9) 13 (1.4)
Other discharge 2 (0.4) 4 (0.9) 6 (0.7)
Missing 2 (0.4) 2 (0.4) 4 (0.4)
Total A&E/MIU/WIC attendances 454 (100.0) 461 (100.0) 915 (100.0)
Admitted to hospital ward, n (%)
Paediatric ward 66 (24.0) 61 (18.9) 127 (21.2)
Assessment unit 7 (2.5) 5 (1.5) 12 (2.0)
Adult ward 5 (1.8) 3 (0.9) 8 (1.3)
ICU/HDU/other specialist unit 6 (2.2) 4 (1.2) 10 (1.7)
Psychiatric inpatient stay 14 (5.1) 11 (3.4) 25 (4.2)
Missing 177 (64.4) 239 (74.0) 416 (69.6)
Total admissions 275 (100.0) 323 (100.0) 598 (100.0)
Length of admission (days)
n 261 313 574
Missing 14 10 24
Mean (SD) 6.2 (29.45) 2.2 (9.15) 4.0 (21.05)
Median (range) 1.0 (0.0–371.0) 1.0 (0.0–114.0) 1.0 (0.0–371.0)
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Primary end point
Hospital follow-up
Following the interim review of primary outcome results, it was agreed that the stopping rule had not
been reached and the DMEC recommended that the trial continue.
Table 44 details the length of follow-up for hospital attendance for all participants.
A final HES data download was obtained from NHS Digital in May 2015, providing HES data to 31 January
2015. The final download provided full data for the majority of participants: 724 (87.0%) recruited prior to
31 July 2013 for whom HES data covered the entire 18 month follow-up period. A further 75 participants
had partial HES coverage during their follow-up period: 71 (8.5%) recruited after 31 July 2013 for whom
HES data covered at least the first 13 months’ follow-up, and four (0.5%) for whom linkage to HES had
been unsuccessful for at least one prior NHS Digital download resulting in incomplete HES data from
randomisation until their first successful linkage (1.3, 3.8, 11.1 and 14.3 months).
For the 75 participants with partial HES coverage and a further 12 (1.4%) participants for whom linkage to
HES was not made during any data download, hospital attendance data were obtained via researcher
follow-up at acute trusts within participants’ recruiting hub. A further 21 (2.5%) participants withdrew
from further clinical data collection during the trial, thus preventing further linkage to HES data or
researcher follow-up.
TABLE 43 Reason for all attendances, overall and per participant
Reason for attendance, n (%) FT (N= 415) TAU (N= 417) Total (N= 832)
Per attendance
Self-harm 207 (28.4) 197 (25.1) 404 (26.7)
Other mental health reason 31 (4.3) 32 (4.1) 63 (4.2)
Non-mental health reason 433 (59.4) 470 (59.9) 903 (59.7)
Other mental health and non-mental health reason 22 (3.0) 29 (3.7) 51 (3.4)
Missinga 36 (4.9) 56 (7.1) 92 (6.1)
Total attendances 729 (100.0) 784 (100.0) 1513 (100.0)
Per participant (not mutually exclusive)
Self-harmb 119 (28.7) 104 (24.9) 223 (26.8)
Other mental health reason 44 (10.6) 41 (9.8) 85 (10.2)
Non-mental health reason 191 (46.0) 196 (47.0) 387 (46.5)
Missing reason for all attendances 2 (0.5) 6 (1.4) 8 (1.0)
No attendances reported 157 (37.8) 164 (39.3) 321 (38.6)
Total participants 415 (100.0) 417 (100.0) 832 (100.0)
a Ninety-eight attendances were classed as unknown in the primary outcome sensitivity analysis for missing presenting
details. This is because six attendances for mental health reasons were missing sufficient further information to rule out
self-harm.
b MIU and WIC attendances are included, hence the number of participants with an attendance caused by self-harm is
higher than the primary outcome.
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In summary, a total of 795 (95.6%) participants had complete follow-up over their entire 18 months post
randomisation. Four (0.5%) participants were completely lost to follow-up and 33 (4%) participants had at
least some but not complete 18-month hospital follow-up.
The duration of follow-up for all participants can be seen to be evenly balanced between the trial arms
(see Table 44).
Summary of primary outcome events
A total of 221 (26.6%) young persons experienced the primary outcome event, that is, having a repeat
self-harm event leading to hospital attendance within 18 months post randomisation: 118 (28.4%) young
persons randomised to receive FT and 103 (24.7%) young persons randomised to receive TAU.
Table 45 details the type and outcome of all primary outcome events. The overall median time to first
post-randomisation self-harm event is 5.2 months. This is earlier for young persons randomised to TAU
(4.3 months, compared with 5.7 months in the case of young persons randomised to FT).
The most common reason for attendance was self-poisoning (57.5% of primary outcome events), with a
further 19.9% attending as a result of cutting. The most common outcome was admission to a hospital
ward, for 161 (72.9%) events, with similar rates of admission between trial arms.
TABLE 44 Duration of hospital follow-up for all participants
Duration of hospital follow-up FT (N= 415) TAU (N= 417) Total (N= 832)
Follow-up description, n (%)
Full HES linkage and follow-up 362 (87.2) 362 (86.8) 724 (87.0)
Linked to HES but researcher follow-up only from
February 2015 onwards
35 (8.4) 36 (8.6) 71 (8.5)
Linked to HES data after randomisation 2 (0.5) 2 (0.5) 4 (0.5)
Not linked to HES data: researcher follow-up only 8 (1.9) 4 (1.0) 12 (1.4)
Withdrawal 8 (1.9) 13 (3.1) 21 (2.5)
Length of hospital follow-up (months), n (%)
18 398 (95.9) 397 (95.2) 795 (95.6)
< 18 15 (3.6) 18 (4.3) 33 (4.0)
< 3 0 (0.0) 1 (0.2) 1 (0.1)
≤ 3 and < 6 1 (0.2) 1 (0.2) 2 (0.2)
≤ 6 and < 9 1 (0.2) 2 (0.5) 3 (0.4)
≤ 9 and < 12 0 (0.0) 2 (0.5) 2 (0.2)
≤ 12 and < 15 5 (1.2) 5 (1.2) 10 (1.2)
≤ 15 and < 18 8 (1.9) 7 (1.7) 15 (1.8)
No follow-up 2 (0.5) 2 (0.5) 4 (0.5)
Length of hospital follow-up (months)
N 415 417 832
Mean (SD) 17.8 (1.59) 17.7 (1.93) 17.7 (1.77)
Median (range) 18.0 (0.0–18.0) 18.0 (0.0–18.0) 18.0 (0.0–18.0)
Note
Of the 21 young persons who withdrew from clinical data collection, four had no hospital follow-up, three had < 6 months’
follow-up, five had < 12 months’ follow-up, eight had < 18 months’ follow-up and one had the full 18 months’ follow-up.
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For participants with a primary outcome event, Table 46 presents the type of event by the method used in
the index event prompting referral into CAMHS. Among those participants whose index episode was self-
poisoning, the first repeat event was also self-poisoning in the majority (38, 73.1%), whereas 11 (21.2%)
self-injured and three (5.8%) used combined methods. Of those who used combined methods at the
index event, similar proportions were observed, with the majority self-poisoning at first repeat (16, 66.7%).
Of those in whom the index event was self-injury, a greater proportion switched method, with only 59
(40.7%) self-injuring at first repeat, 73 (50.3%) self-poisoning and 12 (8.3%) using combined methods.
Table 47 presents the number of participants with one or more event, the number without an event and
censored in the analysis, the reasons for censoring and the time to censoring. The majority of censored
participants (n = 583, 95.4%) were censored because no observed self-harm events resulting in hospital
TABLE 45 Timing, type and outcome of first repeat self-harm events
Timing, type and outcome of first repeat self-harm events FT (N= 415) TAU (N= 417) Total (N= 832)
Number of participants with one or more event, n (%) 118 (28.4) 103 (24.7) 221 (26.6)
Time to first self-harm event (months)
n 118 103 221
Mean (SD) 6.9 (5.47) 6.2 (5.25) 6.6 (5.37)
Median (range) 5.7 (0.1–17.8) 4.3 (0.0–16.8) 5.2 (0.0–17.8)
Type of first self-harm event, n (%)
Poisoning 68 (57.6) 59 (57.3) 127 (57.5)
Cutting 28 (23.7) 16 (15.5) 44 (19.9)
Poisoning and cutting 8 (6.8) 8 (7.8) 16 (7.2)
Other self-injury 6 (5.1) 10 (9.7) 16 (7.2)
Other violent method 1 (0.8) 4 (3.9) 5 (2.3)
Other 6 (5.1) 6 (5.8) 12 (5.4)
Missing 1 (0.8) 0 (0.0) 1 (0.5)
Total 118 (100) 103 (100) 221 (100)
Outcome of first self-harm event, n (%)
Discharged from A&E 32 (27.1) 28 (27.2) 60 (27.1)
Admitted to hospital ward 86 (72.9) 75 (72.8) 161 (72.9)
Total 118 (100) 103 (100) 221 (100)
Treatment received, n (%)
Yes 106 (89.8) 97 (94.2) 203 (91.9)
No 10 (8.5) 6 (5.8) 16 (7.2)
Missing 2 (1.7) 0 (0.0) 2 (0.9)
Total 118 (100) 103 (100) 221 (100)
Level of treatment received, n (%)
Minimal 53 (50.0) 60 (61.9) 113 (55.7)
Significant intervention 23 (21.7) 25 (25.8) 48 (23.6)
Missing 30 (28.3) 12 (12.4) 42 (20.7)
Total 106 (100) 97 (100) 203 (100)
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TABLE 46 Type of primary outcome event by index method
Index event
Primary outcome event, n (%)
Self-poisoning Self-injury Combined Missing
Self-poisoning (N= 52) 38 (73.1) 11 (21.2) 3 (5.8) 0 (0.0)
Self-injury (N = 145) 73 (50.3) 59 (40.7) 12 (8.3) 1 (0.7)
Combined (N= 24) 16 (66.7) 7 (29.2) 1 (4.2) 0 (0.0)
Total (N = 221) 127 (57.5) 77 (34.8) 16 (7.2) 1 (0.5)
TABLE 47 Summary of censoring for participants without an event: reasons and time to censoring
Censored participants FT (N= 415) TAU (N= 417) Total (N= 832)
Number of censored participants, n (%)
Not censored (one or more event) 118 (28.4) 103 (24.7) 221 (26.6)
Censored 297 (71.6) 314 (75.3) 611 (73.4)
Total 415 (100) 417 (100) 832 (100)
Reason for censoring, n (%)
No event in 18-month follow-up period 283 (95.3) 300 (95.5) 583 (95.4)
Not linked to HES data (and without complete 18-month
researcher follow-up)
1 (0.3) 0 (0.0) 1 (0.2)
Participants still in follow-up after the final HES data set
(without further researcher follow-up)
6 (2.0) 6 (1.9) 12 (2.0)
Withdrawal 7 (2.4) 8 (2.5) 15 (2.5)
Total 297 (100) 314 (100) 611 (100)
Time from randomisation to censoring (months), n (%)
0 2 (0.7) 2 (0.6) 4 (0.7)
< 3 0 (0.0) 1 (0.3) 1 (0.2)
≤ 3 and < 6 1 (0.3) 0 (0.0) 1 (0.2)
≤ 6 and < 9 1 (0.3) 1 (0.3) 2 (0.3)
≤ 9 and < 12 0 (0.0) 1 (0.3) 1 (0.2)
≤ 12 and < 15 4 (1.3) 2 (0.6) 6 (1.0)
≤ 15 and < 18 6 (2.0) 7 (2.2) 13 (2.1)
18 283 (95.3) 300 (95.5) 583 (95.4)
Total 297 (100) 314 (100) 611 (100)
Months from randomisation to censoring
N 297 314 611
Mean (SD) 17.7 (1.86) 17.7 (1.90) 17.7 (1.88)
Median 18.0 (0.0–18.0) 18.0 (0.0–18.0) 18.0 (0.0–18.0)
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attendance occurred over the entire 18-month follow-up period; however, 15 (2.5%) participants were
censored because of their withdrawal from further clinical data collection, as no events were observed
prior to their withdrawal; and a further 13 (2.2%) participants were censored either because they were not
linked to HES data and relied on researcher follow-up alone or because their HES data did not include their
full 18-month follow-up period; in both cases researcher follow-up was available only for the periods not
covered via HES data. Similar patterns of censoring are observed between trial arms.
Primary analysis: Cox proportional hazards regression
The results of the Cox proportional hazards regression modelling, adjusted for covariates, are displayed in
Table 48. A HR of > 1 indicates an increased rate of self-harm in the variable listed before ‘vs.’ in the table
(e.g. participants with three or more previous self-harm episodes repeat self-harm at 1.22 times the rate of
participants with just two previous self-harm episodes).
TABLE 48 Primary analysis: Cox proportional hazards model (adjusted for covariates)
Covariate
Parameter
estimate SE HR 95% CI df p-value
Treatment: FT (vs. TAU) 0.13 0.14 1.14 0.87 to 1.49 1 0.3349a
Gender: female (vs. male) 0.47 0.25 1.60 0.98 to 2.61 1 0.0589
Age group: 15–17 (vs. 11–14) –0.36 0.14 0.70 0.53 to 0.92 1 0.0106
Number of previous self-harm episodes: ≥ 3 (vs. 2) 0.20 0.23 1.22 0.78 to 1.92 1 0.3900
Type of index episode 2 0.0333
Combined (vs. self-injury) 0.61 0.24 1.83 1.14 to 2.96 1 –
Self-poisoning (vs. self-injury) 0.03 0.20 1.03 0.69 to 1.54 1 –
Referred via hospital: yes (vs. no) 0.27 0.18 1.31 0.93 to 1.86 1 0.1231
Trust (vs. Y trust 1) 14 0.0938
M trust 3 0.18 0.23 1.20 0.77 to 1.86 1 –
L trust 5 –0.58 0.44 0.56 0.24 to 1.34 1 –
Y trust 3 –0.66 0.37 0.52 0.25 to 1.07 1 –
Y trust 2 –0.22 0.37 0.80 0.39 to 1.67 1 –
M trust 1 0.13 0.28 1.14 0.65 to 1.98 1 –
L trust 6 –0.30 0.73 0.74 0.18 to 3.08 1 –
Y trust 4 –1.18 0.53 0.31 0.11 to 0.87 1 –
L trust 2 –0.70 0.32 0.50 0.26 to 0.93 1 –
M trust 2 –0.23 0.25 0.79 0.48 to 1.30 1 –
L trust 1 –0.35 0.26 0.70 0.42 to 1.17 1 –
Y trust 6 0.19 0.33 1.21 0.64 to 2.29 1 –
L trust 4 –0.59 1.02 0.55 0.08 to 4.08 1 –
L trust 3 –0.29 0.53 0.75 0.26 to 2.11 1 –
Y trust 5 –0.23 0.41 0.80 0.35 to 1.79 1 –
df, degrees of freedom.
a Reduction in –2logL between Cox proportional hazards model with and without treatment effect: 0.932 (p= 0.3344,
1 degree of freedom).
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There was no evidence to suggest a statistically significant difference in self-harm repetition rates between
treatment groups. The HR for FT compared with TAU was 1.14 (95% CI 0.87 to 1.49; p = 0.3349). Figure 17
presents the Kaplan–Meier curve for time to self-harm by randomised treatment arm. There is crossover
between treatment groups until around month 11, after which the curves diverge and the lower curve
represents slightly more FT participants with a primary outcome self-harm event. Further estimates of the
self-harm repetition rate, with 95% CIs, at 1, 3, 6, 12 and 18 months post randomisation, are presented
in Table 49 by arm and for the difference between arms, with a positive difference indicating a higher
repetition rate in the FT arm. As there were few events, it was not possible to obtain the Kaplan–Meier
estimates of the median time to self-harm.
Covariates age group (p = 0.0106) and the type of index self-harm episode (p = 0.0333) were found to
have a significant effect on the risk of self-harm at the 5% level. The rate of self-harm was lower in older
participants (aged 15–17 years) than in those aged 11–14 years (HR 0.7, 95% CI 0.53 to 0.92) and higher
in participants whose index episode combined self-injury and poisoning than in those with self-injury only
(HR 1.83, 95% CI 1.14 to 2.96). There was also weak evidence (at the 10% level) of an effect for gender
and trust, with a higher rate of self-harm in females than in males (HR 1.6, 95% CI 0.98 to 2.61; p = 0.0589)
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FIGURE 17 Kaplan–Meier plot of time to self-harm by randomised treatment group with 95% CIs. Reproduced
from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
4.0 license.
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and substantial variation across centres (p = 0.0938). The occurrence of primary outcome events, overall and
within each treatment arm, for each covariate is further summarised in Tables 50 and 51.
In addition to the primary analysis model, further analysis excluding centre as a fixed effect (see model
checking, Table 52) finds an increased risk of self-harm in participants referred to CAMHS from hospital,
and summary statistics suggest a differential treatment effect based on participants’ source of referral (see
Table 50). The rate of self-harm among participants referred via hospital was higher in the FT arm than in
the TAU arm (37.8% vs. 25.7%), an absolute increase in risk of 12.1% and a relative increase of 47.3%
TABLE 49 Self-harm repetition rates during follow-up
Time from
randomisation FT (N= 415) TAU (N= 417)
Difference (FT – TAU)
(N= 832)
Month 1
Repetition estimate
(95% CI)
4.36% (2.39% to 6.33%) 4.82% (2.76% to 6.88%) –0.46% (–3.31% to 2.39%)
Number with an
event
18 20 –2
Number event free 395 395 0
Month 3
Repetition estimate
(95% CI)
9.69% (6.83% to 12.54%) 9.65% (6.81% to 12.49%) 0.04% (–3.99% to 4.06%)
Number with an
event
40 40 0
Number event free 373 374 –1
Month 6
Repetition estimate
(95% CI)
15.75% (12.23% to 19.26%) 14.48% (11.09% to 17.87%) 1.27% (–3.61% to 6.15%)
Number with an
event
65 60 5
Number event free 347 354 –7
Month 12
Repetition estimate
(95% CI)
22.08% (18.07% to 26.08%) 19.81% (15.97% to 23.65%) 2.27% (–3.28% to 7.82%)
Number with an
event
91 82 9
Number event free 320 330 –10
Month 18
Repetition estimate
(95% CI)
28.74% (24.36% to 33.12%) 24.94% (20.77% to 29.12%) 3.80% (–2.26% to 9.85%)
Number with an
event
118 103 15
Number event free 283 300 –17
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(see Table 46), while there was little difference between groups in the case of participants referred to
CAMHS through the community, 22.8% in the FT arm compared with 24.2% in the TAU arm, an absolute
decrease in risk of 1.4% and a relative decrease of 5.7%. The presence of a moderating effect by source
of referral was investigated in the moderator analysis; however, although there was an indication of an
increased hazard in the FT arm in participants referred via hospital, the interaction between treatment and
referral source was not found to be statistically significant (see Moderator variables).
Model checking
Graphical and statistical tests of the adequacy of the Cox proportional hazards regression model for
treatment and covariates were generally satisfactory and are presented in Appendix 5, along with
Kaplan–Meier curves for time to self-harm for each covariate.
There was, however, evidence of non-proportional hazards for a number of trusts, and further Cox
proportional hazards regression models were fitted to investigate the effect on the treatment estimate
TABLE 50 Summary of self-harm event by covariates (and hub) and treatment arm
Covariate
Primary outcome event reported (yes), n (%)
FT TAU Total
Age group (years)
11–14 (N = 441) 66 (30.0) 62 (28.1) 128 (29.0)
15–17 (N = 391) 52 (26.7) 41 (20.9) 93 (23.8)
Gender
Male (N= 95) 11 (23.4) 7 (14.6) 18 (18.9)
Female (N= 737) 107 (29.1) 96 (26.0) 203 (27.5)
Baseline number of self-harm episodes
2 (N= 93) 10 (21.7) 12 (25.5) 22 (23.7)
≥ 3 (N= 739) 108 (29.3) 91 (24.6) 199 (26.9)
Type of index self-harm episode
Self-poisoning (N= 184) 32 (34.4) 20 (22.0) 52 (28.3)
Self-injury (N= 594) 74 (24.9) 71 (23.9) 145 (24.4)
Combined (N = 54) 12 (48.0) 12 (41.4) 24 (44.4)
Referred into CAMHS via A&E?
Yes (N = 304) 59 (37.8) 38 (25.7) 97 (31.9)
No (N= 528) 59 (22.8) 65 (24.2) 124 (23.5)
Centre hub (non-covariate)
Yorkshire (N= 300) 42 (28.2) 37 (24.5) 79 (26.3)
Manchester (N = 286) 49 (34.3) 42 (29.4) 91 (31.8)
London (N= 246) 27 (22.0) 24 (19.5) 51 (20.7)
Total (N = 832) 118 (28.4) 103 (24.7) 221 (26.6)
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(Table 52). In all three alternative models, the estimated treatment effect matched very closely with that of
the primary analysis, confirming the robustness of the treatment effect to variations in modelling and
assumptions around trust.
Unlike the primary analysis model, there was evidence of an increased risk of self-harm in participants
referred into CAMHS via hospital, with estimates from the frailty model suggesting a HR of 1.39 (95% CI
0.99 to 1.95) with p = 0.0598. A chi-squared test detected a highly significant (p < 0.0001) association
between trust and referral source (see Appendix 5); thus, referral source is not identified as a significant
effect in the primary model because of a lack of independence and collinearity with trust, with each
providing ‘overlapping’ information.
Differences were also found for gender, which was no longer statistically significant when centre was
excluded, with only weak evidence of an effect in the model, including hub and the shared frailty model.
There was no evidence of an overall association between trust and gender (see Appendix 5); however,
in the two trusts with the lowest risk of self-harm the case mix also included the highest proportion of
females. Thus, in excluding centre, the reduced self-harm observed in these trusts is no longer explained by
trust and is instead incorporated into the other covariates for these participants, including gender, thus
diluting the effect of gender overall.
TABLE 51 Summary of self-harm events by recruiting trust (covariate) and treatment arma
Centre trust
Primary outcome event reported (yes), n (%)
FT TAU Total
Yorkshire
Y trust 1 (N= 114) 22 (37.9) 15 (26.8) 37 (32.5)
Y trust 2 (N = 34) 5 (27.8) 4 (25.0) 9 (26.5)
Y trust 3 (N = 52) 3 (11.1) 6 (24.0) 9 (17.3)
Y trust 4 (N= 37) 1 (5.9) 3 (15.0) 4 (10.8)
Y trust 5 (N= 29) 5 (35.7) 2 (13.3) 7 (24.1)
Y trust 6 (N= 34) 6 (40.0) 7 (36.8) 13 (38.2)
Manchester
M trust 1 (N = 53) 11 (40.7) 8 (30.8) 19 (35.8)
M trust 2 (N = 105) 15 (28.3) 13 (25.0) 28 (26.7)
M trust 3 (N = 128) 23 (36.5) 21 (32.3) 44 (34.4)
London
L trust 1 (N= 107) 16 (29.6) 9 (17.0) 25 (23.4)
L trust 2 (N = 73) 8 (21.6) 5 (13.9) 13 (17.8)
L trust 3 (N= 16) 1 (11.1) 3 (42.9) 4 (25.0)
L trust 4 (N= 6) 0 (0.0) 1 (33.3) 1 (16.7)
L trust 5 (N= 34) 2 (11.8) 4 (23.5) 6 (17.6)
L trust 6 (N = 10) 0 (0.0) 2 (28.6) 2 (20.0)
Total (N = 832) 118 (28.4) 103 (24.7) 221 (26.6)
a Shading is used to represent trusts with the same family team.
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TABLE 52 Cox proportional hazards model: excluding centre, including hub, with random centre effects
Covariate
Primary model (excluding centre) Primary model (including hub) Primary model (with random centre effect)
Parameter
estimate SE HR 95% CI p-value
Parameter
estimate
Standard
error HR 95% CI p-value
Parameter
estimate
Standard
error HR 95% CI p-value
Treatment: FT (vs. TAU) 0.13 0.14 1.14 0.88 to 1.49 0.3214 0.13 0.14 1.14 0.87 to 1.48 0.3382 0.13 0.14 1.14 0.87 to 1.48 0.3343
Gender: female (vs. male) 0.38 0.25 1.47 0.90 to 2.38 0.1224 0.42 0.25 1.52 0.93 to 2.47 0.0925 0.43 0.25 1.54 0.94 to 2.50 0.0835
Age group (years): 15–17
(vs. 11–14)
–0.33 0.14 0.72 0.54 to 0.94 0.0171 –0.35 0.14 0.71 0.54 to 0.93 0.0133 –0.35 0.14 0.70 0.53 to 0.93 0.0123
Number of previous self-harm
episodes: ≥ 3 (vs. 2)
0.20 0.23 1.22 0.78 to 1.91 0.3916 0.20 0.23 1.22 0.78 to 1.91 0.3944 0.20 0.23 1.22 0.78 to 1.92 0.3818
Type of index episode 0.0208 0.0173 0.0232
Combined (vs. self-injury) 0.60 0.24 1.83 1.14 to 2.92 0.63 0.24 1.87 1.17 to 2.99 0.62 0.24 1.85 1.15 to 2.98
Self-poisoning (vs. self-injury) –0.04 0.20 0.96 0.65 to 1.42 –0.03 0.20 0.98 0.66 to 1.44 0.00 0.20 1.00 0.67 to 1.49
Referred via hospital: yes (vs. no) 0.38 0.17 1.47 1.05 to 2.06 0.0265 0.34 0.17 1.41 1.01 to 1.98 0.0457 0.33 0.17 1.39 0.99 to 1.95 0.0598
Recruiting hub 0.0169
London (vs. Yorkshire) –0.26 0.18 0.77 0.54 to 1.10
Manchester (vs. Yorkshire) 0.24 0.15 1.27 0.94 to 1.72
Trust (random effect) 0.06 0.05 0.0646
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Figure 18 presents the estimated random centre effect in the primary Cox proportional hazards model with
shared frailty (random centre effect). The impact of these fluctuations across trusts does not, however,
have any bearing on the estimated treatment effect. The model including trust is, therefore, retained for
the primary analysis purposes; however, although referral via hospital does not appear to be statistically
significant, this is an important factor in the repetition of self-harm and retained in the model.
Sensitivity analysis for missing presenting details
Summary of non-primary outcome self-harm hospital events and events missing
presenting details
Hospital attendances reported by NHS Digital but for which it could not be determined whether or not the
reason was self-harm and which remained unclassified at the time of analysis are summarised and the
potential impact of these episodes on the overall event rate is explored. The number of self-harm events
leading to a MIU or WIC attendance, rather than hospital attendance, is also explored, as these events
were not included in the definition of the primary outcome.
Only three MIU or WIC self-harm attendances were reported in three participants within 18 months of
randomisation (Table 53). One of these three participants attended hospital attendance for self-harm
before their MIU attendance, and hence there was no change to their primary outcome or to its timing,
while no other self-harm hospital events were reported for the other two participants (one from each
treatment arm) and, therefore, there was no primary outcome event. The impact of the exclusion of MIU
and WIC attendances from the primary outcome is, therefore, minimal.
Table 54 presents, by randomised treatment group, the overall number of hospital attendances within
18 months of randomisation for which it could not be determined whether or not the reason was self-harm.
There were a total of 47 unclassified hospital attendances in 41 participants: 26 episodes in 22 participants
randomised to receive FT and 21 episodes in 19 participants randomised to receive TAU. There were
also a further 12 unclassified MIU attendances in 10 participants and 39 unclassified WIC attendances
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FIGURE 18 Estimated random centre effect in the primary Cox proportional hazards model with shared frailty
(random centre effect). Estimated random effects > 0 represent higher frailty, that is, shorter time to and higher
rate of self-harm, while estimates < 0 represent lower frailty, that is, longer time to and lower rate of self-harm.
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in 22 participants; however, the impact of these events is not explored further as they did not meet the
definition of the primary outcome.
To assess the potential impact of unclassified hospital attendances on the overall self-harm event rate,
Table 54 further presents these in relation to whether or not the participant had already contributed to the
primary outcome event rate. Of the 41 participants with at least one unclassified hospital episode, only
18 had no self-harm-related hospital attendances and thus had the potential to increase the event rate.
Additionally, for 9 of the remaining 23 participants the unclassified attendance occurred prior to the
known self-harm-related hospital attendance and, thus, had the potential to impact on the timing of the
primary outcome. Thus, in summary, a total of 27 participants (14 in the FT arm and 13 in the TAU arm)
had the potential to influence either the primary event rate or the timing of primary events.
Sensitivity analysis
Assuming that hospital attendances that were unclassified at the time of analysis were self-harm related,
the recalculated HR for treatment was 1.15 (95% CI 0.89 to 1.49) with p = 0.2736 (see Appendix 5).
Hence, as per the primary first event model, there is no evidence to suggest a difference in self-harm
repetition rates between treatment groups and minimal difference for covariates in the model.
TABLE 53 Minor injury unit or WIC attendances caused by self-harm
MIU or WIC attendances FT (n) TAU (n) Total (n)
Number of participants with a MIU or WIC self-harm event
MIU only 1 2 3
Other additional hospital self-harm events?
Hospital self-harm event before MIU attendance for self-harm 0 1 1
No other self-harm events 1 1 2
TABLE 54 Unclassified hospital, MIU and WIC attendances
Unclassified attendances FT (n) TAU (n) Total (n)
Number of unclassified attendances
Hospital attendance 26 21 47a
MIU only 3 9 12
WIC only 12 27 39
Number of participants with an unclassified attendance
Hospital attendance 22 19 41
MIU only 3 7 10
WIC only 7 15 22
Number of participants with an unclassified hospital attendance
With a confirmed primary outcome event (unclassified
attendance prior to primary outcome event)
12 (4) 11 (5) 23 (9)
Without a confirmed primary outcome event 10 8 18
a Of the 47 unclassified hospital attendances, 41 were reported by HES only, 5 from HES and the researcher and 1 by the
researcher alone.
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Sensitivity analysis for clustering
Clustering because of therapists
A total of 286 different therapists were identified as the ‘main’ therapist delivering the greatest number of
sessions (comprising assessment and therapy sessions) within CAMHS per participant (Table 55 and see
Figure 19).
In the FT arm, 47 main therapists delivered treatment to 398 participants; 29 SHIFT family therapists led
therapy for 380 participants, with the remaining 18 participants receiving other treatment within CAMHS
(i.e. as part of a referral) led by 18 TAU CAMHS clinicians (10 of whom were also the main therapist for at
least one TAU participant).
In the TAU arm, many more therapists were involved in delivering treatment, with a total of 250 main
therapists across 333 participants (one of which was a SHIFT FT therapist prior to their involvement in
the trial).
TABLE 55 Main therapist per participant and number of participants seen per therapist
Main therapist FT (N= 415) TAU (N= 417) Total (N= 832)
Type of main therapist per participant, n (%)
SHIFT FT therapist 380 (91.6) 1 (0.2)a 381 (45.8)
TAU clinician 18 (4.3) 332 (79.6) 350 (42.1)
Clinician name missing 1 (0.2) 6 (1.4) 7 (0.8)
N/A – young person attended no sessions 16 (3.9) 33 (7.9) 49 (5.9)
Unknown – young person missing all treatment data 0 (0.0) 45 (10.8) 45 (5.4)
Overall number of different main therapists, n (%)
SHIFT FT therapist 29 (61.7) 1 (0.4) 29 (10.1)
TAU clinician 18 (38.3) 249 (99.6) 257 (89.9)
Total 47 (100.0) 250 (100.0) 286 (100.0)
Number of participants per main therapist
n 47 250 286
Mean (SD) 8.5 (10.19) 1.3 (0.81) 2.6 (4.93)
Median (range) 5.0 (1–46) 1.0 (1–6) 1.0 (1–46)
Number of participants per main therapist, n (%)
1 21 (44.7) 198 (79.2) 202 (70.6)
≥ 2 26 (55.3) 52 (20.8) 84 (29.4)
Overall number of sessions delivered per main therapist
n 47 250 286
Mean (SD) 54.7 (53.97) 9.5 (10.83) 17.3 (29.25)
Median (range) 37.0 (1–235) 6.0 (1–96) 7.0 (1–235)
N/A, not applicable.
a One TAU participant was treated by a SHIFT FT therapist before they were trained in SHIFT FT and before they became
involved in the trial.
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For seven participants the name of the clinician delivering treatment was missing. In addition,
49 participants were known to have been represented at no sessions (i.e. neither the participant nor
family member attended) and for 45 participants all treatment data were missing. These participants were
each classed as belonging to their own cluster, resulting in a total of 387 clusters, 286 main therapist
clusters and 101 individual participant clusters (comprising the seven participants with no clinician name,
the 49 participants who attended no sessions and the 45 participants for whom all treatment data
were missing).
Table 56 presents the Cox proportional hazards model, adjusted for covariates, with shared frailty for
therapist effect and Figure 19 presents estimates of the random therapist effects. The random therapist
effect (estimate of covariance: 0.08535), that is, the between-cluster variance, was found to be not
statistically significant (p = 0.3707) and the results of the fixed effects are very similar to those based on
TABLE 56 Cox proportional hazards model with shared frailty for therapist (adjusted for covariates)
Covariate
Parameter
estimate SE HR (95% CI) df
Adjusted
df
Adjusted
p-value
Treatment: FT (vs. TAU) 0.08 0.15 1.09 (0.81 to 1.46) 1 0.8230 0.4984
Gender: female (vs. male) 0.48 0.25 1.61 (0.98 to 2.63) 1 0.9879 0.0570
Age group (years): 15–17 (vs. 11–14) –0.37 0.14 0.69 (0.52 to 0.91) 1 0.9862 0.0095
Number of previous self-harm episodes:
≥ 3 (vs. 2)
0.19 0.23 1.21 (0.77 to 1.91) 1 0.9812 0.4071
Type of index episode 2 1.9606 0.0347
Combined (vs. self-injury) 0.60 0.25 1.83 (1.13 to 2.98) 1 – –
Self-poisoning (vs. self-injury) 0.02 0.20 1.02 (0.68 to 1.53) 1 – –
Referred via hospital: yes (vs. no) 0.28 0.18 1.33 (0.93 to 1.88) 1 0.9821 0.1115
Trust (vs. Y trust 1) 14 12.9124 0.1452
M trust 3 0.18 0.25 1.19 (0.73 to 1.94) 1 – –
L trust 5 –0.50 0.46 0.61 (0.24 to 1.51) 1 – –
Y trust 3 –0.64 0.39 0.53 (0.25 to 1.13) 1 – –
Y trust 2 –0.19 0.39 0.83 (0.38 to 1.78) 1 – –
M trust 1 0.13 0.30 1.14 (0.63 to 2.05) 1 – –
L trust 6 –0.27 0.73 0.76 (0.18 to 3.22) 1 – –
Y trust 4 –1.14 0.55 0.32 (0.11 to 0.93) 1 – –
L trust 2 –0.68 0.34 0.51 (0.26 to 0.99) 1 – –
M trust 2 –0.24 0.27 0.79 (0.46 to 1.34) 1 – –
L trust 1 –0.37 0.28 0.69 (0.39 to 1.20) 1 – –
Y trust 6 0.24 0.36 1.28 (0.63 to 2.60) 1 – –
L trust 4 –0.42 1.00 0.66 (0.09 to 4.64) 1 – –
L trust 3 –0.18 0.55 0.83 (0.28 to 2.47) 1 – –
Y trust 5 –0.25 0.44 0.78 (0.33 to 1.86) 1 – –
Main therapist (random effect)a – 13.6705 0.3707
df, degrees of freedom.
a Covariance parameter estimates for the random therapist effect are: restricted maximum likelihood estimate 0.08535
with SE 0.09254.
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FIGURE 19 Estimated random therapist effect in the Cox proportional hazards model with shared frailty. Estimated random effects > 0 represent higher frailty, that is, shorter
time to and higher rate of self-harm, while estimates < 0 represent lower frailty, that is, longer time to and lower rate of self-harm.
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the primary analysis without accounting for shared frailty, leading to the same conclusion as the primary
analysis of no evidence to suggest a difference between FT and TAU in delaying the time to, and
occurrence of, self-harm leading to hospital attendance. See Appendix 5 for further discussion and results
relating to the estimated intracluster correlation for the therapist effect.
Secondary end points
Repetition of self-harm leading to hospital attendance within 12 months of randomisation
By 12 months post randomisation, self-harm events leading to hospital attendance were reported for
173 participants, 91 in the FT arm and 82 in the TAU; this gave a repetition rate of 22.1% (95% CI 18.1%
to 26.1%) and 19.8% (95% CI 16.0% to 23.7%), respectively, with a difference of 2.3% (95% CI –3.3%
to 7.8%) (see Table 48).
Table 57 presents results of the Cox proportional hazards regression model (adjusted for covariates) for the
first event within 12 months of randomisation. The HR for treatment is 1.09 (95% CI 0.81 to 1.48) with a
TABLE 57 Cox proportional hazards model with 12 months follow-up (adjusted for covariates)a
Covariate Parameter estimate SE HR (95% CI) df p-value
Treatment: FT (vs. TAU) 0.09 0.15 1.09 (0.81 to 1.48) 1 0.5592
Gender: female (vs. male) 0.47 0.28 1.60 (0.92 to 2.79) 1 0.0938
Age group (years): 15–17 (vs. 11–14) –0.32 0.16 0.72 (0.53 to 0.99) 1 0.0432
Number of previous self-harm episodes: ≥ 3 (vs. 2) 0.27 0.27 1.31 (0.77 to 2.22) 1 0.3194
Type of index episode 2 0.0712
Combined (vs. self-injury) 0.59 0.28 1.80 (1.05 to 3.09) 1 –
Self-poisoning (vs. self-injury) –0.00 0.23 1.00 (0.63 to 1.57) 1 –
Referred via hospital: yes (vs. no) 0.24 0.20 1.27 (0.86 to 1.88) 1 0.2326
Y trust 1 14 0.1354
M trust 3 0.36 0.26 1.44 (0.86 to 2.40) 1 –
L trust 5 –0.36 0.49 0.70 (0.27 to 1.84) 1 –
Y trust 3 –0.66 0.46 0.52 (0.21 to 1.27) 1 –
Y trust 2 0.07 0.41 1.07 (0.48 to 2.38) 1 –
M trust 1 0.35 0.32 1.42 (0.76 to 2.66) 1 –
L trust 6 0.06 0.74 1.06 (0.25 to 4.51) 1 –
Y trust 4 –0.76 0.54 0.47 (0.16 to 1.35) 1 –
L trust 2 –0.77 0.41 0.46 (0.21 to 1.02) 1 –
M trust 2 –0.08 0.29 0.92 (0.52 to 1.63) 1 –
L trust 1 –0.24 0.30 0.79 (0.43 to 1.43) 1 –
Y trust 6 0.38 0.37 1.47 (0.72 to 3.01) 1 –
L trust 4 –0.15 1.03 0.86 (0.12 to 6.44) 1 –
L trust 3 –0.19 0.61 0.83 (0.25 to 2.76) 1 –
Y trust 5 0.18 0.43 1.19 (0.51 to 2.77) 1 –
df, degrees of freedom.
a Reduction in –2logL between Cox proportional hazards model with and without Treatment effect: 0.342 (p= 0.5589,
1 degree of freedom).
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p-value of 0.5592; hence, as per the primary first event model, albeit with a HR closer to 1, there is no
evidence to suggest a difference in self-harm repetition rates between treatment groups.
There is no change in the direction of effects for any covariate with the exception of three centres (two in
Yorkshire and one in London); however, these factors were found to be not significant. Results from
model checks, similar to those for the primary analysis, similarly demonstrated the adequacy of the model.
Characteristics of further episodes of self-harm leading to hospital attendance
Summary of all self-harm events leading to hospital attendance
A total of 401 self-harm events leading to hospital attendance were observed in 221 (26.6%) participants
within 18 months of randomisation: 206 events in 118 (28.4%) participants randomised to FT and 195
events in 103 (24.7%) participants randomised to TAU (Table 58). The overall number of events per
participant ranged from 0 to 18. Figure 20 presents a needle plot of all repeat events per participant.
TABLE 58 Overall number of repeat self-harm events
Repeat self-harm events FT (N= 415) TAU (N= 417) Total (N= 832)
Number of participants with one or more event, n (%) 118 (28.4) 103 (24.7) 221 (26.6)
Number of events reported 206 195 401
Number of events per participant
n 415 417 832
Mean (SD) 0.5 (1.05) 0.5 (1.26) 0.5 (1.16)
Median (range) 0.0 (0–9) 0.0 (0–18) 0.0 (0–18)
Number of events per participant (participants with an event)
n 118 103 221
Mean (SD) 1.7 (1.30) 1.9 (1.93) 1.8 (1.62)
Median (range) 1.0 (1–9) 1.0 (1–18) (1–18)
Number of events per participant, n (%)
0 297 (71.6) 314 (75.3) 611 (73.4)
1 74 (17.8) 60 (14.4) 134 (16.1)
2 22 (5.3) 21 (5.0) 43 (5.2)
3 11 (2.7) 12 (2.9) 23 (2.8)
4 5 (1.2) 7 (1.7) 12 (1.4)
5 4 (1.0) 1 (0.2) 5 (0.6)
6 1 (0.2) 1 (0.2) 2 (0.2)
9 1 (0.2) 0 (0.0) 1 (0.1)
18 0 (0.0) 1 (0.2) 1 (0.1)
Total 415 (100) 417 (100) 832 (100)
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The most frequent reason for hospital attendance was self-poisoning, accounting for 209 (52.1%) events,
with a further 93 (23.2%) attendances for cutting (Table 59). The most common outcome was admission
to a hospital ward, which was the outcome of 265 (66.1%) events, with similar admission rates between
trial arms. Table 60 further details the reasons for attendance (type of self-harm) by outcome, which shows
that self-poisoning was more likely than other reasons for attendance to result in admission.
The majority of young people discharged from A&E (90, 66.2%) were referred to their GP or to outpatient
follow-up or did not require follow-up treatment (36, 26.5%). Ten admission events (3.8%) led to a
psychiatric inpatient stay, with overall length of admission ranging from 0 to 91 days and a mean of 3.1
(SD 10.56) days (Table 61).
Recurrent event analysis
The results of the recurrent event analysis, using a counting process model with robust sandwich variance
estimator for the rate of recurrent events, are presented in Table 62. The HR for treatment is 1.05 (95% CI
0.76s to 1.44) with a p-value of 0.7847, very similar to the primary first event model, albeit with a HR closer
to 1. There is no evidence to suggest a difference in self-harm repetition rates between treatment groups.
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FIGURE 20 Needle plot of all recurrent events (self-harm leading to hospital attendance) ordered by total number
of events and time of last event. (a) FT; and (b) TAU.
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Compared with the primary analysis of the first event, the effect of gender is no longer significant (HR
1.27, 95% CI 0.77 to 2.10; p = 0.3407), while the effect of referral via hospital is no longer masked by the
centre effect and is highly significant, with a higher rate of self-harm in those referred via hospital (HR 1.98,
95% CI 1.18 to 3.32; p = 0.0096) and the centre effect is further enhanced, increasing in significance from
the 10% level to the 5% level. Furthermore, the effect of the number of previous self-harm episodes
increased compared with the first event model, but remained only borderline significant at the 10% level,
while the overall effect of the type of index episode fell (p = 0.0641) and the direction of effect switched
for self-poisoning versus self-injury.
Model checking identified that the model fit was adequate. Details are provided in Appendix 6 (see Figure 65).
Results of the sensitivity recurrent event analysis using the conditional, restricted gap-time Prentice–Williams–
Peterson model85 are also presented; although treatment and covariate estimates vary slightly, the overall
conclusions that can be drawn from these remain similar to those based on the counting process model with
robust sandwich variance estimator.
TABLE 59 Type and outcome of all self-harm events
Type and outcome of all self-harm events FT TAU Total
Number of events reported 206 195 401
Type of self-harm events, n (%)
Poisoning 111 (53.9) 98 (50.3) 209 (52.1)
Cutting 42 (20.4) 51 (26.2) 93 (23.2)
Poisoning and cutting 10 (4.9) 15 (7.7) 25 (6.2)
Other self-injury 21 (10.2) 12 (6.2) 33 (8.2)
Other violent method 3 (1.5) 6 (3.1) 9 (2.2)
Othera 18 (8.7) 12 (6.2) 30 (7.5)
Missing 1 (0.5) 1 (0.5) 2 (0.5)
Total 206 (100) 195 (100) 401 (100)
Outcome of self-harm events, n (%)
Discharged from A&E 72 (35.0) 64 (32.8) 136 (33.9)
Admitted to hospital ward 134 (65.0) 131 (67.2) 265 (66.1)
Total 206 (100) 195 (100) 401 (100)
Treatment received, n (%)
Yes 185 (89.8) 180 (92.3) 365 (91.0)
No 18 (8.7) 13 (6.7) 31 (7.7)
Missing 3 (1.5) 2 (1.0) 5 (1.2)
Total 206 (100) 195 (100) 401 (100)
Level of treatment received, n (%)
Minimal 106 (57.3) 113 (62.8) 219 (60.0)
Significant intervention 37 (20.0) 45 (25.0) 82 (22.5)
Missing 42 (22.7) 22 (12.2) 64 (17.5)
Total 185 (100) 180 (100) 365 (100)
a Other self-injury includes burning (4), head banging (1), punching (23), other (5); other violent methods include
drowning (3), hanging/strangulation (1), jumping (4), other (1); other includes threat/thought of suicide only (17),
psychiatric conditions (11), other (2).
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TABLE 60 Details of self-harm events by outcome
Details of self-harm events, n (%)
Discharged from A&E Admitted to hospital ward
FT TAU Total FT TAU Total
Type of self-harm event
Poisoning 19 (26.4) 14 (21.9) 33 (24.3) 92 (68.7) 84 (64.1) 176 (66.4)
Cutting 20 (27.8) 29 (45.3) 49 (36.0) 22 (16.4) 22 (16.8) 44 (16.6)
Poisoning and cutting 1 (1.4) 1 (1.6) 2 (1.5) 9 (6.7) 14 (10.7) 23 (8.7)
Other self-injury 19 (26.4) 11 (17.2) 30 (22.1) 2 (1.5) 1 (0.8) 3 (1.1)
Other violent method 3 (4.2) 3 (4.7) 6 (4.4) 0 (0.0) 3 (2.3) 3 (1.1)
Other 9 (12.5) 5 (7.8) 14 (10.3) 9 (6.7) 7 (5.3) 16 (6.0)
Missing 1 (1.4) 1 (1.6) 2 (1.5) 0 (0.0) 0 (0.0) 0 (0.0)
Total 72 (100) 64 (100) 136 (100) 134 (100) 131 (100) 265 (100)
Treatment received
Yes 51 (70.8) 49 (76.6) 100 (73.5) 134 (100.0) 131 (100.0) 265 (100.0)
No 18 (25.0) 13 (20.3) 31 (22.8) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 3 (4.2) 2 (3.1) 5 (3.7) 0 (0.0) 0 (0.0) 0 (0.0)
Total 72 (100) 64 (100) 136 (100) 134 (100) 131 (100) 265 (100)
Level of treatment received
Minimal 38 (74.5) 37 (75.5) 75 (75.0) 68 (50.7) 76 (58.0) 144 (54.3)
Significant intervention 12 (23.5) 12 (24.5) 24 (24.0) 25 (18.7) 33 (25.2) 58 (21.9)
Missing 1 (2.0) 0 (0.0) 1 (1.0) 41 (30.6) 22 (16.8) 63 (23.8)
Total 51 (100) 49 (100) 100 (100) 134 (100) 131 (100) 265 (100)
TABLE 61 Details of discharge from A&E and admissions for self-harm events
Discharge and admission details, n (%) FT TAU Total
Discharged form A&E
Type of discharge
Self-discharge 3 (4.2) 5 (7.8) 8 (5.9)
Discharged with referral to GP or outpatient follow-up 51 (70.8) 39 (60.9) 90 (66.2)
Discharged – did not require any follow-up treatment 16 (22.2) 20 (31.3) 36 (26.5)
Transferred to other health-care professional/provider 2 (2.8) 0 (0.0) 2 (1.5)
Total 72 (100) 64 (100) 136 (100)
Admitted
Type of ward
Paediatric ward 45 (33.6) 34 (26.0) 79 (29.8)
Assessment unit 2 (1.5) 3 (2.3) 5 (1.9)
Adult ward 0 (0.0) 1 (0.8) 1 (0.4)
Missing 87 (64.9) 93 (71.0) 180 (67.9)
Total 134 (100) 131 (100) 265 (100)
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Characteristics of all further self-reported episodes of self-harm (SASII)
Characteristics of the first self-reported self-harm episode
Details of the young person’s first episode of self-harm post-randomisation, regardless of whether or not it
led to hospital attendance, as self-reported via the SASII questionnaire, are presented in Table 63.
Self-harm was reported during the first 12–18 months of follow-up for 202 (75.4%) in the FT arm and 147
(70.0%) in the TAU arm (see Table 63) for those with sufficient SASII completion from baseline to 12 or
18 months (completed at 12 months, 12 and 18 months or 18 months only but with a report of self-harm).
Self-harm was reported during the first 12 months for 186 (71.5%) in the FT arm and 131 (65.5%) in the
TAU arm (Table 64).
Figure 21 presents the time to first episode. The researcher rated as a suicide attempt self-harm by 44 (13%)
participants, with similar rates across trial arms. Forty-three participants (21%) in the FT arm and 41 (28%)
participants in the TAU arm were considered to have some intent to die; however, in the majority of these
cases (82%), self-harm was deemed low risk (as defined by the SASII), with medical treatment sought or
received by 28 participants (14%) in the FT arm and 23 participants (16%) in the TAU arm. Timing and
details of the first self-harm episode are missing for 18 participants in whom self-harm was reported at
18 months but for whom there were no 12-month data to indicate the first post-baseline episode.
Suicide Attempt Self-Injury Interview timeline
Summaries of the number, methods and treatment required for self-harm episodes reported on the SASII
timeline are presented in Tables 64–68.
TABLE 61 Details of discharge from A&E and admissions for self-harm events (continued )
Discharge and admission details, n (%) FT TAU Total
Psychiatric inpatient stay?
Yes 6 (4.5) 4 (3.1) 10 (3.8)
No 128 (95.5) 127 (96.9) 255 (96.2)
Total 134 (100) 131 (100) 265 (100)
Length of admission (days)
n 129 129 258
n missing 5 2 7
Mean (SD) 4.5 (14.42) 1.7 (3.52) 3.1 (10.56)
Median (range) 1.0 (0–91) 1.0 (0–24) 1.0 (0–91)
Length of admission (days)
0 22 (16.4) 29 (22.1) 51 (19.2)
1 66 (49.3) 69 (52.7) 135 (50.9)
2 19 (14.2) 15 (11.5) 34 (12.8)
3–9 15 (11.2) 12 (9.2) 27 (10.2)
10–30 1 (0.7) 4 (3.1) 5 (1.9)
> 30 6 (4.5) 0 (0.0) 6 (2.3)
Missing 5 (3.7) 2 (1.5) 7 (2.6)
Total 134 (100) 131 (100) 265 (100)
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TABLE 62 Recurrent event analysis estimatesa
Covariate
Primary recurrent event analysisb Sensitivity analysisc
Parameter Estimate SE HR (95% CI) p-value Parameter estimate SE HR (95% CI) p-value
Treatment: FT (vs. TAU) 0.04 0.16 1.05 (0.76 to 1.44) 0.7847 0.08 0.10 1.08 (0.88 to 1.32) 0.4565
Gender: female (vs. male) 0.24 0.25 1.27 (0.77 to 2.10) 0.3407 0.07 0.17 1.07 (0.76 to 1.51) 0.6883
Age group (years): 15–17 (vs. 11–14) –0.39 0.16 0.67 (0.50 to 0.92) 0.0120 –0.26 0.11 0.77 (0.63 to 0.96) 0.0178
Number of previous self-harm episodes: ≥ 3 (vs. 2) 0.42 0.25 1.52 (0.92 to 2.49) 0.1008 0.28 0.19 1.32 (0.91 to 1.92) 0.1460
Type of index episode 0.0641 0.1861
Combined (vs. self-injury) 0.19 0.30 1.20 (0.66 to 2.18) – 0.19 0.18 1.21 (0.85 to 1.72) –
Self-poisoning (vs. self-injury) –0.33 0.24 0.72 (0.45 to 1.16) – –0.16 0.15 0.85 (0.63 to 1.15) –
Referred via hospital: yes (vs. no) 0.68 0.26 1.98 (1.18 to 3.32) 0.0096 0.38 0.13 1.46 (1.14 to 1.88) 0.0031
Trust (vs. Y trust 1) 0.0493 0.1353
M trust 3 0.44 0.24 1.56 (0.97 to 2.50) – 0.29 0.17 1.33 (0.95 to 1.88)
L trust 5 –0.13 0.52 0.88 (0.32 to 2.44) – –0.07 0.32 0.94 (0.50 to 1.77)
Y trust 3 –0.36 0.41 0.70 (0.31 to 1.57) – –0.23 0.29 0.79 (0.44 to 1.41)
Y trust 2 0.07 0.33 1.07 (0.56 to 2.06) – –0.01 0.28 0.99 (0.57 to 1.70)
M trust 1 0.11 0.29 1.12 (0.63 to 1.97) – 0.04 0.24 1.04 (0.66 to 1.65)
L trust 6 0.19 0.63 1.21 (0.36 to 4.14) – 0.06 0.50 1.06 (0.40 to 2.80)
Y trust 4 –0.94 0.58 0.39 (0.12 to 1.21) – –0.77 0.43 0.46 (0.20 to 1.09)
L trust 2 –0.38 0.33 0.68 (0.35 to 1.31) – –0.24 0.25 0.79 (0.48 to 1.29)
M trust 2 0.08 0.27 1.09 (0.64 to 1.84) – 0.08 0.20 1.08 (0.73 to 1.59)
L trust 1 –0.39 0.26 0.68 (0.41 to 1.13) – –0.29 0.22 0.74 (0.48 to 1.15)
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Covariate
Primary recurrent event analysisb Sensitivity analysisc
Parameter Estimate SE HR (95% CI) p-value Parameter estimate SE HR (95% CI) p-value
Y trust 6 0.87 0.51 2.40 (0.88 to 6.54) – 0.44 0.24 1.56 (0.98 to 2.48)
L trust 4 –0.66 1.08 0.52 (0.06 to 4.26) – –0.47 1.01 0.63 (0.09 to 4.55)
L trust 3 0.11 0.50 1.11 (0.42 to 2.97) – 0.02 0.38 1.02 (0.48 to 2.17)
Y trust 5 0.16 0.47 1.17 (0.47 to 2.94) – 0.08 0.30 1.09 (0.60 to 1.97)
a Four participants were excluded as a result of lack of any follow-up leading to equal start and stop times, invalid under the counting process model. A single event was also excluded
where two events took place on the same day for the same participant (again leading to equal start and stop times). A further participant had an event on the same day as
randomisation (leading to equal start and stop times) and to include this event the time of event was adjusted to 1 day post randomisation.
b Andersen–Gill model with robust sandwich variance estimator: unrestricted counting process.
c Prentice–Williams–Peterson model:85 conditional restricted gap time.
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TABLE 63 Characteristics of the first self-harm episode post randomisation (SASII)
Characteristics of the first self-harm episode FT (N= 415) TAU (N= 417) Total (N= 832)
SASII completed?
Yes at 12 and 18 months, n (%) 187 (45.1) 144 (34.5) 331 (39.8)
Partly at 12 months, n (%) 73 (17.6) 56 (13.4) 129 (15.5)
Partly at 18 months, n (%) 17 (4.1) 21 (5.0) 38 (4.6)
No, n (%) 138 (33.3) 196 (47.0) 334 (40.1)
SASII sufficiently completed,a n (%) 268 (64.6) 210 (50.4) 478 (57.5)
Deliberately harmed self, n (%)
Yes 202 (75.4) 147 (70.0) 349 (73.0)
No 66 (24.6) 63 (30.0) 129 (27.0)
Total 268 (100.0) 210 (100.0) 478 (100.0)
Time of self-harm episode (months)
n 192 136 328
Missing 10 11 21
Mean (SD) 3.2 (4.42) 3.2 (4.16) 3.2 (4.31)
Median (range) 1.1 (0.0–17.9) 1.0 (0.0–16.6) 1.1 (0.0–17.9)
Type of behaviour,b n (%)
Suicide attempt 25 (12.4) 19 (12.9) 44 (12.6)
NSSI 158 (78.2) 113 (76.9) 271 (77.7)
Missing 19 (9.4) 15 (10.2) 34 (9.7)
Intent to dieb (some intent to die) 43 (21.3) 41 (27.9) 84 (24.1)
Medical risk of deathb (low) 164 (81.2) 121 (82.3) 285 (81.7)
Impulsivityb (planned) 41 (20.3) 26 (17.7) 67 (19.2)
Communication/threat of suicide intent (yes) 22 (10.9) 28 (19.0) 50 (14.3)
Interpersonal influence (mentioned) 63 (31.2) 51 (34.7) 114 (32.7)
Emotion relief (mentioned) 170 (84.2) 127 (86.4) 297 (85.1)
Medical treatment sought/received (yes) 28 (13.9) 23 (15.6) 51 (14.6)
Physical condition following episode,b n (%)
No effect 27 (13.4) 22 (15.0) 49 (14.0)
Mild effect 145 (71.8) 105 (71.4) 250 (71.6)
Moderate effect 8 (4.0) 4 (2.7) 12 (3.4)
Severe effect 1 (0.5) 1 (0.7) 2 (0.6)
Missing 21 (10.4) 15 (10.2) 36 (10.3)
Total 202 (100.0) 147 (100.0) 349 (100.0)
a At 12 months, 12 and 18 months or 18 months with self-harm.
b Interviewer-rated items.
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TABLE 64 Self-reported self-harm episodes (SASII timeline)a
Time of self-harm episode FT TAU Total
Proportion with self-harm during, n (%)
0–3 months 136 (52.3) 92 (46.0) 228 (49.6)
> 3–6 months 137 (52.7) 90 (45.0) 227 (49.3)
> 6–9 months 116 (44.6) 86 (43.0) 202 (43.9)
> 9–12 months 125 (48.1) 79 (39.5) 204 (44.3)
Total 260 (100.0) 200 (100.0) 460 (100.0)
> 12–15 months 71 (34.8) 57 (34.5) 128 (34.7)
> 15–18 months 75 (36.8) 54 (32.7) 129 (35.0)
Total 204 (100.0) 165 (100.0) 369 (100.0)
Cumulative proportion with self-harm (forward), n (%)
≤ 3 months 136 (52.3) 92 (46.0) 228 (49.6)
≤ 6 months 164 (63.1) 113 (56.5) 277 (60.2)
≤ 9 months 171 (65.8) 124 (62.0) 295 (64.1)
≤ 12 months 186 (71.5) 131 (65.5) 317 (68.9)
Total 260 (100.0) 200 (100.0) 460 (100.0)
Cumulative proportion with self-harm (backward, up to 12 months), n (%)
> 9 months 125 (48.1) 79 (39.5) 204 (44.3)
> 6 months 148 (56.9) 106 (53.0) 254 (55.2)
> 3 months 168 (64.6) 119 (59.5) 287 (62.4)
> 0 months 186 (71.5) 131 (65.5) 317 (68.9)
Total 260 (100.0) 200 (100.0) 460 (100.0)
a Timing of self-harm unknown for four young people, with young people therefore classed as having self-harm at all
time points.
Time to self-reported self-harm (months)
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FIGURE 21 Time to first self-reported self-harm (SASII). Participants with missing data are censored at
randomisation, as are participants known to have self-harmed but for whom date of first self-harm is missing.
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Overall, self-harm was reported during the first 3 months post randomisation by almost half the young people
completing the SASII (49.6%; see Table 64). Self-harm rates decreased slightly in the following months,
49.3% over 3–6 months post randomisation, 43.9% over 6–9 months and 44.3% over 9–12 months, with
higher rates in the FT arm than in the TAU arm. Rates decreased further but were more similar across arms
post 12 months: 34.7% over 12–15 months and 35% over 15–18 months; however, missing data increased
at 18 months.
Cumulatively, the overall proportion who self-harmed increased from 49.6% by 3 months post randomisation
to 60.2% by 6 months, 64.1% by 9 months and 68.9% by 12 months. Furthermore, in the period up to
12 months post randomisation, self-harm was still being reported for 44.3% participants from 9 months
post randomisation, for 55.2% from 6 months, for 62.4% from 3 months and again for 68.9% from
12 months post randomisation. Figure 22 further depicts the cumulative proportion of participants reporting
self-harm in 3-month intervals.
The number of self-harm episodes per participant is highly skewed, with a large proportion of participants
reporting no self-harm; therefore, the median number of episodes over all participants varies between 0 and 1.
However, the mean number of self-harm episodes (Table 65) in the first 3 months post randomisation was
7.1 (SD 16.22) in the FT arm and 9 (SD 19.96) in the TAU arm; these figures were generally stable over time,
but reduced to a mean of 5.0 (SD 17.23) in the FT arm and 4.5 (SD 12.78) in the TAU arm by 9–12 months.
The number of episodes fell further during later months; however, missing data increased at 18 months. The
mean number of self-harm episodes between 12 and 15 months was 3.6 (SD 11.89) in the FT arm and 2.5
(SD 7.84) in the TAU arm and between 15 and 18 months post randomisation was 3.0 (SD 10.15) in the FT
arm and 2.3 (SD 7.66) in the TAU arm.
The mean total number of self-harm episodes reported overall (of those with at least partial SASII
completion at 12 and/or 18 months) was 29.0 (SD 76.07) in the FT arm and 27.7 (SD 57.67) in the TAU
arm (see Table 65); however, this varied further when broken down by participants with full or partial SASII
completion at 12 and 18 months (Table 66).
Hospital medical treatment was self-reported by a total of 95 (27.2%) participants reporting self-harm in
the SASII timeline, 56 (27.7%) in the FT arm and 39 (26.5%) in the TAU arm, while no medical treatment
was required for any self-harm reported by 225 (64.5%) participants, with similar proportions in each arm
(Table 67).
68.9%
49.6%
60.2%
64.1%
(a)
0 – 3 months
49.6%
3 – 6 months
49.3%
6 – 9 months
43.9% 
9 – 12 months
44.3% 
(b)
68.9%
44.3%
55.2%
62.4%
(c)
FIGURE 22 Proportion of participants who self-reported self-harm up to 12 months post randomisation at 3-month
and cumulative intervals. (a) Forward cumulative proportion with self-harm; (b) proportion with self-harm; and
(c) backward cumulative proportion with self-harm.
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TABLE 65 Frequency of self-reported self-harm episodes (SASII)
Time period post randomisation/trial
arm
Number of self-harm episodes Frequency of self-harm,a n (%)
N Missing Mean (SD)
Median
(range) None
Less than
once a
month
Less than
once a
fortnight
Less than
once a
week
Once or
more a
week
Twice or
more a
week
Most
days
0–3 months post randomisation
FT 257 158 7.1 (16.22) 1.0 (0–162) 124 (47.7) 39 (15.0) 36 (13.8) 22 (8.5) 16 (6.2) 124 (47.7) 39 (15.0)
TAU 199 218 9.0 (19.96) 0.0 (0–166) 108 (54.0) 24 (12.0) 15 (7.5) 14 (7.0) 13 (6.5) 108 (54.0) 24 (12.0)
Total 456 376 7.9 (17.95) 0.0 (0–166) 232 (50.4) 63 (13.7) 51 (11.1) 36 (7.8) 29 (6.3) 232 (50.4) 63 (13.7)
> 3–6 months post randomisation
FT 257 158 7.2 (20.72) 1.0 (0–214) 123 (47.3) 47 (18.1) 31 (11.9) 22 (8.5) 20 (7.7) 9 (3.5) 8 (3.1)
TAU 199 218 6.7 (16.05) 0.0 (0–95) 110 (55.0) 28 (14.0) 20 (10.0) 12 (6.0) 15 (7.5) 6 (3.0) 9 (4.5)
Total 456 376 7.0 (18.81) 0.0 (0–214) 233 (50.7) 75 (16.3) 51 (11.1) 34 (7.4) 35 (7.6) 15 (3.3) 17 (3.7)
> 6–9 months post randomisation
FT 257 158 6.6 (21.59) 0.0 (0–221) 144 (55.4) 42 (16.2) 30 (11.5) 15 (5.8) 12 (4.6) 7 (2.7) 10 (3.8)
TAU 199 218 6.7 (21.61) 0.0 (0–185) 114 (57.0) 30 (15.0) 20 (10.0) 9 (4.5) 12 (6.0) 10 (5.0) 5 (2.5)
Total 456 376 6.6 (21.58) 0.0 (0–221) 258 (56.1) 72 (15.7) 50 (10.9) 24 (5.2) 24 (5.2) 17 (3.7) 15 (3.3)
> 9–12 months post randomisation
FT 258 157 5.0 (17.23) 0.0 (0–186) 135 (51.7) 60 (23.0) 31 (11.9) 15 (5.7) 9 (3.4) 5 (1.9) 6 (2.3)
TAU 199 218 4.5 (12.78) 0.0 (0–92) 121 (60.5) 30 (15.0) 18 (9.0) 14 (7.0) 7 (3.5) 4 (2.0) 6 (3.0)
Total 456 375 4.8 (15.44) 0.0 (0–186) 256 (55.5) 90 (19.5) 49 (10.6) 29 (6.3) 16 (3.5) 9 (2.0) 12 (2.6)
> 12–15 months post randomisation
FT 201 214 3.6 (11.89) 0.0 (0–91) 133 (65.2) 29 (14.2) 18 (8.8) 8 (3.9) 9 (4.4) 4 (2.0) 3 (1.5)
TAU 164 253 2.5 (7.84) 0.0 (0–58) 108 (65.5) 30 (18.2) 13 (7.9) 5 (3.0) 4 (2.4) 3 (1.8) 2 (1.2)
Total 365 467 3.1 (10.27) 0.0 (0–91) 241 (65.3) 59 (16.0) 31 (8.4) 13 (3.5) 13 (3.5) 7 (1.9) 5 (1.4)
continued
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TABLE 65 Frequency of self-reported self-harm episodes (SASII) (continued )
Time period post randomisation/trial
arm
Number of self-harm episodes Frequency of self-harm,a n (%)
N Missing Mean (SD)
Median
(range) None
Less than
once a
month
Less than
once a
fortnight
Less than
once a
week
Once or
more a
week
Twice or
more a
week
Most
days
> 15–18 months post randomisation
FT 201 214 3.0 (10.15) 0.0 (0–92) 129 (63.2) 39 (19.1) 16 (7.8) 8 (3.9) 5 (2.5) 4 (2.0) 3 (1.5)
TAU 164 253 2.3 (7.66) 0.0 (0–60) 111 (67.3) 30 (18.2) 10 (6.1) 7 (4.2) 3 (1.8) 1 (0.6) 3 (1.8)
Total 365 467 2.7 (9.11) 0.0 (0–92) 240 (65.0) 69 (18.7) 26 (7.0) 15 (4.1) 8 (2.2) 5 (1.4) 6 (1.6)
Total self-harm episodes (out of all with at least partial completion)
FT 275 140 29.0 (76.07) 4.0 (0–868)
TAU 221 196 27.7 (57.67) 2.0 (0–396)
Total 496 336 28.4 (68.42) 3.0 (0–868)
a None (0 days), less than once a month (< 3 days), less than once a fortnight (3–6 days), less than once a week (7–12 days), once or more a week (13–25 days), twice or more a week
(26–45 days), most days (46–91 days). When the timing of self-harm was unknown (for four young people) but self-harm was indicated, these young people were classed as having the
lowest frequency of self-harm at all time points.
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The most frequent type of self-harm reported was scratching/cutting, with a reported 11,779 (83.6%)
episodes in 312 (89.4%) participants who reported self-harm with sufficient SASII completion (Table 68).
There were 601 (4.3%) episodes involving drugs/medications among 92 (26.4%) participants and 534
(3.8%) hitting episodes among 24 (6.9%) participants. Similar numbers were observed across trial arms.
However, there were slightly fewer episodes of scratching/cutting in the FT arm than in the TAU arm: 6302
(79.1%) episodes in 178 (88.1%) participants and 5477 (89.4%) episodes in 134 (91.2%) participants,
respectively. In contrast, there were more drugs/medication-related episodes and hitting episodes in the FT
arm than in the TAU arm; however, the numbers of participants and the difference in numbers between
arms are low for both types of episodes, especially for hitting.
TABLE 66 Summary of missing SASII data and total number of self-reported episodes
Missing SASII data FT TAU Total
SASII at 12 and 18 months: total self-harm episodes
n 187 144 331
Mean (SD) 34.6 (82.07) 28.9 (56.17) 32.1 (71.91)
Median (range) 6.0 (0–868) 4.0 (0–396) 5.0 (0–868)
Number with self-harm, n (%) 140 (74.9) 94 (65.3) 234 (70.7)
SASII at 12 months only: total self-harm episodes
n 73 56 129
Mean (SD) 20.0 (65.67) 33.6 (69.30) 25.9 (67.34)
Median (range) 2.0 (0–504) 2.5 (0–338) 2.0 (0–504)
Number with self-harm, n (%) 53 (72.6) 42 (75.0) 95 (73.6)
SASII at 18 months only: total self-harm episodes
n 17 21 38
Mean (SD) 2.7 (5.74) 3.9 (10.40) 3.3 (8.55)
Median (range) 0.0 (0–23) 0.0 (0–47) 0.0 (0–47)
Number with self-harm, n (%) 8 (47.1) 9 (42.9) 17 (44.7)
TABLE 67 Most serious treatment required
Most serious medical treatment required, n (%) FT TAU Total
Hospital medical treatment 56 (27.7) 39 (26.5) 95 (27.2)
Non-hospital medical treatment 15 (7.4) 10 (6.8) 25 (7.2)
No medical treatment 129 (63.9) 96 (65.3) 225 (64.5)
Missing 2 (1.0) 2 (1.4) 4 (1.1)
Total 202 (100.0) 147 (100.0) 349 (100.0)
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Young person- and caregiver-completed questionnaires
Young person questionnaires
The summary statistics of complete data for the young person questionnaire outcomes are presented in
Table 69. The results of the repeated measures modelling (adjusted for baseline scores and covariates),
presenting mean total and subscale scores, differences between the two groups and 95% CIs at each time
point, are shown in Tables 70 and 71. The results of the sensitivity analysis conducted using complete data
were similar, with no change to conclusions. Missing data patterns used to determine the number of
imputations and baseline characteristics of participants lost to follow-up at 12 and 18 months are
presented in Tables 109–112 and Figure 66, Appendix 6.
No significant differences between treatment groups were detected in young person questionnaire
outcomes (CDRS-R, PQ-LES-Q, BSS, Hopelessness, McMaster FAD) with the exception of a number of
subscales on the SDQ and for suicide ideation screening on the BSS.
On the SDQ, there was good evidence (p-value < 0.05) that participants had better outcomes on the
prosocial subscale in the FT arm at both 12 and 18 months and on the impact subscale at 12 months only.
There was good evidence of reduced odds of suicide ideation (as reported on the Beck scale) in the FT arm
at 12 months [odds ratio (OR) 0.64, 95% CI 0.44 to 0.94, p = 0.0242]. By 18 months, suicide ideation had
decreased further in the TAU group, but it decreased to a lesser extent in the FT group, so the difference
between treatment arms was no longer statistically significant.
Unadjusted mean estimates and 95% CIs of complete data are presented in Figures 23, 24 and 25 for
questionnaires and subscales with good evidence of a treatment effect at 12 or 18 months (p < 0.05).
TABLE 68 Methods of all self-harm and per participant and most serious treatment required
Self-harm method
Young person with self-harm
(not mutually exclusive), n (%) All episodes, n (%)
FT TAU Total FT TAU Total
Scratch/cut 178 (88.1) 134 (91.2) 312 (89.4) 6302 (79.1) 5477 (89.4) 11,779 (83.6)
Drugs/medications 57 (28.2) 35 (23.8) 92 (26.4) 548 (6.9) 53 (0.9) 601 (4.3)
Hitting body 15 (7.4) 9 (6.1) 24 (6.9) 423 (5.3) 111 (1.8) 534 (3.8)
Burning 12 (5.9) 5 (3.4) 17 (4.9) 56 (0.7) 35 (0.6) 91 (0.6)
Strangling 4 (2.0) 1 (0.7) 5 (1.4) 6 (0.1) 24 (0.4) 30 (0.2)
Poison/caustic substance 3 (1.5) 1 (0.7) 4 (1.1) 3 (0.0) 1 (0.0) 4 (0.0)
Stepped into traffic 1 (0.5) 2 (1.4) 3 (0.9) 1 (0.0) 4 (0.1) 5 (0.0)
Hanging 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.0) 1 (0.0) 2 (0.0)
Jumping 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.0) 1 (0.0) 2 (0.0)
Stabbing, puncture 0 (0.0) 1 (0.7) 1 (0.3) 0 (0.0) 4 (0.1) 4 (0.0)
Drowning 0 (0.0) 1 (0.7) 1 (0.3) 0 (0.0) 4 (0.1) 4 (0.0)
Transportation-related injury 0 (0.0) 1 (0.7) 1 (0.3) 0 (0.0) 2 (0.0) 2 (0.0)
Method not specified 6 (3.0) 6 (4.1) 12 (3.4) 48 (0.6) 16 (0.3) 64 (0.5)
Other 17 (8.4) 13 (8.8) 30 (8.6) 583 (7.3) 392 (6.4) 975 (6.9)
Total 202 (100.0) 147 (100.0) 349 (100.0) 7972 (100.0) 6125 (100.0) 14097 (100.0)
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TABLE 69 Summary statistics for the young person questionnaire outcomes
Outcome
Baseline 12 months 18 months
FT TAU Total FT TAU Total FT TAU Total
CDRS-R
Total CDRS-R score (17–113),a N 415 416 831 244 187 431 204 165 369
Mean (SD) 48.0 (14.19) 49.4 (13.29) 48.7 (13.76) 36.5 (14.33) 37.2 (13.09) 36.8 (13.80) 33.8 (14.77) 35.0 (14.39) 34.4 (14.59)
Not depressed (< 30), n (%) 45 (10.8) 24 (5.8) 69 (8.3) 94 (38.5) 63 (33.7) 157 (36.4) 96 (47.1) 76 (46.1) 172 (46.6)
Mild depression (30–42), n (%) 108 (26.0) 108 (26.0) 216 (26.0) 72 (29.5) 67 (35.8) 139 (32.3) 57 (27.9) 46 (27.9) 103 (27.9)
Moderate depression (43–57), n (%) 154 (37.1) 168 (40.4) 322 (38.7) 54 (22.1) 45 (24.1) 99 (23.0) 33 (16.2) 28 (17.0) 61 (16.5)
Severe depression (58–72), n (%) 91 (21.9) 102 (24.5) 193 (23.2) 22 (9.0) 10 (5.3) 32 (7.4) 15 (7.4) 10 (6.1) 25 (6.8)
Very severe depression (> 72), n (%) 17 (4.1) 14 (3.4) 31 (3.7) 2 (0.8) 2 (1.1) 4 (0.9) 3 (1.5) 5 (3.0) 8 (2.2)
PQ-LES-Q
Total PQ-LES-Q score (14–70),b N 411 408 819 259 201 460 213 180 393
Mean (SD) 41.2 (9.37) 41.2 (9.45) 41.2 (9.41) 48.5 (10.57) 47.3 (10.26) 47.9 (10.44) 49.1 (11.14) 48.7 (11.25) 48.9 (11.18)
Beck
Beck score (0–38),c N 408 408 816 257 202 459 212 180 392
Mean (SD) 10.8 (8.94) 10.4 (9.42) 10.6 (9.18) 4.6 (7.25) 5.7 (7.91) 5.1 (7.56) 4.6 (7.76) 5.2 (7.76) 4.9 (7.76)
Median 11.0 9.0 10.0 0.0 0.0 0.0 0.0 0.0 0.0
Suicide ideation (screening Q4 and Q5), n (%) 323 (79.2) 306 (75.0) 629 (77.1) 111 (43.2) 98 (48.5) 209 (45.5) 85 (40.1) 80 (44.4) 165 (42.1)
Total hopelessness score (0–17),d N 409 406 815 255 201 456 213 179 392
Mean (SD) 7.7 (4.30) 7.3 (4.19) 7.5 (4.25) 4.9 (4.14) 5.2 (4.14) 5.0 (4.14) 4.6 (4.26) 4.8 (4.00) 4.7 (4.14)
SDQe
Total difficulties score (0–40), N 413 415 828 261 204 465 213 182 395
Mean (SD) 19.6 (5.70) 20.1 (5.60) 19.8 (5.65) 15.5 (6.76) 16.8 (6.93) 16.1 (6.86) 14.2 (7.37) 15.5 (6.84) 14.8 (7.15)
Close to average (0–14), n (%) 84 (20.3) 70 (16.9) 154 (18.6) 123 (47.1) 77 (37.7) 200 (43.0) 117 (54.9) 79 (43.4) 196 (49.6)
Slightly raised (15–17), n (%) 58 (14.0) 68 (16.4) 126 (15.2) 41 (15.7) 29 (14.2) 70 (15.1) 27 (12.7) 30 (16.5) 57 (14.4)
continued
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TABLE 69 Summary statistics for the young person questionnaire outcomes (continued )
Outcome
Baseline 12 months 18 months
FT TAU Total FT TAU Total FT TAU Total
High (18–19), n (%) 60 (14.5) 44 (10.6) 104 (12.6) 19 (7.3) 25 (12.3) 44 (9.5) 19 (8.9) 17 (9.3) 36 (9.1)
Very high (20–40), n (%) 211 (51.1) 233 (56.1) 444 (53.6) 78 (29.9) 73 (35.8) 151 (32.5) 50 (23.5) 56 (30.8) 106 (26.8)
Prosocial score (0–10), N 414 415 829 261 204 465 213 182 395
Mean (SD) 7.1 (1.84) 7.2 (1.87) 7.2 (1.85) 7.7 (1.81) 7.4 (2.07) 7.6 (1.93) 7.8 (1.86) 7.6 (2.00) 7.7 (1.92)
Emotional problems score (0–10), N 414 415 829 261 204 465 213 182 395
Mean (SD) 6.2 (2.34) 6.5 (2.31) 6.4 (2.33) 5.0 (2.73) 5.2 (2.61) 5.1 (2.68) 4.4 (2.97) 4.9 (2.71) 4.6 (2.86)
Conduct problems score (0–10), N 414 415 829 261 204 465 213 182 395
Mean (SD) 3.9 (2.11) 4.0 (1.94) 3.9 (2.02) 2.8 (1.98) 3.0 (2.12) 2.9 (2.05) 2.5 (2.01) 2.5 (1.74) 2.5 (1.89)
Hyperactivity score (0–10), N 413 415 828 261 204 465 213 182 395
Mean (SD) 6.3 (2.22) 6.2 (2.17) 6.2 (2.20) 4.9 (2.52) 5.3 (2.57) 5.1 (2.55) 4.5 (2.58) 4.9 (2.51) 4.7 (2.56)
Peer problems score (0–10), N 413 415 828 261 204 465 213 182 395
Mean (SD) 3.1 (1.87) 3.5 (2.08) 3.3 (1.98) 2.8 (1.95) 3.3 (2.09) 3.0 (2.03) 2.8 (1.87) 3.2 (2.23) 3.0 (2.05)
Impact score (0–10), N 413 414 827 180 147 327 153 127 280
Mean (SD) 3.3 (2.41) 3.5 (2.52) 3.4 (2.47) 2.3 (2.13) 2.9 (2.51) 2.6 (2.32) 2.1 (2.33) 2.9 (2.47) 2.5 (2.42)
Externalising score (0–20), N 413 415 828 261 204 465 213 182 395
Mean (SD) 10.2 (3.80) 10.1 (3.48) 10.2 (3.65) 7.7 (3.98) 8.3 (4.09) 7.9 (4.03) 7.0 (4.15) 7.4 (3.72) 7.2 (3.96)
Internalising score (0–20), N 413 415 828 261 204 465 213 182 395
Mean (SD) 9.4 (3.41) 10.0 (3.63) 9.7 (3.53) 7.8 (3.97) 8.5 (4.02) 8.1 (4.00) 7.2 (4.18) 8.1 (4.28) 7.6 (4.25)
McMaster FAD (1–4)f
Overall FAD score, N 404 405 809 258 202 460 213 179 392
Mean (SD) 2.5 (0.33) 2.4 (0.36) 2.5 (0.35) 2.2 (0.41) 2.2 (0.39) 2.2 (0.40) 2.2 (0.45) 2.2 (0.42) 2.2 (0.44)
General functioning, N 410 408 818 260 203 463 213 181 394
Mean (SD) 2.5 (0.53) 2.5 (0.56) 2.5 (0.54) 2.2 (0.60) 2.2 (0.58) 2.2 (0.59) 2.1 (0.63) 2.1 (0.59) 2.1 (0.61)
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Outcome
Baseline 12 months 18 months
FT TAU Total FT TAU Total FT TAU Total
Unhealthy (≥ 2.0), n (%) 354 (86.3) 339 (83.1) 693 (84.7) 164 (63.1) 130 (64.0) 294 (63.5) 129 (60.6) 107 (59.1) 236 (59.9)
Behaviour control subscale, N 413 409 822 260 204 464 213 181 394
Mean (SD) 2.1 (0.38) 2.1 (0.37) 2.1 (0.38) 1.9 (0.40) 1.9 (0.41) 1.9 (0.40) 1.8 (0.47) 1.9 (0.43) 1.8 (0.45)
Unhealthy (≥ 1.9), n (%) 319 (77.2) 311 (76.0) 630 (76.6) 149 (57.3) 120 (58.8) 269 (58.0) 111 (52.1) 108 (59.7) 219 (55.6)
Affective involvement subscale, N 412 409 821 260 204 464 213 180 393
Mean (SD) 2.5 (0.48) 2.5 (0.49) 2.5 (0.48) 2.3 (0.51) 2.3 (0.48) 2.3 (0.50) 2.2 (0.60) 2.3 (0.55) 2.3 (0.58)
Unhealthy (≥ 2.1), n (%) 345 (83.7) 341 (83.4) 686 (83.6) 173 (66.5) 140 (68.6) 313 (67.5) 129 (60.6) 118 (65.6) 247 (62.8)
Affective responsiveness subscale, N 410 408 818 259 203 462 213 180 393
Mean (SD) 2.6 (0.48) 2.6 (0.51) 2.6 (0.50) 2.4 (0.60) 2.4 (0.58) 2.4 (0.59) 2.3 (0.61) 2.3 (0.56) 2.3 (0.58)
Unhealthy (≥ 2.2), n (%) 343 (83.7) 335 (82.1) 678 (82.9) 177 (68.3) 145 (71.4) 322 (69.7) 136 (63.8) 129 (71.7) 265 (67.4)
Roles subscale, N 412 409 821 260 204 464 213 181 394
Mean (SD) 2.5 (0.35) 2.5 (0.37) 2.5 (0.36) 2.3 (0.41) 2.3 (0.40) 2.3 (0.40) 2.3 (0.47) 2.3 (0.42) 2.3 (0.45)
Unhealthy (≥ 2.3), n (%) 310 (75.2) 309 (75.6) 619 (75.4) 143 (55.0) 118 (57.8) 261 (56.3) 112 (52.6) 95 (52.5) 207 (52.5)
Communication subscale, N 413 409 822 260 203 463 213 181 394
Mean (SD) 2.6 (0.37) 2.6 (0.38) 2.6 (0.37) 2.4 (0.44) 2.3 (0.44) 2.4 (0.44) 2.3 (0.47) 2.3 (0.45) 2.3 (0.46)
Unhealthy (≥ 2.2), n (%) 360 (87.2) 343 (83.9) 703 (85.5) 190 (73.1) 136 (67.0) 326 (70.4) 142 (66.7) 122 (67.4) 264 (67.0)
Problem-solving subscale, N 410 409 819 259 204 463 213 180 393
Mean (SD) 2.5 (0.47) 2.5 (0.53) 2.5 (0.50) 2.3 (0.52) 2.3 (0.53) 2.3 (0.52) 2.2 (0.53) 2.2 (0.50) 2.2 (0.51)
Unhealthy (≥ 2.2), n (%) 331 (80.7) 306 (74.8) 637 (77.8) 164 (63.3) 128 (62.7) 292 (63.1) 117 (54.9) 108 (60.0) 225 (57.3)
Q, question.
a Higher scores represent greater levels of depression.
b Higher scores indicative of greater enjoyment and satisfaction.
c Higher scores indicate a higher level of suicide ideation. Median presented as Beck scores considerably skewed and zero inflated at follow-up.
d Higher scores reflect greater hopelessness or negative expectations towards the future.
e Higher scores in all but the prosocial score represent greater issues in that category. For the prosocial score, lower scores represent greater issues. See Appendix 3 for categorisation of
the total difficulties score (differs for young person and caregiver).
f Higher scores are indicative of poorer family functioning.
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TABLE 70 Mean scores with 95% CIs for young person questionnaire outcomes (adjusted for baseline score and covariates) via multiple imputation (n= 832)
Outcome
12 months 18 months
FT, mean
(95% CI), SE
TAU, mean
(95% CI), SE
Difference,f mean
(95% CI), SE; p-value
FT, mean
(95% CI), SE
TAU, mean
(95% CI), SE
Difference,f mean
(95% CI), SE; p-value
CDRS-Ra 33.2 (30.4 to 36.1),
SE 1.46
33.9 (30.8 to 37.0),
SE 1.57
–0.6 (–3.1 to 1.9),
SE 1.27; p = 0.6170
30.6 (27.6 to 33.6),
SE 1.50
31.6 (28.7 to 34.5),
SE 1.46
–1.0 (–3.5 to 1.5),
SE 1.26; p = 0.4250
PQ-LES-Qb 49.9 (47.7 to 52.1),
SE 1.12
48.8 (46.5 to 51.0),
SE 1.13
1.1 (–0.5 to 2.7),
SE 0.82; p = 0.1774
50.6 (48.4 to 52.8),
SE 1.12
50.4 (48.1 to 52.8),
SE 1.20
0.1 (–1.9 to 2.1),
SE 1.02; p = 0.9013
Hopelessnessc 4.8 (4.0 to 5.6),
SE 0.40
5.1 (4.3 to 6.0),
SE 0.43
–0.3 (–1.1 to 0.4),
SE 0.37; p = 0.3809
4.4 (3.6 to 5.2),
SE 0.42
4.6 (3.7 to 5.4),
SE 0.43
–0.2 (–0.9 to 0.5),
SE 0.36; p = 0.6327
SDQd
Total difficulties 14.8 (13.4 to 16.1),
SE 0.69
15.5 (14.1 to 16.9),
SE 0.70
–0.7 (–1.8 to 0.4),
SE 0.54; p = 0.1885
13.3 (12.0 to 14.6),
SE 0.67
14.1 (12.7 to 15.5),
SE 0.71
–0.8 (–2.0 to 0.4),
SE 0.61; p = 0.1845
Prosocial score 7.7 (7.3 to 8.1),
SE 0.19
7.3 (6. to, 7.7),
SE 0.19
0.4 (0.1 to 0.7),
SE 0.15; p = 0.0064
7.8 (7.4 to 8.1),
SE 0.18
7.4 (7.1 to 7.8),
SE 0.19
0.3 (0.0 to 0.7),
SE 0.16; p = 0.0337
Emotional problems score 4.4 (3.8 to 4.9),
SE 0.28
4.3 (3.7 to 4.8),
SE 0.28
0.1 (–0.4 to 0.5),
SE 0.22; p = 0.8098
3.7 (3.2 to 4.3),
SE 0.27
4.0 (3.5 to 4.6),
SE 0.28
–0.3 (–0.8 to 0.2),
SE 0.24; p = 0.2002
Conduct problems score 2.7 (2.4 to 3.1),
SE 0.19
2.9 (2.5 to 3.3),
SE 0.19
–0.2 (–0.5 to 0.1),
SE 0.15; p = 0.2059
2.4 (2.0 to 2.7),
SE 0.18
2.4 (2.0 to 2.8),
SE 0.19
0.0 (–0.3 to 0.3),
SE 0.16; p = 0.8964
Hyperactivity score 5.0 (4.5 to 5.5),
SE 0.25
5.3 (4.8 to 5.9),
SE 0.26
–0.3 (–0.7 to 0.1),
SE 0.20; p = 0.0978
4.5 (4.1 to 5.0),
SE 0.24
4.9 (4.4 to 5.4),
SE 0.26
–0.4 (–0.8 to 0.1),
SE 0.22; p = 0.1090
Peer problems score 2.6 (2.2 to 3.0),
SE 0.20
2.9 (2.5 to 3.3),
SE 0.20
–0.3 (–0.6 to 0.0),
SE 0.16; p = 0.0501
2.5 (2.1 to 2.9),
SE 0.20
2.8 (2.4 to 3.2),
SE 0.21
–0.3 (–0.6 to 0.1),
SE 0.18; p = 0.1346
Impact score 2.0 (1.5 to 2.6),
SE 0.27
2.7 (2.2 to 3.2),
SE 0.25
–0.7 (–1.1 to –0.2),
SE 0.22; p = 0.0033
1.9 (1.3 to 2.5),
SE 0.29
2.2 (1.6 to 2.8),
SE 0.30
–0.3 (–0.8 to 0.2),
SE 0.26, p = 0.2153
Externalising score 7.7 (7.0 to 8.5),
SE 0.38
8.2 (7.5 to 9.0),
SE 0.39
–0.5 (–1.1 to 0.1),
SE 0.30; p = 0.0817
6.9 (6.2 to 7.6),
SE 0.37
7.2 (6.5 to 8.0),
SE 0.39
–0.3 (–1.0 to 0.3),
SE 0.33; p = 0.3196
Internalising score 7.0 (6.2 to 7.8),
SE 0.40
7.2 (6.4 to 8.0),
SE 0.41
–0.2 (–0.9 to 0.4),
SE 0.32; p = 0.4809
6.3 (5.5 to 7.1),
SE 0.39
6.8 (6.0 to 7.6),
SE 0.41
–0.5 (–1.2 to 0.2),
SE 0.36; p = 0.1373
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Outcome
12 months 18 months
FT, mean
(95% CI), SE
TAU, mean
(95% CI), SE
Difference,f mean
(95% CI), SE; p-value
FT, mean
(95% CI), SE
TAU, mean
(95% CI), SE
Difference,f mean
(95% CI), SE; p-value
McMaster FADe
Overall FAD score 2.3 (2.2 to 2.3),
SE 0.04
2.3 (2.2 to 2.4),
SE 0.04
–0.0 (–0.1 to 0.0),
SE 0.03; p = 0.6720
2.2 (2.1 to 2.3),
SE 0.04
2.2 (2.1 to 2.3),
SE 0.04
0.0 (–0.1 to 0.1),
SE 0.03; p = 0.9321
General functioning 2.2 (2.1 to 2.3),
SE 0.06
2.2 (2.1 to 2.4),
SE 0.06
–0.0 (–0.1 to 0.1),
SE 0.05; p = 0.7364
2.2 (2.1 to 2.3),
SE 0.06
2.2 (2.0 to 2.3),
SE 0.06
0.0 (–0.1 to 0.1),
SE 0.05; p = 0.8115
Behaviour control 2.0 (1.9 to 2.0),
SE 0.04
1.9 (1.9 to 2.0),
SE 0.04
0.0 (–0.0 to 0.1),
SE 0.03; p = 0.6267
1.9 (1.8 to 2.0),
SE 0.04
1.9 (1.8 to 2.0),
SE 0.05
–0.0 (–0.1 to 0.1),
SE 0.04; p = 0.5654
Affective involvement 2.4 (2.3 to 2.5),
SE 0.05
2.4 (2.3 to 2.5),
SE 0.05
–0.1 (–0.1 to 0.0),
SE 0.04; p = 0.2246
2.3 (2.2 to 2.4),
SE 0.05
2.4 (2.3 to 2.5),
SE 0.06
–0.1 (–0.2 to 0.0),
SE 0.05; p = 0.1632
Affective responsiveness 2.4 (2.3 to 2.5),
SE 0.06
2.4 (2.3 to 2.6),
SE 0.06
–0.0 (–0.1 to 0.1),
SE 0.05; p = 0.6644
2.4 (2.3 to 2.5),
SE 0.06
2.4 (2.3 to 2.5),
SE 0.06
–0.0 (–0.1 to 0.1),
SE 0.05; p = 0.9381
Roles 2.3 (2.2 to 2.4),
SE 0.04
2.3 (2.2 to 2.4),
SE 0.04
–0.0 (–0.1 to 0.0),
SE 0.03; p = 0.4592
2.2 (2.2 to 2.3),
SE 0.04
2.2 (2.2 to 2.3),
SE 0.04
–0.0 (–0.1 to 0.1),
SE 0.04; p = 0.8653
Communication 2.4 (2.3 to 2.5),
SE 0.04
2.4 (2.3 to 2.4),
SE 0.04
0.0 (–0.0 to 0.1),
SE 0.04; p = 0.2562
2.3 (2.2 to 2.4),
SE 0.05
2.3 (2.2 to 2.4),
SE 0.05
0.0 (–0.1 to 0.1),
SE 0.04; p = 0.7817
Problem-solving 2.3 (2.2 to 2.4),
SE 0.05
2.3 (2.2 to 2.4),
SE 0.05
–0.0 (–0.1 to 0.1),
SE 0.04; p = 0.8091
2.2 (2.1 to 2.3),
SE 0.05
2.2 (2.1 to 2.3),
SE 0.05
–0.0 (–0.1 to 0.1),
SE 0.05; p = 0.6052
a CDRS-R: higher scores represent greater levels of depression.
b PQ-LES-Q: higher scores indicative of greater enjoyment and satisfaction.
c Hopelessness scale: higher scores reflect greater hopelessness or negative expectations towards the future.
d SDQ: higher scores in all but the prosocial score represent greater issues in that category. For the prosocial score, lower scores represent greater issues.
e McMaster FAD: higher scores are indicative of poorer family functioning.
f Difference: FT – TAU.
Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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Caregiver questionnaires
Summary statistics for the caregiver questionnaire outcomes are presented in Table 72 and results of the
repeated measures modelling (adjusted for baseline scores and covariates) in Table 73. The results of
the sensitivity analysis conducted using complete data were similar and did not result in any change to
the conclusions.
Caregiver questionnaire outcomes on the SDQ and the McMaster FAD differed significantly between the
treatment groups. No significant differences between treatments were detected for the GHQ-12 or the
Family Questionnaire.
TABLE 71 Mean proportions, odds and odds ratios with 95% CIs for suicide ideation as screened by the young
person Beck scale (adjusted for baseline score and covariates) via multiple imputation (n= 832)
Time point
Mean proportion (95% CI), SE Odds (95% CI) OR (95% CI), p-value
FT TAU FT TAU FT vs. TAU
12 months 0.26 (0.17 to 0.36),
SE= 0.05
0.36 (0.25 to 0.46),
SE = 0.05
0.35
(0.22 to 0.58)
0.55
(0.35 to 0.87)
0.64 (0.44 to 0.94),
p= 0.0242
18 months 0.22 (0.14 to 0.31),
SE= 0.04
0.28 (0.18 to 0.37),
SE = 0.05
0.29
(0.18 to 0.47)
0.38
(0.23 to 0.62)
0.76 (0.49 to 1.16),
p= 0.2009
OR, odds ratio.
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FIGURE 23 Unadjusted 95% CIs for young person SDQ prosocial and impact subscales. (a) prosocial and (b) impact.
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On the SDQ, there was good evidence (p-value < 0.05) of significantly better outcomes in the FT arm on
the total difficulties score and on the emotional problems, peer problems and internalising subscores at
both 12 and 18 months, and on the conduct problems and externalising subscores at 18 months only.
There was also good evidence of better outcomes in the FT arm on the impact score at 12 months;
however, by 18 months, scores in the FT arm had risen slightly so that the difference between treatment
arms was no longer statistically significant.
On the McMaster FAD, there was good evidence (p-value < 0.05) of better family functioning on the roles
subscale at 12 months; however, by 18 months, scores remained similar in the FT arm but decreased to a
similar level in the TAU arm so that the difference between treatment arms was no longer statistically
significant.
Unadjusted mean estimates and 95% CIs for complete data are presented in Figures 26, 27 and 28 for
questionnaires and subscales with good evidence of a treatment effect at 12 or 18 months (p-value < 0.05).
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FIGURE 24 Unadjusted 95% CIs for suicide ideation as reported by the young person in the BSS.
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FIGURE 25 Unadjusted 95% CIs for the young person BSS score.
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TABLE 72 Summary statistics for the caregiver questionnaire outcomes
Outcome
Baseline 12 months 18 months
FT TAU Total FT TAU Total FT TAU Total
GHQ-12 score. Likert scale (0–36),a N
n 414 415 829 254 193 447 218 173 391
Mean (SD) 17.7 (7.06) 18.6 (7.24) 18.2 (7.16) 12.6 (6.93) 14.0 (6.15) 13.2 (6.63) 13.0 (6.48) 13.6 (6.75) 13.3 (6.60)
95% CI (17.1 to 18.4) (17.9 to 19.3) (17.7 to 18.7) (11.8 to 13.5) (13.1 to 14.9) (12.6 to 13.8) (12.1 to 13.9) (12.6 to 14.6) (12.6 to 13.9)
Family Questionnaire,b N 415 416 831 241 198 439 210 150 360
Total score (20–80), mean (SD) 52.9 (10.67) 52.9 (10.85) 52.9 (10.75) 49.4 (10.88) 48.3 (10.65) 48.9 (10.78) 45.5 (10.78) 46.9 (12.36) 46.1 (11.47)
Emotional overinvolvement
(10–40), mean (SD)
27.2 (4.93) 27.2 (5.03) 27.2 (4.98) 25.3 (5.26) 24.9 (5.35) 25.1 (5.30) 23.1 (5.37) 23.6 (6.15) 23.3 (5.71)
Criticism (10–40), mean (SD) 25.7 (6.97) 25.7 (7.06) 25.7 (7.01) 24.2 (6.65) 23.5 (6.43) 23.8 (6.55) 22.4 (6.28) 23.2 (7.17) 22.8 (6.67)
SDQc
Total difficulties score (0–40), N 412 415 827 253 194 447 215 173 388
Mean (SD) 19.4 (6.56) 19.8 (6.83) 19.6 (6.69) 14.2 (7.23) 15.3 (7.44) 14.7 (7.33) 13.0 (7.14) 15.0 (7.34) 13.9 (7.29)
Close to average (0–13), n (%) 78 (18.9) 86 (20.7) 164 (19.8) 125 (49.4) 81 (41.8) 206 (46.1) 115 (53.5) 75 (43.4) 190 (49.0)
Slightly raised (14–16), n (%) 51 (12.4) 36 (8.7) 87 (10.5) 36 (14.2) 31 (16.0) 67 (15.0) 29 (13.5) 34 (19.7) 63 (16.2)
High (17–19), n (%) 67 (16.3) 66 (15.9) 133 (16.1) 27 (10.7) 28 (14.4) 55 (12.3) 35 (16.3) 19 (11.0) 54 (13.9)
Very high (20–40), n (%) 216 (52.4) 227 (54.7) 443 (53.6) 65 (25.7) 54 (27.8) 119 (26.6) 36 (16.7) 45 (26.0) 81 (20.9)
Prosocial score (0–10), N 414 416 830 254 194 448 216 173 389
Mean (SD) 6.3 (2.33) 6.3 (2.30) 6.3 (2.31) 6.9 (2.22) 6.8 (2.21) 6.8 (2.22) 7.1 (2.20) 6.9 (2.40) 7.0 (2.29)
Emotional problems score (0–10),
N 414 415 829 253 194 447 217 173 390
Mean (SD) 6.2 (2.39) 6.2 (2.60) 6.2 (2.49) 4.3 (2.72) 4.8 (2.76) 4.5 (2.75) 3.9 (2.74) 4.5 (2.66) 4.2 (2.72)
Conduct problems score (0–10), N 413 416 829 254 194 448 216 174 390
Mean (SD) 4.2 (2.42) 4.3 (2.47) 4.2 (2.44) 2.9 (2.21) 3.1 (2.23) 3.0 (2.22) 2.5 (2.12) 2.9 (2.21) 2.7 (2.17)
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Outcome
Baseline 12 months 18 months
FT TAU Total FT TAU Total FT TAU Total
Hyperactivity score (0–10), N 414 415 829 254 194 448 217 173 390
Mean (SD) 5.5 (2.48) 5.7 (2.56) 5.6 (2.52) 4.1 (2.50) 4.3 (2.55) 4.2 (2.52) 4.1 (2.57) 4.5 (2.50) 4.3 (2.55)
Peer problems score (0–10), N 413 415 828 253 194 447 215 173 388
Mean (SD) 3.5 (2.09) 3.6 (2.14) 3.6 (2.11) 2.8 (2.06) 3.1 (2.06) 3.0 (2.06) 2.6 (1.79) 3.1 (2.27) 2.8 (2.03)
Impact score (0–10), N 410 413 823 193 145 338 133 127 260
Mean (SD) 4.4 (2.73) 4.3 (2.73) 4.4 (2.73) 2.6 (2.67) 3.2 (2.91) 2.8 (2.79) 2.8 (2.81) 3.2 (2.91) 3.0 (2.86)
Externalising score (0–20), N 413 415 828 254 194 448 216 173 389
Mean (SD) 9.7 (4.30) 10.0 (4.50) 9.9 (4.40) 7.0 (4.13) 7.4 (4.30) 7.2 (4.20) 6.5 (4.22) 7.4 (4.28) 6.9 (4.26)
Internalising score (0–20), N 413 415 828 253 194 447 215 173 388
Mean (SD) 9.8 (3.69) 9.8 (4.02) 9.8 (3.86) 7.2 (4.10) 7.9 (4.31) 7.5 (4.21) 6.5 (3.88) 7.6 (4.32) 7.0 (4.12)
McMaster FAD (1–4)d
Overall FAD score, N 408 415 823 251 193 444 215 174 389
Mean (SD) 2.2 (0.36) 2.2 (0.36) 2.2 (0.36) 2.0 (0.36) 2.1 (0.35) 2.0 (0.36) 2.0 (0.38) 2.0 (0.38) 2.0 (0.38)
General functioning, N 415 416 831 253 194 447 216 174 390
Mean (SD) 2.3 (0.48) 2.3 (0.47) 2.3 (0.47) 2.0 (0.46) 2.1 (0.44) 2.1 (0.45) 2.0 (0.47) 2.0 (0.47) 2.0 (0.47)
Unhealthy (≥ 2.0), n (%) 314 (75.7) 316 (76.0) 630 (75.8) 148 (58.5) 115 (59.3) 263 (58.8) 120 (55.6) 96 (55.2) 216 (55.4)
Behaviour control, N 411 416 827 251 194 445 215 174 389
Mean (SD) 1.8 (0.41) 1.8 (0.41) 1.8 (0.41) 1.7 (0.40) 1.7 (0.39) 1.7 (0.40) 1.7 (0.42) 1.7 (0.42) 1.7 (0.42)
Unhealthy (≥ 1.9), n (%) 197 (47.9) 226 (54.3) 423 (51.1) 103 (41.0) 71 (36.6) 174 (39.1) 75 (34.9) 60 (34.5) 135 (34.7)
Affective involvement, N 412 415 827 252 194 446 215 174 389
Mean (SD) 2.2 (0.45) 2.3 (0.51) 2.2 (0.48) 2.1 (0.45) 2.1 (0.45) 2.1 (0.45) 2.1 (0.44) 2.1 (0.50) 2.1 (0.47)
Unhealthy (≥ 2.1), n (%) 270 (65.5) 272 (65.5) 542 (65.5) 135 (53.6) 107 (55.2) 242 (54.3) 119 (55.3) 92 (52.9) 211 (54.2)
continued
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TABLE 72 Summary statistics for the caregiver questionnaire outcomes (continued )
Outcome
Baseline 12 months 18 months
FT TAU Total FT TAU Total FT TAU Total
Affective responsiveness, N 411 415 826 252 194 446 216 174 390
Mean (SD) 2.1 (0.55) 2.1 (0.57) 2.1 (0.56) 1.9 (0.54) 2.0 (0.54) 2.0 (0.54) 1.9 (0.53) 1.9 (0.51) 1.9 (0.52)
Unhealthy (≥ 2.2), n (%) 195 (47.4) 197 (47.5) 392 (47.5) 98 (38.9) 69 (35.6) 167 (37.4) 83 (38.4) 64 (36.8) 147 (37.7)
Roles, N 415 415 830 254 194 448 217 174 391
Mean (SD) 2.5 (0.42) 2.5 (0.42) 2.5 (0.42) 2.3 (0.41) 2.4 (0.40) 2.4 (0.41) 2.3 (0.43) 2.3 (0.43) 2.3 (0.43)
Unhealthy (≥ 2.3), n (%) 304 (73.3) 309 (74.5) 613 (73.9) 152 (59.8) 138 (71.1) 290 (64.7) 120 (55.3) 104 (59.8) 224 (57.3)
Communication, N 413 415 828 254 193 447 215 174 389
Mean (SD) 2.3 (0.44) 2.3 (0.41) 2.3 (0.43) 2.1 (0.41) 2.1 (0.42) 2.1 (0.42) 2.1 (0.43) 2.1 (0.44) 2.1 (0.44)
Unhealthy (≥ 2.2), n (%) 248 (60.0) 255 (61.4) 503 (60.7) 99 (39.0) 92 (47.7) 191 (42.7) 92 (42.8) 71 (40.8) 163 (41.9)
Problem-solving, N 411 416 827 252 193 445 216 174 390
Mean (SD) 2.2 (0.48) 2.2 (0.48) 2.2 (0.48) 2.0 (0.45) 2.1 (0.45) 2.0 (0.45) 2.0 (0.46) 2.0 (0.43) 2.0 (0.45)
Unhealthy (≥ 2.2), n (%) 234 (56.9) 249 (59.9) 483 (58.4) 94 (37.3) 84 (43.5) 178 (40.0) 84 (38.9) 76 (43.7) 160 (41.0)
a Higher scores are indicative of greater psychological distress.
b Higher scores indicate greater levels of expressed emotion.
c Higher scores in all but the prosocial score represent greater issues in that category. For the prosocial score, lower scores represent greater issues. See Appendix 3 for categorisation of
the total difficulties score (differs for young person and caregiver).
d Higher scores are indicative of poorer family functioning.
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TABLE 73 Mean scores with 95% CIs for caregivers questionnaire outcomes (adjusted for baseline and covariates) via multiple imputation (n = 832)
Outcome
12 months 18 months
FT, mean
(95% CI), SE
TAU, mean
(95% CI), SE
Difference,e mean
(95% CI), SE; p-value
FT, mean
(95% CI), SE
TAU, mean
(95% CI), SE
Difference,e mean
(95% CI), SE; p-value
GHQ-12a 12.8 (11.6 to 14.0),
SE = 0.61
13.5 (12.3 to 14.8),
SE = 0.65
–0.7 (–1.8 to 0.3),
SE = 0.54; p = 0.1870
13.0 (11.8 to 14.2),
SE = 0.62
13.2 (11.8 to 14.6),
SE = 0.71
–0.2 (–1.3 to 0.9),
SE = 0.57; p = 0.7307
Family Questionnaire (3 and 6 months)b
Total score 50.9 (49.0 to 52.7),
SE= 0.96
50.2 (48.3 to 52.0),
SE= 0.95
0.7 (–0.7 to 2.1),
SE= 0.73; p= 0.3400
47.4 (45.3 to 49.4),
SE= 1.06
48.8 (46.7 to 50.9),
SE= 1.07
–1.4 (–3.3 to 0.5),
SE= 0.94; p= 0.1369
Emotional subscore 25.9 (24.9 to 26.9),
SE= 0.50
25.5 (24.6 to 26.5),
SE= 0.50
0.4 (–0.4 to 1.1),
SE= 0.38; p= 0.3533
23.8 (22.7 to 24.9),
SE= 0.55
24.4 (23.3 to 25.5),
SE= 0.56
–0.6 (–1.6 to 0.4),
SE= 0.50; p= 0.2614
Criticism subscore 25.0 (23.9 to 26.1),
SE= 0.55
24.7 (23.6 to 25.8),
SE= 0.55
0.3 (–0.5 to 1.2),
SE= 0.43; p= 0.4385
23.6 (22.4 to 24.8),
SE= 0.61
24.4 (23.2 to 25.6),
SE= 0.61
–0.9 (–1.9 to 0.2),
SE= 0.54; p= 0.1150
SDQc
Total difficulties 14.1 (12.7 to 15.5),
SE= 0.72
15.4 (14.0 to 16.8),
SE= 0.71
–1.3 (–2.4 to –0.2),
SE= 0.56; p= 0.0260
13.2 (11.9 to 14.6),
SE= 0.68
14.9 (13.3 to 16.4),
SE= 0.79
–1.6 (–2.9 to –0.4),
SE= 0.65; p= 0.0131
Prosocial score 6.9 (6.5 to 7.3),
SE= 0.21
6.8 (6.4 to 7.2),
SE= 0.22
0.1 (–0.3 to 0.4),
SE= 0.17; p= 0.6005
7.1 (6.6 to 7.5),
SE= 0.22
6.9 (6.5 to 7.4),
SE= 0.22
0.2 (–0.2 to 0.5),
SE= 0.18; p= 0.3877
Emotional problems score 4.0 (3.4 to 4.5),
SE= 0.28
4.5 (3.9 to 5.1),
SE= 0.29
–0.5 (–1.0 to –0.1),
SE= 0.23; p= 0.0166
3.6 (3.1 to 4.2),
SE= 0.28
4.2 (3.6 to 4.8),
SE= 0.30
–0.6 (–1.1 to –0.1),
SE= 0.25; p= 0.0218
Conduct problems score 3.1 (2.7 to 3.4),
SE= 0.20
3.3 (2.9 to 3.7),
SE= 0.20
–0.3 (–0.6 to 0.0),
SE= 0.17; p= 0.0925
2.8 (2.4 to 3.2),
SE= 0.20
3.1 (2.7 to 3.5),
SE= 0.21
–0.3 (–0.6 to -0.0),
SE= 0.16; p= 0.0499
Hyperactivity score 4.3 (3.8 to 4.7),
SE= 0.24
4.4 (3.9 to 4.9),
SE= 0.25
–0.1 (–0.5 to 0.3),
SE= 0.19; p= 0.5494
4.3 (3.8 to 4.8),
SE= 0.24
4.5 (4.0 to 5.1),
SE= 0.28
–0.2 (–0.6 to 0.2),
SE= 0.22; p= 0.3536
Peer problems score 2.9 (2.5 to 3.3),
SE= 0.21
3.2 (2.8 to 3.6),
SE= 0.21
–0.3 (–0.7 to 0.0),
SE= 0.17; p= 0.0366
2.6 (2.2 to 3.0),
SE= 0.20
3.1 (2.7 to 3.6),
SE= 0.23
–0.5 (–0.9 to –0.1),
SE= 0.20; p= 0.0092
Impact score 2.3 (1.7 to 2.9),
SE= 0.31
2.9 (2.2 to 3.7),
SE= 0.37
–0.7 (–1.3 to -0.1),
SE= 0.30; p= 0.0309
2.4 (1.7 to 3.0),
SE= 0.32
2.6 (1.9 to 3.3),
SE= 0.36
–0.3 (–0.9 to 0.3),
SE= 0.31; p= 0.3844
Externalising score 7.3 (6.6 to 8.0),
SE= 0.36
7.7 (6.9 to 8.4),
SE= 0.38
–0.4 (–1.0 to 0.2),
SE= 0.31; p= 0.1827
7.0 (6.2 to 7.8),
SE= 0.39
7.6 (6.9 to 8.4),
SE= 0.39
–0.7 (–1.3 to 0.0),
SE= 0.32; p= 0.0446
continued
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TABLE 73 Mean scores with 95% CIs for caregivers questionnaire outcomes (adjusted for baseline and covariates) via multiple imputation (n = 832) (continued )
Outcome
12 months 18 months
FT, mean
(95% CI), SE
TAU, mean
(95% CI), SE
Difference,e mean
(95% CI), SE; p-value
FT, mean
(95% CI), SE
TAU, mean
(95% CI), SE
Difference,e mean
(95% CI), SE; p-value
Internalising score 6.8 (6.0 to 7.7),
SE= 0.43
7.7 (6.9 to 8.6),
SE= 0.43
–0.9 (–1.5 to –0.2),
SE= 0.34; p= 0.0111
6.2 (5.4 to 7.0),
SE= 0.41
7.3 (6.3 to 8.2),
SE= 0.48
–1.1 (–1.9 to –0.3),
SE= 0.39; p= 0.0074
McMaster FADd
Overall FAD score 2.1 (2.0 to 2.1),
SE= 0.03
2.1 (2.0 to 2.2),
SE= 0.03
–0.0 (–0.1 to 0.0),
SE= 0.03; p= 0.0797
2.0 (2.0 to 2.1),
SE= 0.03
2.1 (2.0 to 2.1),
SE= 0.03
–0.0 (–0.1 to 0.0),
SE= 0.03; p= 0.6436
General functioning 2.1 (2.0 to 2.2),
SE= 0.04
2.1 (2.0 to 2.2),
SE= 0.04
–0.0 (–0.1 to 0.0),
SE= 0.04; p= 0.2444
2.0 (1.9 to 2.1),
SE= 0.05
2.1 (2.0 to 2.2),
SE= 0.04
–0.0 (–0.1 to 0.0),
SE= 0.04; p= 0.2085
Behaviour control 1.7 (1.6 to 1.8),
SE= 0.04
1.7 (1.6 to 1.8),
SE= 0.04
–0.0 (–0.1 to 0.1),
SE= 0.03; p= 0.8728
1.7 (1.6 to 1.7),
SE= 0.04
1.7 (1.6 to 1.8),
SE= 0.04
–0.0 (–0.1 to 0.1),
SE= 0.03; p= 0.8188
Affective involvement 2.1 (2.0 to 2.2),
SE= 0.04
2.1 (2.1 to 2.2),
SE= 0.04
–0.1 (–0.1 to 0.0),
SE= 0.03; p= 0.0648
2.1 (2.0 to 2.2),
SE= 0.04
2.1 (2.0 to 2.2),
SE= 0.05
–0.0 (–0.1 to 0.1),
SE= 0.05; p= 0.5652
Affective responsiveness 2.0 (1.9 to 2.1),
SE= 0.04
2.0 (1.9 to 2.1),
SE= 0.05
–0.0 (–0.1 to 0.1),
SE= 0.04; p= 0.6716
2.0 (1.9 to 2.1),
SE= 0.05
1.9 (1.9 to 2.0),
SE= 0.05
0.0 (–0.1 to 0.1),
SE= 0.04; p= 0.4294
Roles 2.4 (2.3 to 2.4),
SE= 0.03
2.5 (2.4 to 2.5),
SE= 0.04
–0.1 (–0.2 to 0.0),
SE= 0.03; p= 0.0020
2.4 (2.3 to 2.4),
SE= 0.04
2.4 (2.3 to 2.5),
SE= 0.04
–0.0 (–0.1 to 0.1),
SE= 0.03; p= 0.7299
Communication 2.1 (2.0 to 2.2),
SE= 0.04
2.2 (2.1 to 2.3),
SE= 0.04
–0.0 (–0.1 to 0.0),
SE= 0.03; p= 0.1282
2.1 (2.0 to 2.2),
SE= 0.04
2.1 (2.1 to 2.2),
SE= 0.04
–0.0 (–0.1 to 0.0),
SE= 0.04; p= 0.2939
Problem-solving 2.0 (2.0 to 2.1),
SE= 0.04
2.1 (2.0 to 2.2),
SE= 0.04
–0.0 (–0.1 to 0.0),
SE= 0.03; p= 0.2628
2.0 (1.9 to 2.1),
SE= 0.04
2.0 (1.9 to 2.1),
SE= 0.04
–0.0 (–0.1 to 0.1),
SE= 0.04; p= 0.7037
a GHQ-12: higher scores are indicative of greater psychological distress.
b Family Questionnaire: higher scores indicate greater levels of expressed emotion.
c SDQ: higher scores in all but the prosocial score represent greater issues in that category. For the prosocial score, lower scores represent greater issues.
d McMaster FAD: higher scores are indicative of poorer family functioning.
e Difference: FT – TAU.
Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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FIGURE 26 Unadjusted 95% CIs for caregiver SDQ (a) total difficulties; (b) externalising; and (c) internalising.
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FIGURE 27 Unadjusted 95% CIs for caregiver SDQ (a) emotional problems; (b) conduct problems; (c) peer problems;
and (d) impact problems. (continued)
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and (d) impact problems.
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Responder characteristics
Tables 109–112 and Figure 66 in Appendix 6 present the characteristics of participants with and without
missing data (based on young person questionnaire return rates) in terms of responders and non-responders
(followed up or lost to follow-up) by trial arm to explore if differential patterns exist that could impact on
the conclusions for the secondary outcomes. Two logistic models were fitted to explore response status. The
first included main effects for treatment arm, the participant characteristic and their interaction, to evaluate
whether or not the response profile differed by the characteristic overall and further differentially by
treatment arm. As tests for interaction do not provide a very powerful test for moderation, we also modelled
response status by participant characteristics separately for each treatment arm, providing separate tests of
the main characteristic effect in each arm to examine any differential effects.
Overall, participants lost to follow-up had significantly (p < 0.1) higher caregiver scores, representing
particularly concerning participant baseline characteristics on the SDQ conduct problems, impact and
externalising subscale; the FAD total score, roles and affective involvement subscales; the Family
Questionnaire total score; the GHQ-12; and the ICU total score. Participants lost to follow-up at both 12 and
18 months were also more likely to have been referred into CAMHS from hospital. Those lost to follow-up
at 12 months also had particularly concerning characteristics based on the young person FAD total score
and at 18 months on the caregiver SDQ total difficulties score.
Examination of differential loss to follow-up by treatment arm found some indication (p < 0.1) that more
males were lost to follow-up in the TAU arm than in the FT arm, whereas more females were lost to
follow-up in the FT arm than in the TAU arm and that participants lost to follow-up at 18 months were
slightly older in the TAU arm than in the FT arm (see Figure 66a and b, Appendix 6).
There was some indication that participants with particularly concerning initial presentations were lost to
follow-up in the TAU arm and/or participants with particularly concerning initial presentations were
followed up in the FT arm at 12 and/or 18 months based on participants’ baseline method of index
self-harm (self-poisoning and combined methods) and baseline scores for the young person and caregiver
FAD total score; caregiver SDQ total, conduct, externalising and impact scores; caregiver FAD affective
involvement score; caregiver ICU total score; and the caregiver Family Questionnaire score. Furthermore, the
number of participants who self-harmed and who were followed up at 12 months was higher in the FT arm
than in the TAU arm. These characteristics are described in Figure 66 f–p, Appendix 6.
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FIGURE 28 Unadjusted 95% CIs for caregiver McMaster FAD roles score.
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In contrast, there was an indication that more participants with particularly concerning initial presentations
were lost to follow-up in the FT arm and/or followed up in the TAU arm at 12 and/or 18 months, as
indicated through hospital CAMHS referrals and based on baseline scores for the caregiver FAD roles
scores and the caregiver GHQ-12 scores. These characteristics are described in Figure 66 c–e, Appendix 6.
In summary, participants lost to follow-up tended to have particularly concerning baseline characteristics; a
greater proportion of participants were lost to follow-up in TAU than in FT and there was some indication
of differential characteristics across treatment allocation with the majority of differences suggesting that
participants with particulary concerning baseline characteristics lost to follow-up in TAU and/or participants
with particularly concerning initial presentations followed up in FT. Based on these results, despite the high
loss to follow-up for secondary participant-reported outcomes, examination of missing data patterns
suggests that our estimates of treatment effect are conservative, as the potential effect of responses from
those with missing data would likely increase the size of the treatment effect detected and therefore the
conclusions for these outcomes remain valid.
Predictive and process measures
Moderator variables
Moderator analysis was used to explore whether or not the treatment effect in the Cox proportional
hazards model from the primary analysis depended upon participants’ baseline characteristics.
Despite the indication of moderation by referral source in summary statistics (see Table 50), a statistically
significant interaction with treatment was not detected (see Table 74). The magnitude of moderation can
be seen in Figure 29, which shows a HR very close to 1 (no treatment difference) and an increased hazard
in the FT arm compared with the TAU arm for participants referred from the community. The results
therefore provide some evidence, albeit not statistically significant, of a moderating effect, with an
increased risk of self-harm among young people in the FT arm referred to CAMHS via hospital.
Significant interactions with treatment (at the 5% level), indicating moderation, were detected for the
unemotional subscale on the young person-reported ICU (p = 0.0104) and the affective involvement
subscale on the caregiver-reported McMaster FAD for both the overall score (p = 0.0338) and score
categorised by healthy versus unhealthy families (p = 0.0444) (Tables 74–76).
Further potential interactions with treatment were detected, but only at the 10% level: the behaviour
control subscale on the caregiver-reported McMaster FAD for both the score (p = 0.571) and healthy
versus unhealthy families (p = 0.0702), the Beck screening for suicidal ideation (p = 0.0881) and also for
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FIGURE 29 Hazard ratio for FT vs. TAU by referral source.
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TABLE 74 Type 3 tests for moderation based on treatment ×moderator interaction in the primary outcome model
for baseline covariates
Baseline covariates: treatment ×moderator
Potential moderator df Wald chi-squared test p-value
Age 1 0.4730 0.4916
Centre 14 9.6983 0.7839
Referred from hospitala 1 1.7130 0.1906
Baseline number of self-harm episodes 1 0.1549 0.6939
Type of index self-harm episode 2 2.3900 0.3027
Sex 1 1.5219 0.2173
df, degrees of freedom.
a Source of referral was also investigated in the model excluding centre owing to known confounding effects. The
interaction with treatment remained non-significant (p= 0.1334).
TABLE 75 Type 3 tests for moderation based on treatment ×moderator interaction in the primary outcome model
for categorised young person and caregiver baseline questionnaire responses
Potential moderator df Wald chi-squared test p-value
Young person questionnaires: treatment ×moderator
BSS 1 2.9095 0.0881
CDRS-R 1 0.0609 0.8051
McMaster FAD
Affective involvement 1 1.0241 0.3116
Affective responsiveness 1 3.1896 0.0741
Behaviour control 1 0.0525 0.8188
Communication 1 0.0479 0.8268
General functioning 1 0.5484 0.4590
Problem-solving 1 0.0017 0.9671
Roles 1 0.5958 0.4402
Caregiver questionnaires: treatment ×moderator
McMaster FAD
Affective involvement 1 4.0424 0.0444
Affective responsiveness 1 0.0508 0.8217
Behaviour control 1 3.2787 0.0702
Communication 1 1.1161 0.2908
General functioning 1 0.6174 0.4320
Problem-solving 1 0.0048 0.9445
Roles 1 0.9611 0.3269
df, degrees of freedom.
Note
Shading indicates significant findings.
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TABLE 76 Type 3 tests for moderation based on treatment × moderator interaction in the primary outcome model
for continuous young person and caregiver baseline questionnaire responses
Potential moderator df Wald chi-squared test p-value
Young person questionnaires: treatment ×moderator
BSS 1 0.1620 0.6873
CDRS-R 1 0.1108 0.7392
PQ-LES-Q 1 0.0008 0.9774
Hopelessness 1 0.0000 0.9967
McMaster FAD
Affective involvement 1 0.9190 0.3377
Affective responsiveness 1 1.0668 0.3017
Behaviour control 1 0.1908 0.6623
Communication 1 0.3647 0.5459
General functioning 1 0.7798 0.3772
Problem-solving 1 0.5967 0.4399
Roles 1 0.0509 0.8216
Total score 1 0.4413 0.5065
ICU
Callousness 1 0.0876 0.7672
Total score 1 0.6874 0.4071
Uncaring 1 0.0988 0.7533
Unemotional 1 6.5713 0.0104
SDQ
Conduct problems 1 0.0489 0.8250
Emotional problems 1 0.5393 0.4627
Externalising 1 0.0021 0.9638
Hyperactivity 1 0.2173 0.6411
Impact 1 1.1025 0.2937
Internalising 1 0.3037 0.5815
Peer problems 1 0.0008 0.9776
Prosocial 1 0.2672 0.6052
Total difficulties 1 0.2181 0.6405
Caregiver questionnaires: treatment ×moderator
Family Questionnaire
Criticism 1 0.0098 0.9212
Emotional overinvolvement 1 0.4756 0.4904
GHQ-12 (Likert) 1 0.0342 0.8532
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healthy versus unhealthy families according to the young person-reported affective responsiveness subscale
of the McMaster FAD (p = 0.0741); however, this result was not supported by the uncategorised score
(p = 0.3017).
No moderation was detected for other questionnaire responses or covariates.
Moderation varied in direction across the moderators (Table 77 and Figures 30–34).
The risk of self-harm decreased in the TAU arm for young people with more unemotional traits (HR 0.932,
95% CI 0.875 to 0.992, for a 1-point increase), whereas the risk of self-harm increased in the FT arm for
young people with more unemotional traits (HR 1.05, 95% CI 0.982 to 1.122, for a 1-point increase).
TABLE 76 Type 3 tests for moderation based on treatment × moderator interaction in the primary outcome model
for continuous young person and caregiver baseline questionnaire responses (continued )
Potential moderator df Wald chi-squared test p-value
McMaster FAD
Affective involvement 1 4.5066 0.0338
Affective responsiveness 1 0.1042 0.7468
Behaviour control 1 3.6183 0.0571
Communication 1 0.9454 0.3309
General functioning 1 0.0019 0.9656
Problem-solving 1 0.0122 0.9120
Roles 1 1.3937 0.2378
Total score 1 0.9956 0.3184
ICU
Callousness 1 0.7379 0.3903
Total score 1 0.5244 0.4690
Uncaring 1 0.1057 0.7451
Unemotional 1 0.1604 0.6888
SDQ
Conduct problems 1 0.9628 0.3265
Emotional problems 1 0.9752 0.3234
Externalising 1 0.0561 0.8128
Hyperactivity 1 0.1353 0.7130
Impact 1 0.0486 0.8255
Internalising 1 0.5917 0.4418
Peer problems 1 0.0677 0.7947
Prosocial 1 0.4686 0.4936
Total difficulties 1 0.5405 0.4622
df, degrees of freedom.
Note
Shading indicates significant findings.
DOI: 10.3310/hta22120 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 12
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Cottrell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
TABLE 77 Hazard ratios and overall type 3 p-values for moderation based on treatment ×moderator interaction in
the primary outcome model for baseline questionnaire responses
Moderator HR (95% CI) p-value (treatment ×moderator)
Young person ICU unemotional score 0.0104
FT vs. TAU: at mean score = 9.01 1.127 (0.860 to 1.475)
A 1-point score increase: in FT 1.050 (0.982 to 1.122)
A 1-point score increase: in TAU 0.932 (0.875 to 0.992)
Caregiver FAD affective involvement score 0.0338
FT vs. TAU: at mean score = 2.24 1.146 (0.875 to 1.501)
A 1-point score increase: in FT 0.885 (0.585 to 1.339)
A 1-point score increase: in TAU 1.627 (1.107 to 2.390)
Caregiver FAD affective involvement category 0.0444
FT vs. TAU: in healthy 1.695 (1.047 to 2.743)
FT vs. TAU: in unhealthy 0.930 (0.671 to 1.289)
Healthy vs. unhealthy: in FT 1.165 (0.799 to 1.699)
Healthy vs. unhealthy: in TAU 0.639 (0.410 to 0.997)
Caregiver FAD behaviour control score 0.0571
FT vs. TAU: at mean score = 1.84 1.129 (0.862 to 1.477)
A 1-point score increase: in FT 0.772 (0.487 to 1.224)
A 1-point score increase: in TAU 1.466 (0.910 to 2.363)
Caregiver FAD behaviour control category 0.0702
FT vs. TAU: in healthy 1.470 (0.990 to 2.180)
FT vs. TAU: in unhealthy 0.887 (0.610 to 1.289)
Healthy vs. unhealthy: in FT 1.152 (0.794 to 1.672)
Healthy vs. unhealthy: in TAU 0.695 (0.465 to 1.039)
Young person FAD affective responsiveness category 0.0741
FT vs. TAU: in healthy 0.584 (0.276 to 1.234)
FT vs. TAU: in unhealthy 1.215 (0.909 to 1.624)
Healthy vs. unhealthy: in FT 0.496 (0.264 to 0.930)
Healthy vs. unhealthy: in TAU 1.033 (0.621 to 1.716)
Young person BSS category 0.0881
FT vs. TAU: no SI 0.772 (0.464 to 1.284)
FT vs. TAU: yes SI 1.303 (0.948 to 1.791)
SI vs. no SI: in FT 1.814 (1.169 to 2.815)
SI vs. no SI: in TAU 0.931 (0.611 to 1.417)
SI, suicidal ideation.
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FIGURE 30 Hazard ratio for FT vs. TAU by the baseline young person ICU unemotional score. Higher scores
represent higher unemotional traits. Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd.
This is an Open Access article under the CC BY 4.0 license.
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FIGURE 31 Hazard ratio for FT vs. TAU by the baseline caregiver McMaster FAD affective involvement score and
category. Higher scores are indicative of poorer family functioning. (a) Continuous score; and (b) families classified
as healthy vs. unhealthy. Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open
Access article under the CC BY 4.0 license.
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There was only limited evidence (p = 0.0881) of a higher risk of self-harm in the FT arm for young people
with suicidal ideation than for those without, as identified through screening on the BSS (HR 1.814,
95% CI 1.169 to 2.815). Young people’s responses on the affective responsiveness subscale also provided
limited evidence (p = 0.0741) that unhealthy families (as defined by the FAD) had an increased risk of
self-harm in the FT arm compared with the TAU arm (HR 1.215, 95% CI 0.909 to 1.624); however,
moderation was not supported by the continuous score.
On the caregiver-reported affective involvement and behaviour control subscales, moderation differed in
direction compared to moderation by young person-reported unemotional traits, suicide ideation and
affective responsiveness. The risk of self-harm was higher in the TAU arm for participants with higher
caregiver scores indicating poorer family functioning (HR 1.627, 95% CI 1.107 to 2.390, for a 1-point
increase in affective involvement; and HR 1.466, 95% CI 0.910 to 2.363, for behaviour control), whereas
the risk of self-harm was lower in the FT arm for participants with poorer family functioning (HR 0.885,
95% CI 0.585 to 1.339, for a 1-point increase in affective involvement; and HR 0.772, 95% CI 0.487 to
1.224, for behaviour control). This moderation was supported by the categorisation of families as healthy
versus unhealthy based on their scores, with healthy families in the FT arm having on both scales a higher
risk of self-harm than those in the TAU arm (HR 1.695, 95% CI 1.047 to 2.743, for affective involvement;
and HR 1.470, 95% CI 0.990 to 2.180, for behaviour control).
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FIGURE 32 Hazard ratio for FT vs. TAU by the baseline caregiver McMaster FAD behaviour control score and
category. Higher scores are indicative of poorer family functioning. (a) Continuous score; and (b) families classified
as healthy vs. unhealthy.
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and category. Higher scores are indicative of poorer family functioning.
No SI
0.5
1.0
1.5
Yes SI
Young person BSS
H
R
: F
T 
vs
. T
A
U
FIGURE 34 Hazard ratio for FT vs. TAU by baseline suicide ideation screening on the young person BSS.
SI, suicidal ideation. (a) Continuous score; and (b) families classified as healthy vs. unhealthy.
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Mediator variables
Complier average causal effect analysis
A CACE analysis was conducted to model the causal effect of FT receipt (as opposed to randomisation) on
the primary outcome.
Summary statistics showing the proportion of participants with an event in each arm and by receipt of FT
or formal systemic FT as part of usual care are shown in Table 78 and Figures 35 and 36. The highest
overall self-harm rate was exhibited by TAU participants with missing treatment data, with a primary
outcome event reported in 15 (33.3%) participants in this group. The lowest repetition rate was reported
in three (14.3%) participants allocated to receive FT who attended no FT sessions; however, they also
constituted the smallest group. The repetition rate in participants allocated to and who attended SHIFT FT
was 29.2%, while for those in the TAU arm not attending FT the repetition rate was lower, at 24.6%.
Furthermore, in participants allocated to TAU who attended FT, the repetition rate was lower again, at
20.7%. Considering attendance at FT sessions irrespective of randomisation, the repetition rate was
27.7% in those who received at least one FT session and 23.9% in those who did not.
The CACE analysis shows a very similar effect of the intervention among those who received FT [0.12
(SE 0.13); p = 0.3424] compared with the standard ‘ITT’ estimate of the ‘allocation’ of FT [0.11 (SE 0.10);
p = 0.2395] and the ‘as treated’ estimate [0.10 (SE 0.10); p = 0. 3136], with no significant differences
detected between trial arms, or receipt of FT (Table 79). Furthermore, the correlation parameter estimate
from the CACE model indicates that treatment selection bias on the outcome is not a problem [0.03
(SE 0.11); p = 0.7869].
Finally, Figure 37 further displays the time to first event for participants allocated to FT who received FT
and those allocated to TAU who received a form of FT as part of their usual care. The curves appear to
diverge, with an increased rate of self-harm in those allocated to FT; however, 95% CIs around the two
curves overlap at each time point and the log-rank estimate of a difference between trial arms finds no
statistically significant difference (p = 0.1087).
Mediation
Summary statistics showing the proportion of participants with a primary outcome event in each arm by
variables considered to be potential process mediators are shown in Table 80. Young people on a
psychotropic medication during follow-up were more likely to self-harm than those who were not
prescribed such drugs: 41 out of 104 (39.4%) young people on a medication engaged in self-harm,
compared with 164 out of 670 (24.5%) not on medication. In the FT arm, rates of self-harm were higher
in young people whose lead therapist had been working in CAMHS for ≥ 4 years than in those whose lead
therapist had been working for < 4, years with repetition observed for 77 (27.8%) and nine (20.9%)
participants, respectively. Conversely, in the TAU arm, rates of self-harm were lower among participants
seen by more experienced therapists than among those seen by less experienced therapists, with repetition
observed for 24 (19.7%) and 12 (26.7%) participants, respectively. In both arms, participants who self-
harmed attended more sessions overall [mean 11.2 (SD 12.68) sessions] than those who did not [mean 7.5
(10.03) sessions].
For potential mediators based on 3-, 6- and 12-month questionnaire responses, mediation was explored in
relation to the time to event post 3, 6 and 12 months, respectively. Table 81 presents the proportion of
participants with a self-harm event leading to hospital attendance and Figures 38–40 present Kaplan–Meier
plots of time to self-harm for each period.
Following the Baron and Kenny90 steps, there was no evidence that any of the variables investigated
formally mediated the effect of treatment on the time to self-harm, largely because of lack of evidence of
a treatment effect (Table 82).
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TABLE 78 Primary outcome self-harm event observed according to whether or not any formal systemic FT sessions were attended as part of randomisation or TAU
SHIFT FT or formal systemic FT sessions attended?
FT TAU Total
Yes (N= 394)
No
(N= 21)
Total
(N= 415)
Yes
(N= 87)
No
(N= 285)
Missing
(N= 45)
Total
(N= 417)
Yes
(N= 481)
No
(N= 306)
Missing
(N= 45)
Total
(N= 832)
Primary outcome event?
Yes, n (%) 115 (29.2) 3 (14.3) 118 (28.4) 18 (20.7) 70 (24.6) 15 (33.3) 103 (24.7) 133 (27.7) 73 (23.9) 15 (33.3) 221 (26.6)
No, n (%) 279 (70.8) 18 (85.7) 297 (71.6) 69 (79.3) 215 (75.4) 30 (66.7) 314 (75.3) 348 (72.3) 233 (76.1) 30 (66.7) 611 (73.4)
0
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FIGURE 35 Kaplan–Meier plot of time to self-harm by randomised treatment group and receipt of FT. Reproduced from Cottrell et al.70 © The Author(s). Published by Elsevier
Ltd. This is an Open Access article under the CC BY 4.0 license.
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TABLE 79 Adjusted multivariable probit regression estimates for self-harm during follow-up for the ITT, as treated
and CACE analysis
Model parameter
ITT estimate: randomised
treatment
As-treated estimate: FT
receipt
CACE estimate:a stage 2 –
FT receipt with
randomisation
instrumental variable
Parameter
estimate (SE) df p-value
Parameter
estimate
(SE) df p-value
Parameter
estimate (SE) df p-value
Intercept –0.89 (0.24) 1 0.0002 –0.89 (0.24) 1 0.0003 –0.90 (0.25) 1 0.0003
Randomised treatment: FT
(vs. TAU)
0.11 (0.10) 1 0.2395 – – – –
FT received: FT (vs. no FT) – – 0.10 (0.10) 1 0.3136 0.12 (0.13) 1 0.3424
Age group (years): 15–17
(vs. 11–14)
–0.24 (0.10) 1 0.0164 –0.23 (0.10) 1 0.0188 –0.23 (0.10) 1 0.0194
Gender: female (vs. male) 0.29 (0.16) 1 0.0668 0.30 (0.16) 1 0.0645 0.30 (0.16) 1 0.0635
Number of previous self-
harm episodes: ≥ 3 (vs. 2)
0.12 (0.16) 1 0.4654 0.11 (0.16) 1 0.4817 0.11 (0.16) 1 0.4837
Type of index episode
(vs. self-injury)
– – – – – –
Combined 0.49 (0.19) 1 0.0112 0.48 (0.19) 1 0.0129 0.48 (0.19) 1 0.0131
Self-poisoning 0.04 (0.14) 1 0.7739 0.04 (0.14) 1 0.7885 0.04 (0.14) 1 0.7882
Referred via hospital: yes
(vs. no)
0.16 (0.12) 1 0.1880 0.17 (0.12) 1 0.1751 0.17 (0.12) 1 0.1760
Trust (vs. Y trust 1) – – – – – –
M trust 3 0.09 (0.17) 1 0.6120 0.09 (0.17) 1 0.6074 0.09 (0.17) 1 0.6064
L trust 5 –0.42 (0.28) 1 0.1440 –0.42 (0.28) 1 0.1424 –0.42 (0.28) 1 0.1417
Y trust 3 –0.43 (0.24) 1 0.0718 –0.43 (0.24) 1 0.0747 –0.43 (0.24) 1 0.0750
Y trust 2 –0.23 (0.27) 1 0.3864 –0.22 (0.27) 1 0.4105 –0.22 (0.27) 1 0.4149
0
0.55
0.60
0.65
0.70
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FIGURE 36 Kaplan–Meier plot of time to self-harm by receipt of FT: time to first event for young person who
received FT vs. those who did not, regardless of randomisation.
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TABLE 79 Adjusted multivariable probit regression estimates for self-harm during follow-up for the ITT, as treated
and CACE analysis (continued )
Model parameter
ITT estimate: randomised
treatment
As-treated estimate: FT
receipt
CACE estimate:a stage 2 –
FT receipt with
randomisation
instrumental variable
Parameter
estimate (SE) df p-value
Parameter
estimate
(SE) df p-value
Parameter
estimate (SE) df p-value
M trust 1 0.10 (0.22) 1 0.6557 0.10 (0.22) 1 0.6549 0.10 (0.22) 1 0.6562
L trust 6 –0.35 (0.49) 1 0.4671 –0.41 (0.49) 1 0.4054 –0.41 (0.49) 1 0.3998
Y trust 4 –0.75 (0.31) 1 0.0139 –0.76 (0.31) 1 0.0134 –0.75 (0.31) 1 0.0135
L trust 2 –0.50 (0.21) 1 0.0191 –0.52 (0.21) 1 0.0160 –0.52 (0.21) 1 0.0154
M trust 2 –0.17 (0.18) 1 0.3499 –0.17 (0.18) 1 0.3484 –0.17 (0.18) 1 0.3482
L trust 1 –0.28 (0.18) 1 0.1257 –0.28 (0.18) 1 0.1210 –0.29 (0.18) 1 0.1196
Y trust 6 0.17 (0.25) 1 0.4979 0.18 (0.25) 1 0.4834 0.18 (0.26) 1 0.4776
L trust 4 –0.41 (0.61) 1 0.5085 –0.40 (0.61) 1 0.5133 –0.40 (0.61) 1 0.5143
L trust 3 –0.29 (0.37) 1 0.4385 –0.29 (0.37) 1 0.4328 –0.29 (0.37) 1 0.4321
Y trust 5 –0.20 (0.29) 1 0.4797 –0.22 (0.29) 1 0.4406 –0.23 (0.29) 1 0.4305
Rho (selection bias) – – – – 0.03 (0.11) 1 0.7869
df, degrees of freedom; SLaM, South London and Maudsley.
a Stage 1 of the CACE analysis found strong evidence that randomisation was associated with FT receipt [estimate:–2.63
(SE 0.14), p< 0.0001], satisfying the assumption of a non-zero causal effect of the instrumental variable on treatment.
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FIGURE 37 Kaplan–Meier plot of time to self-harm by arm for those receiving FT: time to first event for young
person who received FT in either arm by allocation.
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Considering the effect of randomised treatment on the mediator in step 2 and the effect of the mediator
of self-harm outcomes in step 3, we further discuss potential mediation for variables where significant
associations were detected in both steps (with at least good evidence < 5%).
Process mediators
There was good evidence (step 2) of an association between randomised treatment and psychotropic
medication use during follow-up (less in FT: OR 0.6; p = 0.0158) and strong evidence (step 3) that the use
of psychotropic medication is associated with an increased risk of self-harm (HR 2.10; p < 0.0001). There
was, however, no evidence of a treatment effect on the risk of self-harm (step 1) that could be mediated
(step 3) and, furthermore, there is no evidence of a direct treatment effect despite the positive association
with FT and the mediator (step 3). It should be noted that these data refer to all young people prescribed
any form of psychotropic medication during the treatment period (not specific to selective serotonin
reuptake inhibitors; see Table 37) and that, furthermore, we do not have reliable data on the timing of
medication and therefore its relationship to the timing of primary outcome event.
TABLE 81 Summary of self-harm event from 3, 6 and 12 months post randomisation
Self-harm event FT (N= 415), n (%) TAU (N= 417), n (%) Total (N= 832), n (%)
≥ 3 months post randomisation 97 (23.4) 81 (19.4) 178 (21.4)
≥ 6 months post randomisation 74 (17.8) 65 (15.6) 139 (16.7)
≥ 12 months post randomisation 48 (11.6) 33 (7.9) 81 (9.7)
TABLE 80 Summary of self-harm event by potential process mediator and treatment arm
Potential mediator
Primary outcome event reported
FT TAU Total
Yes
(self-harm)
No
(no self-harm)
Yes
(self-harm)
No
(no self-harm)
Yes
(self-harm)
No
(no self-harm)
Young person on any psychotropic medications, n (%)
Yes (n = 104) 18 (40.9) 26 (59.1) 23 (38.3) 37 (61.7) 41 (39.4) 63 (60.6)
No (n= 670) 100 (27.2) 267 (72.8) 64 (21.1) 239 (78.9) 164 (24.5) 506 (75.5)
Missing (n= 58) 0 (0.0) 4 (100.0) 16 (29.6) 38 (70.4) 16 (27.6) 42 (72.4)
Total (n= 832) 118 (28.4) 297 (71.6) 103 (24.7) 314 (75.3) 221 (26.6) 611 (73.4)
Years spent working in CAMHS, n (%)
< 4 years (n= 88) 9 (20.9) 34 (79.1) 12 (26.7) 33 (73.3) 21 (23.9) 67 (76.1)
≥ 4 years (n= 399) 77 (27.8) 200 (72.2) 24 (19.7) 98 (80.3) 101 (25.3) 298 (74.7)
Missing (n= 345) 32 (33.7) 63 (66.3) 67 (26.8) 183 (73.2) 99 (28.7) 246 (71.3)
Total (n= 832) 118 (28.4) 297 (71.6) 103 (24.7) 314 (75.3) 221 (26.6) 611 (73.4)
Overall number of sessions attended by anyone
n 118 297 88 284 206 581
Mean (SD) 9.9 (10.32) 6.8 (5.32) 12.9 (15.18) 8.2 (13.25) 11.2 (12.68) 7.5 (10.03)
Median (range) 7.0 (0–70) 6.0 (0–47) 8.0 (0–90) 4.0 (0–163) 7.0 (0–90) 5.0 (0–163)
Reproduced from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
4.0 license.
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There was strong evidence (step 3) that the number of therapy sessions was associated with the risk of
self-harm during follow-up (HR 1.02; p < 0.0001), with risk increasing with more sessions. There was only
weak evidence (step 2), however, that treatment group was associated with number of sessions (fewer
sessions in FT: –1.44; p = 0.0640) and no evidence of a treatment effect on the risk of self-harm (step 1)
that could be mediated (step 3). When the number of sessions attended is accounted for, there is weak
evidence of a direct treatment effect (step 3) with an increased risk of self-harm in FT (HR 1.29; p = 0.0825).
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FIGURE 38 Kaplan–Meier plot of time to self-harm from 3 months post randomisation by randomised treatment
group with 95% CIs.
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FIGURE 39 Kaplan–Meier plot of time to self-harm from 6 months post randomisation by randomised treatment
group with 95% CIs.
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There was strong evidence of an association between treatment group and the length of experience of the
lead therapist (more experienced in FT: OR 2.38; p = 0.0003), but no evidence that length of experience
was associated with the risk of self-harm (step 3). Summary statistics, however, do indicate differences
between self-harm rates in relation to therapist experience across the two arms that are not accounted for
via this mediation model and that warrant further investigation.
For both the number of sessions attended and the use of psychotropic medication, although there is no
evidence of a treatment effect in steps 1 or 3, the magnitude of the treatment coefficient is increased and
the suggested relationship between treatment and mediator, and between mediator and self-harm
outcome, warrants further investigation.
Three-month questionnaires
There was strong evidence of a treatment effect on the risk of self-harm (steps 1 and 3) when investigating
responses to the Family Questionnaire as potential mediators. However, this is for a subsample (53%) of
responding trial participants and, as there is no evidence that treatment is associated with either mediator
(step 2) and there is no change in the treatment effect when allowing for the potential mediating effect
(step 3), no mediation effects are suggested.
Twelve-month questionnaires
Significant treatment effects on the mediator (step 2) and significant mediator effects on the risk of
self-harm (step 3) were observed for the young person SDQ impact, caregiver SDQ emotional problems
and caregiver McMaster FAD roles subscales. Participants in the FT arm had improved outcomes on each
mediator at 12 months (step 2), and the risk of self-harm decreased as mediator scores improved. The
positive treatment effect on the mediator outcome did not, however, translate through to self-harm
outcomes in either step 1 or 2; rather, the estimated treatment effect actually increased in favour of TAU,
although not significantly so. Therefore, further investigation is warranted to explore why improved
mediator outcomes did not translate to self-harm outcomes.
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FIGURE 40 Kaplan–Meier plot of time to self-harm from 12 months post randomisation by randomised treatment
group with 95% CIs.
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TABLE 82 Mediators analysis: assessment of the Baron and Kenny mediation stepsa
Mediator
variable n
Step 1 [Y=h0(t)exp (β10 X)] Step 2 (Me= β20+ β21 X) Step 3 [Y=h0(t)exp (β31 X+ β32 Me)]
Suggestion
of potential
for mediation
Total effect of Rand on outcome –
c (β10) Effect of Rand on mediator – a (β21)
Effect of mediator on outcome –
b (β32)
Direct effect of Rand on outcome –
c’ (β31)
Coefficient
(SE) HR (95% CI) p-value
Coefficient
(SE) (95% CI) p-value
Coefficient
(SE) HR (95% CI) p-value
Coefficient
(SE) HR (95% CI) p-value
Process mediators
Overall young
person on any
psychotropic
medicationsb
774 0.17 (0.14) 1.19
(0.90 to 1.58)
0.2209 –0.26 (0.11) OR 0.60
(0.39 to 0.91)
0.0158 0.74 (0.18) 2.10
(1.47 to 3.00)
< 0.0001 0.23 (0.14) 1.26
(0.95 to 1.67)
0.1096 X
Years spent
working in CAMHS
by lead therapistb
487 0.26 (0.20) 1.30
(0.88 to 1.93)
0.1933 0.43 (0.12) OR 2.38
(1.49 to 3.82)
0.0003 –0.24 (0.27) 0.78
(0.46 to 1.33)
0.3650 0.30 (0.21) 1.35
(0.90 to 2.02)
0.1505 X
Number of sessions
attended
787 0.18 (0.14) 1.20
(0.91 to 1.59)
0.1970 –1.44 (0.77) (–2.95 to 0.08) 0.0640 0.02 (0.00) 1.02
(1.01 to 1.03)
< 0.0001 0.25 (0.14) 1.29
(0.97 to 1.71)
0.0825 X
3-month caregiver questionnaires
Family Q criticism 439 0.73 (0.24) 2.08
(1.31 to 3.33)
0.0021 0.33 (0.46) (–0.56 to 1.23) 0.4624 0.03 (0.02) 1.03
(0.98 to 1.08)
0.2250 0.73 (0.24) 2.07
(1.29 to 3.31)
0.0024
Family Q emotional
involvement
439 0.73 (0.24) 2.08
(1.30 to 3.32)
0.0022 0.51 (0.40) (–0.28 to 1.29) 0.2061 0.11 (0.03) 1.11
(1.05, 1.18)
0.0005 0.74 (0.24) 2.09
(1.30 to 3.34)
0.0022
6-month caregiver questionnaires
Family Q criticism 360 0.51 (0.29) 1.66
(0.94 to 2.93)
0.0802 –0.86 (0.57) (–1.98 to 0.26) 0.1302 0.05 (0.03) 1.05
(1.00, 1.10)
0.0564 0.56 (0.29) 1.74
(0.98 to 3.09)
0.0567
Family Q emotional
involvement
360 0.50 (0.29) 1.66
(0.94 to 2.92)
0.0815 –0.64 (0.53) (–1.68 to 0.40) 0.2264 0.11 (0.03) 1.11
(1.05, 1.18)
0.0005 0.57 (0.29) 1.76
(1.00 to 3.11)
0.0517
12-month young person questionnaires
Beck (continuous
score)
449 0.23 (0.32) 1.26
(0.67 to 2.36)
0.4801 –1.00 (0.69) (–2.36 to 0.35) 0.1467 0.08 (0.02) 1.08
(1.04, 1.12)
< 0.0001 0.36 (0.33) 1.43
(0.75 to 2.73)
0.2806
Beck (SI screen)b 449 0.23 (0.32) 1.26
(0.67 to 2.36)
0.4801 –0.17 (0.10) OR 0.71
(0.47 to 1.06)
0.0968 1.04 (0.35) 2.83
(1.43, 5.57)
0.0027 0.30 (0.33) 1.35
(0.71 to 2.55)
0.3639
CDRS-R 430 0.29 (0.32) 1.33
(0.71 to 2.50)
0.3676 –0.40 (1.30) (–2.95 to 2.15) 0.7566 0.04 (0.01) 1.05
(1.02, 1.07)
0.0002 0.28 (0.32) 1.32
(0.70 to 2.48)
0.3902
PQ-LES-Q 453 0.21 (0.32) 1.24
(0.66 to 2.32)
0.5122 1.11 (0.91) (–0.68 to 2.89) 0.2234 –0.08 (0.02) 0.92
(0.89, 0.96)
< 0.0001 0.32 (0.33) 1.37
(0.72 to 2.63)
0.3417
SDQ total
difficulties
463 0.27 (0.32) 1.31
(0.70 to 2.47)
0.3946 –0.70 (0.55) (–1.78 to 0.39) 0.2074 0.12 (0.03) 1.13
(1.06, 1.20)
0.0001 0.38 (0.32) 1.47
(0.78 to 2.78)
0.2357
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TABLE 82 Mediators analysis: assessment of the Baron and Kenny mediation stepsa (continued )
Mediator
variable n
Step 1 [Y=h0(t)exp (β10 X)] Step 2 (Me= β20+ β21 X) Step 3 [Y=h0(t)exp (β31 X+ β32 Me)]
Suggestion
of potential
for mediation
Total effect of Rand on outcome –
c (β10) Effect of Rand on mediator – a (β21)
Effect of mediator on outcome –
b (β32)
Direct effect of Rand on outcome –
c’ (β31)
Coefficient
(SE) HR (95% CI) p-value
Coefficient
(SE) (95% CI) p-value
Coefficient
(SE) HR (95% CI) p-value
Coefficient
(SE) HR (95% CI) p-value
SDQ prosocial 463 0.28 (0.32) 1.33
(0.71 to 2.49)
0.3777 0.41 (0.16) (0.10 to 0.72) 0.0098 –0.18 (0.09) 0.84
(0.70, 1.00)
0.0550 0.34 (0.32) 1.40
(0.74 to 2.64)
0.2967
SDQ impact 325 0.12 (0.39) 1.13
(0.52 to 2.44)
0.7593 –0.56 (0.25) (–1.05 to –0.07) 0.0253 0.24 (0.09) 1.28
(1.08, 1.51)
0.0047 0.32 (0.41) 1.37
(0.62 to 3.07)
0.4376 X
McMaster FAD
overall
450 0.27 (0.33) 1.31
(0.69 to 2.49)
0.4139 –0.02 (0.03) (–0.08 to 0.04) 0.4760 1.99 (0.50) 7.33
(2.75, 19.58)
0.0001 0.35 (0.33) 1.41
(0.74 to 2.71)
0.2985
12-month caregiver questionnaires
GHQ-12 445 0.30 (0.34) 1.35
(0.70 to 2.62)
0.3689 –0.71 (0.59) (–1.86 to 0.45) 0.2296 0.04 (0.02) 1.04
(1.00, 1.09)
0.0758 0.34 (0.34) 1.41
(0.72 to 2.74)
0.3127
SDQ total
difficulties
447 0.16 (0.32) 1.18
(0.62 to 2.22)
0.6195 –1.35 (0.59) (–2.52 to –0.18) 0.0238 0.05 (0.03) 1.05
(1.00, 1.11)
0.0635 0.22 (0.33) 1.24
(0.65 to 2.37)
0.5050
SDQ emotional
problems
447 0.15 (0.33) 1.17
(0.62 to 2.21)
0.6344 –0.52 (0.24) (–0.99 to –0.04) 0.0332 0.14 (0.07) 1.15
(1.01, 1.31)
0.0390 0.24 (0.33) 1.27
(0.67 to 2.42)
0.4666 X
SDQ peer problems 447 0.17 (0.32) 1.18
(0.63 to 2.24)
0.6035 –0.34 (0.17) (–0.68 to –0.00) 0.0471 0.08 (0.09) 1.08
(0.91, 1.29)
0.3815 0.20 (0.33) 1.22
(0.64 to 2.32)
0.5403
SDQ impact 336 0.27 (0.37) 1.31
(0.63 to 2.69)
0.4675 –0.52 (0.30) (–1.10 to 0.07) 0.0838 0.12 (0.07) 1.13
(0.99, 1.28)
0.0687 0.32 (0.37) 1.37
(0.66 to 2.85)
0.3924
SDQ internalising 447 0.16 (0.32) 1.18
(0.62 to 2.22)
0.6191 –0.88 (0.36) (–1.58 to –0.17) 0.0149 0.08 (0.04) 1.08
(0.99, 1.18)
0.0776 0.25 (0.33) 1.28
(0.67 to 2.44)
0.4546
McMaster FAD
overall
441 0.10 (0.33) 1.11
(0.58 to 2.12)
0.7541 –0.05 (0.03) (–0.10 to 0.01) 0.0796 2.32 (0.61) 10.13
(3.06, 33.53)
0.0002 0.21 (0.34) 1.23
(0.63 to 2.39)
0.5398
McMaster FAD
roles
448 0.16 (0.32) 1.17
(0.62 to 2.22)
0.6234 –0.09 (0.03) (–0.15 to –0.04) 0.0018 2.70 (0.55) 14.85
(5.03, 43.89)
< 0.0001 0.37 (0.34) 1.44
(0.75 to 2.80)
0.2755 X
McMaster FAD
affective
involvement
445 0.07 (0.33) 1.07
(0.56 to 2.04)
0.8426 –0.07 (0.04) (–0.14 to 0.01) 0.0778 0.82 (0.40) 2.27
(1.04, 4.95)
0.0391 0.10 (0.33) 1.10
(0.57 to 2.12)
0.7701
SI, suicidal ideation; Q, questionnaire.
a The effect of Rand is in reference to FT compared with TAU (TAU is the reference category). For the binary mediators psychotropic medications and Beck screening for suicide ideation
the reference category is ‘No’, hence the effect of the mediator is in relation to yes; young person was on psychotropic medications during follow-up and suicide ideation indicated at
12 months, respectively; and for years spent working in CAMHS the reference category is < 4 years, hence the effect of the mediator is in relation to young person with a lead therapist
working in CAMHS for ≥ 4 years.
b Binary mediators: step 2 uses a logistic regression model (excluding centre covariate).
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Therapist alliance
Therapist alliance, reported in the FT arm, was further explored by participants’ primary outcome. Figures 41
and 42 present the total and subscale scores for SOFTA alliance as reported by the young person, caregiver
and therapist according to whether or not the young person has a primary outcome event. The greatest
differences for those with and without a primary outcome event, although not statistically significant, can
be seen based on the young person’s perception of purpose, engagement and safety and the caregiver’s
perception of safety, with lower scores (weaker alliance) for those with self-harm during follow-up. Note
that the rate of self-harm was similar in participants who completed the SOFTA and those who did not,
albeit slightly higher in the former (29.6% vs. 26.2% repetition rate, respectively).
SO
FT
A
 s
co
re
Young person Caregiver Therapist
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67.5
65.0
62.5
60.0
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Self-harm during follow-up
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     Yes
     No
Completed by?
FIGURE 41 System for Observing Family Therapy Alliances total score by completer and primary outcome.
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FIGURE 42 System for Observing Family Therapy Alliances subscale scores by completer and primary outcome.
(a) Purpose subscale; (b) engagement subscale; (c) emotional subscale; and (d) safety subscale. (continued )
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FIGURE 42 System for Observing Family Therapy Alliances subscale scores by completer and primary outcome.
(a) Purpose subscale; (b) engagement subscale; (c) emotional subscale; and (d) safety subscale.
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Chapter 4 Health economics results
Introduction
The health economics analysis was designed to provide an economic evaluation of the management of
self-harm in adolescents using FT compared with TAU. The aim was to assess the cost-effectiveness of
FT versus TAU in the management of self-harm in adolescents from the NHS perspective. A societal
perspective for costs was not included in the sensitivity analysis owing to the very limited private expenses,
productivity costs and out-of-pocket expenses reported in the trial.
Unit cost data
Unit cost of resource use
Individual-level resource use was combined with unit costs to calculate the total health services cost for each
participant. Participants’ resource use was self-reported by the young person as well as being reported
separately by the caregiver. When missing, young people’s resource use was replaced by the caregiver
reports. Visits to A&E and inpatient visits were available from NHS Digital records; they included the type of
event that led to a hospital visit, namely whether it was self-harm related or not self-harm related, and the
admission and discharge dates. A&E visits were combined with the national average cost by type of event.
The costs for hospital inpatient stays were calculated using the average length of stay and the type of event.
Specifically, if the event that led to hospital admission was related to self-harm, hospital stays were costed at
£430.72 for a day case, £413.79 for a non-elective overnight admission and £1373.43 for longer stays;
equally, for events not related to self-harm, a day case was costed at £697.55, a non-elective overnight was
costed at £602.52 and longer stays were costed at £2837.31. Excess bed-days were used when a young
person experienced a length of stay beyond the average length of stay. For instance, if the event was related
to self-harm, extra bed-day costs of £254.09 were added to the long stay costs of £1373.43. Information on
unit costs was taken from national databases such as the PSSRU Unit Costs of Health and Social Care 201498
and the Department of Health’s National Schedule of Reference Costs.97 Table 83 presents the summary of
unit costs.
TABLE 83 Participant-reported health-care use and associated unit costs
Item
Unit
cost (£) Source
Health services
GP surgery visit 46.00 PSSRU (2014),98 p. 195, including direct care staff costs with qualification,
per participant contact lasting 11.7 minutes
GP home visit 117.00a PSSRU (2014),98 p. 191, including direct care staff costs with qualification,
per participant contact lasting 23.4 minutes
GP telephone/e-mail 28.00 PSSRU (2014),98 p. 195, including direct care staff costs with qualification,
per participant contact lasting 7.1 minutes
Practice or district nurse 59.50 PSSRU (2014),98 p. 187 and pp.192 (average), per hour, including qualifications
Physiotherapist 36.00 PSSRU (2014),98 p. 179, per hour, including qualifications
Occupational therapist 36.00 PSSRU (2014),98 p. 180, per hour, including qualifications
Drug and alcohol worker 56.00 PSSRU (2014),98 p. 67, per clinic consultation, including qualifications
continued
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Unit cost of medications
Unit costs for any psychotropic medication were obtained from the electronic market information tool
(eMIT) [2014; URL: www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-
information-emit (accessed 1 December 2016)] and the BNF.99 Medication details including the dosage,
date started and date stopped were collected directly from the participants and/or from CAMHS notes by
the study researchers at baseline and at 12 and 18 months. Using the aforementioned dates, the number
of days on which the medication was taken was calculated. To account for cases in which the dosage
was not reported, the recommended dose for adolescents was referenced. In cases where the reported
medication was not licensed for use in those aged < 18 years, the lowest recommended dose was used, as
suggested by a clinical expert on the TMG. Table 84 shows all the unit costs and standard dosage details
for the psychotropic drugs that were reported in the trial. The unit costs, package and dosage details as
well as the number of days the medication was taken were combined to calculate the cost of psychotropic
medication for each participant.
TABLE 83 Participant-reported health-care use and associated unit costs (continued )
Item
Unit
cost (£) Source
Family planning service 50.00 PSSRU (2014),98 p. 212, per hour
CAMHS 115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
Other (non-hospital-based
health service)
57.00 National Schedule of Reference Costs Year 2013–2014,97 community health
services, national average
Hospital services
Self-harm related
Non-elective short stay 413.79 National Schedule of Reference Costs Year 2013–2014,97 non-elective
inpatients – short stay, code: WA11B
Non-elective long stay 1373.43 National Schedule of Reference Costs Year 2013–2014,97 non-elective
inpatients – long stay, code: WA11B
Excess day, non-elective 254.09 National Schedule of Reference Costs Year 2013–2014,97 non-elective
inpatients – excess bed-days, code: WA11B
Day case 430.72 National Schedule of Reference Costs Year 2013–2014,97 day case, code:
WA11B
Not self-harm related
Non-elective short stay 602.52 National Schedule of Reference Costs Year 2013–2014,97 no-elective inpatients
– Short stay, national average
Non-elective long stay 2837.31 National Schedule of Reference Costs Year 2013–2014,97 non-elective
inpatients – long stay, national average
Excess day, non-elective 275.05 National Schedule of Reference Costs Year 2013–2014,97 non-elective
inpatients – excess bed-days, national average
Day case 697.55 National Schedule of Reference Costs Year 2013–2014,97 day case, national
average
Self-harm related/not self-harm related
Hospital outpatient clinic 128.31 National Schedule of Reference Costs Year 2013–2014,97 outpatients –
consultant led, national average
Hospital A&E department 123.67 National Schedule of Reference Costs Year 2013–2014,97 emergency medicine,
national average
CCEMG-EPPI, Campbell & Cochrane Economics Methods Group – Evidence for Policy and Practice Information and
Coordinating Centre Cost Converter.
a These costs have been adjusted to 2014 prices using the CCEMG-EPPI Centre Cost Converter (http://eppi.ioe.ac.uk/
costconversion/).
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Unit cost of delivering the intervention
The cost of the intervention was calculated separately for the FT arm and the TAU arm. Participants
allocated to TAU received care by local CAMHS teams, and clinicians (or researchers) recorded any
treatment details (including duration, number of therapists involved in the session, type, attendance and
telephone contact with the family between sessions). In addition, the frequency and duration of any
supervision meetings were recorded.
Participants allocated to FT had sessions with qualified family therapists and details of these sessions were
recorded in a similar way as in the TAU arm. Family therapists also received supervision, but it was reported
differently from the supervision in the TAU arm; precisely, supervision in the FT arm was done in group
sessions with the number of patients being discussed in each session, and frequency and duration being
recorded. The unit costs for TAU and FT are presented in Table 85. It is important to note that PSSRU provides
costs for CBT delivered in CAMHS, but not for any other modalities of treatment. Generic multidisciplinary
CAMHS costs were thus used for all non-CBT in both arms; as tier three CAMHS teams often include family
therapists and often provide FT, it was deemed a reasonable assumption to make in the absence of any other
reported costs. The unit costs were combined with the duration, number of sessions reported and the number
of therapists involved in the sessions in the trial data to provide the pragmatic intervention cost for the FT and
TAU groups, which are referred to in the analysis as ‘actual intervention costs’.
To test the sensitivity of the results, and as discussed with clinical experts, two other costing scenarios
were explored for FT as an intervention. In the first scenario, it was assumed that only one therapist was
involved in each treatment session by local CAMHS in the FT arm (intervention costs from scenario 1). In
the second scenario, the average number of therapists involved in each CAMHS session in the FT arm was
used (intervention costs from scenario 2). For the TAU arm, the number of therapists involved in each
session, as recorded in the trial data, was used.
TABLE 84 Young person-reported medication use, dosage and associated unit costs
Item Standard dosage Unit cost (£) Source
Atomoxetine 40 mg (once per day) 15.38a BNF 2015,99 package of 7
Methylphenidate 5 mg (twice per day) 2.49 eMIT 2014, code: DDD026, package of 30
Propranolol 80 mg (twice per day) 2.55 eMIT 2014, code: DBD56, package of 56
Olanzapine 5 mg (once per day) 0.68 eMIT 2014, code: DDE000, package of 28
Risperidone 0.5 mg (once per day) 1.32b eMIT 2014, code: DDB098, package of 60
Citalopram 20mg (once per day) 0.28 eMIT 2014, code: DDC135, package of 28
Fluoxetine 10 mg (once per day) 0.26b eMIT 2014, code: DDI014, package of 30
Sertraline 50 mg (once per day) 0.45 eMIT 2014, code: DDC039, package of 28
Venlafaxine 12.5 mg (once per day) 1.79b eMIT 2014, code: DDI015, package of 56
Mirtazapine 15mg (once per day) 1.08 eMIT 2014, code: DDC177, package of 28
Benzodiazepine – diazepam 2mg (twice per day) 0.16 eMIT 2014, code: DDA062, package of 28
Benzodiazepine – temazepam 10mg (once per day) 3.86 eMIT 2014, code: DDA054, package of 28
Melatonin 2–3mg (once per day) 15.18a BNF 2015, package of 30
Promethazine 10mg (once per day) 2.75 eMIT 2014, code: DCD094, package of 56
Zopiclone 3.75 mg (once per day) 0.47 eMIT 2014, code: DDA045, package of 28
CCEMG-EPPI, Campbell & Cochrane Economic Methods Group – Evidence for Policy and Practice Information and
Coordinating Centre Cost Converter.
a These costs have been adjusted to 2014 prices using the CCEMG-EPPI Centre Cost Converter [http://eppi.ioe.ac.uk/
costconversion/ (accessed 2 December 2016)].
b For risperidone 1 mg, fluoxetine 20 mg and venlafaxine 37.5 mg tablets.
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The average number of CAMHS sessions per young person was 10 in the TAU arm, compared with seven
in the FT arm (Table 86). In addition, these sessions on average were shorter and involved more therapists
per session in the FT arm than in the TAU arm. The average number of telephone contacts with the family
between treatment sessions differed only very slightly between trial arms, but calls lasted longer in the
TAU arm. It was not possible to obtain an average number of supervision sessions per young person in
the TAU arm as only the total amount of supervision per young person was recorded. Any conclusions on
the duration of supervision should be treated with caution given the different ways in which supervision
was reported in the two arms.
TABLE 85 Unit costs of delivering the interventions
Item
Unit cost
(£) Source
FT
Qualified family therapist
sessions
115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
TAU (by local CAMHS)
CBT 93.00 PSSRU (2014),98 p. 94, per session
Formal systemic FT 115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
Family work 115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
Psychoeducation 115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
Interpersonal therapy 115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
Psychodynamic
psychotherapy
115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
DBT 115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
Supporting therapy/
counselling
115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
Problem-solving therapy 115.00 PSSRU (2014),98 p. 223, per hour per team member for face-to-face contact
FT/TAU
Telephone contact 91.00 PSSRU (2014),98 p. 223, cost per hour per team member for participant-
related activities
Supervision 56.00 PSSRU (2014),98 p. 223, cost per hour per team member
TABLE 86 Session details of delivering the intervention
Session type
Average number of
sessions per participanta
Average duration
per participant
(minutes)
Average number of
therapists involved in
each sessiona
TAU FT TAU FT TAU FT
CAMHS sessions/qualified
family therapist sessionsb
9.80 (13.73) 6.51 (3.90) 588.7 481.8 1.23 (0.50) 2.35 (0.45)
Telephone contact with
family sessions
2.79 (2.82) 2.83 (2.26) 90.2 77.4 N/A N/A
Supervision sessions N/Ac 2.11 (1.46) 88.4 77.5 N/A N/A
N/A, not applicable.
a SD in parentheses.
b CAMHS sessions in the TAU arm and qualified family therapist sessions in the FT arm.
c It is not applicable for TAU because the frequency of supervision was reported rather than the actual number of sessions.
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Missing data
A total of 832 young people were recruited to take part in the trial (417 were allocated to TAU and
415 to FT). The complete case refers to all those participants for whom complete EQ-5D and cost data are
available at any time point and number 125 young people (44 allocated to TAU and 81 allocated to FT).
Details of the quality of life and cost data available at each time point are shown in Table 87. Missing
utility scores and/or total health services and hospital services costs at 6, 12 and 18 months were imputed
using multiple imputation via chained equations assuming missingness at random at each time point in
order to use as much as possible of the available information for each variable. For consistency with the
statistical analysis, but also to ensure best fit of the imputed results, we used as predictor variables in the
imputation process: treatment allocation, gender, age, centre, total number of self-harm episodes, type of
index episode, source of referral and derived scores at baseline for a number of assessment instruments
(BSS, CDRS-R, Hopelessness Scale for Children and PQ-LES-Q). It would be very speculative to impute
missing utility at baseline; therefore, 37 participants (4.4%) are excluded from the health economics study
sample. Additionally, imputation was not possible for a further 13 participants (i.e. it was not possible to
impute any missing utility or cost data for these participants at any of the follow-up periods) and this was
because of missing scores in at least one of the predictors. The base case sample (i.e. after imputation)
was 782 participants (388 allocated to TAU and 394 allocated to FT); this is the sample used for the
cost-effectiveness analyses.
Cost-effectiveness analysis
Descriptive statistics of participant characteristics and the additional predictors used in multiple imputations
are presented in Table 88. More than 50% of the participants in the TAU or FT arm were between 11 and
14 years old. More than two-thirds of the participants in both arms were young women in whom more
than three self-harm episodes occurred over the duration of the trial. Self-harm was primarily caused by
self-injury and did not vary across trial arms. Differences in any of the assessment instruments were
marginal across arms and more than 25% of the participants presented with mild or moderate depression
at baseline. These results are consistent across samples (base case and complete case) and with the main
statistical analysis in Chapter 3.
TABLE 87 Availability of quality-of-life and cost data (before imputation)
Quality of life and cost data
Baseline,
n (%)
6 months,
n (%)
12 months,
n (%)
18 months,
n (%) Overall, n (%)
Quality of life
EQ-5Da 795 (95.6) 341 (41.0) 455 (54.7) 390 (46.9) 190 (22.8)
Costs
Health and social services costsa N/A 405 (48.7)b 453 (54.4) 395 (47.5) 221 (26.6)
Hospital outpatient visits costsa N/A 420 (50.5)b 426 (51.2) 363 (43.6) 196 (23.6)
Hospital inpatient stays and A&E visits costsc N/A 832 (100.0) 832 (100.0) 832 (100.0) 832 (100.0)
Quality of life and costs – 250 (30.0) 410 (49.3) 355 (42.7) 125 (15.0)
N/A, not applicable.
a Self-reported information.
b Non-missing costs at 3 months were multiplied by 2 to replace only those missing costs at 6 months.
c Information collected from participants’ records.
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TABLE 88 Participants’ baseline characteristics by trial arm
Baseline characteristic
Base case Complete case
TAU (N= 388) FT (N= 394) TAU (N= 44) FT (N= 81)
Gender, n (%)
Male 47 (12) 45 (11) 6 (14) 14 (17)
Female 341 (88) 349 (89) 38 (86) 67 (83)
Age (years), n (%)
11–14 204 (53) 204 (52) 29 (66) 43 (53)
15–17 184 (47) 190 (48) 15 (34) 38 (47)
Centre, n (%)
Yorkshire 142 (37) 141 (36) 15 (34) 39 (48)
Manchester 135 (35) 136 (35) 16 (36) 23 (28)
London 111 (29) 117 (30) 13 (30) 19 (23)
Total number of self-harm episodes, n (%)
2 42 (11) 42 (11) 2 (5) 8 (10)
≥ 3 346 (89) 352 (89) 42 (95) 73 (90)
Type of index episode, n (%)
Self-poisoning 87 (22) 89 (23) 7 (16) 21 (26)
Self-injury 274 (71) 280 (71) 34 (77) 56 (69)
Combined 27 (7) 25 (6) 3 (7) 4 (5)
Source of referral (from hospital), n (%)
Yes 139 (36) 149 (38) 14 (32) 26 (32)
No 249 (64) 245 (62) 30 (68) 55 (68)
BSS
Mean (SD) 10.07 (9.35)a 10.86 (8.89)a 11.23 (9.71)a 11.84 (8.82)
Min. 0 0 0 0
Max. 35 38 29 28
CDRS-R,b n (%)
Not depressed (< 30) 23 (6) 41 (10) 5 (11) 11 (14)
Mild depression (30–42) 103 (27) 102 (26) 15 (34) 25 (31)
Moderate depression (43–57) 152 (39) 147 (37) 15 (34) 25 (31)
Severe depression (58–72) 96 (25) 88 (22) 9 (20) 19 (23)
Very severe depression (> 72) 13 (3) 16 (4) – 1 (1)
Hopelessness Scale for Children
Mean (SD) 7.18 (4.22)c 7.64 (4.27)c 8.14 (4.19)c 8.01 (4.38)c
Min. 0 0 1 1
Max. 17 17 15 16
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Intervention costs
Table 89 shows the average cost of each of the different components that were used to calculate the
intervention costs. It is not possible to make any comparison between arms in terms of costs for the
CAMHS or qualified family therapists, as part of the intervention, because these services were not offered
to both arms. The average cost of telephone contacts with the family between sessions is slightly higher
in the FT arm and the average cost of supervision is about four times higher in the FT arm than in the
TAU arm.
TABLE 88 Participants’ baseline characteristics by trial arm (continued )
Baseline characteristic
Base case Complete case
TAU (N= 388) FT (N= 394) TAU (N= 44) FT (N= 81)
PQ-LES-Q
Mean (SD) 41.18 (9.53) 41.25 (9.28) 41.93 (9.31) 42.52 (9.72)
Min. 17 16 22 22
Max. 70 67 61 62
Max., maximum; min., minimum.
a The score was not available for one participant in the TAU arm (either base or complete case) and one participant in the
FT arm (base case).
b The scale was not available for one participant in the TAU arm (base case).
c The score was not available for one participant in each trial arm (either base or complete case).
TABLE 89 Average intervention costs by trial arm
Type of service
Cost (£)
TAU (n= 388) FT (n= 394)
CAMHS
Mean (SD) 800.73 (1412.65) N/A
Min. 0 N/A
Max. 18,103.49 N/A
Qualified family therapists
Mean (SD) N/A 2075.51 (1506.28)
Min. N/A 0
Max. N/A 9265.98
Telephone contact
Mean (SD) 56.05 (219.69) 59.58 (255.93)
Min. 0 0
Max. 3640 4095
Therapist’s supervision
Mean (SD) 18.50 (46.87) 48.08 (60.50)
Min. 0 0
Max. 373.35 438.70
Max., maximum; min., minimum; N/A, not applicable.
Reproduced from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
4.0 license.
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Health-care resource use
Table 90 shows the average resource use per participant in each trial arm observed in the data for the
complete cases only. Participants in the TAU arm were more likely to use the majority of health services
than those in the FT arm, independently of the follow-up period. Similarly, participants in the TAU arm
seemed to have used more social or hospital services than those in the FT arm. Any other conclusions
should be tempered given that very little was reported in the trial follow-up questionnaires.
TABLE 90 Average resource use per participant by trial arm (complete case)
Health services
0–6 months 6–12 months 12–18 months
TAU (n= 44) FT (n= 81) TAU (n= 44) FT (n= 81) TAU (n= 44) FT (n= 81)
GP (family doctor), surgery visit
Mean (SD) 0.84 (1.07) 0.70 (1.36) 1.05 (1.41) 0.96 (1.29) 1.18 (1.81) 1.16 (1.58)
Min. 0 0 0 0 0 0
Max. 4 9 6 6 10 8
GP (family doctor), home visit
Mean (SD) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Min. 0 0 0 0 0 0
Max. 0 0 0 0 0 0
GP (family doctor), telephone/e-mail
Mean (SD) 0 (0) 0 (0) 0.09 (0.47) 0.02 (0.16) 0.02 (0.15) 0 (0)
Min. 0 0 0 0 0 0
Max. 0 0 3 1 1 0
Practice or district nurse
Mean (SD) 0.18 (0.66) 0.14 (0.54) 0.11 (0.39) 0.21 (0.52) 0.09 (0.42) 0.19 (0.53)
Min. 0 0 0 0 0 0
Max. 4 3 2 3 2 3
Physiotherapist
Mean (SD) 0 (0) 0 (0) 0.07 (0.33) 0.05 (0.27) 0.02 (0.15) 0.21 (1.21)
Min. 0 0 0 0 0 0
Max. 0 0 2 2 1 9
Occupational therapist
Mean (SD) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.01 (0.11)
Min. 0 0 0 0 0 0
Max. 0 0 0 0 0 1
Drug and alcohol worker
Mean (SD) 0 (0) 0 (0) 0 (0) 0.14 (1.22) 0 (0) 0.01 (0.11)
Min. 0 0 0 0 0 0
Max. 0 0 0 11 0 1
Family planning service
Mean (SD) 0.07 (0.33) 0.07 (0.31) 0.05 (0.21) 0.04 (0.19) 0.09 (0.36) 0.05 (0.31)
Min. 0 0 0 0 0 0
Max. 2 2 1 1 2 2
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TABLE 90 Average resource use per participant by trial arm (complete case) (continued )
Health services
0–6 months 6–12 months 12–18 months
TAU (n= 44) FT (n= 81) TAU (n= 44) FT (n= 81) TAU (n= 44) FT (n= 81)
CAMHS
Mean (SD) 2.36 (4.00) 2.55 (10.41) 2.18 (4.13) 1.21 (2.48) 2.30 (4.55) 1.05 (2.51)
Min. 0 0 0 0 0 0
Max. 17 90 15 12 20 12
Any other non-hospital-based health service (e.g. NHS Direct)
Mean (SD) 0.07 (0.33) 0.11 (0.61) 0.09 (0.36) 0.05 (0.22) 0 (0) 0.09 (0.57)
Min. 0 0 0 0 0 0
Max. 2 5 2 1 0 5
Social services
Social worker
Mean (SD) 0.16 (0.68) 0.28 (1.63) 0.07 (0.33) 0.10 (0.44) 0.14 (0.90) 0.02 (0.22)
Min. 0 0 0 0 0 0
Max. 4 14 2 3 6 2
Helpline (Childline, Samaritans)
Mean (SD) 0 (0) 0 (0) 0.02 (0.15) 0.15 (0.87) 0.02 (0.15) 0.02 (0.22)
Min. 0 0 0 0 0 0
Max. 0 0 1 6 1 2
Family or young person support or self-help groups
Mean (SD) 0.84 (2.98) 0.22 (1.11) 0.73 (2.73) 0.27 (1.41) 0.27 (1.52) 0.02 (0.16)
Min. 0 0 0 0 0 0
Max. 12 8 12 8 10 1
Any other social services
Mean (SD) 0 (0) 0 (0) 0 (0) 0.04 (0.33) 0 (0) 0.01 (0.11)
Min. 0 0 0 0 0 0
Max. 0 0 0 3 0 1
Hospital services
Hospital inpatient stay (staying in hospital overnight)
Mean (SD) 0.12 (0.63) 0.40 (1.36) 0.49 (1.26) 0.35 (0.78) 0.58 (1.78) 0.42 (1.02)
Min. 0 0 0 0 0 0
Max. 4 10 7 4 10 7
Hospital outpatient clinic (doctor visits, scans, etc.)
Mean (SD) 0.30 (0.67) 0.33 (0.85) 0.30 (0.79) 0.26 (0.74) 0.18 (0.58) 0.12 (0.43)
Min. 0 0 0 0 0 0
Max. 3 4 4 5 3 2
Hospital A&E department
Mean (SD) 0.09 (0.60) 0.16 (0.43) 0.32 (0.77) 0.19 (0.57) 0.41 (1.41) 0.30 (0.66)
Min. 0 0 0 0 0 0
Max. 4 2 3 4 9 3
Max., maximum; min., minimum.
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Mean health-care provider costs broken down by type of service, trial arm and for each time point are
presented in Table 91. With or without imputing for missing data, it is difficult to see any patterns
between the different follow-up periods, which is consistent with the discussion earlier on the participant-
reported resource use.
TABLE 91 Average health-care provider costs by trial arm
Health-care
provider costs (£) 0–6 months 6–12 months 12–18 monthsa
Before imputation
TAU
(n = 44)
FT
(n = 81)
TAU
(n = 44)
FT
(n = 81)
TAU
(n = 44)
FT
(n = 81)
Health and social services costs (excluding intervention cost)
Mean (SD) 789.06
(942.62)
703.20
(1312.58)
726.77
(1125.69)
491.85
(678.42)
698.61
(1045.22)
427.11
(679.17)
Min. 0 0 0 0 0 0
Max. 4571 10,994 4894 2852 4611.98 3375.44
Hospital services costs from the NHS Digital records (inpatient stays and A&E visits)b
Mean 294.98
(1036.52)
367.69
(992.05)
353.18
(857.64)
259.32
(633.66)
479.53
(1455.01)
313.7
(737.59)
Min. 0 0 0 0 0 0
Max. 6572.4 6784.06 4480.41 3286.2 7996.47 4480.41
Reported hospital outpatient visits costs
Mean (SD) 75.82
(144.63)
83.96
(179.36)
75.82
(203.95)
66.53
(189.35)
46.66
(149.25)
31.68
(110.25)
Min. 0 0 0 0 0 0
Max. 513.24 898.17 1026.48 1283.1 769.86 513.24
Medication costsb
Mean (SD) 0.07 (0.31) 0.01 (0.08) 0.06 (0.30) 0 (0) 0.03 (0.22) 0 (0)
Min. 0 0 0 0 0 0
Max. 1.82 0.64 1.83 0 1.47 0
After imputationc
TAU
(n = 388)
FT
(n = 394)
TAU
(n = 388)
FT
(n = 394)
TAU
(n = 388)
FT
(n = 394)
Health and social services costs
Mean (SD) 639.30
(846.01)
492.29
(834.68)
359.52
(677.17)
411.65
(714.27)
405
(829.79)
355.19
(605.82)
Min. 0 0 0 0 0 0
Max. 9648 10,994 4894 5520 7195.17 3829.56
Hospital services costs from the NHS Digital records (inpatient stays and A&E visits)b
Mean (SD) 484.37
(1067.78)
490.66
(1033.11)
421.4
(885.74)
441.84
(1121.65)
430.08
(1024.74)
480.34
(1133.52)
Min. 0 0 0 0 0 0
Max. 8522.76 8693.99 4931.94 11,747.48 8960.82 10,785.98
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The total costs to the NHS providers are shown in Table 92. They comprise the total health and social
services costs, total hospital costs (separately by data source), total intervention costs and medication costs,
as well as any costs of appointments that occurred after randomisation, but before the first treatment
appointment (only in the FT arm). Overall, they substantially vary from one participant to the other, as
illustrated by the large SDs.
In detail, the average total costs for the use of health and social services (before imputation) were
£2214.44 (SD £2334.32) for the TAU arm compared with £1622.16 (SD £1866.72) for the FT arm.
Furthermore, the average total costs for the use of any hospital services (before imputation) were higher
for the participants in the TAU arm: the average cost of inpatient stays and A&E visits was £1127.7 (SD
£2782.9) in the TAU arm, compared with £940.71 (SD £1563.95) in the FT arm. The corresponding costs
of outpatient visits were £198.3 (SD £405.24) in the TAU arm and £182.17 (SD £299.45) in the FT arm.
The mean total costs of any psychotropic medications were also higher for the TAU group. However,
the average total intervention costs observed within the trial were much higher in the FT arm [£2928.74
(SD £1541.14)] than in the TAU arm [£1005.41 (SD £1034.46)]. The intervention costs and the cost of
appointments that took place post randomisation but before the first treatment appointment in the FT arm
are likely to drive the average total costs to the NHS. Pragmatically, the mean total costs to the NHS
(before imputation) were £5588.21 (SD £3399.39) for the FT arm and £4461.22 (SD £4280.41) for the
TAU arm. Most patterns remain even after imputing for the missing cost data; an exception is the average
total costs of reported hospital outpatient visits, which were higher for the FT arm. Mann–Whitney tests
show the average total NHS costs to be marginally different (at the 5% significance level) between the trial
arms, but significantly different (at the 1% significance level) after the imputations.
Quality of life
Table 93 shows the mean EQ-5D scores at each time point between the two arms of the trial when scores
were not imputed (complete case) and when scores were imputed (base case). In both arms, there was an
increase in EQ-5D from baseline to 18 months. The fluctuations between 6 months and 12 months, and
between 12 months and 18 months, were small for both arms.
TABLE 91 Average health-care provider costs by trial arm (continued )
Health-care
provider costs (£) 0–6 months 6–12 months 12–18 monthsa
Reported hospital outpatient visits costs
Mean (SD) 57.82
(184.9)
64.67
(354.82)
29.75
(120.87)
46.05
(161.86)
30.11
(213.02)
25.93
(135.14)
Min. 0 0 0 0 0 0
Max. 1411.41 6415.5 1026.48 1283.1 3849.3 1539.72
Medication costsb
Mean (SD) 0.38
(5.88)
1.11
(20.20)
0.29
(4.77)
1.11
(20.31)
0.05
(0.58)
1.09
(19.96)
Min. 0 0 0 0 0 0
Max. 114.25 399.85 93.51 402.05 8.81 395.19
Max., maximum; min., minimum.
a These are the discounted estimates.
b Hospital services costs from IC records and medication costs were not imputed.
c Include estimated costs after imputation – these figures were used in the cost–utility analyses.
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TABLE 92 Total costs of NHS resources used by trial arm
Before imputation TAU (n= 44) FT (n= 81) p-value (Mann–Whitney test)
Total NHS costsa (including actual intervention cost) (£)
Mean (SD) 4461.22 (4280.41) 5588.21 (3399.39) 0.012
Min. 164.01 1012.4
Max. 17,889.53 17,546.38
Total actual intervention costsb (£)
Mean (SD) 1005.41 (1034.46) 2928.74 (1541.14) < 0.001
Min. 0 121.39
Max. 4329.91 9349.98
Total health and social services costs (£)
Mean (SD) 2214.44 (2334.32) 1622.16 (1866.72) 0.426
Min. 0 0
Max. 9712.70 12,451.16
Total hospital services costs from IC records (inpatient stays and A&E visits)b (£)
Mean (SD) 1127.7 (2782.9) 940.71 (1563.95) 0.438
Min. 0 0
Max. 15,390.42 7766.61
Total reported hospital outpatient visits costs (£)
Mean (SD) 198.3 (405.24) 182.17 (299.45) 0.464
Min. 0 0
Max. 2052.96 1539.72
Total costs of appointments post randomisation but before first treatment appointmentb (£)
Mean (SD) N/A 4.26 (28.43) N/A
Min. N/A 0
Max. N/A 230
Medication costsb (£)
Mean (SD) 0.17 (0.81) 0.01 (0.08) 0.410
Min. 0 0
Max. 5.12 0.64
After imputationc TAU (n= 388) FT (n= 394) p-value (Mann–Whitney test)
Total NHS costsa (including actual intervention costs) (£)
Mean (SD) 3725.49 (3785.98) 4991.72 (3766.88) < 0.001
Min. 164.01 403.37
Max. 29,215.88 32,085.23
Total actual intervention costsb (£)
Mean (SD) 875.28 (1471.21) 2183.17 (1558.77) < 0.001
Min. 0 0
Max. 18,683.46 9349.98
Total health and social services costs (£)
Mean (SD) 1403.82 (1760.43) 1259.13 (1462.82) 0.121
Min. 0 0
Max. 15,650.02 12,451.16
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The change in mean EQ-5D between the two arms of the trial at any time point is presented in Table 94.
The observed changes in either the complete or the base case were marginal. The largest changes were
observed at 6 months and 12 months, showing mostly that participants in the FT arm had higher utility
scores than participants in the TAU arm; differences were not significant in the complete case but were
significant at 5% significance level in the base case at 6 and 12 months.
TABLE 92 Total costs of NHS resources used by trial arm (continued )
Before imputation TAU (n= 44) FT (n= 81) p-value (Mann–Whitney test)
Total hospital services costs from NHS Digital records (inpatient stays and A&E visits)b (£)
Mean (SD) 1335.85 (2217.43) 1412.85 (2550.78) 0.285
Min. 0 0
Max. 15,390.42 24,190.24
Total reported hospital outpatient visits costs (£)
Mean (SD) 117.67 (325.83) 136.65 (444.62) 0.783
Min. 0 0
Max. 3852.82 7194.35
Total costs of appointments post randomisation but before first treatment appointmentb (£)
Mean (SD) N/A 5.25 (39.84) N/A
Min. N/A 0
Max. N/A 575
Medication costsb (£)
Mean (SD) 0.72 (11.04) 3.31 (60.47) 0.709
Min. 0 0
Max. 214.8 1197.1
Max., maximum; min., minimum; N/A, not applicable.
a The cost of appointments that took place after randomisation but before the first treatment appointment in the FT arm
is also included.
b These costs were not imputed.
c Includes estimated costs after imputation – these figures were used in the cost–utility analyses.
Reproduced from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license.
TABLE 93 Mean EQ-5D scores (unadjusted) by trial arm
Time point
Complete case Base case (imputed)
TAU (n= 44),
mean (SD)
FT (n= 81),
mean (SD)
TAU (n= 388),
mean (SD)
FT (n= 394),
mean (SD)
Baseline 0.663 (0.260) 0.663 (0.263) 0.682 (0.264) 0.674 (0.277)
6 months 0.798 (0.203) 0.814 (0.201) 0.760 (0.161) 0.799 (0.178)
12 months 0.841 (0.176) 0.825 (0.229) 0.780 (0.181) 0.811 (0.193)
18 months 0.865 (0.184) 0.852 (0.204) 0.804 (0.159) 0.813 (0.189)
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Cost-effectiveness results
Primary analysis
Table 95 shows the costs and QALYs for the TAU and FT arm for the primary analysis. In addition, it
provides the incremental cost and incremental effectiveness expressed as QALY gains. On average, FT
participants incurred £1266.23 (95% CI £736.04 to £1796.43) higher costs and gained 0.034 (95% CI
–0.004 to 0.065) extra QALYs than TAU participants, which is equivalent to an extra 12.4 days of perfect
health. The ICER equalled £36,811.80 per QALY, which is above the recommended threshold range
currently specified for NICE decision-making in England and Wales (£20,000–30,000 per QALY gain),
indicating that FT was unlikely to be cost-effective.93
Figure 43 shows the cost-effectiveness plane for FT compared with TAU based on 10,000 bootstrapped
estimates of costs and QALYs. The diagonal line represents a willingness to pay per QALY threshold of
£20,000. The average costs from the bootstrapped estimates were £3725.03 (SD £191.31) and £4979.54
(SD £190.01) for the TAU and FT arms, respectively. The corresponding mean QALYs were 1.122 (SD
0.010) for the TAU arm and 1.156 (SD 0.011) for the FT arm. The simulation estimates were all above the
x-axis, showing that FT was always more costly than TAU. Most of the estimates were spread in the north-
east quadrant, suggesting that FT was likely to lead to better health outcomes, although some estimates
were also in the north-west quadrant, where FT is likely to result in a lower number of QALYs than TAU.
TABLE 94 Changes in mean EQ-5D scores (unadjusted) between the two arms of the trial
Time point Differencea Complete case Base case (imputed)
Baseline FT vs. TAU (p-value) –0.001 (0.988) 0.008 (0.680)
6 months FT vs. TAU (p-value) –0.016 (0.669) –0.039 (0.002)
12 months FT vs. TAU (p-value) 0.016 (0.688) –0.031 (0.020)
18 months FT vs. TAU (p-value) 0.013 (0.731) –0.009 (0.493)
a p-value of t-test of the difference.
TABLE 95 Base-case cost-effectiveness results (outcome measure: QALY, NHS perspective including actual
intervention costs)
Treatment arm Cost-effectiveness
TAU
Costs (£), mean (SD) 3725.49 (3785.98)
QALY, mean (SD) 1.122 (0.203)
FT
Costs (£), mean (SD) 4991.72 (3766.88)
QALY, mean (SD) 1.157 (0.226)
FT vs. TAU
Incremental cost (95% CI) 1266.23 (736.04 to 1796.43)
Incremental QALY (95% CI) 0.034 (–0.004 to 0.065)
ICER (£/QALY) 36,811.80
Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license.
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A cost-effectiveness acceptability curve of FT compared with TAU is presented in Figure 44. At a threshold
of £20,000, FT had a 12% chance of being cost-effective, and this percentage increased to 36% when the
threshold was £30,000. There is a positive relationship between the cost-effectiveness threshold and the
chance of FT being cost-effective, and this is because FT was, on average, more effective (in terms of QALY
gains) than TAU.
To account for uncertainty in the incremental costs and QALYs estimation, a number of sensitivity analyses
were conducted, including a non-parametric bootstrapping (Table 96). The mean incremental cost and QALY
estimates from the bootstrapping were along the lines of the deterministic base-case scenario, yielding an ICER
of £36,705.79 per QALY gain. Other sensitivity analyses included making different assumptions about the
number of therapists involved in each of the treatment sessions in the FT arm, that is, using either intervention
costs from scenario 1 or intervention costs from scenario 2 as defined earlier in the analysis; in any of these
scenarios, FT remained unlikely to be cost-effective. When adjusting for EQ-5D differences at baseline,
participants in the FT arm gained an incremental QALY of 0.039 (equivalent to an extra 14.2 days at perfect
health) compared with those in the TAU arm and the ICER was £32,852.22 per QALY gain. In any of these
analyses, the ICER lay above the recommended NICE threshold (£20,000–30,000) and it was concluded that FT
was unlikely to be cost-effective. Considering the complete cases only (i.e. no missing costs or quality of
life data at any time point), FT was dominated by TAU (i.e. FT was more costly and less effective). Finally,
information was exploited on caregivers’ quality of life and cumulated QALY gains for both young people and
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caregivers. An aggregate QALY was created by simply summing the young people’s and caregivers’ QALYs.103
The associated cost-effectiveness ratio was then £20,808.21 per QALY gain, demonstrating a potential for FT
to bring a total of 21.2 extra days at full health for both the young person and caregiver and hence to be
cost-effective, as it was below the recommended NICE threshold (£20,000–30,000). The cost-effectiveness
plane and the cost-effectiveness acceptability curve of FT compared with TAU when young people’s and
caregivers’ quality of life are taken into account can be found in Appendix 7.
Secondary analysis
Table 97 shows the costs and the number of self-harm events for each of the trial arms to the end of trial
follow-up (18 months). It also shows the incremental cost and incremental number of self-harm events
avoided because of FT. More self-harm events were avoided in the TAU arm than in the FT arm over the
full trial period and, together with the higher cost to the NHS providers of FT, suggests that FT was
dominated by TAU (i.e. FT was both more costly and less effective).
TABLE 96 Sensitivity analyses (outcome measure: QALY, NHS perspective)
FT vs. TAU Incremental cost (£) (95% CI) Incremental QALY (95% CI) ICER (£/QALY)
Bootstrapped average (10,000
replications)
1254.51 (1149.23 to 1259.80) 0.034 (0.0338 to 0.0344) 36,705.79
Assume intervention costs from
scenario 1
1380.36 (747.98 to 2012.75) 0.034 (–0.004 to 0.065) 40,129.79
Assume intervention costs from
scenario 2
1546.38 (909.59 to £2183.17) 0.034 (–0.004 to 0.064) 44,956.26
Adjusting for baseline EQ-5D
differences
1266.23 (736.04 to 1796.43) 0.039 (0.035 to 0.042) 32,852.22
Complete case 1135.13 (267.39 to 2537.64) –0.003 (–0.086 to 0.080) FT dominated
Including caregivers’ QALYs 1207.16a (662.33 to 1752.00) 0.058 (0.002 to 0.114) 20,808.21
a The incremental cost is different from that presented in Table 95 because the sample size in this analysis is different;
364 participants and their caregivers in the TAU arm and 379 participants and their caregivers in the FT arm were considered.
Adapted from Cottrell et al.70 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
4.0 license.
TABLE 97 Cost-effectiveness results (outcome measure: self-harm events avoided, NHS perspective)
Treatment arm Cost-effectiveness result
TAU
Costs (£),a mean (SD) 3733.85 (3788.80)
Number of self-harm events, mean (SD) 0.468 (1.268)
FT
Costs (£),a mean (SD) 4986.41 (3758.29)
Number of self-harm events, mean (SD) 0.501 (1.063)
FT vs. TAU
Incremental cost (£), (95% CI) 1252.57 (724.80 to 1780.33)
Incremental number of self-harm events (95% CI) 0.033 (–0.130 to 0.197)
ICER (£/self-harm event avoided) FT dominated
a The costs are different from those presented in Table 95 because the sample size in the secondary analysis is different;
391 participants in the TAU arm and 397 participants in the FT arm were considered.
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Decision model analysis
As the difference in QALY gains between FT and TAU was marginal at 18 months in the within-trial
analysis and did not exist in the complete-case analysis, a decision-analysis model would not have been
required. However, as planned in the original protocol, a discrete-time state-transition (modified Markov)
model was developed in order to estimate the cost-effectiveness of FT compared with TAU over a horizon
of 5 years. In line with the within-trial analysis, the base-case model adopted a NHS perspective and future
costs and QALYs were discounted at an annual rate of 3.5% following the NICE guidelines.93 The model
was built and analysed using Microsoft Excel® version 2013 (Microsoft Corporation, Redmond, WA, USA).
Model parameters
The model structure was presented in Figure 3. The full list of the model parameters and distributions
applied in the model is given in Table 98, with the chosen distributions being based on the observed
variance data.
TABLE 98 Markov input parameters
Parameter Name Mean Distribution SE Source
Global parameters Discount rate 0.035 Fixed NICE guidance
Health state costs in TAU arm
(6 months)
SH £1182 Log-normal £1493 SHIFT trial data
Health state costs in TAU arm
(12 months)
SH £1698 Log-normal £1628
noSH £709 Log-normal £1116
Death 0 Fixed –
Health state costs in TAU arm
(18 months)
SH £1510 Log-normal £1022
noSH £817 Log-normal £1432
Death 0 Fixed –
Health state costs in FT arm
(6 months)
SH £1049 Log-normal £1482
Health state costs in FT arm
(12 months)
SH £2186 Log-normal £2198
noSH £763 Log-normal £1228
Death 0 Fixed –
Health state costs in FT arm
(18 months)
SH £2530 Log-normal £2282
noSH £649 Log-normal £1054
Death 0 Fixed –
Health state utilities in TAU arm
(6 months)
SH 0.760 Beta 0.161
Health state utilities in TAU arm
(12 months)
SH 0.751 Beta 0.187
noSH 0.784 Beta 0.180
Death 0 Fixed –
Health state utilities in TAU arm
(18 months)
SH 0.754 Beta 0.033
noSH 0.808 Beta 0.157
Death 0 Fixed –
Health state utilities in FT arm
(6 months)
SH 0.799 Beta 0.178
SH 0.793 Beta 0.184
continued
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Base-case model results
The results of the base-case analyses are presented in Tables 99 and 100. Taking into account uncertainty
around the model parameters (i.e. looking at the probabilistic results), FT was associated with an extra cost
of £1262.13 and a 5-year QALY gain of 0.065 (equivalent to 23.7 extra days of full health) compared with
TAU. The ICER indicated that 1 QALY would be gained for every £19,486.97 spent by adopting FT; the
ICER was below the NICE-recommended threshold (£20,000–30,000) and, therefore, FT was expected to
be cost-effective in the longer term.
The results of the probabilistic analysis are presented in Figure 45. Each point on the graph represents the
result of one probabilistic simulation of the model and indicates a potential incremental cost and
incremental QALY for FT compared with TAU. The diagonal line represents the NICE willingness-to-pay
threshold of £20,000 per QALY. The points were widely distributed around the origin, in both cost-effective
and non-cost-effective regions, which indicated a high level of uncertainty around the cost-effectiveness of
FT compared with TAU over a 5-year horizon.
TABLE 98 Markov input parameters (continued )
Parameter Name Mean Distribution SE Source
Health state utilities in FT arm
(12 months)
noSH 0.813 Beta 0.194
Death 0 Fixed –
Health state utilities in FT arm
(18 months)
SH 0.732 Beta 0.239
noSH 0.823 Beta 0.179
Death 0 Fixed –
Transition probabilities
(at 6 months)
Proportion of young persons
stopping SH (noSH) from SH in
the TAU arm
0.858 Beta 0.0003
Proportion of young persons
stopping SH (noSH) from SH in
the FT arm
0.845 Beta 0.0003
Transition probabilities
(at 12 months)
Proportion of young persons
stopping SH (noSH) from SH in
the TAU arm
0.716 Beta 0.004
Proportion of young persons SH
from noSH in the TAU arm
0.066 Beta 0.0002
Proportion of young persons
stopping SH (noSH) from SH in
the FT arm
0.803 Beta 0.003
Proportion of young persons SH
from noSH in the FT arm
0.078 Beta 0.0002
Transition probabilities
(at 18 months)
Proportion of young persons
stopping SH (noSH) from SH in
the TAU arm
0.775 Beta 0.004
Proportion of young persons SH
from noSH in the TAU arm
0.063 Beta 0.0002
Proportion of young persons
stopping SH (noSH) from SH in
the FT arm
0.684 Beta 0.006
Proportion of young persons SH
from noSH in the FT arm
0.095 Beta 0.0002
noSH, no self-harm; SH, self-harm.
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TABLE 99 Deterministic 5-year model cost-effectiveness results
Treatment arm Cost-effectiveness result
TAU
Total costs (£) 10,338.77
Total QALYs 4.201
FT
Total costs (£) 11,650.18
Total QALYs 4.272
FT vs. TAU
Incremental cost (£) 1311.41
Incremental QALY 0.070
ICER (£/QALY) 18,659.74
TABLE 100 Probabilistic 5-year model cost-effectiveness results
Treatment arm Cost-effectiveness result
TAU
Costs (£), mean (SD) 11,0301.58 (11,092.43)
QALY, mean (SD) 4.187 (0.623)
FT
Costs (£), mean (SD) 11,563.70 (8,111.12)
QALY, mean (SD) 4.251 (0.698)
FT vs. TAU
Incremental cost (£), (95% CI) 1262.13 (1106.62 to 1417.62)
Incremental QALY (95% CI) 0.065 (0.053 to 0.075)
ICER (£/QALY) 19,486.97
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FIGURE 45 Long-term cost-effectiveness plane of FT compared with TAU (outcome measure: QALY, NHS perspective).
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The cost-effectiveness acceptability curve presented in Figure 46 shows the proportion of model simulation
points being under different cost-effectiveness threshold values and indicated the probability that each
treatment was cost-effective at given willingness-to-pay values. At low cost per additional QALY thresholds,
FT was associated with a low probability of being cost-effective. As the threshold value increased, the
probability of FT being cost-effective increased marginally. In particular, at a threshold of £20,000 per QALY,
FT had a 50% chance of being cost-effective, and this increased to 52% when the threshold was £30,000.
Sensitivity analyses
A number of deterministic one-way sensitivity analyses were undertaken, the results of which are
presented in Table 101. They included making different assumptions about the number of therapists
involved in each of the treatment sessions in the FT arm, similarly to the within-trial analysis; we considered
intervention costs from scenario 1 and then intervention costs from scenario 2, as defined earlier in the
analysis. In both cases, participants in the FT arm incurred higher costs than those in the TAU arm, but
with an incremental QALY of 0.070, giving ICERs between £1000 and £4500 per QALY, implying that FT
was likely to be cost-effective in the longer term. Another analysis considered using the costs and utilities
from the trial data at 6 months but without using the observed costs and utilities at 12 or 18 months. In
this case, participants in the FT arm incurred costs that were £1041.55 higher than those incurred in the
TAU arm and achieved a 5-year QALY gain of 0.077 (28.1 days at full health). The final sensitivity analysis
included the derivation of QALYs after adjusting for EQ-5D differences at baseline and a set of baseline
characteristics. Again, FT was found to be more costly and more effective than TAU, with an ICER of
£16,533.03 per QALY, which was below the recommended NICE threshold of £20,000.
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FIGURE 46 Long-term cost-effectiveness acceptability curve of FT compared with TAU (outcome measure: QALY,
NHS perspective).
TABLE 101 Deterministic sensitivity analyses for 5-year model
FT vs. TAU
Incremental
cost (£)
Incremental
QALY
ICER
(£/QALY)
Assume intervention costs from scenario 1 117.59 0.070 1673.21
Assume intervention costs from scenario 2 282.89 0.070 4025.21
Costs and utilities from trial data at 6 months and after 6 months 1041.55 0.077 13,458.40
Adjusting for baseline EQ-5D differences 1311.41 0.079 16,533.03
HEALTH ECONOMICS RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
154
Chapter 5 Discussion
Summary of results
Primary outcome: self-harm
In this study, 221 (26.6%) participants inflicted self-harm leading to hospital attendance within 18 months
of randomisation. Older participants (aged 15–17 years) had a lower rate of repeat self-harm than younger
ones (aged 11–14 years). Participants recruited via referral direct from hospital to CAMHS had higher
rates of repeat self-harm, as did females and participants whose index episode combined self-injury and
poisoning as opposed to self-injury alone. The self-harm method used for the primary outcome event was
commonly not the same as that used at the index event, with just over half of those whose index event
involved self-injury ‘switching’ to self-poisoning.
In this study, in young people aged 11–17 years who had self-harmed and had at least one previous
episode of self-harm, there was no evidence of a difference in subsequent repetition of self-harm between
those receiving TAU and FT within 18 months.
Secondary outcomes: self-harm
There was no evidence of a difference in subsequent repetition of self-harm within 12 months between
those receiving TAU and those receiving FT, nor in all further repeat episodes of self-harm leading to
hospital attendance within 18 months.
Researchers rated young people’s self-report of their index episode of self-harm. The behaviour of 313
(37.6%) participants was classified as a suicide attempt. Remaining episodes were largely classed as NSSI.
It was considered that just under half the participants (412, 49.5%) exhibited some intent to die, and in
over three-quarters there was a low medical risk of death. Nevertheless, medical treatment was sought or
received for 659 (79.2%) participants.
Although loss to follow-up means we have data (or partial data) on self-reported self-harm at 18 months
from only 478 participants, it is clear that in our sample there were many self-harm events that did not
lead to hospital attendance (the primary outcome), with 349 out of 478 (73.0%) participants reporting
self-harm. An unadjusted analysis of time to first self-reported self-harm event does not contradict the
primary outcome analysis.
Secondary outcomes: health economics
Both trial arms showed an increase in the mean EQ-5D over the 18 months’ trial follow-up. The largest
differences in EQ-5D scores between the two arms were at 6 and 12 months, with participants in the FT
arm exhibiting significantly higher scores than those in the TAU arm, whereas there were no significant
differences in quality of life between the two study arms at 18 months.
A cost-effectiveness analysis indicated that FT was £1266.23 more expensive and slightly more effective in terms
of QALY gains (equivalent to 12.4 extra days of perfect health) than TAU, leading to an ICER of £36,811.80 per
QALY gained. Hence, FT was found unlikely to be cost-effective at 18 months compared with TAU.
Secondary outcomes: other clinical outcomes
We also found no significant treatment differences for young person questionnaire outcomes on the
CDRS-R, PQ-LES-Q, Hopelessness scale or McMaster FAD. However, young people in the FT arm reported
significantly better outcomes on the prosocial scale of the SDQ at 12 and 18 months and on the impact of
their problems scale at 12 months, but not at 18 months. They also reported significantly lower rates of
suicidal ideation on the BSS at 12 months, but not at 18 months.
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There were no significant differences between treatment groups in participants’ caregiver questionnaire
outcomes on the GHQ-12 or Family Questionnaire. However, caregivers in the FT arm reported a range of
significantly better outcomes than those in TAU arm: on the total difficulties score of the SDQ; on the
emotional problems, peer problems and internalising scales of the SDQ at 12 and 18 months; on the
conduct problems and externalising scales of the SDQ at 18 months, but not at 12 months; and on
the impact scale of the SDQ at 12 months, but not at 18 months. Caregivers also reported significantly
better outcomes in FT on the roles scale of the McMaster FAD at 12 months but not at 18 months.
The number of participants with other ‘administrative’ outcomes, such as referrals to other services,
including to inpatient units, and safety outcomes including re-referrals to CAMHS, A&E attendances and
hospital admissions for any reason, were similar across the arms.
Moderator analyses
The risk of self-harm among young people whose scores on the unemotional subscale at baseline
suggested that they had difficulty in talking about feelings was higher in the FT arm than in the TAU arm,
but among those whose scores indicated that they found talking about feelings easier was lower in the FT
arm than in the TAU arm.
Among young people whose caregivers reported healthier affective involvement scores (degree to which
family members are involved and interested in one another) on the McMaster FAD, risk of self-harm was
higher in the FT am than in the TAU arm, while among those with poorer affective involvement scores risk
of self-harm was lower in the FT arm than in the TAU arm.
Additional health economic analyses
In a secondary analysis in which the number of self-harm events avoided over 18 months was the outcome
measure, FT was found to be less effective than TAU, with 0.033 more self-harm events on average, and
more expensive by £1252.57, indicating that TAU dominated FT (i.e. was more effective and less costly) in
the management of repeated self-harm in adolescents.
When combining young people’s and caregivers’ QALY gains, FT was associated with higher costs
and better health outcomes than TAU, with an ICER of £20,808.21 per QALY gain (within the NICE
cost-effectiveness range of £20,000–30,000 per QALY) and with a probability of being cost-effective of
41% at a threshold of £20,000 per QALY and of 64% at a threshold of £30,000 per QALY. Hence, when
health benefits were considered beyond the young person’s own health benefits, FT would be considered
a cost-effective use of NHS money.
Mediator analysis
Complier average causal effect analyses were conducted to model the causal effect of FT receipt (as
opposed to randomisation) on the primary outcome, finding a very similar effect as in the primary analysis.
Exploratory analyses of the time to first event for participants who were allocated to and received FT, and
those allocated to TAU who received a form of FT as part of their usual care, show that the curves appear
to diverge, with an increased rate of self-harm in those allocated to FT, but no statistically significant
difference was found.
There was no evidence that any of the variables investigated formally mediated the effect of treatment on
the time to self-harm, largely because of lack of evidence of a treatment effect. However, further analysis
using alternative approaches to explore mediation in the absence of a treatment effect could be
undertaken for a number of potential mediators identified (therapist experience, young person SDQ
impact, caregiver SDQ emotional problems and caregiver McMaster FAD roles subscales).
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Interpretation of results
The nature of the sample and generalisability
The proportion of females in the sample (88.3%) is not dissimilar to that seen in hospital samples13,104 and
is also similar to that seen in a well-conducted community survey of 15- to 16-year-olds in England,5 and
highly similar to a number of randomised controlled trials among this population47,105–109 in the UK and in
countries with similar health-care arrangements, including Australia.110,111
Baseline data on the sample as a whole suggest that the recruited group has experienced significant
difficulties and significant mental disorders. A total of 26.2% reported a health or disability problem, 29.3%
had been involved with CAMHS in the past, 21.4% reported marked physical abuse, 16.6% reported sexual
abuse and 16.0% reported experience of being bullied. On the total difficulties score of the SDQ, 66.2% of
participants scored in the high/very high range, with their caregivers reporting that 69.6% scored in this
range. On the general functioning subscale of the FAD, 84.7% of participants scored their families as
‘unhealthy’, with the equivalent figure from caregivers being 75.8%. On the CDRS-R, 65.7% of participants
scored themselves as being in the moderate, severely or very severely depressed category.
To be eligible for the trial, young people needed to have self-harmed at least twice; in the event, most
(88.8%) had self-harmed at least three times prior to randomisation. The index events leading to enrolment
in the trial was cutting in 63.3% of participants (71.4% if other forms of self-injury are included, e.g. biting
and burning), self-poisoning in 22.7% and a combination of cutting and self-poisoning in 6.5%. Ratings on
the SASII suggested that 62.0% of index events would be classified as NSSI, but 49.5% of participants
were rated as having some intent to die. This suggests that the decision to use UK definitions of self-harm
‘regardless of motive’ is justified because of the ambiguity about and difficulty of interpretation of
statements about intent.
The self-harm method used by the young people in the sample is much more slanted towards self-injury
than seen in hospital-referred cases – around 71.4% in the study, but only 17% in a monitoring study in
three English cities of 5200 consecutive episodes of hospital attendance caused by self-harm in those aged
under 18 years.13 This is likely to be related to the fact that, although the primary outcome was self-harm
leading to hospital attendance, the eligibility criteria for enrolment in the study included adolescents who
had recently self-harmed and, as a consequence, been referred to CAMHS – irrespective of whether or not
they had attended hospital. In fact, 63.5% of the sample were community referrals and were not referred
directly by hospital services to CAMHS following self-harm. Some of the community referrals to SHIFT had
been discharged from hospital following self-harm without a CAMHS referral and had then been referred
to the trial via community services. Others had never presented to hospital in the first place but were
referred from primary care following a self-harm episode. Interestingly, although the largest proportion of
those screened were hospital referrals, many of these were ineligible, mostly because this was their first
episode of self-harm. Although a smaller proportion of those screened were community referrals, more
were eligible for the trial.
The method and location of recruitment are comparable with those of several more recent studies in the
UK, using a mixture of hospital and CAMHS-presenting populations. Several older studies in the UK have
focused on CAMHS participants106,107,109 with more recent studies diversifying into A&E plus CAMHS47 or
A&E plus GP referrals.105 A study in Australia recruited from both A&E and CAMHS.111 Interestingly, none
of these combined sample-source studies has noted any effect or diversity in response to the interventions
by source of referral.
The primary outcome
Interpretation of any results related to self-harm is complicated by debates about terminology – in particular,
differences in usage between clinicians and researchers in the USA and those in the UK and Europe. In
this trial, which was a pragmatic trial taking place in a UK setting, self-harm was defined as any form of
non-fatal self-poisoning or self-injury (such as cutting, taking an overdose, hanging, self-strangulation,
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jumping from a height and stepping into traffic), regardless of motivation or the degree of intention to die.
This was in line with the commissioning brief, but also with clinical practice and UK policy, where this
definition is standard practice.16 This definition includes what in the USA would be described as NSSI as well
as suicidal behaviour.
In the USA, self-harm is often seen as synonymous with self-injury and implies a lack of suicidal intent,
whereas in the UK the term encompasses self-injury and self-poisoning and is associated with concerns
about making judgements about suicidal intent from the methods used to self-harm (see, for example,
Wilkinson et al.,108 Kapur et al.,112 Butler and Malone,113 Klonsky et al.114 and Edmondson et al.115).
There is increasing evidence, supported by data from this trial, that a significant proportion of people
who repeatedly harm themselves will change methods in subsequent episodes116 and that ‘non-suicidal
self-injury’ should be taken more seriously.117
Overall, 26.6% of participants attended hospital as a result of repeated self-harm within 18 months of
randomisation. Repetition of self-harm among the young people in the English multicentre monitoring
study was around 28% in an average of more than 4 years of follow-up.13 Repetition of around the same
frequency in just 18 months in the present trial is not surprising, because participants were all young
people who had already self-harmed on more than one occasion, while the monitoring study was a mix of
first-time and repeat episodes: the monitoring study found a HR of 1.8 for repetition among those with a
history of earlier episodes compared with those with no such history.13 Similarly, the HR for repetition
where the method was cutting or other injury was 1.5 and the present trial had a very high proportion of
self-injury among the methods used at the most recent self-harm episode.
Age-related repetition in this study showed a pattern that does not reflect the picture seen in large-scale
monitoring of hospital attendance because of self-harm. We found that that younger people in the trial
(aged 11–14 years) were significantly more likely to show repeated self-harm than older adolescents (aged
15–17 years), but that was not the case in the three cities monitoring study, in which the 1-year repetition
rate was exactly the same among those aged 10–14 years as those aged 15–18 years (18%).16
In the monitoring study,13 over a median 6 years of follow-up after an index episode, there was a suicide
(or probable suicide) rate of 1.0%. On the basis of that rate, from a sample with some comparability, and
in one-quarter of that follow-up time, the present study might have expected something in the region of
two suicides; plainly zero suicides during the SHIFT trial follow-up period is therefore unsurprising.
Recent reviews have set out mixed findings in relation to interventions to prevent subsequent self-harm,48,49
noting that the studies reviewed have relatively small sample sizes, with an average follow-up of 6 months,
with most not powered for ascertaining risk of repetition, which is statistically a relatively rare event.
This trial therefore adds to the existing literature that suggests that there is no clear evidence of any one
intervention being more effective than others in reducing repeat self-harm in adolescents. It is, however,
a significantly more robust study than others. It should be noted that the primary outcome in this study
was self-harm leading to hospital attendance. Many of the other studies reviewed by Ougrin et al.49
and Brent et al.48 are based on self-reports of self-harm, again making comparisons with the existing
literature problematic.
The pragmatic design of this study conferred a potential advantage on TAU as experienced CAMHS
clinicians in the TAU arm had greater flexibility in selecting treatments (or combinations of treatments)
based on the results of their clinical assessment and discussions with the young person and family about
their preferred treatment strategies.
Secondary outcomes
There were marked improvements on nearly all measures from baseline to 18 months, but only for those
summarised below were there significant between-group differences. The absence of a between-group
difference on scores for depression and hopelessness is somewhat unexpected, given that depression is
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most frequently identified as the strongest psychiatric risk factor associated with a range of self-harming
behaviours.14,21 It has been found in previous studies of both depression itself (see, for example, Hazell et al.118
and Pineda and Dadds119) and suicidal behaviour to have an impact on responsiveness to treatment120 or to
frequently respond to treatments for adolescent self-harm.46,121 Similarly, hopelessness has been identified
in a number of epidemiological and clinical population studies as being associated with risk of repetition108
and having an impact on treatment responsiveness.118,122
There was good evidence of reduced odds of suicidal ideation in the FT arm at 12 months but not at
18 months. However, this was because suicidal ideation had decreased further in the TAU group between
12 and 18 months, while suicidal ideation decreased to a lesser extent in the FT arm. It might be argued
that if FT reduces suicidal ideation sooner, this is a potentially important clinical benefit. This is consistent
with research using attachment-based FT,123 a slightly different form of FT to that used here, but also
addressing specific issues related to self-harm. The similarity of the findings strengthens our conclusions.
The significantly better outcomes on different elements of the SDQ (a widely used measure of general
emotional and behavioural difficulties) for the FT arm reported by young people and their caregivers suggest
that FT did have a significant, positive impact on general mental health, even if this did not translate into
reduced repetition of self-harm. Caregivers reported a wide range of benefits across the total difficulties
score and the subscales of the SDQ.
It has long been known that self-report questionnaire findings from caregivers and their children will differ. In
the field of self-harm, in Pineda and Dadds’ 2013111 evaluation of an interactive psychoeducation programme,
parents reported greater improvements in family functioning (FAD general scale) and adolescents reported
lower levels of suicidal behaviour (including ideation, plans, self-harm or attempts) in the intervention group.
Similarly, in a much cited study by Huey et al.,124 young people, but not parents, reported lower repetition in
the experimental group.
Moderator analyses
It might seem to make intuitive sense that families who report poorer family functioning in relation to
affective involvement obtain benefits from an intervention that focuses specifically on family function.
However, other studies have suggested that it is families with good functioning that benefit most from
FT.125 The unemotional subscale of the ICU71 focuses on an absence of emotional expression with items
related to the ability to express feelings openly and to show feeling to others. That adolescents who find
this difficult may do less well in an intervention like FT, where such expression is encouraged, is more in
line with the literature, but the two findings together suggest a more complex relationship between
adolescent and family functioning and the ability to talk about feelings than has hitherto been reported.
From a clinical perspective it may be that, where adolescents themselves have difficulty in expressing
feelings after self-harm, a different approach from FT or a modification of FT practice may be indicated. In
eating disorders, for example, it has been shown that families with high levels of criticism tend to drop out
of FT and do worse in conjoint FT than when parents and adolescents are seen in parallel.126,127
Summary statistics appear to suggest a differential treatment effect according to source of referral, with an
increased rate of self-harm in participants referred through hospital in FT. However formal testing for
moderation did not detect a statistically significant difference, but it is recognised that interaction testing
for moderation is not particularly powerful and the possibility that referral source might have an influence
should be explored further in future research.
Health economics
The SHIFT approach required family therapists to work in teams and, therefore, more therapists were
involved with each participant. It is interesting that, despite this, FT did not cost substantially more
than TAU.
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As the difference in QALY gains between FT and TAU was marginal at 18 months and did not exist in the
complete-case analyses, the cost-effectiveness within-trial results would not have required a decision-analysis
model. However, as the model was planned in the original protocol, the within-trial analysis was completed
with a decision-analysis model using a 5-year horizon. When extrapolating the analysis beyond 18 months,
it was found that participants in the FT incurred arm higher costs (by £1262.13) and experienced a 5-year
QALY gain of 0.065 compared with those in the TAU arm. The ICER was below the £20,000 recommended
threshold, indicating that FT was likely to be cost-effective in the longer term, although the level of
uncertainty around this estimate was high and the cost-effectiveness acceptability curve exhibited a
probability to be cost-effective of 50%. All the sensitivity analyses undertaken confirmed that FT could be
cost-effective over a 5-year follow-up but with a very high level of uncertainty. The decision-analysis model
showed that the cost-effectiveness of FT as an intervention in the management of self-harm in young people
is highly uncertain in the longer term.
The finding that FT could be considered cost-effective when considering benefits beyond just those for the
participants relies on the strong assumption that QALYs can be aggregated across individuals as a simple
aggregation; while this has been done in prior studies on child health,128 this is not yet part of the NICE
reference case. It is, however, consistent with other health economic research showing benefits to other family
members.129 Such considerations require a theoretical justification and a discussion on the interdependence
between the utility function of the adolescent and the parent that has not been pursued in this report, as it
was not part of the trial’s objective. This sensitivity analysis result suggests that caregivers’ QALYs affected the
conclusions of the economic evaluation, probably because the incremental participant QALYs were small and
the base-case ICER was near the threshold value.103
Study strengths
The SHIFT team believe this to be among the largest (by participant number) studies in the world evaluating
a psychological intervention in CAMHS. Many other studies in adolescent self-harm have much smaller
sample sizes. The combined total of randomised participants in the 19 studies in Ougrin et al.’s49 systematic
review of self-harm interventions was 2432, with the smallest study randomising just 39 participants and the
largest 448. By selecting a primary outcome that was measurable without contact with participants it was
possible to ascertain the primary outcome in a very high proportion of participants, 795 (95.6%) and
partially (< 18 months) for a further 33 (4.0%). This is thus an adequately powered study with a very high
success rate in obtaining the primary outcome and an ITT analysis suggesting that the findings are robust.
The follow-up period of 18 months is longer than many self-harm intervention studies, which typically have
a 6-month follow-up.48
The piloting and subsequent use of routinely collected HES data obtained from NHS Digital (supplemented
by researcher visits when clarification was needed for the reason for attendance or method of self-harm)
was novel and effective and should be considered in other trials.
The presence of a full cost-effectiveness analysis is also unusual in trials aimed at reducing repeat self-harm
and is a further strength.
This trial recruited ‘high-risk’ participants, as young people had to have self-harmed at least twice to be
eligible; in fact, nearly all had self-harmed at least three times. This complicates comparison with other
studies, as the number of previous attempts is not always reported consistently. The exclusion criteria largely
related to conditions that would necessitate alternative, more specialist treatments – for example, anyone
presenting with self-harm and an eating disorder would have been excluded and referred to a specialist
eating disorder clinic. This, combined with sample baseline descriptive data described above, means that
the sample is broadly typical of young people presenting to CAMHS and the findings are generalisable to
those services. The small number of participants in foster care means that caution should be exercised in
generalising to that group of young people. Although the sample comprised a mix of referrals to CAMHS
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direct from hospital and from community sources, this is also typical of CAMHS referral, albeit different from
the pattern often seen in adult services. TAU was also broadly comparable to CAMHS practice in the UK
with a mixture of supportive/individual counselling, CBT, family work and more formal FT (although see
Study weaknesses for commentary on this latter intervention).
A further strength of the SHIFT study is that there is detailed self-report information regarding the range of
self-harm behaviours an adolescent may engage in, with these data available in a small number of recent
randomised controlled trials but not generally for older studies in this area.48
This was also an evaluation of FT as it is practised in the UK. Therapists were relatively senior and had
formal qualifications. They worked in teams and had regular supervision. Analysis of session recordings
suggests that they did adhere to the manualised version of therapy designed for the trial.
Study weaknesses
There was significant loss to follow-up and therefore there are many missing data for secondary
participant-reported outcomes and for the health economic analyses. Participants lost to follow-up
tended to have particularly concerning baseline characteristics, the proportion of participants were lost to
follow-up was higher in the TAU arm than in the FT arm and there was some indication of differential
characteristics for those lost to follow-up across treatment allocation. Clinically, young people who
self-harm do not readily engage with treatment and our choice of a primary outcome that could be
obtained without contact with the young person was for this reason. Nevertheless, despite the relatively
large numbers involved, interpretation of secondary outcome data has to be made with some caution
because of the number of missing data.
The primary outcome used also has a built-in disadvantage in that it misses those who do not attend
hospital following a self-harm episode. If the two treatments differ in changing the level of awareness of
self-harm in the family and the willingness to act on this, then there is potential confounding. The large
number of missing self-report data makes it difficult to test this hypothesis.
It is known that many incidents of self-harm never lead to hospital attendance,5 and, indeed, in this study,
nearly three-quarters of participants self-reported further episodes of self-harm within 18 months, in
addition to those leading to hospital attendance, with only one in seven episodes resulting in medical
attention being sought. The extent of missing self-report data in this sample at the 12- and 18-month
follow-up means that we are unable to comment on between-arm differences in self-reported self-harm.
When recruiting centres for the trial, there was the expectation that they would be compliant with UK
guidance on management of self-harm and not be already routinely offering formal FT to those who had
self-harmed. It was therefore surprising that so many participants in the TAU arm received formal FT
(between 10% and 20%, although sometimes only for one session). Strictly speaking, this was not a
protocol violation. This was a pragmatic trial and TAU was not restricted in any way. As described in the
methods section, clear steps were taken to avoid those delivering FT within TAU becoming aware of
the specific manualised form of FT that was being delivered in the FT arm. There had always been the
expectation that participants in the TAU arm would receive some form of ‘family work’, as in the UK
occasional family meetings are a routine part of practice, but we did not expect so many TAU participants
to receive FT. As noted earlier, analysis exploring the primary outcome for those in TAU who received a
version of FT suggest that this group did not do significantly better than those in the FT arm or those in
the TAU group who received other interventions.
In addition, the high degree of variability in TAU could also have also impacted on and limited interpretation
of study findings. If there was a lot of geographical variation in standard care, then it is difficult to evaluate
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what FT was ultimately being compared against. It remains possible that it may have been more effective
(and cost-effective) depending on the actual alternative package of care in specific cases.
We used the Baron and Kenny approach90 to provide a preliminary analysis exploring the mediating effect of
process variables and self-reported participant outcomes on the primary outcome; however, because of the
lack of an overall treatment effect, interpretation of these results is limited. Further methods exist in order
to explore mediation in the absence of a treatment effect and also hidden confounding (selection effects),
such as structural equation modelling, instrumental variable, principle stratification130 and counterfactual
methods.131 However, such current methodology largely focuses on linear outcomes and mediators, with
limited guidance for survival outcomes130 in particular, although, Valeri and VanderWeele132 have recently
extended their work in the counterfactual framework to account for survival data. Further exploration of
potential mediators currently identified could therefore be beneficial, if methods allow, to further
understand the impact of therapist experience across arms and self-reported outcomes on the young person
SDQ impact, caregiver SDQ emotional problems and caregiver McMaster FAD roles subscales.
Dissemination and patient and public involvement
In addition to presentations at appropriate academic and clinical conferences and academic publications,
the research team convened a SHIFT conference in Leeds in the autumn of 2016 in order to share the
results of the trial with all of the clinical teams that participated and other interested CAMHS clinicians.
Results are posted on the SHIFT website (URL: www.medhealth.leeds.ac.uk/info/615/research/315/shift).
The research team have had fruitful consultation with the NIHR-funded Young People’s Mental Health
Advisory Group in order to plan how best to present the findings of the research and will continue to liaise
with this group.
In order to ensure that the research findings are available to service users and carers, the research team
will publicise trial findings with the help of organisations such as Young Minds and will also liaise with the
clinical teams that took part in the trial to ensure that findings are disseminated to their local PPI groups.
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Chapter 6 Conclusions
Clinical implications
l This trial did not demonstrate that SHIFT manualised FT following repeated self-harm reduced
subsequent hospital attendances for self-harm compared with TAU.
l The trial does not demonstrate that brief psychological interventions generally, or some form of family
intervention (received by nearly one-third of the TAU group), are ineffective. It demonstrates that this
particular version of FT did not seem to confer extra benefits in terms of reducing the risk of further
self-harm in an unselected group of adolescents referred after repeat self-harm when compared
with TAU.
l An important caveat is that this was a higher-risk group and therefore conclusions cannot be drawn
about those presenting for the first time following self-harm.
l It should also be noted that in the TAU arm clinicians had considerable flexibility in tailoring treatments
offered to individual needs.
l The high proportion of participants whose index episode of self-harm involved self-injury and the fact
that two-thirds of the sample was not recruited directly following admission to hospital mean that,
although the sample is representative of all self-harm referrals to CAMHS, the findings may not be
generalisable to the smaller subset of adolescents who present to hospital following a first episode of
self-harm. Generalisation to those in foster care may also be inappropriate given the small number of
such participants in the sample.
l There is good evidence that FT has a positive impact on general emotional and behavioural problems at
12 and 18 months and may reduce suicidal ideation faster than TAU.
l There is some evidence to support the increased effectiveness of FT compared with TAU in reducing
self-harm where caregivers report poor family functioning or young people report ease in discussing
emotions.
l Conversely, when young people reported difficulty in expressing emotion or families reported healthy
functioning, other interventions or modifications of FT may be indicated.
l Although there was no evidence of the cost-effectiveness of FT in the primary analyses focused on
health benefits to young people, there is a suggestion that FT may be cost-effective if health benefits to
the caregivers are additionally taken into account.
l This trial adds further to the evidence that young people are likely to switch methods in subsequent
episodes of self-harm and that the method of self-harm itself may not be a useful indicator of suicidal
intent or risk.
l There are indications that participants randomised to FT exhibited higher levels of engagement, with
fewer participants who ‘did not attend at all’ and less ‘drop-out with no negotiation’ and higher rates
of participants ‘completing all required sessions’. This aligns with other trials of FT in which higher
levels of engagement have been noted in the management of self-harm and in evaluation of FT for
other conditions.21,133
Research implications
Young people who self-harm form a varied and heterogeneous group. Self-harm may be the final common
pathway for a wide range of interpersonal and mental health predicaments. This was a commissioned call
that specified a family intervention, and that is what we evaluated. It is possible that interventions based on
other theoretical models may be more effective, although the lack of evidence of effectiveness of a wide
range of approaches from earlier studies suggests that this may not be the case. Future research needs to
evaluate interventions targeted at the characteristics of specific subgroups within the self-harming
population. It may also be the case that family-oriented interventions are effective for only some of these
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subgroups. Obvious candidate groups arising from this research would be families that self-report poorer
family functioning and young people who are more unemotional and those referred to CAMHS directly
from hospital rather than the community. The match in perceptions of family functioning between young
people and their caregivers may also be an area worth exploring.
Further research into the characteristics of these two groups is also indicated: what is the exact nature of
the family dysfunction that some groups report and how might psychological interventions be targeted at
this group? Are unemotional traits shared by other family members and is it possible that these two
findings are aspects of the same underlying issue?
Collecting follow-up data from participants was clearly problematic. Collecting data about therapeutic
alliance also proved difficult in the TAU arm and yet is of potential benefit in understanding complex
treatment effects. Further consideration needs to be given as to how this might be achieved in future
studies; exploring the potential benefits of routine data and/or new technologies in enhancing such data
collection would be valuable.
At 18 months, this trial already has a longer follow-up period than many other published reports, but
18 months is still a relatively short time, given that self-harming behaviour continues into adult life. Longer
follow-up studies are needed. For SHIFT, the NIHR Health Technology Assessment (HTA) programme has
agreed funding to extend follow-up by 18 months. This means that the research team will be able to use
routinely collected data to obtain the primary outcome (and hospital attendances for other reasons) for all
consenting participants at 3 years and for some at 6–7 years post randomisation, and will also collect adult
mental health records of participants who are now aged > 18 years. Given the availability of routine data,
follow-up could and should continue beyond this and ideally should explore, with appropriate consent,
linkage to other relevant national databases.
The possibility that FT may have benefits beyond that of the identified participant requires further
exploration as to how health economic benefits might be aggregated for family members.
The significant differences observed in self-reported episodes of self-harm and episodes requiring hospital
attendance and the very different patterns of self-harm recorded suggest that further work is needed to
clarify the most appropriate outcome measures in self-harm research and how they might best be measured.
CONCLUSIONS
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Appendix 1 Health Technology Assessment
Programme Commissioning Brief (07/33)
NHS R&D Health Technology Assessment Programme   HTA no 07/33 
Family therapy for adolescents who self-harm 
Introduction 
The aim of the HTA programme is to ensure that high quality research information on the costs, 
effectiveness and broader impact of health technologies is produced in the most efficient way for 
those who use, manage, provide care in or develop policy for the NHS.  Topics for research are 
identified and prioritised to meet the needs of the NHS.  Health technology assessment forms the 
largest portfolio of work in the NHS Research and Development Programme and each year about 
fifty new studies are commissioned to help answer questions of direct importance to the NHS.  The 
studies include both primary research and evidence synthesis. 
 
Question 
What is the clinical- and cost-effectiveness of family therapy for adolescents who self-harm? 
 
1 Technology:  Family therapy - researchers to define explicitly the elements of family therapy 
to be delivered. 
2 Patient group: Adolescents (11-17 years) who have had more than one episode of deliberate 
self-harm (including self-poisoning and self-injury), excluding those who are severely 
depressed and suicidal. Researchers should define the selection of the patient group to 
exclude those for whom family therapy would be likely to be detrimental. Researchers should 
consider if there are meaningful subgroups.  
3 Setting: Any – though patients will have been referred by a specialist service.  
4 Control or comparator treatment:  Conventional care. 
5 Design: A randomised controlled trial. 
6 Primary outcomes: Repetition of self-harm. Secondary outcomes: suicidal ideation, 
measures of quality of life for patient and family (researchers to define and justify scales 
used), adherence, cost, cost-effectiveness. 
7 Minimum duration of follow-up:  One year. 
 
Background to commissioning brief: 
 
Deliberate self-harm (DSH) among young people is a major public health issue in the UK, 
affecting at least one in 15 young people. As many as 30% of adolescents who self-harm report 
previous episodes, and a history of DSH is a significant risk factor for suicide. There continues 
to be insufficient evidence on which to make firm recommendations about the most effective 
forms of treatment for DSH patients. This is a serious situation given the size of the DSH 
population and the need to target this population as part of national suicide prevention 
strategies.  
 
The limited studies to date have been relatively small and hence of limited power. Benefits of 
family therapy have been reported in one small RCT, but there is a need for robust information 
from a large trial evaluating family therapy. 
 
 
Notes to Applicants 
 
For many of the questions posed by the HTA programme, a randomised controlled trial is likely to be 
the most appropriate method of providing an answer. However, there may be practical or ethical 
reasons why this might not be possible. Applicants proposing other research methods are invited to 
justify these choices. 
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Applicants are asked to: 
 
1. Follow the Medical Research Council’s Good Clinical Practice guidelines 
(http://www.mrc.ac.uk/pdf-ctg.pdf) when planning how studies, particularly RCTs, will be 
supervised.  Further advice specific to each topic will be given by the HTA programme at full 
proposal and contract stages. 
 
2. Note that trials involving medicinal products must comply with "The Medicines for Human 
Use (Clinical Trials) Regulations 2004". In the case of such trials, the DH expects the 
employing institution of the chief investigator to be nominated as the sponsor. Other 
institutions may wish to take on this responsibility or agree co-sponsorship with the 
employing institution. The DH is prepared to accept the nomination of multiple sponsors. 
Applicants who are asked to submit a full proposal will need to obtain confirmation of a 
sponsor(s) to complete their application. The DH reserve the right to withdraw from funding 
the project if they are not satisfied with the arrangements put in place to conduct the trial. 
 
The MHRA (info@mhra.gsi.gov.uk, http://www.mhra.gov.uk) can provide guidance as to whether 
your trial would be covered by the regulations. The DH/MRC website (http://www.ct-toolkit.ac.uk/) 
also contains the latest information about Clinical Trials regulations and a helpful FAQ page. 
 
 
Making an application 
 
If you wish to submit an outline proposal on this topic, complete the electronic application form and 
return it to the HTA Commissioning Manager at the National Coordinating Centre for Health 
Technology Assessment, Mailpoint 728 Boldrewood, University of Southampton, Southampton SO16 
7PX by Wednesday 25 April 2007.  Outline applications will be considered by the HTA 
Commissioning Board at its meeting in July 2007.  If they are acceptable, investigators will be given 
a minimum of eight weeks to submit a full proposal. 
 
Applications received after 1300 hours on the due date will not be considered. 
 
Please see GUIDANCE ON APPLICATIONS overleaf. 
 
The HTA programme expects, where appropriate, that applicants will work with the relevant research 
network. 
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Guidance on applications 
 
Required expertise 
 
HTA is a multidisciplinary enterprise. It needs to draw on the expertise and knowledge of clinicians 
and of those trained in health service research methodologies such as health economics, medical 
statistics, study design and qualitative approaches. HTA expects applicants to engage a qualified 
Trial Manager for appropriate projects. Applicants will need to show a commitment to team working 
and may wish to consider a collaborative approach between several institutions. It is expected that the 
research will be undertaken only following a thorough literature review. 
 
Public involvement in research 
 
The HTA programme recognises the increasing active involvement of members of the public in 
research and would like to support research projects appropriately. The HTA programme encourages 
applicants to consider how the scientific quality, feasibility or practicality of their proposal might be 
improved by involving members of the public. Research teams wishing to involve members of the 
public should include in their application: the aims of active involvement in this project; a description 
of the members of the public (to be) involved; a description of the methods of involvement; and an 
appropriate budget. Applications that involve members of the public will not, for that reason alone, 
be favoured over proposals that do not but it is hoped that the involvement of members of the public 
will improve the quality of the application. 
 
Outcomes 
 
Wherever possible, the results of HTA should provide information about the effectiveness and cost-
effectiveness of care provided in its usual clinical setting and for the diverse subjects who would be 
eligible for the interventions under study. The endpoints of interest will in most cases include disease 
specific measures, health related quality of life and costs (directly and indirectly related to patient 
management). Wherever possible, these measurements should be made by individuals who are 
unaware of the treatment allocation of the subjects they are assessing. We encourage applicants to 
involve users of health care in the preparation of their proposal, for instance in selecting patient-
oriented outcomes. A period of follow up should be undertaken which is sufficient to ensure that a 
wider range of effects are identified other than those which are evident immediately after treatment. 
These factors should guide applicants in their choice of subjects, settings and measurements made. 
 
Sample size 
 
A formal estimate should be made of the number of subjects required to show important differences 
in the chosen primary outcome measure. Justification of this estimate will be expected in the 
application. 
 
Communication 
 
Communication of the results of research to decision makers in the NHS is central to the HTA 
Programme. Successful applicants will be required to submit a single final report for publication by 
the HTA programme. They are also required to seek peer-reviewed publication of their results 
elsewhere and may also be asked to support the NCCHTA in further efforts to ensure that results are 
readily available to all relevant parties in the NHS. Where findings demonstrate continuing 
uncertainty, these should be highlighted as areas for further research. 
 
Timescale 
 
There are no fixed limits on the duration of projects or funding and proposals should be tailored to 
fully address the problem (including long-term follow-up if necessary).  Applicants should consider 
however that there is a pressing need within the NHS for this research, and so the duration of the 
research needs to be timely. 
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Appendix 2 Protocol amendments summary
Trial first approved by the Research Ethics Committee in April 2009
Amendment 1: non-substantial – April 2009
l Inclusion in the adult participant information sheet (PIS) that social care records may be reviewed.
l Inclusion in the adult PIS that NHS trusts may also review relevant records.
l Clarification of the exclusion criteria, and inclusion of those in stable foster care.
l Addition of the following minimisation criterion: ‘living arrangements (with parents or guardians vs.
foster care)’.
Amendment 2: substantial and non-substantial – July 2009
i. Update to inclusion criteria:
¢ Where the presenting episode is due to alcohol or recreational drugs, the young person has
explicitly stated that he/she was intending self-harm by use of alcohol/recreational drugs.
¢ Where it is intended to offer CAMHS follow-up for self-harm.
ii. Update to exclusion criteria:
¢ Sibling has been randomised to SHIFT.
iii. Update to Family therapy section:
¢ Approximately 8 sessions expected.
¢ Family therapists will work in teams of 3 or 4 and provide trial FT as a team for a cluster of services.
Each local CAMHS will identify a named case manager for the family therapists to link with to
provide assurance about clinical governance. Where a family therapist is a full-time employee within
the local CAMHS, the family therapist and case manager may be one and the same person.
¢ Training and supervision protocols will be developed to ensure consistency of approach throughout
the duration of the trial.
¢ It is intended that there will be central review (by appropriately qualified members of the Trial
Management Group) of a selection of FT tapes to ensure, and allow reporting of, overall adherence
to the manual (included in the updated PIS).
¢ Collection of therapist data at baseline.
iv. Use of troublesome behaviour sections of the Development and Well-Being Assessment (DAWBA)
[(v) updated publication policy and (vi) piloting baseline questionnaires] for suitability for the population
(health economics).
Amendment 3: substantial and non-substantial – September 2009
l Inclusion of the EQ-5D in place of the HUI2 for young people (following outcome of health economic
pilot work).
l Updated information sheets to include the possibility of long-term follow-up.
l Clarification that related, unexpected SAEs will be collected for the young person only.
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Amendment 4: substantial and non-substantial – October 2009
l Inclusion of the ICU in place of the DAWBA.
l Update to secondary end points to clarify that information on all further episodes of self-harm would
be collected, not just the events that result in hospital attendance.
l Submission of a ‘case management protocol’ to the main REC for ‘information only’ (clarification for
sites re: case management processes for families allocated SHIFT FT).
Opened to screening in the first site – November 2009
Amendment 5: non-substantial – November 2009
l Updated wording regarding exclusion of those without sufficient proficiency in English to provide data
for the trial.
Amendment 6: non-substantial – November 2009
l Updated wording for the Leeds information sheets – changing ‘therapist’ to ‘CAMHS worker’.
Amendment 7: substantial – February 2010
l Update to process for gaining consent from family members to recording FT sessions. Development of
DVD consent form to be signed by each family member at every session.
Amendment 8: substantial – August 2010
l Removal of the 7-day time window for GP referrals. Participants referred by their GP could now enter
SHIFT as long as ‘recent self-harm was a key feature of referral’.
l Randomisation of family therapists. Participants allocated FT in the Greater Manchester, Calderdale and
Bradford CAMHS were also to be randomly allocated a lead FT. It was also clarified that, in the other
participating CAMHS, where there was a clear ‘lead’ therapist, s/he would take that lead role
wherever possible.
l Recording FT sessions and transfer of data. Detail added to the protocol regarding the process for
obtaining consent for recording sessions and subsequent transfer of recorded data between locations.
A revised ‘recording FT sessions for research’ consent form was approved, which required one-off
consent from each participant rather than repeated consent at each session attended.
l Follow-up processes. Researchers to contact families via telephone at 3 and 6 months prior to
questionnaires being sent by the CTRU.
l Personnel changes. The main REC were informed of the new trial researchers and the involvement of
‘back-up’ researchers – both Mental Health Research Network (MHRN) CSOs (in London and Greater
Manchester) and the Systemic Therapy for At Risk Teens (START) trial researcher in Leeds.
l Comprehensive Local Research Network (CLRN) support for screening. CLRN support by way of
CAMHS records review was noted.
Amendment 9: non-substantial – August 2010
l Change of trial co-ordinator.
l General practitioner letters: CTRU to send all GP letters on CTRU-headed paper on behalf of
the CAMHS.
l CLRN support for screening.
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Amendment 10: substantial – November 2010
l Consent to researcher contact: this should be written wherever possible, but verbal consent acceptable
if documented in the young person’s case notes.
l Consent for researcher contact – where parent does not attend the appointment: accept consent to
researcher contact from the young person alone where he/she is aged 16 years or older or is aged
under 16 years and deemed ‘Gillick competent’.
l Full trial consent: where young person does not live with parent – full trial consent will be obtained
from young people aged > 16 years, regardless of whether or not they live with a parent. For young
people under the age of 16 years, parental consent will be obtained wherever the parent is the primary
caregiver and/or part of the ‘family group’. Where a parent is not a part of the ‘family group’, does not
live with the young person and is not involved in active parenting, consent will be acceptable from
the (competent) young person and from whoever is seen as the primary caregiver, regardless of
‘parental responsibility’.
l Blinding of researchers: a different researcher to undertake follow-up assessments, enabling the
assessment researcher to take an active role in data collection. (An anticipatory amendment given
difficulties obtaining treatment data from clinicians without researcher input.)
Amendment 11: substantial – September 2011
l Family Therapy Leaflet (developed by Leeds Family Therapy team as an additional information resource
for those randomised to FT).
Amendment 12: substantial – December 2011
l Sending of Christmas cards by researchers to participants (following suggestion from previous research
that this improves engagement).
Amendment 13: substantial – February 2012
l Clarification of eligibility criteria – inclusion of self-harm as a key feature of ‘presentation’ and exclusion
of child protection investigations ‘which would make treatment difficult to deliver’ and ‘siblings
receiving family therapy in CAMHS’.
l Different member of the family can complete the SOFTA at session 3 if the consenting primary
caregiver is not present.
l Clarification that clinical data can be collected by the researchers or other authorised individuals from
the research team.
l Clarification of acute trust (primary outcome) data collection methods.
l Amendments to the consent form.
l Collection of multiple contacts at baseline to aid follow-up contact.
l Reducing GP contact at follow-up.
l Addition of individuals involved in development of the FT adherence protocol.
Amendment 14: substantial – June 2012
l Research Ethics Committee re: informed re: extension possibility.
l Consent form changes.
l Change in 3-month and 6-month follow-up alerting processes.
l Change in 12-month and 18-month follow-up alerting processes.
l Removal of SOFTA completion from TAU arm.
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Amendment 15: substantial – August 2013
l Introduction of the use of participant incentives (£20 shopping voucher) at the end of their
trial involvement.
l Amendment of the information in the PIS re: trial duration – saying that they may be followed up for
18 months (to allow for slightly early completion for those recruited at the end of the recruitment
phase, because of grant time constraints).
l Amended wording in the 3-month letter providing clarity that TAU is part of SHIFT and that their data
are still important even if they have not started (or had much) treatment yet.
l Additional chase and thank-you letters for questionnaires sent postally at 12 and 18 months.
l Inclusion of additional members of the trial team who will be undertaking adherence process
development work.
l Submission (for information only) of the revised ‘case management protocol’ for sites.
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Appendix 3 Questionnaire scoring details
Description of questionnaire scores, subscales, cut-off points
for categorisation and scoring
Questionnaire: description of scores and cut-off points
Young person Children’s Depression Rating Scale – Revised
l Higher scores represent greater levels of depression.
l Total score: ranges 17–113.
l Categorisation: not depressed (< 30), mild (30–42), moderate (43–57), severe (58–72), very severe
depression (≥ 73).
l Scoring with missing data: half-rule used, scores scaled up pro rata if ≥ 50% completed.
Young person Beck Scale for Suicide Ideation
l Higher scores indicate a higher level of suicide ideation.
l Total score: ranges 0–38.
l Categorisation: suicide ideation indicated if Q4 or Q5 are non-zero, indicating: a weak or moderate desire
to kill myself, or would take a chance on life or death, or would not avoid death, if found myself in a
life-threatening situation.
l Scoring with missing data: half-rule used, scores scaled up pro rata if ≥ 50% completed.
Young person Hopelessness Scale
l Higher scores reflect greater hopelessness or negative expectations towards the future.
l Total score: ranges 0–17.
l Scoring with missing data: half-rule used, scores scaled up pro rata if ≥ 50% completed.
Young person Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire measure
l Higher scores indicative of greater enjoyment and satisfaction.
l Total score: ranges 14–70.
l Scoring with missing data: half-rule used, scores scaled up pro rata if ≥ 50% completed.
Young person EuroQoL-5 Dimensions
l Higher utility score reflects greater quality of life.
l Total score: ranges 0–1.
l Subscales: mobility, self-care, usual activities, pain/discomfort, anxiety/depression.
l Scoring with missing data: missing values and ambiguous values (e.g. two boxes are ticked for a single
dimension) should be treated as missing and coded as ‘9’. Various imputation techniques might be considered.
Caregiver Family Questionnaire
l Higher scores indicate greater levels of expressed emotion (negative).
l Total score: ranges 20–80.
l Subscales: emotional overinvolvement and criticism subscales each ranging 10–40.
l Scoring with missing data: half-rule used, scores scaled up pro rata if ≥ 50% completed.
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Caregiver General Health Questionnaire, 12 questions
l Higher scores are indicative of greater psychological distress.
l Total score: ranges 0–36 (Likert-type scoring method of 0–1–2–3).
l Scoring with missing data: half-rule used, scores scaled up pro rata if ≥ 50% completed.
Caregiver Health Utilities Index 3
l Higher utility score reflects greater quality of life.
l Total score: ranges 0–1.
l Subscales: vision, hearing, speech, ambulation, dexterity, emotion, cognition, pain.
l Scoring with missing data: respondents can answer ‘do not know’, for which there is no scoring
instruction, to any given question. Various imputation techniques might be considered.
Young person and caregiver Inventory of Callous-Unemotional Traits
l Higher scores represent higher callous and unemotional traits.
l Completed in reference to the young person.
l Total score ranges 0–72.
l Subscales (range): callousness (0–33), uncaring (0–24) and unemotional (0–15).
l Scoring with missing data: half-rule used, scores scaled up pro rata if ≥ 50% completed.
Young person and caregiver Strengths and Difficulties Questionnaire
l Higher scores in all but the prosocial score represent greater issues in that category. For the prosocial score
lower scores represent greater issues.
l Total difficulties score: ranges 0–40 (sum of all but the prosocial subscales).
l Subscales: five subscales – prosocial, emotional problems, conduct problems, hyperactivity and peer
problems, ranging 0–10. Impact supplement ranging 0–10 in the caregiver version. Externalising (sum of
conduct and hyperactivity subscales) and internalising (sum of emotional and peer problems subscales)
scores ranging 0–20.
l Categorisation:
¢ Young person total difficulties: close to average (0–14), raised (15–17), high (18–19), very
high (20–40).
¢ Caregiver total difficulties: close to average (0–13), raised (14–16), high (17–19), very high (20–40).
l Scoring with missing data: subscales are scaled up pro rata if ≥ 60% completed. Total difficulties score
missing if any of the 5 subscales are missing.
Young person and caregiver McMaster Family Assessment Device
l Higher scores are indicative of poorer family functioning.
l Overall FAD score: all subscales range 0–4.
l Subscales: general functioning, behaviour control, affective involvement, affective responsiveness, roles,
communication, problem-solving.
l Categorisation: unhealthy on each subscale for – general functioning ≥ 2.00, behaviour control ≥ 1.90,
affective involvement ≥ 2.10, affective responsiveness ≥ 2.20, roles ≥ 2.30, communication ≥ 2.20,
problem-solving ≥ 2.20.
l Scoring with missing data: overall score and subscales are scaled up pro rata if > 60% completed.
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System for Observing Family Therapy Alliances
l Higher scores represent greater alliance.
l Subscales: engagement in the process, emotional connection, safety, shared sense of purpose
ranging 4–20.
l Scoring with missing data: half-rule used, scores scaled up pro rata if ≥ 50% completed.
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Appendix 4 Recruitment, retention and
characteristics: additional tables
TABLE 102 Recruitment by CAMHS
Hub and trust CAMHS Date opened to screening
FT (N= 415),
n (%)
TAU (N= 417),
n (%)
Total (N= 832),
n (%)
Yorkshire 149 (35.9) 151 (36.2) 300 (36.1)
Y trust 1 Y1 23 November 2009 29 (7.0) 29 (7.0) 58 (7.0)
Y2 23 November 2009 11 (2.7) 10 (2.4) 21 (2.5)
Y3 23 November 2009 18 (4.3) 17 (4.1) 35 (4.2)
Y trust 2 Y4 14 June 2010 16 (3.9) 15 (3.6) 31 (3.7)
Y5 14 June 2010 2 (0.5) 1 (0.2) 3 (0.4)
Y trust 3 Y6 14 June 2010 9 (2.2) 6 (1.4) 15 (1.8)
Y7 14 June 2010 18 (4.3) 19 (4.6) 37 (4.4)
Y trust 4 Y8 23 September 2010 5 (1.2) 9 (2.2) 14 (1.7)
Y9 18 October 2010 11 (2.7) 10 (2.4) 21 (2.5)
Y10 18 October 2010 1 (0.2) 1 (0.2) 2 (0.2)
Y trust 5 Y11 27 September 2010 14 (3.4) 15 (3.6) 29 (3.5)
Y trust 6 Y12 28 September 2010 7 (1.7) 9 (2.2) 16 (1.9)
Y13 28 September 2010 1 (0.2) 3 (0.7) 4 (0.5)
Y14 28 September 2010 7 (1.7) 7 (1.7) 14 (1.7)
Manchester 143 (34.5) 143 (34.3) 286 (34.4)
M trust 1 M1 19 July 2010 6 (1.4) 5 (1.2) 11 (1.3)
M2 19 July 2010 9 (2.2) 7 (1.7) 16 (1.9)
M3 19 July 2010 5 (1.2) 5 (1.2) 10 (1.2)
M4 19 July 2010 7 (1.7) 9 (2.2) 16 (1.9)
M trust 2 M5 19 July 2010 12 (2.9) 13 (3.1) 25 (3.0)
M6 19 July 2010 12 (2.9) 13 (3.1) 25 (3.0)
M7 19 July 2010 6 (1.4) 6 (1.4) 12 (1.4)
M8 19 July 2010 4 (1.0) 4 (1.0) 8 (1.0)
M9 19 July 2010 6 (1.4) 7 (1.7) 13 (1.6)
M10 17 February 2011 13 (3.1) 9 (2.2) 22 (2.6)
M trust 3 M11 19 July 2010 22 (5.3) 21 (5.0) 43 (5.2)
M12 19 July 2010 20 (4.8) 19 (4.6) 39 (4.7)
M13 19 July 2010 6 (1.4) 5 (1.2) 11 (1.3)
M14 19 July 2010 8 (1.9) 12 (2.9) 20 (2.4)
M15 19 July 2010 7 (1.7) 8 (1.9) 15 (1.8)
continued
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TABLE 102 Recruitment by CAMHS (continued )
Hub and trust CAMHS Date opened to screening
FT (N= 415),
n (%)
TAU (N= 417),
n (%)
Total (N= 832),
n (%)
London 123 (29.6) 123 (29.5) 246 (29.6)
L trust 1 L1 14 January 2010 18 (4.3) 18 (4.3) 36 (4.3)
L2 14 January 2010 18 (4.3) 18 (4.3) 36 (4.3)
L3 14 January 2010 9 (2.2) 10 (2.4) 19 (2.3)
L4 14 January 2010 9 (2.2) 7 (1.7) 16 (1.9)
L trust 2 L5 14 January 2010 7 (1.7) 7 (1.7) 14 (1.7)
L6 14 January 2010 12 (2.9) 10 (2.4) 22 (2.6)
L7 14 January 2010 18 (4.3) 19 (4.6) 37 (4.4)
L trust 3 L8 6 September 2011 9 (2.2) 7 (1.7) 16 (1.9)
L trust 4 L9 5 May 2011 3 (0.7) 3 (0.7) 6 (0.7)
L trust 5 L10 5 May 2011 17 (4.1) 17 (4.1) 34 (4.1)
L trust 6 L11 22 January 2013 3 (0.7) 7 (1.7) 10 (1.2)
TABLE 103 All self-harm methods, treatment and suicide attempts reported over the past year (SASII timeline)
Self-harm method/s (not mutually exclusive)
FT (N= 415),
n (%)
TAU (N= 417),
n (%)
Total (N= 832),
n (%)
Alcohol 0 (0.0) 2 (0.5) 2 (0.2)
Drugs/medications 142 (34.2) 149 (35.7) 291 (35.0)
Poison/caustic substance 5 (1.2) 4 (1.0) 9 (1.1)
Burning 17 (4.1) 15 (3.6) 32 (3.8)
Scratch/cut 338 (81.4) 352 (84.4) 690 (82.9)
Stabbing, puncture 10 (2.4) 8 (1.9) 18 (2.2)
Hanging 7 (1.7) 14 (3.4) 21 (2.5)
Strangling 17 (4.1) 8 (1.9) 25 (3.0)
Asphyxiation 0 (0.0) 1 (0.2) 1 (0.1)
Jumping 11 (2.7) 5 (1.2) 16 (1.9)
Drowning 5 (1.2) 7 (1.7) 12 (1.4)
Hitting body 32 (7.7) 29 (7.0) 61 (7.3)
Stopped required medical treatments or medications 1 (0.2) 2 (0.5) 3 (0.4)
Transportation-related injury 0 (0.0) 1 (0.2) 1 (0.1)
Stepped into traffic 6 (1.4) 7 (1.7) 13 (1.6)
Method not specified 8 (1.9) 3 (0.7) 11 (1.3)
Other 39 (9.4) 53 (12.7) 92 (11.1)
Missing 13 (3.1) 2 (0.5) 15 (1.8)
Most serious medical treatment required
Hospital medical treatment 127 (30.6) 126 (30.2) 253 (30.4)
Non-hospital medical treatment 132 (31.8) 134 (32.1) 266 (32.0)
No medical treatment 145 (34.9) 156 (37.4) 301 (36.2)
Missing 11 (2.7) 1 (0.2) 12 (1.4)
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Appendix 5 Primary outcome: further details
and tables
Proportional hazards assumption
Figures 47–62 present the log-cumulative hazard plots of time to self-harm for treatment and covariates
included in the modelling, and are used to demonstrate the proportional hazards assumption is met if lines
are parallel.
Investigation of Figure 47 for treatment suggests some crossover in hazards around log(time) = 0 – 2.2;
however, at this point there is little differentiation between the curves as they are very close. With the
exception of trust, the remaining covariates adequately satisfy the proportional hazards assumptions, as,
although there is some early cross-over in lines for some covariates, this occurs prior to log(time) = 1
corresponding to the first few months of follow-up when the Kaplan–Meier curves are very close, after
which there is differentiation between roughly parallel lines.
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FIGURE 47 Proportional hazards assumption for treatment: log of negative log of estimated survivor functions.
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FIGURE 48 Kaplan–Meier plot of time to self-harm by treatment: product limit survival estimates.
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FIGURE 49 Proportional hazards assumption for age group: log of negative log of estimated survivor functions.
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FIGURE 50 Kaplan–Meier plot of time to self-harm by age group: product limit survival estimates.
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FIGURE 51 Proportional hazards assumption for gender: log of negative log of estimated survivor functions.
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FIGURE 53 Proportional hazards assumption for number of previous self-harm episodes at baseline: log of negative
log of estimated survivor functions.
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FIGURE 54 Kaplan–Meier plot of time to self-harm by the number of previous self-harm episodes at baseline: limit
survival estimates.
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FIGURE 52 Kaplan–Meier plot of time to self-harm by gender: product limit survival estimates.
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FIGURE 56 Kaplan–Meier plot of time to self-harm by the type of index self-harm episode: product limit
survival estimates.
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FIGURE 57 Proportional hazards assumption for referral from A&E: log of negative log of estimated survivor functions.
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FIGURE 55 Proportional hazards assumption for the type of index self-harm episode: log of negative log of
estimated survivor functions.
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FIGURE 58 Kaplan–Meier plot of time to self-harm by referral from A&E: product limit survival estimates.
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FIGURE 59 Proportional hazards assumption for hub: log of negative log of estimated survivor functions.
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FIGURE 60 Kaplan–Meier plot of time to self-harm by hub: product limit survival estimates.
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Table 104 further presents the results of the Kolmogorov-type supremum test of the validity of the
proportional hazards assumption for treatment and covariates based on 1000 simulations. There is no
evidence to reject the assumption of proportional hazards for treatment (p = 0.2950) or other covariates,
again with the exception of trust for which it can be seen that the proportional hazards assumption is
violated for trusts 5 Boroughs Partnership NHS Foundation Trust (p = 0.0610) and York (p = 0.0490).
Figures 63 and 64 further investigate the adequacy of the model. In Figure 63 (index plot of deviance
residuals) it can be seen that, although there are outlying values [cases poorly predicted by the model
lying outside (–2 to 2)], there is a similar pattern of outliers among the two treatment groups. As per the
log-cumulative hazard plot and Kolmogorov-type supremum test, Figure 64 (scatterplot of Schoenfeld
residuals) assesses the proportional hazard assumption for treatment, in which a horizontal line represents
proportional hazards. There is a slight non-horizontal trend, suggesting that the HR varies with respect to
time; however, as per the previous tests, this is not a significant trend.
0
0.0
0.2
0.4
0.6
0.8
1.0
5 10 15
Time (months)
Su
rv
iv
al
 p
ro
b
ab
ili
ty
+ Censored
FIGURE 62 Kaplan–Meier plot of time to self-harm by trust: product limit survival estimates.
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FIGURE 61 Proportional hazards assumption for trust: log of negative log of estimated survivor functions.
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TABLE 104 Supremum test for proportional hazards assumption: model 1
Variable Max. absolute value Replications
Probability>max.
absolute value
Treatment: TAU vs. FT 0.9381 1000 0.2950
Sex: male vs. female 0.4704 1000 0.9120
Age group (years): 11–14 vs. 15–17 0.7532 1000 0.5880
Self-harm number: 2 vs. ≥ 3 0.9464 1000 0.2710
Self-harm type: self-injury vs. combined 1.1758 1000 0.1910
Self-harm type: self-injury vs. self-poisoning 0.6618 1000 0.8840
Hospital referral: no vs. yes 0.8251 1000 0.7340
Centre trust: Y trust 1 vs.
M trust 3 1.6729 1000 0.0610
L trust 5 0.6133 1000 0.6730
Y trust 3 1.1154 1000 0.1560
Y trust 2 0.5226 1000 0.8460
M trust 1 0.8751 1000 0.4580
L trust 6 0.6387 1000 0.5030
Y trust 4 0.6800 1000 0.4720
L trust 2 0.8643 1000 0.4390
M trust 2 1.1367 1000 0.2790
L trust 1 0.7393 1000 0.7450
Y trust 6 1.2182 1000 0.1750
L trust 4 0.9399 1000 0.2980
L trust 3 0.8893 1000 0.3550
Y trust 5 1.4832 1000 0.0490
Max., maximum.
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FIGURE 63 Index plot of deviance residuals for model 1 by treatment.
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FIGURE 64 Scatterplot of Schoenfeld residuals for model 1 by treatment.
TABLE 105 Gender by recruiting trust
Trust
Gender, n (%)
Male Female
Y trust 1 (n= 114) 14 (12.3) 100 (87.7)
Y trust 2 (n= 34) 5 (14.7) 29 (85.3)
Y trust 2 (n= 52) 11 (21.2) 41 (78.8)
Y trust 2 (n= 37) 2 (5.4) 35 (94.6)
Y trust 2 (n= 29) 3 (10.3) 26 (89.7)
Y trust 2 (n= 34) 5 (14.7) 29 (85.3)
M trust 1 (n= 53) 7 (13.2) 46 (86.8)
M trust 1 (n= 105) 8 (7.6) 97 (92.4)
M trust 1 (n= 128) 21 (16.4) 107 (83.6)
L trust 1 (n= 107) 9 (8.4) 98 (91.6)
L trust 2 (n= 73) 3 (4.1) 70 (95.9)
L trust 3 (n= 16) 1 (6.3) 15 (93.8)
L trust 4 (n= 6) 0 (0.0) 6 (100.0)
L trust 5 (n= 34) 5 (14.7) 29 (85.3)
L trust 6 (n= 10) 1 (10.0) 9 (90.0)
Total (n = 832) 95 (11.4) 737 (88.6)
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Sensitivity analysis
TABLE 106 Referral into CAMHS via hospital by trust
Trust
Referral into CAMHS via hospital, n (%)
Yes No
Y trust 1 (n = 114) 49 (43.0) 65 (57.0)
Y trust 2 (n = 34) 20 (58.8) 14 (41.2)
Y trust 2 (n = 52) 17 (32.7) 35 (67.3)
Y trust 2 (n = 37) 5 (13.5) 32 (86.5)
Y trust 2 (n = 29) 9 (31.0) 20 (69.0)
Y trust 2 (n = 34) 7 (20.6) 27 (79.4)
M trust 1 (n= 53) 22 (41.5) 31 (58.5)
M trust 1 (n= 105) 36 (34.3) 69 (65.7)
M trust 1 (n= 128) 60 (46.9) 68 (53.1)
L trust 1 (n = 107) 42 (39.3) 65 (60.7)
L trust 2 (n = 73) 27 (37.0) 46 (63.0)
L trust 3 (n = 16) 6 (37.5) 10 (62.5)
L trust 4 (n = 6) 0 (0.0) 6 (100.0)
L trust 5 (n = 34) 2 (5.9) 32 (94.1)
L trust 6 (n = 10) 2 (20.0) 8 (80.0)
Total (n= 832) 304 (36.5) 528 (63.5)
Chi-squared test for an association between recruiting trust and referral into CAMHS via hospital: p = 0.0000148314
(14 degrees of freedom).
TABLE 107 Cox proportional hazards model including unclassified events (adjusted for covariates)
Covariate Parameter estimate SE HR (95% CI) df p-value
Treatment: FT (vs. TAU) 0.14 0.13 1.15 (0.89 to 1.49) 1 0.2736
Gender: female (vs. male) 0.50 0.24 1.65 (1.03 to 2.65) 1 0.0388
Age group (years): 15–17 (vs. 11–14) –0.28 0.14 0.75 (0.58 to 0.98) 1 0.0382
Number of previous self-harm episodes: ≥ 3 (vs. 2) 0.18 0.22 1.20 (0.78 to 1.85) 1 0.4107
Type of index episode 2 0.0200
Combined (vs. self-injury) 0.64 0.24 1.90 (1.20 to 3.02) 1 –
Self-poisoning (vs. self-injury) 0.08 0.20 1.09 (0.74 to 1.60) 1 –
Referred via A&E: yes (vs. no) 0.22 0.17 1.24 (0.88 to 1.74) 1 0.2121
Trust (vs. Y trust 1) 14 0.0767
df, degrees of freedom.
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Clustering because of therapists: intraclass correlation coefficient
Frailty model
The frailty model with log-normal frailty for therapist effects provides an estimate of covariance, that is, the
between-cluster variance of 0.08535 (SE 0.09254) for participants treated by the same therapist. There is,
however, no standard formula available or literature supporting the calculation of the ICC from this model
based on validated methods implementable in standard statistical software. This estimate of covariance
was not found to be statistically significant and did not improve the fit of the model (based on the
marginal likelihood) compared with that without the random therapist effect.
Logistic model
To allow us to investigate the likely ICC, we dichotomised time to self-harm according to whether or not
an event was observed. Estimates were obtained using a logistic regression random intercept model, both
with no covariates and separately including covariates (with hub rather than centre-fixed effect) in the
linear predictor as fixed effects. We obtained an estimate of the logistic ICC for the overall data set and
estimated the ICC for each study arm separately; for the latter, we applied the method to subsets of the
data corresponding to the study arm. The latent intraclass correlation was calculated based on (as the
standard logistic distribution has variance π2/3):
ρlogit =
σ2u
σ2u + π
2

3
. (7)
The unadjusted ICC was 0.0415 overall across both treatment arms, 0.0395 in the FT arm and 0.0108 in
the TAU arm. Furthermore, the adjusted ICC over both treatment arms reduced to 0.0185.
Adjusted ICCs by arm were not calculated, as in the presence of covariates it is not appropriate to obtain
these independently for subsets of the data. Estimates of the ICC from this model should be interpreted
with caution as the logistic random effect model assumes the random effect follows a normal distribution,
however, this is violated when there are lots of clusters of size one (as we have here with many therapists
seeing only a single participant), leading to a high proportion of clusters within which the proportion of
self-harm is zero or one. The ICCs from the logistic model are therefore included to report only on the
plausible range of the ICC, with all estimates reported to be < 0.05.
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Appendix 6 Secondary outcomes: further details
and tables
Recurrent event analysis
Figure 65 (scatterplot of Schoenfeld residuals) assesses the proportional hazard assumption for treatment
in the recurrent event model, in which a horizontal line represents proportional hazards. There is a slight
non-horizontal trend, suggesting that the HR varies with respect to time; however, this is in line with the
primary analysis model for which further tests confirmed this was not a significant trend.
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FIGURE 65 Model checking for the counting process model with robust sandwich variance estimator for recurrent
events: scatterplot of Schoenfeld residuals for treatment; Andersen–Gill model with robust sandwich variance
estimator for recurrent events.
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Missing data patterns
TABLE 108 Missing data pattern for questionnaire outcomes
Missing data pattern Young person, n (%) Caregiver, n (%)
Caregiver (3 and
6 months), n (%)
Pattern Baseline 12 months 18 months BSS PQ-LES-Qa CDRS-R SDQb
Hopelessness
Scale
McMaster
FADa SDQb GHQ-12
McMaster
FADa
Family
Questionnairec
1 Yes Yes Yes 313 (37.6) 320 (38.5) 301 (36.2) 327 (39.3) 312 (37.5) 315 (37.9) 317 (38.1) 316 (38.0) 313 (37.6) 316 (38.0)
2 Yes Yes No 136 (16.3) 133 (16.0) 129 (15.5) 136 (16.3) 134 (16.1) 135 (16.2) 130 (15.6) 129 (15.5) 128 (15.4) 123 (14.8)
3 Yes No Yes 69 (8.3) 67 (8.1) 67 (8.1) 66 (7.9) 70 (8.4) 67 (8.1) 70 (8.4) 75 (9.0) 74 (8.9) 44 (5.3)
4 Yes No No 298 (35.8) 299 (35.9) 334 (40.1) 299 (35.9) 299 (35.9) 292 (35.1) 310 (37.3) 309 (37.1) 308 (37.0) 348 (41.8)
5 No Yes Yes 8 (1.0) 4 (0.5) 1 (0.1) 1 (0.1) 8 (1.0) 7 (0.8) 0 (0.0) 0 (0.0) 2 (0.2) 0 (0.0)
6 No Yes No 2 (0.2) 3 (0.4) 0 (0.0) 1 (0.1) 2 (0.2) 3 (0.4) 0 (0.0) 2 (0.2) 1 (0.1) 0 (0.0)
7 No No Yes 2 (0.2) 2 (0.2 0 (0.0) 1 (0.1) 2 (0.2) 3 (0.4) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0)
8 No No No 4 (0.5) 4 (0.5) 0 (0.0) 1 (0.1) 5 (0.6) 10 (1.2) 4 (0.5) 1 (0.1) 6 (0.7) 1 (0.1)
Missing items over all time points 829 (33.2) 828 (33.2) 865 (34.7) 808 (32.4) 833 (33.4) 835 (33.5) 834 (33.4) 829 (33.2) 840 (33.7) 866 (34.7)
a Total score.
b Total difficulties score.
c Total score (at 3 and 6 months rather than 12 and 18 months).
A
PPEN
D
IX
6
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
204
Responder characteristics
Two models were fitted to explore participants’ response status (followed up or lost to follow-up) by
participant baseline characteristics and treatment arm. The first (model 1) modelled response status with
main effects for treatment arm, the participant characteristic and the interaction between the two to
evaluate whether or not the response profile differed by the participant characteristic overall and further
differentially by arm. As tests for interaction do not provide a very powerful test for moderation, a 10%
significance level is used and we therefore also modelled response status by participant characteristics
separately for each treatment arm (model 2), providing separate tests of the main characteristic effect in
each arm to examine any differential effects.
Results are presented in Tables 109–112 and green cells are used to highlight significant effects at the
10% level; interpretation is detailed in Chapter 3, Responder characteristics.
TABLE 109 Distribution of 12-month questionnaire response status by participant characteristics and treatment
arm with tests for main and interaction effects
Variable
FT: responder? TAU: responder?
Model 1: interaction
testa
Model 2: main
effect testb
Yes
(N= 261),
n (%)
No
(N= 154),
n (%)
Yes
(N= 204),
n (%)
No
(N= 213),
n (%)
Main
effect
p-value
Interaction
effect
p-value
FT
p-value
TAU
p-value
Self-harm by
12 months
(yes)
56 (21.5) 35 (22.7) 35 (17.2) 47 (22.1) 0.2674 0.4932 0.7624 0.2084
Patient gender
(female)
230 (88.1) 138 (89.6) 181 (88.7) 188 (88.3) 0.8145 0.6618 0.6443 0.8824
Total number
of self-harm
episodes (≥ 3)
233 (89.3) 136 (88.3) 183 (89.7) 187 (87.8) 0.5187 0.8310 0.7634 0.5375
Type of
most recent
self-harm
episode
– – –
Self-poisoning 59 (22.6) 34 (22.1) 39 (19.1) 52 (24.4) – – –
Self-injury 187 (71.6) 110 (71.4) 156 (76.5) 141 (66.2) 0.0559 0.1042 0.8407 0.0115
Combined 15 (5.7) 10 (6.5) 9 (4.4) 20 (9.4) 0.1598 0.3408 0.7508 0.0926
Referred from
A&E (yes)
90 (34.5) 66 (42.9) 68 (33.3) 80 (37.6) 0.0654 0.5627 0.0894 0.3676
a Response status ≈treatment + characteristic + (treatment × characteristic).
b Response status ≈characteristic. Interaction and main effect test via logistic regression (Wald chi-squared tests).
Green cells are used to highlight significant effects at the 10% level.
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TABLE 110 Distribution of 18-month questionnaire response status by participant characteristics and treatment
arm with tests for main and interaction effects
Variable
FT: responder? TAU: responder?
Model 1: interaction
testa
Model 2: main
effect testb
Yes
(N= 261),
n (%)
No
(N= 154),
n (%)
Yes
(N= 204),
n (%)
No
(N= 213),
n (%)
Main effect
p-value
Interaction
effect
p-value
FT
p-value
TAU
p-value
Self-harm by
18 months (yes)
57 (26.8) 61 (30.2) 41 (22.5) 62 (26.4) 0.2340 0.8995 0.4380 0.3657
Patient gender
(female)
180 (84.5) 188 (93.1) 158 (86.8) 211 (89.8) 0.0089 0.1791 0.0073 0.3465
Total number
of self-harm
episodes (≥ 3)
193 (90.6) 176 (87.1) 161 (88.5) 209 (88.9) 0.4882 0.3644 0.2606 0.8789
Type of most
recent self-harm
episode
– – –
Self-poisoning 43 (20.2) 50 (24.8) 37 (20.3) 54 (23.0) – – –
Self-injury 158 (74.2) 139 (68.8) 133 (73.1) 164 (69.8) 0.2611 0.7993 0.3375 0.5323
Combined 12 (5.6) 13 (6.4) 12 (6.6) 17 (7.2) 0.8305 0.9804 0.8693 0.8906
Referred from
A&E (yes)
71 (33.3) 85 (42.1) 54 (29.7) 94 (40.0) 0.0045 0.7741 0.0664 0.0293
a Response status ≈TRT+ characteristic + TRT*characteristic.
b Response status ≈characteristic. Interaction and main effect test via logistic regression (Wald chi-squared tests).
Green cells are used to highlight significant effects at the 10% level.
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TABLE 111 Distribution of 12-month questionnaire response status by participant characteristics and treatment arm with tests for main and interaction effects
Variable
FT: responder? Mean (SD) TAU: responder? Mean (SD) Model 1: interaction testa
Model 2: main
effect testb
Yes (N= 261),
n (%)
No (N= 154),
n (%)
Yes (N= 204),
n (%)
No (N= 213),
n (%)
Main effect
p-value
Interaction effect
p-value
FT
p-value
TAU
p-value
Age 14.3 (1.36) 14.4 (1.42) 14.3 (1.34) 14.4 (1.37) 0.3749 0.8086 0.4288 0.6452
Young person Hopelessness Scale 7.6 (4.31) 7.9 (4.29) 7.3 (4.08) 7.3 (4.30) 0.7817 0.6210 0.5861 0.8776
Young person BSS 10.7 (8.81) 11.1 (9.18) 10.2 (9.11) 10.5 (9.72) 0.6183 0.9238 0.6865 0.7663
Young person CDRS-R 47.8 (14.25) 48.3 (14.12) 48.5 (13.70) 50.4 (12.85) 0.1901 0.4270 0.7101 0.1439
Young person PQ-LES-Q 41.6 (9.45) 40.6 (9.23) 41.4 (9.31) 41.0 (9.60) 0.2894 0.6877 0.3113 0.6350
Young person SDQ total difficulties 19.3 (5.76) 20.0 (5.60) 20.1 (5.41) 20.1 (5.79) 0.4265 0.3728 0.2389 0.9451
Young person SDQ prosocial 7.0 (1.86) 7.3 (1.80) 7.3 (1.87) 7.1 (1.87) 0.5762 0.1190 0.1463 0.4659
Young person SDQ impact 3.3 (2.30) 3.4 (2.60) 3.5 (2.40) 3.6 (2.63) 0.4251 0.8282 0.4883 0.6702
Young person FAD total score 2.4 (0.33) 2.5 (0.34) 2.4 (0.36) 2.5 (0.36) 0.0280 0.9352 0.1559 0.0873
Young person ICU total score 28.0 (9.15) 28.7 (9.02) 28.1 (8.93) 28.9 (9.25) 0.2635 0.8999 0.4870 0.3743
Caregiver SDQ total difficulties 19.3 (6.36) 19.6 (6.91) 19.2 (6.70) 20.4 (6.91) 0.1233 0.3696 0.6601 0.0734
Caregiver SDQ emotional problems 6.2 (2.47) 6.2 (2.25) 6.1 (2.49) 6.2 (2.70) 0.7376 0.8490 0.9231 0.6921
Caregiver SDQ conduct problems 4.1 (2.28) 4.5 (2.63) 3.9 (2.43) 4.6 (2.47) 0.0028 0.4613 0.1185 0.0072
Caregiver SDQ peer problems 3.6 (2.05) 3.4 (2.16) 3.6 (2.14) 3.6 (2.15) 0.3824 0.3560 0.2193 0.9710
Caregiver SDQ impact 4.4 (2.70) 4.5 (2.79) 4.0 (2.64) 4.6 (2.78) 0.0429 0.2476 0.5431 0.0231
Caregiver SDQ externalising 9.5 (4.10) 10.1 (4.61) 9.4 (4.55) 10.5 (4.41) 0.0072 0.5050 0.1672 0.0138
Caregiver SDQ internalising 9.9 (3.73) 9.6 (3.64) 9.7 (3.98) 9.8 (4.07) 0.7721 0.5132 0.5289 0.7833
Caregiver FAD total score 2.2 (0.36) 2.2 (0.35) 2.2 (0.37) 2.3 (0.35) 0.0039 0.4234 0.1456 0.0082
Caregiver FAD roles 2.5 (0.41) 2.6 (0.43) 2.5 (0.42) 2.5 (0.42) 0.0069 0.5409 0.0206 0.1341
continued
D
O
I:10.3310/hta22120
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.12
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
C
ottrellet
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
207
TABLE 111 Distribution of 12-month questionnaire response status by participant characteristics and treatment arm with tests for main and interaction effects (continued )
Variable
FT: responder? Mean (SD) TAU: responder? Mean (SD) Model 1: interaction testa
Model 2: main
effect testb
Yes (N= 261),
n (%)
No (N= 154),
n (%)
Yes (N= 204),
n (%)
No (N= 213),
n (%)
Main effect
p-value
Interaction effect
p-value
FT
p-value
TAU
p-value
Caregiver FAD affective involvement 2.2 (0.45) 2.2 (0.45) 2.2 (0.50) 2.3 (0.51) 0.0321 0.0821 0.7877 0.0034
Caregiver FAD behaviour control 1.8 (0.42) 1.8 (0.40) 1.8 (0.42) 1.9 (0.39) 0.3875 0.8717 0.6252 0.4609
Caregiver Family Questionnaire total score 52.5 (10.32) 53.6 (11.24) 51.4 (10.80) 54.4 (10.71) 0.0064 0.2353 0.2850 0.0048
Caregiver GHQ-12 (Likert) 16.9 (6.77) 19.2 (7.30) 17.9 (7.28) 19.2 (7.17) 0.0003 0.2303 0.0010 0.0815
Caregiver ICU total score 31.9 (10.98) 33.7 (12.51) 31.3 (12.10) 34.5 (10.55) 0.0023 0.3416 0.1363 0.0047
a Response status ≈TRT + characteristic + TRT*characteristic.
b Response status ≈characteristic. Interaction and main effect test via logistic regression (Wald chi-squared tests).
Green cells are used to highlight significant effects at the 10% level.
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TABLE 112 Distribution of 18-month questionnaire response status by participant characteristics and treatment arm with tests for main and interaction effects
Variable
FT: responder? Mean (SD) TAU: responder? Mean (SD) Model 1: interaction testa
Model 2: main
effect testb
Yes (N= 213),
n (%)
No (N= 202),
n (%)
Yes (N= 182),
n (%)
No (N= 235),
n (%)
Main effect
p-value
Interaction effect
p-value
FT
p-value
FT
p-value
Age 14.3 (1.29) 14.3 (1.48) 14.2 (1.42) 14.5 (1.29) 0.1299 0.2128 0.8465 0.0554
Young person Hopelessness Scale 7.8 (4.30) 7.6 (4.31) 7.4 (4.14) 7.2 (4.24) 0.6111 0.9967 0.7164 0.7218
Young person BSS 11.2 (8.62) 10.5 (9.28) 10.3 (9.27) 10.4 (9.55) 0.6277 0.5638 0.4630 0.9469
Young person CDRS-R 47.9 (13.97) 48.0 (14.45) 48.2 (14.02) 50.4 (12.66) 0.2085 0.2500 0.9368 0.1015
Young person PQ-LES-Q 41.2 (9.23) 41.2 (9.55) 42.0 (9.54) 40.6 (9.35) 0.2965 0.2958 1.0000 0.1414
Young person SDQ total difficulties 19.3 (6.01) 19.8 (5.37) 20.2 (5.40) 20.0 (5.77) 0.6946 0.4419 0.4073 0.7923
Young person SDQ prosocial 7.0 (1.81) 7.3 (1.87) 7.3 (1.90) 7.1 (1.85) 0.7799 0.1823 0.2565 0.4537
Young person SDQ impact 3.2 (2.28) 3.4 (2.54) 3.6 (2.47) 3.5 (2.56) 0.8034 0.3524 0.4140 0.6229
Young person FAD total score 2.4 (0.33) 2.5 (0.33) 2.4 (0.36) 2.5 (0.35) 0.1048 0.3383 0.6483 0.0601
Young person ICU total score 28.1 (8.89) 28.4 (9.33) 28.0 (9.26) 28.9 (8.96) 0.3487 0.6416 0.7358 0.3268
Caregiver SDQ total difficulties 19.0 (6.56) 19.9 (6.55) 19.3 (6.90) 20.2 (6.76) 0.0604 0.9676 0.1832 0.1851
Caregiver SDQ emotional problems 6.1 (2.41) 6.3 (2.36) 6.2 (2.56) 6.1 (2.63) 0.5938 0.3454 0.3152 0.7623
Caregiver SDQ conduct problems 4.0 (2.40) 4.5 (2.42) 4.0 (2.50) 4.5 (2.42) 0.0061 0.8851 0.0674 0.0400
Caregiver SDQ peer problems 3.6 (2.10) 3.5 (2.08) 3.6 (2.12) 3.7 (2.16) 0.9464 0.3659 0.4965 0.5504
Caregiver SDQ impact 4.4 (2.77) 4.5 (2.70) 4.0 (2.59) 4.6 (2.81) 0.0765 0.1734 0.7694 0.0285
Caregiver SDQ externalising 9.3 (4.22) 10.1 (4.36) 9.5 (4.64) 10.4 (4.37) 0.0068 0.9349 0.0535 0.0579
Caregiver SDQ internalising 9.7 (3.78) 9.8 (3.61) 9.8 (4.03) 9.8 (4.02) 0.7796 0.9094 0.7888 0.9026
Caregiver FAD total score 2.2 (0.36) 2.2 (0.35) 2.2 (0.37) 2.2 (0.35) 0.0190 0.9633 0.1048 0.0900
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TABLE 112 Distribution of 18-month questionnaire response status by participant characteristics and treatment arm with tests for main and interaction effects (continued )
Variable
FT: responder? Mean (SD) TAU: responder? Mean (SD) Model 1: interaction testa
Model 2: main
effect testb
Yes (N= 213),
n (%)
No (N= 202),
n (%)
Yes (N= 182),
n (%)
No (N= 235),
n (%)
Main effect
p-value
Interaction effect
p-value
FT
p-value
FT
p-value
Caregiver FAD roles 2.5 (0.41) 2.6 (0.43) 2.5 (0.42) 2.5 (0.41) 0.0047 0.5262 0.0143 0.1223
Caregiver FAD affective involvement 2.2 (0.45) 2.3 (0.45) 2.2 (0.49) 2.3 (0.52) 0.0037 0.2644 0.2256 0.0030
Caregiver FAD behaviour control 1.8 (0.42) 1.8 (0.39) 1.8 (0.43) 1.9 (0.39) 0.1784 0.7043 0.2222 0.4948
Caregiver Family Questionnaire total score 52.4 (10.38) 53.4 (10.97) 51.2 (10.57) 54.3 (10.89) 0.0058 0.1857 0.3084 0.0040
Caregiver GHQ-12 (Likert) 17.2 (6.97) 18.3 (7.12) 18.0 (6.99) 19.1 (7.41) 0.0227 0.9004 0.0920 0.1244
Caregiver ICU total score 31.7 (11.18) 33.5 (11.97) 31.1 (12.22) 34.4 (10.57) 0.0016 0.2978 0.1273 0.0037
a Response status ≈TRT + characteristic + TRT*characteristic.
b Response status ≈characteristic. Interaction and main effect test via logistic regression (Wald chi-squared tests).
Green cells are used to highlight significant effects at the 10% level.
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FIGURE 66 Characteristics of questionnaire responders and non-responders by arm at 12 and 18 months, where some
differences (main effect in each arm and/or interaction) were detected. CG, caregiver; YP, young person. Black text,
particularly concerning cases not indicated; blue text, particularly concerning cases lost to follow up in FT/particularly
concerning cases followed up in TAU; green text, particularly concerning cases lost to follow up in TAU/particularly
concerning cases followed up in FT. (continued )
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FIGURE 66 Characteristics of questionnaire responders and non-responders by arm at 12 and 18 months, where some
differences (main effect in each arm and/or interaction) were detected. CG, caregiver; YP, young person. Black text,
particularly concerning cases not indicated; blue text, particularly concerning cases lost to follow up in FT/particularly
concerning cases followed up in TAU; green text, particularly concerning cases lost to follow up in TAU/particularly
concerning cases followed up in FT. (continued )
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FIGURE 66 Characteristics of questionnaire responders and non-responders by arm at 12 and 18 months, where some
differences (main effect in each arm and/or interaction) were detected. CG, caregiver; YP, young person. Black text,
particularly concerning cases not indicated; blue text, particularly concerning cases lost to follow up in FT/particularly
concerning cases followed up in TAU; green text, particularly concerning cases lost to follow up in TAU/particularly
concerning cases followed up in FT. (continued )
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FIGURE 66 Characteristics of questionnaire responders and non-responders by arm at 12 and 18 months, where some
differences (main effect in each arm and/or interaction) were detected. CG, caregiver; YP, young person. Black text,
particularly concerning cases not indicated; blue text, particularly concerning cases lost to follow up in FT/particularly
concerning cases followed up in TAU; green text, particularly concerning cases lost to follow up in TAU/particularly
concerning cases followed up in FT. (continued )
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FIGURE 66 Characteristics of questionnaire responders and non-responders by arm at 12 and 18 months, where some
differences (main effect in each arm and/or interaction) were detected. CG, caregiver; YP, young person. Black text,
particularly concerning cases not indicated; blue text, particularly concerning cases lost to follow up in FT/particularly
concerning cases followed up in TAU; green text, particularly concerning cases lost to follow up in TAU/particularly
concerning cases followed up in FT. (continued )
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FIGURE 66 Characteristics of questionnaire responders and non-responders by arm at 12 and 18 months, where some
differences (main effect in each arm and/or interaction) were detected. CG, caregiver; YP, young person. Black text,
particularly concerning cases not indicated; blue text, particularly concerning cases lost to follow up in FT/particularly
concerning cases followed up in TAU; green text, particularly concerning cases lost to follow up in TAU/particularly
concerning cases followed up in FT. (continued )
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FIGURE 66 Characteristics of questionnaire responders and non-responders by arm at 12 and 18 months, where some
differences (main effect in each arm and/or interaction) were detected. CG, caregiver; YP, young person. Black text,
particularly concerning cases not indicated; blue text, particularly concerning cases lost to follow up in FT/particularly
concerning cases followed up in TAU; green text, particularly concerning cases lost to follow up in TAU/particularly
concerning cases followed up in FT. (continued )
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FIGURE 66 Characteristics of questionnaire responders and non-responders by arm at 12 and 18 months, where some
differences (main effect in each arm and/or interaction) were detected. CG, caregiver; YP, young person. Black text,
particularly concerning cases not indicated; blue text, particularly concerning cases lost to follow up in FT/particularly
concerning cases followed up in TAU; green text, particularly concerning cases lost to follow up in TAU/particularly
concerning cases followed up in FT.
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Appendix 7 Health economics analysis:
additional information
F igure 67 shows the cost-effectiveness plane for FT compared with TAU based on 10,000 bootstrappedestimates of costs and aggregate QALYs. The average costs from the bootstrapped estimates were
£3751.21 (SD £197.67) and £4942.7 (SD £197.8) for the TAU and FT arms, respectively. The corresponding
mean (aggregate) QALYs were 2.236 (SD 0.020) for the TAU arm and 2.288 (SD 0.020) for the FT arm.
The simulation estimates are above the x-axis, showing that FT is always more costly than TAU. As with the
main analysis, most estimates are spread in the north-east quadrant, suggesting that FT will probably lead
to better health outcomes when caregivers’ QALY gains are taken into account. However, some estimates
are also in the north-west quadrant, where the FT arm is likely to have lower QALYs than the TAU arm.
The cost-effectiveness acceptability curve of FT compared with TAU when caregivers’ quality of life is
taken into account is presented in Figure 68. At a threshold of £20,000, FT has a 41% chance of being
cost-effective and this percentage increases to 64% when the threshold is £30,000.
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FIGURE 68 Cost-effectiveness acceptability curve of FT compared with TAU (outcome measure: aggregate QALY,
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FIGURE 67 Cost-effectiveness plane of FT compared with TAU (outcome measure: aggregate QALY,
NHS perspective).
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Appendix 8 End-of-trial information sheet
for participants
What were you trying to do?
The aim of the SHIFT study was to find out more about how to help young people who have self-harmed,
and in particular to see what could be done to support them not self-harming again. By self-harm we
meant taking an overdose, cutting or some other form of hurting yourself. We wanted to look at how
young people got on after family therapy compared to usual treatment in CAMHS (child and adolescent
mental health services).
What was the main finding?
We found that those who had family therapy went to hospital after self-harm about the same number of
times as those who had treatment as usual. This means that there was no real difference between the
treatments; they were about as good as each other.
What did you do?
We worked with around 40 child and adolescent mental health teams in Yorkshire, Manchester and
London. We invited over 800 young people aged between 11 and 17 years old who had self-harmed at
least twice to take part in the research. As well as the young person, their main caregiver (for example,
Mum or Dad) also took part. If they both agreed they were then randomly allocated to either family
therapy or the usual treatment in their local CAMHS.
We collected lots of information about the young person and their family at the beginning, before
treatment started. Treatment lasted around 6–8 sessions although some people had more and some less.
We collected more information over the next 18 months including whether the young person had
self-harmed again and had to go to hospital.
Did you find out anything else?
Yes, we found that:
l Young people who were older (aged 15–17), who combined an overdose with cutting, and who went
to hospital rather than directly to CAMHS were more likely to self-harm again.
l Those who had been in the family therapy group reported improvements in sociability (kindness and
caring for others), and their caregivers reported improvements in their levels of emotional and
behavioural problems.
l There was some evidence to suggest that family therapy might be more effective in reducing self-harm
where caregivers reported poor family functioning at the start of the study (particularly in relation to
talking about feelings). Family therapy also seemed to be helpful where young people reported that
they found it easy to discuss their emotions.
l On the other hand, where the young person themselves reported difficulty in expressing emotion, or
caregivers reported that they already discussed emotion quite well, family therapy was not as effective
as usual treatment.
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We also looked at the cost-effectiveness (value for money) of the two treatments. There was no evidence
that family therapy was cost-effective when compared with treatment as usual when we focused on
just the young people who took part. However, there was a suggestion that family therapy may be
cost-effective if the health benefits to caregivers are also taken into account.
What are you going to do next?
We collected lots of information from our participants and there is still more work to do analysing all the
information and understanding more about self-harm in general.
We have also received funding from the National Institute for Health Research (the part of the
government’s Department of Health that funds research) to extend the study and see if any differences
between the family therapy and treatment as usual groups can be seen if we look again at the end of
2016. To do this we will be collecting data directly from NHS Digital (where data is held from all the
hospitals in England about people’s visits to hospital). You will have received an earlier information sheet
explaining a bit more about this, but if you have any questions please contact the research team (see
below). Please note that we will not collect any more information if you have already asked us not to.
How can I find out more?
You can look at our web site (TBC) or contact the research team directly:
David Cottrell Liz Graham
E-mail: XXXX E-mail: XXXX
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